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Summary 
Extracellular vesicles (EVs) are submicron vesicles released from cells as 
intercellular communicators. EV research is hindered by a current lack of 
standardisation. However, mounting evidence suggests a role for EVs in both 
physiological and pathophysiological processes. Little is known about adipocyte-
derived EVs despite the recognition of adipose tissue (AT) as an endocrine organ 
and the role of dysfunctional AT in disease. Obese AT develops regions of hypoxia 
and inflammation, leading to obesity-associated metabolic complications. The aim of 
this thesis was to explore EVs as novel adipocyte communicators, characterising 
their release under physiological and disease-like conditions. 
 
Nanoparticle tracking analysis (NTA) and tunable resistive pulse sensing (TRPS) 
were assessed for their accuracy and usability for EV quantification. NTA and TRPS 
both accurately quantified EVs though NTA was more user-friendly. The choice of 
anticoagulant, filtering and storage of EVs all affected EV concentration.  
 
Physiological EV release from 3T3-L1 adipocytes was characterised pre- and post-
adipogenesis. EV generation increased prior to adipogenesis and EVs were enriched 
in pro-signalling fatty acids and proteins characteristic of the original cell. Therefore, 
EVs may aid the initiation of adipogenesis. Hypoxia was then used to pathologically 
generate EVs to mimic adipocyte obesity. Adipocyte EV release increased in 
hypoxia; these EVs were enriched in pro-signalling fatty acids and monocyte 
chemoattractant protein-1. Hypoxic EVs were then analysed for their interaction 
with macrophages (Mϕ). Hypoxic EVs may increase Mϕ migration and promote an 
anti-inflammatory Mϕ phenotype; further repeats are needed to confirm this. 
 
Finally, adipocyte markers were detected in plasma EVs suggesting the presence of 
circulating adipocyte-derived EVs in vivo. Plasma EVs were also reduced in 
hypercholesterolaemia patients by routine apheresis treatment. 
 
In conclusion, adipocytes release EVs which may assist intercellular communication 
in both physiological and disease-like conditions. Adipocyte-derived EVs can be 
detected in vivo and may provide novel biomarkers of obesity-associated diseases. 
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1. General Introduction 
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The emergence of extracellular vesicles (EVs) as novel cellular communicators and 
potential biomarkers has led to an exponential growth in EV research. Similarly to 
the history of adipocyte research itself, the study of adipocyte-derived EVs is 
somewhat behind the rest of the EV field. Data presented in this thesis describes the 
physiological and potential pathophysiological characteristics of adipocyte-derived 
EVs. 
It is important to state that from the onset of this thesis, the EV field has been rapidly 
and continually changing in suggested protocols and methods. Therefore in order to 
keep up with the dynamics of the field, methods may differ slightly with progression 
through the chapters; though consistency was maintained wherever possible. In 
particular, the methods and protocols employed in Chapter 8 (which was conducted 
at the beginning of my PhD) were based on those recommended at the time. 
Therefore, some of these methods such as the use of FC without beads or instead of 
time resolved fluorescence to phenotype EVs are now regarded suboptimal. Though 
frustrating, it provides an important insight into ever changing field of EV research, 
which is described in detail below.  
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1.1 EXTRACELLULAR VESICLES 
Extracellular vesicles (EVs) are cell-derived submicron vesicles. EVs are spherical, 
ranging from 30 nm to 1 µm in size, and are contained by a phospholipid bilayer. 
The following section provides a detailed account of the current classification, 
functions and potential clinical relevance of EVs. 
 
1.1.1 History 
The first visual evidence of EVs was published in 1967 by Peter Wolf (1). In this 
study, plasma EVs were visualised by electron microscopy (EM) and termed 
“platelet dust”. Wolf‟s study aimed to explain a study from 1946 where platelet-free 
plasma (PFP) had been shown to possess thrombin generation capacity and that this 
could be reduced by high speed centrifugation (2). This was in fact, the first 
experimental evidence for the existence and functional capacity of EVs, though the 
visual evidence of this was not supplied until 20 years later by Wolf. In 1970, 
Webber and Johnson eloquently illustrated the blebbing of particles from activated 
platelets by EM (Figure 1.1.1 A).  
Concurrently, the works of George Palade and in later years, James Rothman, helped 
to delineate the role of vesicles in the secretory pathway of intracellular protein 
transport, largely in relation to the secretion of enzymes, hormones and 
neurotransmitters (3–6). However, it also provided important evidence for: a role of 
vesicles in the transfer of cellular material; fusion of vesicles with the plasma 
membrane; and discharge of intravesicular contents into the extracellular space. It 
was later demonstrated that reticulocytes package the transferrin receptor into 
vesicles to allow for maturation into erythrocytes (7). The authors later proved this 
shedding of the transferrin receptor was specifically mediated by exosomes (8) 
(Figure 1.1.1 B/C). Over the next few decades, EV research was slow to progress, 
and only in the last 15 years has the EV field seen a rapid expansion. 
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Figure 1.1.1: Early evidence of EVs. Transmission EM images of EV release. (A) 
Activated platelets releasing submicron vesicles via a direct blebbing of the plasma 
membrane. (B) Invagination of the plasma membrane of reticulocytes leads to packaging of 
the transferrin receptor into intracellular vesicles contained within a larger vesicle which 
fuses with the plasma membrane to release the vesicles from the cell via exocytosis (C). 
Image A is reproduced with permission from (9) © 1970, American Society for Investigative 
Pathology. Published by Elesevier Inc. All rights reserved. Images B and C are reproduced 
with permission from Rockefeller University Press, ©Pan et al. Journal of Cell Biology (8). 
  
Page | 5  
 
1.1.2 Nomenclature 
Whilst the interest in and impact of the EV field has boomed over recent years, it has 
been accompanied by a varied use of terminology (10). Unfortunately, this causes 
confusion within the field and the published literature as to the precise nature and 
classification of the vesicles being studied. The varied nomenclature has primarily 
arisen from the vast subject areas of EV researchers, who have named the vesicles 
after the cell from which they originate (11). For example: tolerosomes (intestinal 
epithelial cells) (12), oncosomes (cancer cells) (13), prostasomes (prostate cancer 
cells) (14) and matrix vesicles (bone cells and cartilage) (15). In addition to cell-
specific terminology, terms referring to the mechanism of biogenesis such as 
“exosomes”, “microvesicles”, “microparticles” and “apoptotic bodies” are often used 
interchangeably, and often mean different things to different researchers. Thus, in 
2014, the International Society of Extracellular Vesicles (ISEV) produced a position 
paper to unify these discrepancies. The statement encourages the use of “EVs” as an 
umbrella term to encompass all secreted vesicles and requests that authors in the 
field provide complete clarity in reporting the defined EV population(s) of study 
(10,16). Secreted vesicles that fall under the generic EV umbrella and their typical 
characteristics are summarised in Figure 1.1.2. It should be noted that Figure 1.1.2 
summarises characteristics of EVs that are generally accepted by the field. However, 
some of the specific characteristics are not strictly evidenced, for example, some 
exosomes may be >100 nm and some microvesicles may be <100 nm (17). 
Specificity and further characterisation is likely to be improved in future years. 
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Figure 1.1.2: Summary of EV nomenclature. The term “EV” is used as a generic term to 
encompass all cell-derived secretory vesicles. This includes exosomes, microvesicles and 
apoptotic bodies. CD = cluster of differentiation; GM1 = monosialotetrahexosylganglioside; 
PS = phosphatidylserine; TSG101 = tumour susceptibility gene 101. 
 
As the name indicates, apoptotic bodies are released by cells undergoing apoptosis 
(18) and therefore do not represent EVs from viable cells. Thus, the term EV in this 
thesis refers to both exosomes and microvesicles but does not include apoptotic 
bodies.  
Page | 7  
 
1.1.3 Formation 
EV biogenesis is categorised into two pathways: the classical pathway for exosome 
formation, and the direct pathway for microvesicle budding (Figure 1.1.3); although, 
EVs may not be limited to these pathways of biogenesis. Exosome-like vesicles with 
a diameter, density and tetraspanin expression akin to those of exosomes have been 
shown to be released via the direct pathway (19). However, it is not yet possible with 
current technology to discriminate between EV subtypes with similar sizes (10). 
 
1.1.3.1 The classical pathway 
The mechanisms of the classical pathway are part of those in the endocytic pathway. 
The endocytic pathway primarily regulates the expression of cell surface receptors, 
which can be internalised and degraded or recycled depending on the needs of the 
cell (20). Indeed, the endocytic formation of exosomes was first illustrated as a novel 
mechanism of receptor recycling (8). However, exosomes are now considered to 
play a major role in intercellular communication and hence, this pathway has now 
been widely studied with respect to exosome formation.  
The process begins with the invagination of the plasma membrane and endocytosis 
of membrane proteins and surrounding material to form an intracellular vesicle 
(Figure 1.1.3 A). Intraluminal vesicles (ILVs) are then formed from an inward 
budding of the intracellular vesicle membrane. ILV generation is governed by the 
endosomal sorting complex required for transport (ESCRT) of which there are 4 
main complexes (21). ESCRT complexes 0, I and II recognise and ubiquitinate 
endocytosed proteins in the intracellular vesicle membrane (22). The ESCRT III 
complex (including alix and TSG101) then orchestrates the inward budding and 
scission of the ILV to form multi-vesicular bodies (MVBs). ESCRT-derived MVBs 
may then be degraded in lysosomes or secreted as exosomes. Knockdown of ESCRT 
complex proteins such as TSG101 impairs, but does not abolish exosome secretion 
(23) suggesting an alternative pathway for MVB formation. Furthermore, the 
differential targeting of MVBs for either lysosomal degradation or exocytosis is 
suggestive of subtle alterations in the compositions of ILVs and MVBs that 
determine the fate of the MVBs and their contents. 
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Figure 1.1.3: Schematic of EV biogenesis. The two main pathways for EV biogenesis are summarised. (A) The classical pathway: inward budding of the 
plasma membrane creates intracellular vesicles which process endocytosed material forming intraluminal vesicles (ILV). ILV are contained within 
multivesicular bodies (MVB) which may then be targeted for lysosomal degradation or fuse back with the plasma membrane to release ILV as exosomes. (B) 
The direct pathway: alterations in plasma membrane asymmetry cause an outward budding of the membrane directly into the extracellular space producing 
microvesicles that contain surface proteins of the parent cell. Image created using Servier Medical Art (Servier, France). 
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The precise processing of MVB subpopulations is currently unknown, though data is 
accumulating for a role of lipids in an ESCRT-independent process. MVBs that were 
cholesterol rich were found to be destined for release as exosomes (24). Furthermore, 
association of exosomal proteins with lipid-raft microdomains was found to 
segregate MVBs for exosome secretion rather than lysosomal degradation (25). 
Ceramide was also detected within exosomes, which is hydrolysed from the 
phospholipid sphingomyelin by sphingomyelinase enzymes. Addition of exogenous 
sphingomyelinases to cells induced aggregation of lipid-raft microdomains in 
intracellular vesicles and inward budding, producing ILVs. Furthermore, inhibition 
of sphingomyelinases reduced secretion of exosomal markers such as tetraspanins 
and TSG101 (26) suggesting a role for ceramide in the production of ILVs destined 
for exosome secretion. However, others have shown that inhibition of 
sphingomyelinases has little or no effect on exosome secretion (27) suggesting this 
process may be cell-specific. Tetraspanins, particularly CD63, have also been 
proposed as ESCRT-independent stimulators of ILV formation and exosome 
secretion (27,28) and are known to be enriched in ILVs and exosomes (29). 
Phospholipase D2 (PLD2) which is highly enriched in exosomes, is necessary for the 
formation of CD63-containing ILVs (30,31). PLD2 targets phosphatidylcholine (PC) 
in the plasma membrane to yield phosphatidic acid which, similarly to ceramide, has 
been implicated in the formation of MVBs. Recently, ESCRT-dependent and –
independent mechanisms were shown to form ILVs of different sizes (32), providing 
a potentially simple method of distinguishing ILV populations. 
The majority intracellular vesicle trafficking is controlled by Rab GTP (guanosine 
triphosphate)-ases, a family of conserved, small cytosolic proteins (33). Several Rab 
GTPases have been implicated in exosome secretion, particularly Rab 27. These 
Rabs have been shown to play a fundamental role in exosome secretion by directing 
MVBs to the plasma membrane and assisting their docking for fusion and exocytosis 
(34). Inhibition of Rab 27A in cancer cells prevented exosome secretion in vitro and 
also reduced tumour metastasis in vivo (35,36).  
The final stage of the classical pathway involves fusion of MVBs with the plasma 
membrane and exocytosis of exosomes. The “SNARE hypothesis” (37) has been 
proposed as a mechanism for MVB fusion with the plasma membrane. The SNARE 
complex is formed between the attached vesicle and the plasma membrane by: 
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syntaxin and SNAP (soluble NSF (N-ethylmaleimide-sensitive fusion) attachment 
protein) which protrude from the cytosolic plasma membrane, and vesicle-associated 
membrane protein (VAMP) in the vesicle membrane. The folding of the SNARE 
proteins between the docking vesicle and the plasma membrane provides the 
thermodynamic energy to pull apart the membranes, creating a pore for exosomes 
release (38). The involvement of the SNARE complex in MVB fusion and exosome 
release has not yet been widely studied, though several groups have indicated 
SNARE and accessory proteins may be crucial to exosome secretion (39–42). 
 
Though a plethora of research exists detailing the classical pathway, the exact 
mechanisms of exosome biogenesis are by no means clear. Currently, it seems that 
the endocytic pathway of exosome formation may involve several different proteins 
and share similarities between cell types, though some aspects may be cell-specific. 
Figure 1.1.4 summarises the major current theories surrounding exosome 
biogenesis. Further investigation is needed to draw parallels between different cell 
types to further our understanding of how MVB heterogeneity can result from 
different mechanisms of ILV formation and hence impact upon exosome biogenesis. 
 
Figure 1.1.4: Summary of classical exosome biogenesis. A summary of the major steps 
and inducers of classical exosome biogenesis. ILV formation may arise from actions of the 
ESCRT complexes, ceramide, tetraspanins or PLD2 to form MVBs. RabGTPases then aid 
the translocation and docking of MVBs to the plasma membrane where the SNARE complex 
assembles. Energy created by the association of the SNARE complex pulls the docked 
vesicle and plasma membranes apart creating a fusion pore to allow for exosome secretion.  
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1.1.3.2 The direct pathway 
During resting conditions where cells are unstimulated, the phospholipid bilayer 
exists in an asymmetric state (43). Aminophospholipids phosphatidylserine (PS) and 
phosphatidylethanolamine (PE) are preferentially situated on the cytoplasmic side of 
the bilayer whilst PC and sphingomyelin are positioned on the outer leaflet (44). 
This physiological asymmetry is generated by synthesis of phospholipids on a 
specific leaflet of the membrane and is maintained by three phospholipid translocase 
enzymes embedded in the plasma membrane. Flippase is an adenosine triphosphate 
(ATP)ase which causes rapid translocation of aminophospholipids to the inner 
membrane leaflet, with a higher affinity for PS. Floppase is also an ATPase and a 
member of the ATP-binding cassette (ABC) transporter family (45). It acts to move 
phospholipids to the outer membrane leaflet, but does so at a much slower rate than 
flippase when the cell is at rest (43). Scramblase does not require ATP and causes 
random bidirectional transport of phospholipids across the membrane. When the cell 
is at rest, transport of phospholipids between the membrane leaflets is slow and 
generally mediated by flippase. 
Activation of the cell usually results in an increase in cytosolic calcium which causes 
concurrent activation of floppase and scramblase and inhibition of flippase (45). The 
resulting effect is a dissemination of phospholipid asymmetry with a profound 
exposure of PS on the outer membrane leaflet. Furthermore, increased cytosolic 
calcium concentrations also cause a disruption in the actin cytoskeleton (46). The 
proteolysis of the actin cytoskeleton may require the actions of several enzymes. 
Rho-kinase (RhoK)-II has been shown be essential for endothelial microvesicle 
production (46) and RhoK inhibitors are able to block microvesicle blebbing (47). 
Furthermore, the production of adipocyte-derived EVs has been shown to be 
dependent on RhoK following cleavage by caspase-3 (48). Caspases can also 
modulate the actions of calpain to cause cytoskeletal reorganisation and microvesicle 
blebbing in neutrophils (49) and macrophages (Mϕ) (50). Though a number of 
proteins have been implicated in microvesicle budding, the precise mechanism 
remains unclear and similarly to exosome biogenesis, is likely to vary between cells. 
The resulting exposure of PS and cleavage of the actin cytoskeleton following 
cellular activation causes budding and shedding of the plasma membrane in the form 
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of microvesicles. Typically between 100 and 1000 nm in diameter, microvesicles 
often harbour surface antigens from their cell of origin in their own plasma 
membrane as well as specific lipid signalling molecules, messenger ribonucleic acid 
(mRNA), micro RNA (mIR) and soluble proteins (Figure 1.1.5). 
 
 
Figure 1.1.5: Summary of microvesicle formation. The membrane of resting cells has an 
asymmetric distribution of phospholipids which is primarily maintained by the action of the 
enzyme, flippase. This causes anionic phospholipids such as PS to remain facing the 
cytoplasm. Upon cellular activation and calcium (Ca
2+
) influx, flippase is inhibited and 
scramblase is activated. This causes PS to be externalised to the outer membrane leaflet. 
Concurrently, increased cytosolic Ca
2+
 activates enzymes such as RhoK, calpain, and 
caspases which cleave the actin cytoskeleton. Together, this causes an external budding of 
the plasma membrane, into which surface receptors and antigens, and cytosolic enzymes, 
nucleic acids and lipids are incorporated. Image created using Servier Medical Art (Servier, 
France). 
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1.1.4 Composition of extracellular vesicles 
Owing to their different methods of biogenesis, EV subtypes are likely to alter in 
composition despite originating from the same cell. Broadly, EVs have been shown 
to contain proteins (membrane-bound, secretory, cytosolic and enzymes), nucleic 
acids and lipids. The specific cargo of EVs is likely to reflect the originating cell but 
also may determine their eventual function. 
 
1.1.4.1 Protein markers 
Exosomes have been more intensely studied than microvesicles or EV fractions as a 
whole, and therefore much more data exists detailing their composition. The current 
canonical markers of EVs are largely associated with EV biogenesis and can be split 
into luminal (intravesicular) and membrane-associated markers. Intravesicular 
markers include cytoskeletal proteins such as actin, tubulin, and ezrin, endosomal 
trafficking proteins such as RabGTPases, ESCRT complexes, heat shock proteins 
(HSPs), Alix and TSG101 and enzymes such as glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH). Membrane-associated EV markers include tetraspanins 
(CD9, CD63 and CD81), membrane trafficking proteins such as annexins, flotillin 
and milk fat globule-epidermal growth factor VIII (MFG-E8), lysosome-associated 
membrane glycoprotein (LAMPs) and major histocompatibility complex (MHC) I 
and II (21,51). EVs also harbour an array of cell-specific markers which assists in the 
identification of their cell of origin in complex biological fluids. The most 
commonly used markers are summarised in Table 1.1.1. 
Proteomic analysis of plasma membrane-derived vesicles is beginning to reveal that 
markers previously regarded as “exosome specific” may also be present on 
microvesicles (52). For example, CD9 is frequently used to confirm the presence of 
exosome populations. Silencing of Rab27A reduced expression of classical exosome 
markers such as CD63, alix and TSG101 but had little effect on CD9. Furthermore, 
larger vesicles (as viewed by EM and separated at a different density to exosomes) 
were also found to be CD9 positive (53) suggesting CD9 may be more of a 
ubiquitous marker of EVs than other tetraspanins. 
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Cell type Marker/antigen Citations 
B cells B cell receptor, CD19  (51,54) 
Dendritic cells CD11c  (51) 
Endothelial cells CD31, CD62E, CD144, CD146  (54–60) 
Erythrocytes CD235a, CD236  (54–57,60,61) 
Leukocytes CD15, CD45  (54,57,61) 
Monocytes CD11b, CD14  (61,62) (60) 
Platelets CD41, CD42a, CD42b, CD61  (54–57,59–63) 
Reticulocytes CD71  (57) 
T cells CD2, CD3, CD86  (51,54) 
Table 1.1.1: Cell-specific markers used for EV analysis. Common markers used in EV 
analysis of complex biological fluids to identify the cellular origin. 
 
MFG-E8 has been historically associated with exosomes (64) though recent evidence 
suggests it may also be a more universal marker of EVs (35,65,66). MFG-E8 is able 
to bind PS, which has repeatedly been used to identify microvesicle populations due 
to the phospholipid rearrangement that occurs prior to their formation. PS exposure 
is frequently used to gate EV populations by flow cytometry (FC) and is usually 
quantified using annexin V or MFG-E8. However, the use of PS as a microvesicle 
marker has been contested in recent years as not all microvesicles appear to expose 
PS (63,67) and some exosomes seem to contain an enrichment of PS (21,68).  
As more detailed proteomic analyses of EVs continue to be published, it is hoped 
that more ubiquitous markers of EVs and both cell- and subtype-specific markers 
will be identified. As such, a database of such proteins identified in EV populations 
(Vesiclepedia) has been compiled and is managed by members of the EV field (69). 
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1.1.4.2 RNA 
It was not until relatively recently (2007) that EVs were conclusively shown to 
contain RNA (70). The original study of murine mast cell exosomes showed a 
number of important features:  
1. Exosomes contained significant amounts of mRNA and mIR but no DNA or 
ribosomal RNA. 
2. RNA was not susceptible to RNAse degradation and was therefore 
intravesicular. 
3. RNA could be translated to functional proteins when incubated with protein 
machinery. 
4. Exosomes could transfer RNA to human mast cells and be translated into 
protein. 
Concomitant studies also showed that microvesicles from tumour cells (71) and 
embryonic stem cells (72) could also transfer functional mRNA to recipient cells. 
Since these key discoveries, countless studies have indicated the presence of mRNA 
and mIR in EVs from a variety of cell types. A recent study visualised the transfer of 
functional RNA contained within glioma-derived EVs to Mϕ in vivo, illustrating the 
subsequent effect on Mϕ gene and protein expression and modulation of the tumour 
microenvironment (73). EV-mediated transfer of mRNA has also been proposed 
between mother and neonate in breast milk (74) suggesting post-natal transfer of 
maternal genetic material via EVs. Cells infected with Epstein-Barr virus (EBV) 
were able to produce EVs packaged with mIRs that could selectively silence genes in 
B cells, thereby promoting and maintaining viral infection (75). Furthermore, 
circulating EVs in a cohort of young women with polycystic ovary syndrome 
(PCOS) had an altered profile of mIR compared to healthy controls (76) which might 
accelerate the progression of cardiovascular disease (CVD) in these individuals.  
In EV therapeutics, dendritic cell exosomes were successfully loaded with short 
interfering RNA and systemically injected into mice. The exosomes harboured a 
protein that enabled them to translocate to the brain and silence specific genes 
including a gene target for Alzheimer‟s disease therapy (77). Therefore, the capacity 
of EVs to carry functional nucleic acids is an exciting prospect, not only in the 
identification of novel disease biomarkers but also for targeted therapy. 
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1.1.4.3 Lipids 
Lipid signalling mediators are the least studied of the biochemical components of 
EVs despite being important precursors and mediators of a number of signalling 
pathways. Typically, lipid bilayers are ~ 5 nm thick, meaning >60% of the smallest 
EVs (~30 nm) are made of lipids (78). Compositional analysis of mast, dendritic, 
prostate cancer and B cell-derived EVs have all revealed the enrichment of 
sphingomyelin within EVs compared to cells (79–81) suggesting a higher reserve of 
ceramide which is required for exosome biogenesis. EV lipids are more tightly 
packed (79) with lipid rafts (80) and are more detergent-resistant (80) compared to 
the cells. The decreased membrane fluidity and resistance to detergents suggests EVs 
are more resistant to degradation in the circulation (79). The randomised distribution 
of PE observed in EVs indicates EV membranes retain the phospholipid 
reorganisation that precedes their biogenesis (79). Furthermore, the overall lipid 
composition of EVs bore both similarities and differences to the cell of origin (81); a 
concept also observed between circulating EVs and corresponding plasma (55,76). 
Lipid analyses of EVs are gaining popularity with the increased accessibility of in-
depth analysis techniques such as gas chromatography-mass spectrometry (GC-MS). 
For example, a recent lipidomic study using platelet EVs illustrated compositional 
differences in lipids between EV subpopulations (82). Increased knowledge of the 
type of lipids packed into EVs may help to elucidate alternative biological roles and 
biomarkers for EVs that are not based on proteomic or nucleic acid detection. 
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1.1.5 Uptake and trafficking of extracellular vesicles 
1.1.5.1 EV internalisation 
Much of the evidence for the internalisation of EVs arose from the presence of the 
EV cargo within recipient cells, however, the mechanism of uptake was not studied 
in parallel. Recognition and internalisation of EVs is likely to differ between cell 
types and perhaps also between EV subpopulations; as such, a variety of uptake 
mechanisms have been proposed. 
The initiation of EV uptake by a cell is likely to involve a receptor-ligand interaction 
between the EV and the target cell. Evidently, this may be extremely cell-specific 
and depend upon the origin of the secreted EV and the target cell, though a number 
of less specific interactions have also been described. PS exposure on activated T 
cell EVs was recognised by the anti-PS receptor on Mϕ. Consequent EV 
internalisation resulted in the accumulation of cholesterol and tumour necrosis factor 
(TNF)-α in the Mϕ, which may initiate the transition towards a foam cell (83). 
However, inhibition of PS did not completely prevent EV uptake suggesting 
alternative methods of uptake. Integrins have also been implicated in the engulfment 
of EVs. The presence of α4β1 integrins on endothelial progenitor cell (EPC)-derived 
EVs were essential for uptake by endothelial cells (84) and uptake of dendritic EVs 
was partially blocked by the inhibition of αvβ3 (85). The latter study also illustrated 
a role for tetraspanins in EV-cell recognition as blocking antibodies to CD9 and 
CD81 reduced EV uptake (85). Interestingly, the tetraspanin Tspan8 was shown to 
form a complex with the integrin α4 in EV membranes, both of which were then 
required for exosome internalisation (86). These results suggest that tetraspanins and 
integrins may have both isolated and concomitant roles in EV uptake. Proteoglycans, 
lectins and immunoglobulins have all been implicated in EV-cell interactions, 
though in more cell-specific circumstances (87). 
Following recognition of EVs by the target cells, internalisation ensues. The majority 
of studies analysing EV uptake suggest an active, endocytic mechanism of 
internalisation, of which, there are several pathways (87). The most studied of these 
pathways is clathrin-mediated endocytosis, which involves an intracellular 
accumulation of clathrin-coated vesicles in the target cell which assemble to cause 
invagination of the plasma membrane and endocytosis of the EV. Inhibitors of 
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clathrin-mediated endocytosis can stem EV uptake including chlorpromazine (88–
90) which inhibits clathrin-coated pit formation, or silencing of dynamin 2, (90,91) a 
GTPase required for endocytic vesicle formation and cleavage. 
Endocytosis of EVs can also be mediated by lipid raft-associated calveolae, which 
form small chasms in the plasma membrane (87). Knockdown of Calveolin-1, a key 
component of calveolae , suppresses internalisation of EVs (92). This study also 
showed that dynamin inhibition reduced EV uptake, though this may have been due 
to blockade of clathrin-mediated endocytosis.  
Phagocytosis of EVs has also been proposed as a mechanism for EV internalisation, 
particularly of larger EVs (21) and more so by professional phagocytes (93). 
However, exosomes were rapidly internalised by Mϕ suggesting smaller vesicles 
may also be phagocytosed (93). Interestingly, this study also showed that dynamin 2 
was required for exosome phagocytosis, illustrating the parallels between different 
endocytic mechanisms. Dendritic cells (DCs) have also been shown to phagocytose 
EVs as EVs were labelled and tracked to the phagosome of the target cell and the 
content of EVs was later detected in the cytosol (94). 
Finally, endocytosis of EVs has been shown to occur via macropinocytosis, which is 
often utilised by the cell to sample the extracellular milieu. Macropinocytosis occurs 
in a phagocytosis-like manner, though the process is constitutive and not targeted 
(87). Microglia were shown to employ macropinocytosis to internalise 
oligodendrocyte EVs as inhibition of macropinocytosis-associated proteins, Rac-1 
and the Na
+
/H
+
 exchanger, inhibited uptake of EVs. 
Direct membrane fusion has also been suggested as a non-endocytic mechanism of 
EV internalisation in a process that may resemble the fusion of MVBs with the 
plasma membrane (Section 1.1.3.1). Metastatic melanoma cell EVs were internalised 
into melanoma cells by direct fusion, a process which was enhanced when EVs were 
isolated from acidic melanoma cells (95). This suggests the tumour 
microenvironment can release EVs which are more efficient in being internalised 
into cells and therefore have a greater metastatic potential. Furthermore, Mϕ-derived 
EVs were shown to fuse with activated platelets and induce coagulation via the 
transfer of tissue factor (TF) (96). 
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It seems that cells may utilise several different mechanisms to recognise and 
internalise EVs, though the significance of each particular mechanism is not 
currently understood. The pathway of internalisation may perhaps be determined by 
the initial interaction of the EV with the cell, which is likely to be affected by 
receptors and ligands carried by the EV. 
 
1.1.5.2 Intracellular trafficking of EVs  
With the exception of direct fusion of EVs with target cells, the uptake of EVs 
appears to leave the EV intact, and hence the EV cargo remains contained within the 
endocytosed EVs. Indeed, endothelial-derived EVs endocytosed by human umbilical 
vein endothelial cells (HUVECs) were visualised by confocal microscopy as intact 
vesicles (97). This suggests that the EV membrane undergoes intracellular 
degradation to liberate the delivered EV cargo. Fusion of EVs with the limiting 
membrane of endosomes has been illustrated using the lipid mixing probe R18, 
which quenches to form a fluorescent probe upon fusion with an unlabelled 
membrane (94,98). Furthermore, endocytosed tumour cell EVs were shown to 
demonstrate two distinct forms of intracellular translocation (98). The “confined 
mode” of movement was associated with diffusion into the cytoplasm whereas the 
“rapid directed mode” was associated with an active movement of EVs along 
microtubules or actin filaments. Transport of endocytosed glioblastoma EVs were 
also visualised along microtubules using live confocal imaging (99). Recent data 
presented at the ISEV annual meeting (100) (Washington DC, 2015) by Hartjes et 
al., (O-6C-1) demonstrated the uptake and translocation of individual fluorescently 
labelled exosomes via microtubules using high speed spinning disk microscopy. 
 
The development and application of more sophisticated microscopy techniques to 
visualise the uptake and intracellular trafficking of EVs is likely to further our 
understanding of the fate of EVs within target cells. However, from the diversity of 
uptake mechanisms, it seems likely that intercellular communication via EVs is 
highly specific to the cell types involved. 
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1.1.6 Pre-analytical processing 
The rapid growth of EV research proposes exciting functional prospects of EVs, but 
data must also be reviewed with a degree of circumspection. The diversity of 
biological fluids analysed combined with different levels of experience in working 
with EVs and the variety of isolation procedures employed, highlights the lack of 
consistency in pre-analytical processing of EVs. Consequently, a position statement 
from ISEV was issued in 2014, highlighting a need for researchers to meet a set of 
“minimal requirements” for the classification of an EV population (16). The 
requirements include the presence and absence of particular markers and techniques 
that should be used in combination to claim the presence of EVs (Table 1.1.2). 
 
1.1.6.1 Sample collection and handling  
Sample collection for EV processing will ultimately depend on the starting 
biological fluid. Due to the nature of data presented in this thesis, only the 
processing of blood and culture medium will be covered in detail, though processing 
of EVs from other biological fluids has been reviewed elsewhere (17). 
Blood is a complex biological fluid and therefore, there are many stages at which 
variation could be introduced. Before blood is drawn from a patient or individual, a 
full history should be taken to collect information on age, sex, ethnicity, 
medications, health complications and potentially anthropometric and biochemical 
measurements such as weight, height, blood glucose etc. depending on the study. 
The fasting or fed state of the individual may be important to establish, due to 
postprandial elevations in circulating lipoproteins and chylomicrons, which fall 
within the same size range as EVs. A postprandial increase in EV concentration has 
also been observed (101,102) suggesting a fasted state may be better for EV isolation 
to avoid a false overestimation of EV concentration. The time of sample collection 
may also be important to consider as the activation of platelets, one of the major 
sources of EVs in the blood, varies throughout the day (103). Interestingly, TF
+
 EVs 
follow the same pattern of variation throughout the day, peaking at 9am (104). 
Therefore, EV samples should be collected after this time to minimise false 
estimations of platelet-derived EVs.  
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Requirement Examples 
 
Evidence of transmembrane or lipid-
bound proteins derived from 
extracellular membranes 
(Present or enriched in EV fractions) 
Tetraspanins (CD9, CD63, CD81) 
Integrins or cell adhesion molecules 
Growth factor receptors 
Heterotrimeric G-proteins 
Phosphatidylserine-binding proteins (MFG-
E8, annexin V) 
Evidence of cytosolic proteins with 
membrane- or receptor-binding 
capacity 
(Present or enriched in EV fractions) 
Endosomal proteins (TSG101, Alix, Rab 
GTPases) 
Signal transduction or scaffolding proteins 
(syntenin) 
Lack of non-endocytic intracellular 
proteins  
(i.e. proteins not directly related to 
EV biogenesis, associated with other 
intracellular compartments) 
Endoplasmic reticulum proteins (Grp94, 
calnexin) 
Golgi proteins (GM130) 
Mitochondrial proteins (cytochrome c) 
Nuclear proteins (histones, argonautes, RISC 
complexes) 
Cell-specific extracellular proteins 
that may bind specifically or non-
specifically to EV membranes 
(Variable association with EVs 
depending on cell type) 
Acetylcholinesterases 
Serum albumin 
Extracellular matrix proteins (fibronectin, 
collagen) 
Soluble and secretory proteins (cytokines, 
growth factors, matrix metalloproteinases) 
Indication of heterogeneity Electron microscopy or atomic force 
microscopy images of individual EVs and 
multiple EVs 
Size distribution measurements Nanoparticle tracking analysis or tunable 
resistive pulse sensing measurements of the 
size and concentration distributions of EVs 
to correlate with microscopy images 
Table 1.1.2: ISEV minimal requirements. Details of the minimal requirements 
outlined by ISEV for the classification of an EV population.   
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The processing of blood for EV isolation presents a number of important 
considerations, primarily because circulating platelets are easily activated, causing a 
release of EVs in vitro. The type of needle, vacutainer and time between collection 
and processing may all influence EV concentration. Shear stress may be higher in 
smaller gauge needles due to an increased pressure, however, no differences were 
observed between 19 and 21G needles on EV concentration (60) and these diameters 
are frequently used in the literature. A slow, gentle removal of blood into a syringe is 
recommended to minimise shear stress activation of platelets and the first 2-3 mL of 
blood are then usually discarded to avoid contaminating factors resulting from 
vascular injury (60). Previously used anticoagulants for EV isolation have included 
protease inhibitors such as heparin sulphate and hirudin, and calcium chelators such 
as sodium citrate, ethylenediaminetetraacetic acid (EDTA), acid citrate dextrose 
(ACD) and citrate-theophylline-adenosine-dipyridamole (CTAD). Unfortunately, 
only 2 studies have directly compared the effects of anticoagulants on EV 
concentration. Both studies found an increased concentration of EVs with the use of 
protease inhibitors compared to chelating anticoagulants (59,60). However, the 
authors of each study reached different conclusions as to the observed difference in 
EV concentration. Jayachandran et al., concluded that chelating anti-coagulants 
caused EVs to bind to platelets in whole blood, resulting in fewer EVs in the plasma 
that was later analysed for EVs (following depletion of platelets) (59). Conversely, 
Shah et al., hypothesised that the anticoagulant properties of chelating anticoagulants 
were superior to those of protease inhibitors, resulting in a greater platelet activation 
and ex vivo generation of EVs in blood collected in protease inhibitor anticoagulants 
(60). The correct conclusion remains a mystery as neither of the authors provided 
evidence for their theory. However, Jayachandran et al., did observe a reduction in 
endothelial-derived EVs with chelating agents but not with protease inhibitors. 
Endothelial cells are not present in the circulation and therefore, ex vivo generation 
of endothelial EVs is unlikely, suggesting protease inhibitor anticoagulants may 
provide a truer reflection of circulating EVs than chelating agents. The use of 
heparin for downstream EV analyses has however, been advised against (17). 
Heparin sulphate has inhibitory effects on the polymerase chain reaction (PCR) 
(105) and is therefore unsuitable for mRNA and mIR analysis using blood-derived 
EVs. Moreover, heparin sulphate was an effective inhibitor of EV internalisation into 
recipient cells (106), suggesting heparin sulphate should not be used if functional 
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interactions of EVs with target cells are being studied. Additional comparisons of the 
effects of anticoagulants on EVs are needed to decipher the optimal reagent. These 
comparisons should be accompanied by functional evidence of the negative effects 
of other anticoagulants (e.g. proof of EV-platelet binding with calcium-chelating 
anticoagulants) and should preferably not use FC for enumeration of EVs (see 
Section 1.1.7.2). 
The length of time following collection of blood should also be considered. A time-
dependent increase in EV concentration has been reported following blood collection 
which was attributed to ex vivo microvesiculation of blood cells (107,108), however 
others have observed no differences in EV counts (59,109). Despite conflicting 
results, it may be best to process samples immediately after venepuncture to avoid 
the risk of misleading data. At the very least, the time between sample collection and 
processing should be kept consistent between samples and experiments. 
EVs isolated from cell lines in culture are released directly into the surrounding 
medium and therefore provide a pure source of EVs from a specific cell type. 
However, there are a number of important points to consider when using cultured 
cells for EV analysis. Firstly, the time of incubation used to generate EVs. Twenty-
four hour incubation with fresh medium is the most widely used incubation time as 
this is often optimal in allowing enough time for sufficient EV generation; though, 
both shorter and longer incubation times have been used (110–112). Secondly, the 
modification or exclusion of foetal calf serum (FCS) or other serum from the media 
for the incubation period is commonly used as serum contains an abundance of EVs 
that are morphologically similar to EVs analysed with EM and nanoparticle tracking 
analysis (NTA) (113). Serum-derived EVs not only contaminate the EV population 
of the cultured cells but may also affect downstream functional assays using EVs. 
FCS-derived EVs stimulated migration of lung epithelial cancer cells (113). 
However, serum-depleted or –starved media has been shown to reduce cell growth 
(114) and to change the size, concentration and protein composition of EVs 
(115,116). Therefore, it is important to first establish that serum-deprived or –free 
media has no effect on cell viability to ensure cellular stress is minimised. Cells that 
do not survive in serum-depleted or –free media may be supplemented with 1% 
(w/v) bovine serum albumin (BSA) (117).  
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1.1.6.2 Methods of EV isolation 
A number of techniques are currently employed to isolate EVs including differential 
centrifugation, density gradient ultracentrifugation, size exclusion chromatography 
(SEC), immunoaffinity capture assays, filtration and commercially available 
products such as ExoQuick™; or a combination of several of these methods. The 
method employed usually reflects the EV population being studied and/or the 
downstream application. 
Differential centrifugation requires a number of sequential centrifugation steps (often 
with increasing centrifugal force) and is one of the most popular techniques for EV 
isolation. The number and speed of centrifugation steps may vary between groups 
and especially between biological fluids. Typical differential centrifugation of EVs 
from blood and conditioned culture medium are summarised below (Figure 1.1.6). 
 
Figure 1.1.6: Differential centrifugation. Typical differential centrifugation steps used to 
isolate EVs from blood and conditioned culture media. Number of steps, centrifugal force 
and times may vary between groups and biological fluids.  
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The popularity of differential centrifugation as an isolation technique may be due to 
its simplicity and short preparation time. However, several limitations are associated 
with differential centrifugation. For instance, the final ultracentrifugation step may 
pellet some soluble material in the remaining supernatant. Therefore the preparatory 
spins prior to ultracentrifugation are crucial to remove contaminating artefacts such 
as platelets and cell debris. Supernatants, particularly those derived from blood, are 
likely to contain a mixture of lipoproteins and soluble proteins as well as EVs 
(21,118,119) which may co-pellet following ultracentrifugation. Ultracentrifugation 
may also alter the physical properties of EVs by inducing EV aggregation with 
protein complexes (117,120), fusion with other EVs (11,121), and increasing PS 
exposure (122) which may lead to erroneous results. Therefore, differential 
centrifugation is proposed as an enrichment method rather than a purification method 
for EV analysis. Calculating the ratio between the number of vesicles and the amount 
of protein detected in the EV sample was recently suggested as a simple method of 
determining EV sample purity (123).  
Alternatively, successive filtration of EVs has long been used as a less vigorous 
method of purification (124). A number of studies have applied the use of simple 
submicron filters to remove larger vesicles and protein aggregates 
(58,59,110,117,123). However, it is unknown whether any interaction occurs 
between the EV and the filter and whether the higher concentrations of EVs 
observed post-filtration are due to increase purity, or deformation and disintegration 
of EVs by the filter. More sophisticated filtering systems have used to separate  free 
protein from EVs such as tangential flow filtration (TFF), in which samples are 
passed through a hollow fibre 500 kDa filter (124,125) or ultrafiltration which 
combines centrifugation and filtration (typically a 100 kDa filter) (126,127). 
Filtration is often then combined with other techniques such as differential 
centrifugation or density centrifugation to aid purification.  
Density gradient ultracentrifugation is regarded as the current “gold standard” EV 
isolation technique as it allows EVs to be separated from protein contaminants which 
are denser, and EVs can also be validated to their expected density (1.13 – 1.19 g/mL 
for exosomes (128) and 1.03 – 1.08 g/mL for microvesicles (129)). EVs sediment at 
the point where their density is equal to that of the surrounding media. Each density 
fraction can then be probed for EV markers to confirm enrichment (Figure 1.1.7) 
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and then be pooled for further analysis. Sucrose (64,66,74,128,130) or iodixanol 
(106,131,132) are often used as mediums for density ultracentrifugation of EVs. The 
process is typically longer than differential centrifugation (Figure 1.1.6) taking up to 
16 hours (117) and is usually performed overnight (17). Interestingly, EVs separated 
by density gradient ultracentrifugation have usually first been pelleted by differential 
centrifugation. Density separation is then used to improve the purity of the EV 
sample for downstream analyses. However, lipoproteins have similar densities to 
EVs, suggesting EVs isolated by density ultracentrifugation may still be 
contaminated with lipoproteins. Moreover, EVs are still exposed to the initial 
ultracentrifugation and therefore may have been fused or damaged before loading 
onto the density gradient. Pooling of specific EV fractions may also introduce a 
selective bias towards a certain EV population, causing others to be discarded. 
 
Figure 1.1.7: Density ultracentrifugation enrichment of EV markers. Example data of 
EVs separated by density ultracentrifugation and probed for (A) the generic EV marker, 
CD9, using FC and latex beads and (B) for the exosomal marker, TSG101 using Western 
blot. Data are courtesy of Dr Joanne Welton (Cardiff Metropolitan University). 
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The application of SEC as a novel EV isolation technique has been relatively well 
received as prior ultracentrifugation processing may not be required. SEC, also 
termed gel filtration, separates particles based on their relative size to porous 
polymer beads packed into a column (133) (Figure 1.1.8).  
SEC columns have been tested for plasma-derived EV isolation by directly adding 
isolated plasma to columns packed with Sepharose CL-2B (118,119,134–136), 
Sepharose CL-4B, Sephacryl S-400 (134) or the commercial qEV column (126) 
(IZON Science, NZ). Most columns used a 10 mL bed volume collecting 500 μL 
elution fractions following loading of 1-1.5 mL plasma (depleted or free of platelets). 
All studies found SEC successfully separated EVs in distinct fractions to the 
majority of serum proteins such as albumin by enrichment of tetraspanins, cleaner 
transmission EM (TEM) images and good particle to protein ratios. Two studies also 
illustrated a successful separation of lipoprotein makers (118,135) from EVs 
following SEC, however this was not reproducible in other studies that measured 
lipoprotein markers (119) and in our own pilot experiments (unpublished 
observations). Muller et al., observed that SEC had no effect on the ability of cancer 
exosomes to immuno suppress CD4
+
 T cells (136) indicating EVs isolated by SEC 
retain their functionality. This is also important to demonstrate the effect is due to 
the EV itself rather than co-pelleted contaminants. The relative potential of SEC for 
EV isolation is reflected in the marketing of two commercial SEC columns 
specifically for EV isolation: Exo-Spin™ Midi Columns (Cell Guidance Systems, 
UK) and qEV™ (IZON Science, NZ). However, further optimisation of SEC is 
needed to improve separation from lipoproteins and to design a repeatable workflow. 
The labour-intensiveness and time of fraction collection could be reduced following 
optimisation, by pooling fraction collection into larger volumes (119,135,136). 
However, this may also introduce bias through the selection of specific fractions and 
EV populations. Due to the relatively small volume loaded in comparison to the bed 
volume, dilution of signal could be a limitation of SEC, particularly for less 
abundant markers. Welton et al., experienced difficulties in concentrating eluted 
fractions back up for subsequent analysis (119). Furthermore, dilution of signal in 
combination with the pooling of fractions may make it difficult to relate the 
measured concentration of EVs to that in circulating plasma. 
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Figure 1.1.8: Principle of SEC: SEC columns are usually prepared in 10 mL syringes by 
pouring the matrix (commonly Sepharose) and allowing it to pack under gravity. Complex 
biological fluids such as plasma containing a heterogeneous mix of EVs, proteins and 
lipoproteins can then be added directly onto the SEC column. Larger particles are unable to 
pass through the pores in the beads and so pass quickly through the column, whereas smaller 
particles are able to pass through the pores, therefore taking longer to elute. Fractions can 
then be collected at set intervals (volume or time) and analysed for protein markers, EV 
concentration and lipoprotein markers to monitor the progress of the sample through the 
SEC column.  
 
Immunoaffinity isolation of EVs involves the coupling of an antibody of interest to 
magnetic beads (or beads that are pelleted at relatively low centrifugal forces). The 
beads are then incubated with EVs which bind to the antibody-bead complex and the 
beads can be subsequently removed from unbound EVs and contaminants by a 
magnet or low speed centrifugation. The technique is well characterised for cells and 
was first demonstrated for EV isolation using exosomes bearing MHC II in 2001 
(137). Despite the demonstration of successful isolation of EVs without the need for 
high-speed centrifugation using a quick, simple method, the use of immunoaffinity 
isolation has been slow to catch on in the EV field. Recently, magnetic beads were 
used to isolate TF
+
 EVs from plasma (138) and annexin V positive EVs isolated by 
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immunoaffinity were then used for downstream analysis of EV RNA (139). 
Antibody-coated beads have also been used to capture EVs for flow cytometric 
measurements as often the bead is ~1 – 10 μm in diameter (140). This overcomes the 
major limitations of using FC for EV measurements (Section 1.1.7.2) and also allows 
for dual staining of EVs. However, immunoaffinity assays isolate specific 
populations of EVs and may therefore bias towards certain EV subsets. Furthermore, 
recovery may not be 100% efficient and therefore downstream analyses may be 
underestimated.  
Commercial techniques for EV isolation are also available including SEC-based 
methods, ExoSpin™ and qEV™, and the precipitation technique, ExoQuick™ 
(System Biosciences, USA). The exact mechanism of action of ExoQuick™ has not 
been disclosed though the process uses a polymer to precipitate exosomes directly 
from biofluids such as plasma using a mixture of specific reagents and low speed 
centrifugation (141). ExoQuick™ has been reported to provide superior isolation of 
exosomal RNA and proteins compared to ultracentrifugation, SEC and 
immunoaffinity-based methods (142) however, other studies have indicated low 
enrichment of EV markers and high contamination of non-EV protein with 
ExoQuick™ isolations (126,141). Therefore, commercial isolation techniques such 
as ExoQuick™ should not be used without prior validation of sufficient EV 
purification. 
A summary of the methods outlined above with respective advantages and 
disadvantages is given in Table 1.1.3. Irrespective of the protocol used for EV 
isolation, the method must first be validated for the biological fluid and shown to 
fulfil the minimal requirements outlined by ISEV to confirm the isolation of a true 
EV population (16).  
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Method Subpopulation isolated Advantages Disadvantages 
Differential 
centrifugation 
Exosomes 
Microvesicles 
EVs 
→ Fast 
→ Little training required 
→ Enriches EV markers 
→ Can be adapted to remove larger 
microvesicles/isolate only exosomes 
→ Crude separation of EVs (contamination 
from soluble protein and lipoprotein) 
→ May cause EVs to fuse 
→ May increase PS exposure 
Filtration 
(including tangential 
flow filtration (TFF)) 
Exosomes 
EVs 
→ Fast and simple 
→ Remove protein contaminants (TFF) 
→ Unknown interaction of EVs with filter 
→ May require additional purification 
steps 
Density gradient Exosomes 
Microvesicles 
EVs 
→ Separation from protein contaminants 
→ EVs can be verified by density 
→ Lengthy procedure 
→ Requires training 
→ May not separate lipoproteins 
→ May require additional processing 
Size exclusion 
chromatography 
(including qEV™ and 
ExoSpin™) 
Exosomes 
Microvesicles 
EVs 
→ Fast and simple 
→ Requires minimal pre-processing 
→ Separation from protein and potentially 
lipoprotein contaminants 
→ Labour-intensive 
→ Sample diluted by column so may 
require concentration afterwards 
→ Workflow needs refining and further 
validation of homemade and 
commercial columns needed 
Immunoaffinity Exosomes 
Microvesicles 
EVs 
→ Fast and simple 
→ Allows isolation of specific sub 
population 
→ Recovery may not be 100% 
→ May bias towards specific population 
→ Needs further validation 
ExoQuick™ Exosomes → Fast and simple → Impure isolation 
→ Low enrichment of exosomes 
Table 1.1.3: Summary of methods of EV isolation. Current methods employed for EV isolation and their respective advantages and disadvantages.
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1.1.6.3 Storage of isolated EVs 
For EVs to serve as clinical biomarkers in large-scale studies or routine diagnostic 
analyses, storage of EV samples is paramount. Therefore, optimal storage vessels, 
medium, method and length must be established to minimise changes in EV profiles. 
Though a number of studies have reported differences in EVs when varying storage 
parameters, results are often conflicting and as such, no standardised protocols are in 
place for EV storage. Furthermore, many of these studies have been undertaken 
using FC to enumerate EVs, which as discussed in Section 1.1.7.2, is sub-optimal.  
The material of the storage vessel has been proposed to affect EVs as certain plastics 
may cause EV aggregation and adherence to the vessel. Silicone storage vessels have 
been suggested as an alternative (17), however no physical evidence exists in the 
literature demonstrating the effect of storage material on EV characteristics. The 
most widely-used medium for EV resuspension and storage is phosphate buffered 
saline (PBS) (117). Recent advice suggests the PBS must be completely free of 
calcium to avoid formation of calcium phosphate complexes (16), which are in the 
same size range as EVs and may therefore skew size and concentration analyses. 
Other solutions have also been used to store EVs, including 4-(2-hydroxyethyl)-1-
piperazineethanesulphonic acid (HEPES), water, dimethyl sulphoxide (DMSO) and 
glycerol (16). DMSO and glycerol, commonly used in the cryo-freezing of cells, 
reportedly cause partial lysis of EVs (143); however, our own observations with 
glycerol do not marry with this (P8B-301) (144). Storage mediums should also be 
filtered (using a 0.22 μm filter) to remove any EV-sized contaminants prior to 
resuspension of EVs, or a commercial sterile medium should be purchased. 
Analysis of EV samples on the same day as isolation is often not feasible, 
particularly if a lengthy isolation procedure is used. Therefore, it is important to 
understand the impact of the method and of short- and long-term storage on EV 
characteristics. Although a number of studies have analysed the effects of storage on 
EVs, much of the data are contradictory, making it difficult to interpret the “best 
option”. Studies have illustrated that EV isolation from the biofluid before storage is 
optimal, particularly with blood-derived samples. Plasma frozen prior to EV 
isolation contained a greater contamination of protein aggregates in subsequent EV 
isolations (136). Additionally, storage of platelets at -80°C resulted in an increased 
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concentration of platelet-derived EVs with a reduced diameter and a greater 
thrombin-generation (procoagulant) capacity (145,146). 
Currently, most studies store samples at -80°C in PBS (17). Concentration, 
functionality (143) and EV diameter were shown to be unchanged following storage 
at -80°C and repeated freeze-thaw cycles also had no effect on EV size (147) 
suggesting stability of EVs at this storage temperature. Furthermore, small RNAs 
within EVs were stable following 1 month of storage at room temperature and also 
following 20 freeze-thaw cycles at -80°C (110). The size, concentration and 
morphology of EVs from conditioned culture medium, platelet and erythrocyte 
concentrates and urine were also unaffected by storage at -80°C (109). 
Conversely, others report that storage of EVs at -80°C resulted in an immediate 
decrease in diameter of EVs and a gradual (>2 months storage) degradation of EV 
RNA (148). Ayers et al., observed increases in annexin V and platelet-positive 
(CD41+/CD31+) plasma EVs following 1 month storage at -80°C (107), supported 
by Yuana et al., who reported an increase in lactadherin-positive EVs following 
storage at -80°C (109). Storage of EVs at -80°C with repeated freeze-thaw cycles 
also reduced the EV RNA (139). Long-term storage was also detrimental to the 
concentration of plasma-derived EVs which was significantly decreased between 1 
(59) and 2 years of storage at -80° C (107). Storage of EVs at temperatures above 
freezing has also been shown to have conflicting effects on EV characteristics. 
Storage of EVs at 20°C or 4°C for >1 week resulted in decreased EV concentration 
and a loss of functional activity (143). The diameter of EVs was also rapidly reduced 
following storage at 37°C, and to a lesser extent at 4°C (147). However, others have 
observed stability in EV concentrations following storage at room temperature for 4 
days (59). 
 
There are evidently many problems regarding the pre-analytical processing of EVs 
and few concrete solutions to these issues from which to design a protocol. Until 
more is known about the effects of EV processing steps, consistency between 
samples and experiments and complete clarity in reporting methods are paramount to 
enable comparisons with the rest of the field.   
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1.1.7 Measurement 
A variety of optical and non-optical techniques are available for the measurement of 
EVs, and the chosen technique often reflects the desired outcome or application. 
TEM is commonly used to determine the ultrastructure, FC to analyse surface 
phenotypic makers, and NTA to quantitate the size and concentration of EVs (149). 
 
1.1.7.1 Methods for determining EV morphology  
The minimal requirements outlined by ISEV (16) (Table 1.1.2) indicate a need for 
visual evidence of individual and multiple EVs in samples. TEM is the most widely-
used technique to visualise EV structure; originally described as a “cup-like 
morphology” though this has since been shown to be an artefact of TEM preparation 
(117). Heavy metals such as uranyl acetate allow staining of lipid membranes, and 
these are visualised following fixation and dehydration onto grids (17). EVs can also 
be stained with antibodies (such as CD63) coupled to nano-gold particles to allow 
further confirmation of an EV population (150). Cryo-EM may relinquish the need 
for dehydration and fixation by fast-freezing EV samples, and has recently identified 
a number of different EV structures such as “vesicle-within-vesicle” structures (151). 
Atomic force microscopy (AFM) is also used to visualise EV structures by scanning 
the surface of EVs without contact, using deflections of a directed laser beam to 
build a 3D image with nanometre resolution (108,152). EVs are bound to a flat 
surface onto which antibodies can also be conjugated, allowing the application of 
immuno-detection to analyse specific EV populations (152). 
Though size distributions and structures of EVs can be visualised by TEM and AFM, 
EV concentration cannot be calculated and experiments may take hours to conduct. 
 
1.1.7.2 Phenotyping EVs 
Perhaps the most interesting aspect of EV research is the analysis of the markers 
carried by EVs, and particularly how these may change in disease. Once again, the 
ISEV minimal requirements outline the need for analysis of EVs to show the 
presence of certain markers and the absence of others (Table 1.1.2). FC is the most 
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widely used technique for both qualitative and quantitative EV measurements. 
Samples are introduced into the system surrounded by a fluid sheath which then 
directs the sample through a laser beam (Figure 1.1.9). The constituents of the 
sample (usually cells) scatter light forwards depending on their size (forward scatter) 
and sideways depending on their granularity (side scatter). Both scatter profiles are 
collected by detectors and used to create a dot plot from which samples can be gated 
to allow enumeration of particles within the sample. Additionally, specific antibodies 
can be used bearing a fluorochrome which is excited by a certain laser to allow 
quantification and phenotyping of subpopulations. Multiple antigens can be analysed 
simultaneously by using different lasers and antibody-fluorochrome combinations, 
providing fluorochrome emission spectra do not overlap.  
Unfortunately, the use of FC for EV analysis is hampered by a number of 
limitations. Many conventional flow cytometers are unable to detect EVs <300 nm in 
diameter, which is the range in which most EVs fall (120). This is due to the low 
refractive index of EVs (149) meaning the majority of EVs fall within the noise of 
the cytometer. Furthermore, the gating of EV populations is usually based on the 
forward and side scatter properties of submicron polystyrene beads (17,149). The 
refractive index of a 200 nm polystyrene bead can be up to 15 times higher than that 
of an EV of equal diameter (149) leading to false comparisons of size between beads 
and EVs, as EVs would scatter less light and appear to be smaller. Silica beads 
reportedly have a refractive index more akin to that of EVs than polystyrene and may 
be more representative for EV gating (153). The limited diameter of EVs also 
prevents the flow cytometer from efficiently sorting EVs into a single particle stream 
for individual analysis, meaning individual EV counts may be the result of “swarm” 
detection (multiple EVs) (154). 
Steps have been taken to improve the flow cytometric detection of EVs such as high 
resolution FC which may detect EVs ~100 nm in diameter (155) though this requires 
expensive machinery and an experienced user. Alternatively, similarly to 
immunoaffinity isolation (Section 1.1.6.2), EVs can be conjugated to latex beads (>1 
µm in diameter) carrying an antibody to a marker of interest (117), e.g. CD9. EVs 
bound to the beads are then within a detectable range for analysis and can be probed 
with further antibodies. 
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Figure 1.1.9: Flow cytometry. A schematic illustrating the mechanism of FC. The sample 
(e.g. cells) is drawn into the machine and surrounded by sheath fluid. The fluid and the 
shape of the tube allow the hydrodynamic focusing of the sample into a stream of single 
cells. Individual cells then pass through a laser and the resulting forward and side scatter are 
collected by positioned detectors. Scatter profiles can then be plotted and gated (right). 
 
Western blotting and quantitative real-time (qRT)-PCR are also useful techniques for 
analysing the protein and RNA content of EVs. Western blots are frequently 
presented alongside density ultracentrifugation data to provide evidence for 
enrichment of EV proteins in the correct density fractions (Figure 1.1.7). More 
sensitive proteomic techniques (primarily using MS) can be applied to EVs that are 
able to simultaneously analyse an array of proteins to highlight potential biomarkers 
(156–158). Microarray analysis can also be used to analyse a wide variety of RNA 
species in EV samples to highlight potentially interesting changes in specific 
mRNAs and mIRs (76). Lipid species (lipidomics) of EVs can be identified using 
GC alone (55,76,159) or combined with MS (GC-MS) (78). Generally, large-scale 
analyses of EVs are useful to analyse a range of markers within EVs and may 
highlight potential biomarkers of interest for further study. However, due to the 
amount of data generated by these methods, great care should be taken with data 
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interpretation and an experienced user should be consulted. Markers of interest 
should then be validated using Western blot or qRT-PCR to confirm results. These 
types of techniques are usually expensive and time-consuming.  
Immunophenotyping of EVs has been proposed as an alternative method to Western 
blotting that allows analysis of multiple antigens in synchrony (119,158). The 
principles of EV immunophenotyping are shown in Figure 1.1.10. EVs are settled 
onto high-binding enzyme-linked immunosorbent assay (ELISA) plates and probed 
for antibodies of interest. EVs may also be partially permeabilised to analyse 
antigens within EVs as well as surface markers. A biotinylated secondary antibody 
then allows binding of streptavidin-europium conjugates. The bound europium probe 
can then be dissociated from the streptavidin and excited at 340 nm by a series of 
flashes. The resulting fluorescence emission is monitored using time resolved 
fluorescence (TRF) and a narrow emission peak is produced with a large Stokes‟ 
shift and long decay time, thereby giving a good signal-to-noise ratio. The technique 
has been successfully applied to measure markers within prostate cancer EVs (158), 
plasma-derived EVs (119) and by ourselves in adipocyte-derived EVs (159). Though 
the technique requires initial efforts to validate EV and antibody concentrations, it is 
a promising simple and rapid technique for phenotyping multiple markers on the 
surface of and within EVs. 
 
Figure 1.1.10: Immunophenotyping of EVs. EV immunophenotyping is performed on 
high-binding ELISA plates. A primary antibody of choice can be added to the well and the 
same sample can be probed with other antibodies using remaining wells. A biotinylated 
secondary antibody is then added which allows binding of a streptavidin-europium 
conjugate. Flash excitation of wells allows generation of fluorescence which can then be 
measured in a plate reader with TRF settings.  
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1.1.7.3 Quantification of EVs 
The enumeration and accurate sizing of EV populations may also be important in 
comparing EVs between healthy and disease states. Several techniques have been 
used to determine the size and concentration of EV samples, each with their own 
advantages and limitations. Dynamic light scattering (DLS) measures the light 
scattered from EVs in suspension (i.e. under Brownian motion) and uses the 
information to determine EV size and concentration (143,160). However, the 
scattering of EVs is collected by a single detector (160,161), meaning the signal is 
averaged for the whole EV population. Therefore larger EVs scattering more light 
bias the average signal and potentially overestimate the overall size. For 
monodisperse populations such as exosomes however, DLS may produce relatively 
accurate size and concentration data.  
NTA is a technique which incorporates the principles of DLS but uses additional 
video tracking of EVs over time for detection. This overcomes the shortfalls of DLS 
by tracking the light scattering and Brownian motion of individual EVs over time to 
calculate EV size and concentration distributions. However, large EVs will still 
scatter considerably more light than smaller EVs, and hence may still dominate 
recordings. Analytical software settings have the potential to introduce subjectivity 
into EV analysis with NTA, though a recently published technical report provides 
advice on how to minimise sources of variation (162). Due to its simplicity and the 
relatively short sampling time, NTA is one of the most popular techniques for EV 
quantification. The addition of a syringe pump and more advanced software which 
can be programmed to continuously introduce samples into the viewing chamber 
allows measurement of replicates in quick succession (162) and reduces the input 
time of the user. NTA is also moving towards the measurement of fluorescently 
labelled EVs using different laser and camera attachments (161,163). A current 
limitation of NTA and other EV quantification methods is the inability to distinguish 
EVs from contaminating material such as protein complexes and lipoproteins. 
Although fluorescence NTA is not yet in routine use, it has great potential in 
combining the direct labelling of EVs with accurate size and concentration data. 
Tunable resistive pulse sensing (TRPS) is a non-optical method for determining EV 
size and concentration. TRPS measures the disruption in current generated by EVs as 
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they pass through a tunable nanopore that is suspended between two wells of 
electrolyte buffer (164). EVs are measured on a particle-by-particle basis, allowing 
data to be recorded for each EV traversing the pore. The magnitude of the blockade 
event (disruption in current) is proportional to the EV size and the frequency of 
blockade events is proportional to the concentration of EVs. TRPS has been used to 
accurately quantify EVs in a variety of biological fluids (55,165); however, issues 
with pore clogging and the need for multiple nanopores to cover the EV size range 
have perhaps prevented TRPS becoming as widely used as NTA. Furthermore, 
sample analysis is much more labour intensive than NTA as continuous monitoring 
is needed to identify pore blockages and (especially less concentrated) samples may 
take up to 10 minutes to record per replicate. However, a unique ability of TRPS is 
the measurement of EV surface charge from the duration of the blockade event 
(166). This may have interesting applications in the phenotyping of EVs based on 
changes in surface charge. Aptamers are single strands of nucleic acids (DNA or 
RNA) with high specificity and affinity to a target (e.g. protein) (164,167). Aptamers 
conjugated to beads and incubated with thrombin were shown to traverse the 
nanopore differently due to a change in surface charge from binding of thrombin to 
the aptamer-bead complex (167). This work was then extended using two aptamers 
(for vascular endothelial growth factor (VEGF) and platelet-derived growth factor 
(PDGF)) conjugated to beads of different sizes allowing multiplexing of samples 
(168). The combined use of aptamers for specific EV markers and TRPS may allow 
for simultaneous analysis of size, concentration and surface markers of EVs. 
 
Currently no “gold standard” technique exists for measurement of EVs, and the 
chosen technique is often dictated by the desired outcome. As with EV isolation, it 
seems that complete clarity in the methods used to analyse EVs is needed to enable 
comparison with the rest of the field. Users must also have a good understanding and 
be aware of the advantages and limitations of each analytical technique to avoid 
erroneous results. Clearly, most of the measurement techniques used for EVs are 
striving to improve their methods and capabilities, so it is hoped in the future that 
standardisation of EV measurements will be achieved.  
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1.1.8 Physiological roles of extracellular vesicles 
EVs from a variety of sources can be detected in a number of biological fluids of 
healthy individuals and have been recognised as important cell-cell communicators. 
The field has been dominated by pathological roles of EVs in disease, though it is 
clear that EVs are also important homeostatic mediators (Figure 1.1.11). 
 
1.1.8.1 Biodistribution of EVs 
The biodistribution of circulating EVs is dependent upon the ratio between EV 
biogenesis and EV clearance (169). Little is known about the half-life of circulating 
EVs, though a number of studies indicate the rapid clearance (within 30 minutes) of 
exogenously isolated EVs following re-introduction (170–172). EVs bearing a MFG-
E8-luceriferase label were cleared from the circulation within 2 minutes of injection 
(173). In vivo studies however, reported a much slower clearance from the 
circulation (~6 hours). EV internalisation by cells is likely to account for the 
majority of clearance, which is a cell-specific process, depending on the cellular 
origin of the EV and the target cell (Section 1.1.5).  
 
1.1.8.2 Role of EVs in haemostasis  
One of the most studied functions of EVs is their contribution to the coagulation 
cascade; primarily the role of platelet-derived EVs. Some of the earliest studies into 
EVs insinuated a procoagulant effect of platelet-derived EVs (1,2) and platelet-
derived EVs were recently shown to enhance thrombin generation in vitro (174,175). 
The exposure of PS on platelet-derived EVs provides a platform for the assembly of 
factors of the coagulation cascade such as Factors VII and X and prothrombin (176). 
However, flow cytometric analyses of PS exposure of platelet-derived EVs using 
annexin V or MFG-E8 indicates that not all EVs expose PS at their surface (63,177). 
TF is a potent stimulator of coagulation and has also been shown to be present in 
EVs (169). Interestingly, platelet-derived EVs seem to contain very little TF (169) 
suggesting EVs derived from other cell types contain procoagulant TF. Indeed, 
procoagulant EVs have been shown to be released from leukocytes, endothelial cells, 
monocytes (169), erythrocytes (178) and vascular smooth muscle cells (179). The 
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presence of TF within these EVs seems to be the reason for their procoagulant 
characteristics (176). Some studies suggest the presence of EVs with anticoagulant 
properties in the circulation, harbouring inhibitors of the TF pathway (180,181) and 
also those with a fibrinolytic phenotype (182). Interestingly, these subsets of EVs 
were not of platelet origin, indicating many of the haemostatic properties of EVs are 
not regulated by platelet-derived EVs. Furthermore, non-blood derived EVs such as 
those derived from saliva and urine, possess procoagulant properties. Salivary EVs 
were found to contain TF and were able to initiate coagulation in EV-free plasma. 
The authors hypothesised that the presence of procoagulant EVs in our saliva may 
explain why we lick wounds, in order to enhance coagulation and sealing of the 
wound from pathogens (183). 
The regulatory role of EVs in coagulation is illustrated by individuals with Scott 
Syndrome, who have lower levels of circulating platelet-derived EVs (184). A 
scramblase enzyme in the plasma membrane of platelets is mutated, preventing PS 
externalisation (185). These individuals are at an increased risk of severe bleeding 
due to a reduced ability of platelets and platelet-derived EVs to initiate coagulation. 
 
1.1.8.3 Role of EVs in angiogenesis  
EVs derived from a number of cell types regulate vascular cell growth. Endothelial 
cells were shown to generate EVs containing the Notch signalling ligand, delta-like 4 
(Dll4) which is crucial for the regulation of angiogenesis (186). These EVs were then 
shown to induce sprouting and branching of endothelial cells in vitro and in vivo. 
Platelet-derived EVs were also shown to contain pro-angiogenic lipids and VEGF 
which could induce endothelial cell proliferation and capillary sprouting in vivo 
(187). The transfer of phosphoinositide 3-kinase (PI3K) protein and mRNA from 
EPCs can stimulate angiogenesis in endothelial cells (84). Furthermore, EVs derived 
from hypoxic placental mesenchymal stem cells (MSCs) were shown to aid the 
adaptation of the placental vasculature to low oxygen (O2) concentrations by 
enhancing endothelial cell angiogenesis (188). 
 
Page | 41  
 
1.1.8.4 Role of EVs in the immune system 
EVs are also implicated in modulating cells of the innate and adaptive immune 
system. Polymorphonuclear neutrophils (PMNs) secrete EVs that promote an anti-
inflammatory phenotype in DCs and monocytes (189) and control the phagocytosis 
of apoptotic PMNs to promote resolution (190). Additionally, PMN-EVs impaired 
leukocyte adhesion and infiltration to endothelial cells, preventing subsequent 
leukocyte extravasation and initiation of tissue inflammation (191,192). EVs are also 
involved in antigen presentation. Intestinal epithelial cell-derived EVs harbouring 
MHC class I and II are able to transfer orally ingested antigens from the apical 
lumen to antigen presenting cells at the basolateral membrane of the gut epithelia 
(193,194). Antigen presenting cells can also secrete EVs carrying MHCs class I and 
II to present the antigen to T cells (195) showing EVs are heavily involved in 
modulating immune responses. MSC EVs harbour the same anti-inflammatory and 
immunosuppressive properties as MSCs (169) and were shown to induce Mϕ 
polarisation towards an M2 (anti-inflammatory) phenotype and enhance T regulatory 
(Treg) cell production. (196).  
 
1.1.8.5 Role of EVs in bone formation  
The role of EVs in bone formation was first documented over 40 years ago, 
providing one of the earliest examples for a physiological role for EVs (197). These 
EVs are often referred to as matrix vesicles, and they are required for the initiation of 
mineralisation (198). Matrix vesicles are secreted from chondrocytes in response to 
retinoic acid (199) and are enriched in Ca
2+
-binding proteins to promote transport of 
Ca
2+
 into the vesicle lumen and phosphatases to liberate phosphate (198). 
Accumulation of Ca
2+
 and phosphate within matrix vesicles leads to the formation of 
calcium-phosphate complexes (hydroxyapatite) (200). EVs then release 
hydroxyapatite into the extracellular matrix where further hydroxyapatite formation 
can occur in clusters around matrix vesicles and between collagen fibres leading to 
mineralisation (198). 
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Figure 1.1.11: Physiological roles of EVs. A summary of documented physiological roles of EVs in vivo. Ca
2+
 = calcium; DC = dendritic cell; Dll4 = delta-
like 4; EPC = endothelial progenitor cell; IEC = intestinal epithelial cell; MSC = mesenchymal stem cell; Mϕ = macrophage; PI3K = phosphoinositide 3-
kinase; PMN = polymorphonuclear neutrophil; PO4 = phosphate; PS = phosphatidylserine; TF = tissue factor; VEGF = vascular endothelial growth factor.  
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1.1.9 Pathophysiological roles of extracellular vesicles 
Despite the diversity of physiological roles for EVs, the vast majority of EV research 
is centred on the role of EVs in pathology. Altered concentrations and differences in 
biochemical composition in disease states make EVs promising biomarkers.  
 
1.1.9.1 EVs in cardiovascular diseases 
CVD is the global leading cause of mortality, accounting for over 30% of deaths 
worldwide in 2012 (201). CVD is an umbrella term for a number of disorders that 
afflict the heart and vasculature such as coronary artery disease (CAD). CVDs are 
multifaceted and often present alongside co-morbidities such as diabetes mellitus. 
EVs have been implicated in a plethora of CVDs and co-morbidities, a number of 
which are outlined below. 
In CAD, coronary arteries are occluded by fatty deposits in the artery wall, 
increasing the risk of myocardial infarction. Studies have found elevations in 
endothelial EVs in CAD (202,203), perhaps reflecting the underlying endothelial 
dysfunction. Endothelial EVs also displayed a procoagulant phenotype (202) and 
contained elevated CD144 (vascular endothelial cadherin) (204) which may indicate 
changes in endothelial cell permeability in patients with CAD. Endothelial EVs have 
also been shown to possess anti-inflammatory mIRs; mIR-216, involved in vascular 
repair, and mIR-222, which is able to reduce endothelial cell expression of 
intercellular adhesion molecule (ICAM)-1 and hence reduce leukocyte adhesion to 
endothelial cells (205). However, these mIRs were reduced in hyperglycaemic 
conditions, thus enhancing leukocyte adhesion and extravasation. Furthermore, EVs 
from hyperglycaemic endothelial cells induced endothelial dysfunction and increased 
Mϕ infiltration leading to subsequent development of atherosclerosis in vivo (206). 
EVs derived from atherosclerotic plaques were rich in ICAM-1 which could then be 
transferred to healthy endothelial cells to induce leukocyte adhesion and 
atherosclerotic plaque formation (207). Taken together, alterations in endothelial EV 
concentration and composition may provide an indication of CVD status. Indeed, 
endothelial EVs correlated with a subset of diabetic patients with no symptomatic 
evidence of angina, but with evidence of CAD on angiography (204). The 
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concentration of endothelial EVs from patients with high risk coronary lesions was 
over twice that of patients with low risk lesions. However, concentrations of 
endothelial EVs in patients with severe occlusions of the coronary artery were 
comparable with healthy controls (208). This suggests that endothelial EVs may be 
useful biomarkers of early CAD, before the development of severe stenosis.  
Age- or disease-related arterial stiffening increases the risk of CVD and mortality 
(209). Vascular calcification plays a major role in arterial stiffening and is often 
found in association with atherosclerotic plaques. Vascular smooth muscle cells 
(VSMCs) have been heavily implicated in calcification as they are able to transition 
towards a phenotype associated with bone formation (210). Physiological VSMCs 
release EVs enriched with osteogenic inhibitors such as matrix Gla protein (211) and 
fetuin-A (212). In conditions of endothelial dysfunction and/or conditions of 
elevated extracellular Ca
2+
/PO4, VSMC EV release is altered (213). These EVs 
contain low amounts of osteogenic inhibitors and high levels of Ca
2+
-binding 
annexins and PS that can initiate nucleation of hydroxyapatite (213,214). These EVs 
also contain specific mIRs that target markers of osteogenic differentiation (215) and 
matrix metalloproteinase-2, which assists calcification via degradation of elastin 
fibres (214). Therefore vascular calcification is mediated by EVs as in chondrocyte 
calcification and bone formation. However, VSMCs release EVs via the classical 
pathway (Section 1.1.3.1) as EVs contain exosomal markers and arise from MVBs 
whilst chondrocyte-derived EVs arise from a direct budding of the plasma membrane 
(216). Mϕ within atherosclerotic lesions are also capable of releasing EVs that 
promote local microcalcification (217). Interestingly, these Mϕ were also shown to 
possess an M1-like phenotype (217) suggesting a proinflammatory role for Mϕ in 
addition to calcifying capabilities. Microcalcification within atherosclerotic plaques 
causes the plaque to become unstable, hence increasing the risk of rupture and 
subsequent MI or stroke (218). A recent review of EV-mediated vascular 
calcification suggested that calcifying EVs are “erroneously caught in the ECM” and 
inadvertently induce microcalcification in vessel walls due to being trapped in the 
ECM (219). In light of the data presented here, this notion seems unfounded as it 
appears EVs produced by changes in the extracellular environment are specifically 
packaged with a cargo to deliberately induce an osteogenic phenotype in vessels. 
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Obesity is a major risk factor for CVD and has also been associated with an altered 
profile of circulating EVs. Studies have found increases in circulating EVs in 
“healthy” obese women (with no clinical presentation of CVD or diabetes) compared 
to healthy lean women (220,221). Increases in specific subsets of EVs such as 
platelet-EVs (220,222,223) and endothelial EVs (220,223–225) were also found in 
healthy obese subjects versus healthy lean controls. An increase in platelet-EVs was 
also observed in obese women with PCOS compared to age- and body mass index 
(BMI)-matched controls (226). However, this increase may not be due to obesity as 
others have found increases in annexin V positive EVs and platelet-derived EVs in 
PCOS women over a range of BMIs compared to age/BMI-matched controls 
(76,227). A number of studies have also observed reductions in platelet- and 
endothelial-derived EV concentrations in obese subjects following weight loss 
accompanied by a reduction in procoagulant markers (222,228,229) suggesting 
weight loss in apparently “healthy” but obese subjects, may have cardiovascular 
benefits. Further work is needed to analyse EVs associated with obesity, particularly 
those from other cellular sources. For example, our own group is currently analysing 
circulating EVs carrying inflammatory and adipocyte markers in a group of subjects 
across a range of BMIs. 
 
1.1.9.2 EVs in cancer 
The intercommunication of tumour cells with non-tumour cells via EVs is an 
intensely studied area of EV research. Tumour cells utilise EVs to promote tumour 
survival and progression through evasion of the immune system, modulating the 
tumour microenvironment and promoting angiogenesis for metastases.  
Remodelling of the extracellular milieu allows the tumour to control the 
microenvironment so that tumour growth, proliferation and angiogenesis are 
supported (230). Tumour cells can both release EVs and modulate the EV release of 
MSCs to reduce tumour suppression and promote tumour growth (231). Tumour cell 
EVs also assist tumour progression and angiogenesis by driving the transition of 
stromal fibroblasts towards a myofibroblast phenotype via transfer of transforming 
growth factor (TGF)-β and induction of α-smooth muscle actin expression (232). 
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Tumours also use EVs to avoid immune recognition, helping to establish the tumour 
in the early stages of growth. Tumour cells shed the ligand for the natural killer 
group 2D (NKG2D) receptor via EVs to reduce recognition and destruction of 
tumour cells by cytotoxic NK and CD8
+
 T cells (233). Transfer of TGF-β within 
tumour-derived EVs plays an important role in immune evasion by preventing 
dendritic cell antigen presentation (234) and encouraging the transition of CD8
+
 
cytotoxic T cells towards a regulatory T cell phenotype (235). Additionally, tumour 
EVs express Fas ligand on their surface which is able to bind to Fas
+
 lymphocytes 
and suppress their response (236), and induce lymphocyte apoptosis (237). 
The ability of tumours to induce neovascularisation enables tumour growth and 
enhances metastatic potential. EVs facilitate tumour-mediated angiogenesis through 
a number of mechanisms, usually by targeting VEGF expression. As described in 
Section 1.1.8.3, the Notch ligand Dll4 is carried by endothelial EVs and is essential 
for angiogenesis (186). Tumour EVs also harbour Dll4 and VEGF which stimulate 
local angiogenesis (238). Alternatively, tumour EVs were shown to carry a mutated, 
but functional form of the epidermal growth factor receptor (EGFR) (239). The 
mutated EGFR could be transferred to other tumour cells via EVs, increasing VEGF 
expression and oncogenic activity in these cells (240). These EVs could also be 
detected in the serum of glioblastoma patients, illustrating the mobility and 
metastatic potential of these EVs once in the systemic circulation. A major stimulus 
for tumour-mediated angiogenesis in vivo is hypoxia which results from rapid 
tumour growth. Secretion of EVs enriched in angiogenic proteins and mIRs is 
enhanced in hypoxic cancer cells in a hypoxia-inducible factor (HIF)-dependent 
manner (241). HIF proteins are able to regulate Rab22a which is involved in EV 
release. Inhibition of Rab22a abrogated tumour metastasis, highlighting the role of 
hypoxic-derived EVs in the co-ordination of tumour progression.  
 
1.1.9.3 EVs in inflammatory diseases  
In stark contrast to the immunosuppressive role of EVs in cancers, the general role of 
EVs in inflammatory disorders is immune-activating, highlighting the diversity of 
biological functions of EVs. EVs have been shown to possess auto-antigens that 
trigger and/or aid the progression of a number of autoimmune diseases such as 
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Rheumatoid arthritis (RA), systemic lupus erythematosus and multiple sclerosis 
(242). RA is an autoimmune disorder characterised by chronic inflammation of 
joints. Platelet-derived EVs have been strongly implicated in RA as circulating 
concentrations are elevated compared to healthy controls and the number of platelet 
EVs correlates with the severity of disease (243). However, very few platelet-derived 
EVs are detected within the synovial fluid of arthritic joints (244), suggesting a more 
systemic role for platelet-derived EVs in RA, perhaps by increasing the risk of CVD. 
Leukocyte EVs, particularly those derived from granulocytes were found to be the 
predominant EV population in RA synovial fluid (244,245). These EVs were highly 
annexin V positive and thrombogenic, suggesting a role in stimulating local 
coagulation and fibrin formation (244). Furthermore, these EVs enhanced the 
secretion of proinflammatory cytokines interleukin (IL)-8 and IL-6, and cytokines 
including monocyte chemoattractant protein (MCP)-1, soluble ICAM-1 and VEGF 
from synovial fibroblasts in an autologous fashion (245). Therefore, leukocyte EVs 
within synovial fluid may mediate and sustain inflammation within the arthritic joint. 
EVs were also shown to exacerbate inflammation caused by infectious diseases. Mϕ 
infected with Mycobacterium tuberculosis release EVs containing microbial antigens 
and pathogen-associated molecular patterns that induce an inflammatory response in 
uninfected Mϕ via toll-like receptor activation (246). Also, cells infected with the 
malaria parasite produce EVs that strongly stimulate Mϕ activation and TNF-α 
secretion, contributing to the systemic inflammation associated with malaria (247). 
Systemic inflammation from sepsis is also associated with increases in circulating 
platelet and endothelial-derived EVs. Injection of EVs from septic patients into mice 
induces proinflammatory cytokine production and oxidative stress, further 
highlighting the potential immune-activating roles of EVs (248). 
 
Evidently, EVs have a variety of different roles in the induction, progression and 
maintenance of disease pathology. Those covered here are summarised in Figure 
1.1.12. 
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Figure 1.1.12: Roles of EVs in disease. A summary of the potential roles of EVs in cardiovascular diseases, cancers and inflammatory diseases. CAD = 
coronary artery disease; DC = dendritic cell; Dll4 = Delta-like 4; EGFR = epidermal growth factor receptor; HIF = hypoxia inducible factor; Mϕ = 
macrophage; MSC = mesenchymal stem cell; NKG2D = natural killer group 2D; TF = tissue factor; TGF-β = transforming growth factor-β; TNF-α = tumour 
necrosis factor-α; VEGF = vascular endothelial growth factor; VSMC = vascular smooth muscle cell 
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1.1.10 Therapeutic applications of extracellular vesicles 
The biological properties of EVs and their roles in cell-cell communication has 
prompted research into their potential use as therapeutic agents, and also, their 
capacity to be altered in disease has highlighted EVs as potential circulating 
biomarkers. The potential clinical applications of EVs as therapeutic agents and 
biomarkers of disease are outlined below. 
 
1.1.10.1 EV therapeutics  
EVs can be used as delivery vehicles for pharmacological agents, but also nucleic 
acids such as mIRs. EVs have been shown to be superior to liposomes in this respect 
as the lipid and protein content are more compatible than synthetic liposomes. MSCs 
genetically modified to produce mIR-143 were shown to produce EVs containing the 
transfected mIR which could then go on to inhibit the migration of osteocarcinoma 
cells (249). Similarly, DCs modified to overexpress IL-10 were shown to produce 
IL-10 containing EVs which were capable of suppressing the onset of collagen 
induced arthritis in a mouse model (250). Alternatively, other methods have 
exploited the native antigens expressed on EVs to generate therapeutic agents. For 
example, pulsing of antigen presenting cells with tumour-derived EVs isolated from 
ascites resulted in the presentation of the tumour antigen. This was then shown to 
prime a set of leukocytes specifically targeted to the tumour for expansion (251). 
EVs produced from microbe-infected cells have also been used effectively as 
vaccines (252). A further example of using unmodified EVs for therapy is the use of 
stem cell EVs. Stem cell therapy has received a great deal of attention in previous 
years as a novel therapeutic strategy for a wide variety of conditions. However, 
potential issues include the proliferation of undifferentiated stem cells towards an 
oncogenic phenotype and the poor survival of transplanted stem cells (253). Stem 
cell EVs may help to circumvent these problems by eliminating the need for cellular 
transplantation. For example, in vivo delivery of EVs from cardiac progenitor cells to 
a mouse model of myocardial infarction diminished caspase activation and 
subsequent apoptosis of cardiomyocytes (254). Finally, EVs themselves could be 
targeted to attenuate cell-cell communication. For example, inhibition of heparin 
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sulphate proteoglycans required for EV uptake was shown to reduce migration of 
cancer cells (255). 
 
1.1.10.2 EVs as biomarkers of disease 
The application of more in-depth analyses such as proteomics and lipidomics to EVs 
has allowed for identification of a number of novel biomarkers in a range of 
diseases, particularly using cancer EVs. For example, myeloma EVs were shown to 
express CD44 which was shown to be prognostic for disease progression (156). 
Prostate cancer EVs have also been shown to express prostate specific membrane 
antigen which indicates the progressive status of the tumour (256). Less laborious 
methods have also been suggested for the use of EVs as biomarkers. For example, 
circulating levels of TF
+
 EVs may be useful in predicting the risk of venous 
thrombosis (176). 
 
EVs offer a non-invasive approach to diagnostics due to their presence in a number 
of biological fluids. However, the field is currently hindered by a lack of 
standardisation of nomenclature and pre-analytical processing that makes inter-study 
comparison a challenge. As our understanding of the composition and roles of EVs 
in homeostasis and disease continues to expand, the therapeutic manipulation and 
targeting of EVs is likely to be an extremely important and exciting area of research. 
In parallel with these developments however, standardisation of pre-analytical 
protocols is essential for the progression of the EV field towards clinical diagnostics 
and therapeutics.  
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1.2 ADIPOSE TISSUE 
In the early 1970‟s, adipose tissue (AT) was shown to possess aromatase activity for 
the enzymatic conversion of circulating reproductive hormones (257). Despite such 
evidence for the participation of AT in endocrine signalling and a known association 
of obesity with cancers of the female reproductive tract, AT was long regarded as a 
latent storage tissue. It was over 20 years later before AT became firmly established 
as an endocrine organ through the identification of the “fat gene” and adipocyte-
derived protein, leptin (258). In the past 20 years, over fifty different proteins have 
been shown to be produced by adipocytes within AT, termed „adipokines‟, with 
diverse biological functions (259). This section will examine AT in more detail, with 
a specific focus on adipocytes and their role in physiology and disease. 
 
1.2.1 Types of adipose tissue 
There are currently 3 distinguishable types of AT: white AT (WAT), brown AT 
(BAT) and the more recently discovered beige AT (260). The composition and 
characteristics differ between types of AT (Figure 1.2.1), and consequently, the 
tissues serve different functions.  
 
1.2.1.1 White adipose tissue 
WAT is commonly stored subcutaneously (more so in women) and within the 
peritoneum (visceral, more so in men), forming the major reserve for surplus energy 
intake from the diet. In addition to storage of energy, WAT also provides basic 
insulation and cushioning of internal organs, including blood vessels (perivascular 
AT). White adipocytes are the primary constituents of WAT though preadipocytes, 
adipocyte progenitors (such as MSCs), immune cells and endothelial cells (261) also 
form a major part of WAT. White adipocytes are histologically simple, consisting of 
a unilocular triglyceride lipid droplet with a small number of mitochondria. In fact, 
triglycerides constitute more than 85% of WAT mass (262) and lipid droplets can 
comprise up to 90% of cellular volume (263), illustrating the dominance of lipid 
storage in white adipocytes. Adipokines such as leptin and adiponectin are released 
from white adipocytes allowing proximal and distal endocrine signalling of WAT. 
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White adipocytes are also capable of expansion (hypertrophy) to cater for increases 
in triglyceride influxes and are typically between 50 and 100 μm in diameter (264) 
but can reach up to 200 μm in diameter in obese AT (265,266). If the storage 
capacity of the adipocyte is exceeded, tissue-resident preadipocytes and adipocyte 
progenitors are induced to differentiate into mature adipocytes (hyperplasia) to 
accommodate the extra lipid. This allows WAT to safely store lipid and prevent 
ectopic lipid deposition and lipotoxicity in other organs. Hypertrophy and 
hyperplasia of white adipocytes may allow the indefinite expansion of WAT, as 
demonstrated in morbidly obese patients where WAT can account for over 50% of 
total body weight (261). 
 
1.2.1.2 Brown adipose tissue 
BAT is essential for thermogenesis in neonates and is thought to be progressively 
lost into adulthood as skeletal muscle and other thermogenic mechanisms develop 
(267). However positron emission tomography (PET) imaging studies have 
suggested regions of BAT are present in adults, predominantly located in cervical 
and supraclavicular locations (268). PET imaging also found BAT was more 
abundant in: women; the youngest and least obese individuals; and those with the 
lowest levels of fasting glucose (268). Brown adipocytes contain large amounts of 
mitochondria and very few, multilocular lipid droplets (263). This abundance of 
mitochondria (which are usually large with multiple cristae) is responsible for the 
utilisation of fat by BAT as opposed to the storage of fat in WAT. The expression of 
uncoupling protein (UCP)-1 on the inner mitochondrial membrane of brown 
adipocytes drives oxidative phosphorylation of cellular respiration away from ATP 
production, towards the dissipation of energy as heat (261). BAT is densely 
vascularised with capillary networks and innervated by noradrenergic fibres. Under 
cold conditions, sympathetic nerve stimulation of BAT via noradrenaline and β3 
adrenoreceptors activates lipolysis of triglycerides, liberating free fatty acids (FFAs) 
which in turn activate thermogenesis (267). Interestingly, ablation of UCP-1 in mice 
not only leads to a lack of thermogenic control, but also to obesity (269). 
Furthermore, BAT is reduced in obese subjects (263,268). Together, this suggests 
that activation of BAT is triggered by changes in temperature and diet and the 
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reduction in BAT in obesity may aid weight gain in order to restore the thermogenic 
balance. 
 
1.2.1.3 Beige adipose tissue 
Beige adipocytes are so called due to their intermediary morphology between white 
and brown adipocytes. They are also referred to as “brite (brown-in-white)” or 
“paucilocular” adipocytes and are generally found within WAT (263). Similarly to 
brown adipocytes, beige adipocytes contain high numbers of mitochondria and 
express UCP-1 (270). Unstimulated beige adipocytes also share similarities in gene 
expression with white adipocytes, including fatty acid binding protein (FABP) 4, 
adiponectin, and peroxisome proliferator-activated receptor (PPAR) γ (271). In 
addition to the shared similarities with white and brown adipocytes, beige adipocytes 
are enriched in distinct genes such as TBX1 and surface markers including CD137 
(271). Several factors are implicated in the browning of WAT, including cyclic 
guanosine monophosphate (cGMP) as stimulation of the β3 adrenoreceptor leads to 
downstream increases in cGMP levels (272,273). Prostaglandins and nitric oxide 
(NO) signalling pathways also converge on cGMP generation, both of which (NO 
via reduction from inorganic nitrate) were shown to stimulate browning of WAT 
(272,273). Roberts et al., also showed that the nitrate-induced beige phenotype was 
only achieved with differentiating adipocyte progenitors and not with mature 
adipocytes (273), suggesting beige adipocytes originate from adipocyte progenitors 
and not transdifferentiation of white adipocytes. Analysis of BAT from adult humans 
has shown gene expression patterns similar to those of beige adipocytes, suggesting 
that the presumed BAT in adults may actually be beige AT (271). 
 
1.2.1.4 Adipocyte lineage 
It is well established that white and brown adipocytes originate from different 
mesodermal lineages. White adipocytes derive from mesodermal stem cells that give 
rise to adipoblast progenitors, followed by preadipocytes and finally mature 
adipocytes (274). Conversely, BAT arises from a progenitor population of the 
mesoderm expressing Pax7
+
/Myf5
+
 genes which also give rise to skeletal muscle 
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cells (275). The transcriptional regulator PR domain-containing 16 (PRDM16) 
controls the fate of progenitor cells by activating PPARγ to induce adipogenesis and 
promote differentiation to brown adipocytes (275). The exact lineage of beige 
adipocytes is unclear though two theories have been proposed. The first suggests that 
white adipocytes may undergo transdifferentiation to beige adipocytes in response to 
cold environments or prolonged β3 adrenoreceptor activation (263,276). However, 
recent evidence suggests that adipocyte progenitors within WAT respond to low 
temperatures and/or increased sympathetic activity by differentiating into beige 
adipocytes to increase thermogenesis and utilisation of energy stores to produce heat 
(270,273). It has also been hypothesised that beige adipocytes may be capable of 
transdifferentiation to white adipocytes in conditions of high energy influx (270). 
Therefore, the plasticity often associated with WAT may be attributed to the ability 
of adipocyte progenitors and subsequent beige adipocytes to respond to changes in 
the microenvironment.  
 
Figure 1.2.1: Types of AT. A simplified summary of the 3 main types of AT and their 
typical characteristics.   
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1.2.2 Adipose tissue depots 
In addition to total body fat, the distribution of adiposity is also an important 
determinant for metabolic health. The deposition of fat in specific anatomical 
locations and the association with metabolic disease and CVDs has been an area of 
great controversy in recent years. Depots of WAT can be visualised using imaging 
techniques such as computed tomography and are broadly grouped into subcutaneous 
(SC), visceral and perivascular, each of which seem to have specialised compositions 
and functions. 
 
1.2.2.1 Subcutaneous AT 
Typically, up to 85% of body fat is SC (277) most of which is stored in abdominal, 
gluteal and femoral regions. Women tend to have greater proportions of SC AT than 
men, perhaps to aid the continuous supply of energy to the foetus during pregnancy, 
as lipolysis in SC AT is slow and continuous (278). The lifespan of a typical SC 
white adipocyte is reportedly 8-10 years (279) illustrating the stability and slow 
turnover of adipocytes. Cells of the SC stromal vascular fraction (containing 
adipocyte progenitors and preadipocytes) show a high efficiency of differentiation 
(270) (usually in response to PPARγ) (280), suggesting SC AT expansion is 
mediated through adipocyte hyperplasia. The general size of adipocytes in SC AT is 
debated with some studies reporting high proportions of small adipocytes which are 
more insulin sensitive (281) and others arguing the presence of large diameter 
adipocytes that secrete the majority of adipokines (such as leptin) and adipocyte-
derived oestrogens (from aromatase conversion of androgens) (280). SC AT 
deposition is generally regarded as physiological, as the primary function of 
adipocytes is “liposynthetic” characterised by high levels of insulin sensitivity (280). 
In fact, the obesity of SC AT that is not associated with metabolic syndrome may be 
characterised as “metabolically healthy” (282). This phenotype tends to be 
associated with gluteal and femoral SC adiposity as opposed to abdominal SC AT 
deposition which is associated with an increased risk of CVD and type 2 diabetes 
(T2D) (283).  
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1.2.2.2 Visceral AT 
Visceral or intra-abdominal AT surrounds the internal organs and accounts for up to 
10% of total body fat in women and up to 20% in men. Visceral AT is associated 
with a rapid energy release state, perhaps a conserved evolutionary mechanism to 
quickly liberate high amounts of energy for hunting (278). Visceral adipocytes are 
reportedly smaller in women, suggesting a reduced capacity for rapid calorie release 
(280). Visceral adipocytes are indeed highly lipolytic, due to a high level of 
triglyceride influx, sympathetic nerve fibre innervation and expression of β3 
adrenoreceptors (280). Increased catecholamine stimulation of visceral AT induces 
lipolysis and liberation of FFAs, which are drained into the circulation (via the liver) 
by the portal vein. Obesity with accompanying metabolic syndrome is associated 
with an increased circulating level of FFAs (284), suggesting visceral AT activity 
may play an important role. Furthermore, visceral adipocytes are much less sensitive 
to the anti-lipolytic effects of insulin than SC adipocytes (280) suggesting an 
increased mass and/or activity of visceral AT could contribute to the reduced 
sensitivity of insulin in metabolic syndrome and obesity. Unlike SC AT, 
adipogenesis within visceral AT is not induced by PPARγ and adipocytes 
predominantly expand by hypertrophy (285). Similarly to abdominal SC AT, 
visceral AT is associated with an increased risk of developing CVD and T2D (283).  
 
1.2.2.3 Perivascular AT 
Perivascular AT is a form of visceral AT surrounding blood vessels that is able to 
directly affect the responsiveness of the underlying vessel due to the absence of a 
fascial plane between the vessel and AT (286). Perivascular AT of resistance vessels 
is predominantly WAT whereas larger vessels are surrounded by a combination of 
WAT and BAT (286). In vitro isolated vessel experiments have traditionally 
removed perivascular AT prior to testing however, Soltis et al., showed the 
vasoconstriction of noradrenaline was attenuated when the perivascular fat was left 
intact (287). This effect was later attributed to a soluble substance, termed adipose-
derived relaxing factor (ADRF), as transfer of bath solution from aortic rings with 
perivascular AT intact to aortic rings with fat removed induced rapid relaxation 
(288). The identity of ADRF is still unknown though adipocyte-derived vasodilators 
Page | 57  
 
have since been proposed (289) including adiponectin and angiotensin 1-7 which 
produce NO in an endothelium-dependent manner, and hydrogen peroxide which 
induces vasodilation in an endothelium-independent manner (290). Interestingly, 
perivascular AT has also been shown to enhance contractility of vessels via 
thromboxane A2 (291). Variations in the composition of perivascular AT and the 
type of vessel may result in differences in regulation of vessel tone. Perivascular fat 
volume is higher in men and shows a positive correlation with BMI, regardless of 
gender (292). The anti-contractile properties of perivascular AT in lean individuals 
was completely absent in obese individuals (293). Furthermore, the vasodilatory 
effects of lean perivascular AT were lost by addition of inflammatory mediators 
(TNF-α and IL-6) and hypoxia. This suggests that dysfunctional perivascular AT in 
obesity (and obese-like conditions) is unable to regulate vascular tone, and hence 
may increase the risk of hypertension. Increased contractility of small arteries could 
deprive tissues downstream of nutrients and O2, thus enhancing local inflammation 
and hypoxia (discussed in more detail in Section 1.2.5).  
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1.2.3 Methods of studying adipose tissue and adipocytes 
With various roles in homeostasis and disease (discussed in Sections 1.2.4 and 1.2.5 
respectively), understanding adipocyte function is hugely important. Several 
methods exist to study adipocytes in vitro and in vivo including the use of 
preadipocyte cell lines, isolation of adipocytes from primary human explants and 
genetic mouse models.  
 
1.2.3.1 Preadipocyte cell lines: 3T3-L1 
Much of our current understanding of adipocyte biology comes from the use of 
preadipocyte cell lines (Table 1.2.1), primarily using 3T3-L1 cells. Preadipocyte cell 
lines have undergone determination from mesodermal precursors and can therefore 
either remain as preadipocytes, or can be differentiated to mature adipocytes (294). 
3T3-L1 cells were the first preadipocyte cell line to be developed (295,296) and have 
been (and still are) used extensively to study adipocyte biology and adipogenesis 
(294). Differentiated 3T3-L1 cells possess the major hallmarks of mature adipocytes: 
lipid storage, insulin sensitivity and endocrine signalling. 
 
Cell line Origin Characteristics 
3T3-L1 Mouse Sub-line of 3T3 embryonic fibroblasts (295,296) 
3T3-F442A Mouse Sub-line of 3T3 embryonic fibroblasts (295,296) 
AP-18 Mouse Derived from sub-epidermis of ear skin from 
adult C3H/HeM mouse (297)  
SGBS Human Derived from SC AT stromal cells from an infant 
with Simpson-Golabi-Behmel syndrome (298) 
Ob 17 Mouse Derived from epididymal fat pad of C57BL/6J 
ob/ob mouse (299) 
HGFu Mouse Derived from epididymal fat pad of wild-type 
C57BL/6J mouse (300) 
Table 1.2.1: Preadipocyte cell lines. Details of commonly used, established preadipocyte 
cell lines to study adipogenesis.  
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Upon confluency, 3T3-L1 preadipocytes are stimulated to differentiate using a 
simple cocktail of adipogenic inducers (Figure 1.2.2). Differentiation cocktails 
always include insulin to stimulate insulin-like growth factor signalling pathways, a 
glucocorticoid (e.g. dexamethasone) to enhance nuclear gene expression (e.g. 
CCAAT/enhancer binding proteins (C/EBP)-δ), an agent to increase intracellular 
cyclic adenosine monophosphate (e.g. 3-isobutyl-1-methylxanthine or indomethacin) 
to stimulate specific G-protein pathways and C/EBPβ, and serum (containing 
essential growth factors and cytokines) (294,301). 
 
Figure 1.2.2: 3T3-L1 differentiation. Major stages and genes involved in 3T3-L1 
differentiation from a preadipocyte to a mature adipocyte. Upon confluency, lipoprotein 
lipase (LPL) expression is induced, one of the earliest markers of differentiation. Around 48 
hr post-confluency differentiation cocktail (DC) is added and genes including c-myc and 
C/EBPβ and δ are rapidly induced. c-myc induces clonal expansion of preadipocytes (~2 
rounds of mitosis) before cellular growth arrest. C/EBP-β and δ enhance PPARγ and CEBP-
α expression which induce the transcription of adipocyte genes such FABP4, adiponectin 
and GLUT-4 that generate and sustain the mature adipocyte phenotype. Markers highlighted 
in bold are used in this thesis to assess the stage of differentiation in 3T3-L1 cells and EVs. 
 
Adipogenesis is a complex process of co-ordinated transcriptional activation to 
differentiate the fibroblast-like preadipocyte to a rounded cell containing lipid 
droplets. Differentiation is usually confirmed by morphological changes (i.e. 
rounding, lipid accumulation), observed using light microscopy and lipid droplet 
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accumulation, which can be visualised and measured (semi-quantitatively) using Oil 
Red O staining. Ideally, the above are performed in combination with qRT-PCR 
measurements of early adipogenic markers (e.g. preadipocyte factor (PREF)-1) and 
late adipogenic markers (e.g. FABP4) compared to housekeeping genes (e.g. 
GAPDH). 
A recent study also demonstrated the capability of 3T3-L1 adipocytes to acquire a 
brown adipocyte phenotype upon stimulation with noradrenaline (302). The authors 
of this study suggest this is due to a previously unidentified plasticity of 3T3-L1 
cells and that the differences in lineage between white and brown adipocytes may 
not be as straightforward as initially thought. Further characterisation of the 3T3-L1 
brown adipocyte is needed, though this may point to an additional application of 
3T3-L1 cells in vitro. Preadipocyte cell lines such as 3T3-L1 provide robust models 
from which to study adipocyte differentiation and biology. Their ease of use and 
accessibility make preadipocyte cell lines useful adipocyte research models.  
 
1.2.3.2 Primary human adipocyte culture  
Mouse and human primary adipocyte cultures have also been used as adipocyte 
research models. Excised AT can be digested using collagenase to separate adipocyte 
progenitor cells from free lipid and mature adipocytes. Preadipocytes can then be 
cultured in vitro and stimulated to differentiate for ~2 weeks to produce mature 
adipocytes (303). Mature adipocytes can also be separated using the collagenase 
digest (304,305), though their subsequent culture is tricky as the adipocytes float 
(and are therefore less likely to adhere) and are prone to bursting during isolation. 
The rate and extent of differentiation may differ between donors and AT depots, and 
may therefore introduce variation between experiments. 
Isolated pre- and mature primary adipocytes are also available commercially (e.g. 
PromoCell, Lonza). These adipocytes are isolated and fully characterised by the 
vendor to ensure an adipocyte population. Adipocytes from specific depots including 
SC and visceral AT, and from different disease sets, including obese and diabetic 
patients can be purchased allowing analysis of specific adipocyte populations. 
Unsurprisingly, these cells are often expensive. 
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Culture of AT explants has also been used to study adipocytes (306–308). In this 
setting, intact sections of AT may be analysed ex vivo and may be used to compare 
AT function between depots. However, the explant contains a mixture of cells 
present within AT, making it difficult to pinpoint the origin of any observed effects. 
 
1.2.3.3 Adipocyte progenitor cells  
The mesodermal origin of adipocytes provides an alternative source of precursory 
adipocyte cells that can differentiate in vitro into preadipocytes and subsequently, 
mature adipocytes (Figure 1.2.3). MSCs and pluripotent stem cells (PSCs) have both 
been used to generate adipocytes in vitro. MSCs can be isolated from bone marrow 
or AT extracts and are multipotent cells, capable of differentiating into osteocytes, 
myocytes, chondrocytes and adipocytes (309). Commercially available MSCs are 
also frequently used, reducing the need for invasive tissue sampling. Differentiation 
of MSCs to adipocytes follows a similar timeframe and differentiation cocktail to 
that of 3T3-L1 cells. Although as a human source, MSCs may provide a more 
relevant adipocyte population compared to 3T3-L1 cells, their use is disadvantaged 
by a limited proliferative potential and varied adipogenic differentiation between 
sources (310). 
Isolated human PSCs (hPSCs) can be cultured in vitro indefinitely whilst retaining 
their ability to differentiate along a variety of lineages, including adipocytes (311). 
Adipogenic medium requires the addition of a PPARγ agonist (e.g. Rosiglitazone) 
(311) to that described for 3T3-L1 cells. More recently, a lentiviral construct 
containing a PPARγ2 promoter has been shown to vastly improve the extent of hPSC 
differentiation (310). Interestingly, the use of a PRDM16 promoter-containing 
lentiviral construct could induce differentiation of hPSCs to a brown adipocyte 
population. Furthermore, when both hPSC-derived white and brown adipocytes were 
implanted in vivo, they were successfully incorporated and functional as brown and 
white AT (310). Culture in vitro to mature adipocytes typically takes ~3 weeks, and 
as described above, may require the use of more complex techniques to ensure 
sufficient adipogenic differentiation. However, the extent and variation of 
differentiation of hPSCs is superior to that of MSCs (310) and perhaps provides a 
more relevant adipocyte population compared to 3T3-L1 cells. 
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Figure 1.2.3: Mesodermal lineage of pluripotent stem cells. The mesodermal lineage; 
both pluripotent stem cells and mesenchymal stem cells can be used to generate adipocytes. 
 
1.2.3.4 Genetic mouse models of obesity  
Genetic mouse models have also been employed to analyse the in vivo role of AT. 
The most widely used mouse model is the ob/ob mouse carrying a mutation in the 
“obese” gene that encodes for the adipokine leptin, resulting in leptin deficiency 
(258). Mice with the ob mutation display a phenotype akin to that in morbid obesity, 
becoming profoundly obese, developing diabetes, demonstrating hyperphagia, and 
showing impairments in immune and reproductive function (258,312). Alternatively, 
db/db mice carry a mutation in the “diabetic” gene that encodes for the leptin 
receptor. These mice also become significantly obese and develop diabetes and 
dyslipidaemia (313). Furthermore, leptin mRNA increases ~20 fold in db/db mice 
(314). Though ob/ob mice are more frequently used db/db mice may provide a more 
accurate representation of obesity, as leptin is present and increased in obese subjects 
(Sections 1.2.4.1 and 1.2.5.1).  
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1.2.4 Adipokines and the role of AT in physiology 
The majority of research into endocrine factors released from AT has focused on 
those derived from WAT, as this is the largest store of AT in the body. A diverse 
range of factors have been identified, collectively termed “adipokines” to encompass 
factors produced and released from WAT. Adipokines can act locally within AT in 
an autocrine and/or paracrine fashion, and also distally in the central nervous system 
and systemic circulation in an endocrine manner. Consequently, adipokines play 
important roles in a range of physiological functions. 
Mice carrying a genetic mutation that prevents the actions of C/EBP transcription 
factors (Figure 1.1.2) leaves them devoid of WAT. These mice also display stunted 
development, infertility, an enlarged liver, diabetes, elevated levels of circulating 
glucose and lipids and eventually premature death (315). This provides a stark 
illustration of the importance of WAT not only in the regulation of lipid metabolism 
and deposition, but also in normal growth and development.  
 
1.2.4.1 Regulation of lipid metabolism and appetite  
The major endocrine factor produced by adipocytes for energy homeostasis is leptin. 
Leptin is produced by adipocytes and the circulating levels of leptin relate to the 
level of energy storage, i.e. leptin tends to be elevated in fed states and reduced 
during fasted states (316). The effects of leptin are mediated through the leptin 
receptor (LR), of which there are several isoforms. LR-b is highly expressed in 
hypothalamic regions of the brain, where leptin mediates the majority of its 
metabolic effects. Binding of leptin to hypothalamic receptors induces the expression 
of anorectic peptides (e.g. α-melanocyte stimulating hormone) and also stems the 
secretion of orexigenic hormones (e.g. neuropeptide Y (316)). The combined effect 
leads to release of appetite-suppressing hormones such as oxytocin. Release of these 
hormones also increases fatty acid oxidation and decreases circulating glucose levels 
to restore energy balance following feeding.  
Adiponectin also plays a role in regulating lipid metabolism and is produced 
exclusively by mature adipocytes. Adiponectin displays a multimeric conformation 
and can exist in high, middle and low molecular weight forms (317). Two main 
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isoforms of the adiponectin receptor have been described, adipoR1 which is highly 
expressed in muscle, and adipoR2 which shows high prevalence in the liver, though 
both receptors are also expressed in other peripheral tissues and the brain (318). 
Adiponectin confers its metabolic effects via phosphorylation of adenosine 
monophosphate-activated protein kinase (AMPK) leading to increased fatty acid 
oxidation and an inhibition of hepatic gluconeogenesis. The latter gives rise to the 
insulin-sensitising properties of adiponectin by reducing circulating glucose levels 
(319). The importance of adiponectin and AT in the regulation of insulin sensitivity 
is highlighted by pharmacological insulin-sensitising agents such as 
thiazolidinediones (TDZs) which increase circulating adiponectin levels (317). The 
actions of adiponectin in peripheral areas such as skeletal muscle help to induce 
energy expenditure, thereby reducing the risk of ectopic lipid deposition (318). 
The transcription factor PPARγ is highly expressed in adipocytes, particularly the 
PPARγ2 isoform. In addition to controlling adipocyte differentiation, PPARγ 
regulates transcription of genes central to metabolism (301,320) such as lipoprotein 
lipase (involved in the storage, release and transport of lipids (321)). PPARγ also has 
an insulin-sensitising effect by directly inducing insulin-mediated uptake of glucose 
thus decreasing levels of FFAs and promoting lipid storage (321). PPARγ also 
reduces ectopic lipid deposition in the liver and muscles by mobilising lipids from 
these sites and promoting adipocyte storage. Furthermore, activation of PPARγ 
signalling leads to a redistribution of lipids from visceral to SC depots (321), thereby 
reducing the risks associated with visceral AT storage. TDZs such as Pioglitazone 
are pharmacological PPARγ agonists used to improve insulin sensitivity in T2D 
(322). Interestingly, as indicated above, treatment with TDZs can also increase 
adiponectin levels (317,322) suggesting PPARγ also regulates adiponectin secretion. 
FABP4 is a cytosolic and secretory fatty acid trafficking protein highly expressed in 
adipocytes, accounting for ~1% of the total protein (323). FABP4
-/-
 mice display 
increased circulating levels of triglycerides and FFA, and up to a 40% reduction in 
cellular lipolysis (324). This suggests FABP4 is involved in the cellular uptake and 
trafficking of lipids into adipocytes and their subsequent metabolism. 
Resistin is a hormone that is preferentially secreted by adipocytes. Similarly to 
FABP4, the role of resistin was elucidated using knockout or gene silencing models 
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(325). Silencing RNA targeting resistin was shown to reduce the activity of 
transcription factors controlling lipogenic gene expression. Furthermore, lipid 
droplet size was reduced in resistin knockout adipocytes. Therefore, resistin seems to 
play a role in controlling lipid accumulation in the early stages of adipogenesis.  
Visfatin is a relatively newly identified adipokine that was initially thought to be 
specific to visceral AT (326) though it has now been identified in SC AT. Visfatin is 
able to both control the secretion of insulin from pancreatic β-cells (327) and mimic 
the signalling effects of insulin (326). 
 
1.2.4.2 Role in vascular function 
As discussed in Section 1.2.2.3, perivascular AT is able to control local vascular 
function through the secretion of adipokines. Adipocytes in SC and visceral depots 
also secrete adipokines that can regulate haemostasis, angiogenesis and blood 
pressure that help AT to meet metabolic and physical demands. Circulating 
adiponectin induces NO production and reduces reactive oxygen species (ROS) 
generation in endothelial cells (328) thereby promoting vasodilation and protecting 
against ROS-induced vascular damage. Plasminogen activator inhibitor (PAI)-1 is a 
small protein secreted from a number of cells including adipocytes (329). As its 
name suggests, PAI-1 inhibits plasminogen which is involved in fibrinolysis. PAI-1 
is produced by mature adipocytes and its expression is controlled by both resistin 
and PPARγ (330). The precise role of adipocyte-derived PAI-1 is unclear, though it 
may play both local and systemic roles in haemostasis. TF expression and release has 
also been observed in AT though similarly to PAI-1, the reason behind the presence 
of TF in AT is unknown (331). TF is a well-known initiator of coagulation and 
therefore may represent a mechanism for AT to control local haemostasis. TF is also 
vital for vascular development and may therefore play a role in formation of the AT 
microcirculation. Visfatin has also been shown to induce relaxation of aortic rings 
and stimulate endothelial proliferation and angiogenesis, the latter effect being 
through the generation of VEGF (332). 
Adipocytes grow in close proximity to endothelial cells within AT in order to 
efficiently exchange nutrients and waste (333). As part of their adipokine repertoire, 
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adipocytes secrete factors that promote endothelial cell growth and angiogenesis. In 
fact, the growth of AT in ob/ob mice was inhibited by anti-angiogenic factors (334), 
indicating AT expansion is dependent  upon local angiogenesis. Adipocytes express 
and secrete VEGF to promote local angiogenesis, but also leptin (335). Leptin was 
shown to induce angiogenesis of endothelial cells in vitro and in vivo indicating a 
peripheral role for leptin in addition to its central role in energy homeostasis. 
Adipocytes also contain several components of the renin-angiotensin system (RAS), 
allowing them to regulate blood pressure. Angiotensinogen produced by adipocytes 
can be converted into angiotensin II by angiotensin converting enzymes present in 
AT (336) which can go on to induce vasoconstriction.  
 
1.2.4.3 Immune interaction of AT 
AT is recognised as an immunological organ, due to a vast network of immune cells 
present within WAT. The most abundant of these cells are Mϕ which are polarised 
towards an M2, anti-inflammatory phenotype. M2 Mϕ secrete IL-10 that helps to 
maintain insulin sensitivity and regulate glucose homeostasis (337). Polarisation of 
Mϕ towards an M2 phenotype is regulated by: adipocyte PPARγ expression (338); 
AT-resident eosinophils which secrete IL-4 (339); and a specialised subset of NK 
cells and Treg cells that secrete IL-10. Additionally, Treg cells participate in 
important crosstalk with adipocytes by reducing adipocyte secretion of MCP-1 and 
enhancing adipocyte insulin sensitivity via PPARγ (338).  
 
1.2.4.4 AT and ageing 
Ageing is associated with phenotypic and functional changes in AT. AT mass 
declines with age, coinciding with an accumulation of lipid in ectopic sites such as 
the liver and bone (340). Therefore, although AT mass undergoes redistribution, the 
overall proportion of body fat remains unchanged. Increases in ectopic lipid 
deposition account for many age-associated conditions, for example, the deposition 
of lipid in bone decreases mineral density, leading to osteoporosis and insulin 
resistance (IR) (341). Furthermore, preferential SC AT tissue cachexia prior to 
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visceral AT increases the risk of metabolic syndrome (340). The precise mechanisms 
behind age-related changes in AT are unknown, though several important alterations 
have been identified. Expression of pre-adipogenic markers (such as C/EBP and 
PPARγ) is reduced in aged AT, therefore reducing the capacity of preadipocytes to 
undergo adipogenesis (342). Additionally, increased differentiation of other cells, 
such as Mϕ towards an adipocyte-like phenotype has been reported, which express 
FABP4 and drive the progression of atherosclerosis (343). AT PAI-1 expression is 
also elevated with ageing, suggesting an increased procoagulant propensity of AT 
(329), though this may be a consequence of an increased ratio of visceral to SC AT. 
 
Through the secretion of adipokines, AT is able to play a role in a diverse range of 
physiological functions from establishing metabolic functioning before birth to 
operating as an immune organ (summarised in Figure 1.2.4). Clearly, AT plays an 
important role in a number of homeostatic mechanisms in addition to its basic roles 
in energy storage, structural support and insulation.  
 
Figure 1.2.4: Physiological role of WAT. A summary of the physiological processes 
regulated by WAT and the adipokines involved.  
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1.2.5 Adipose tissue in disease 
The ability of AT to serve as an endocrine organ facilitates its role in physiological 
processes. However, this endocrine signalling becomes detrimental in disease. The 
major cause of AT dysfunction is obesity. In 2014, just under 2 billion adults were 
overweight (39% of the world‟s adult population) (344). Dysregulation of AT in 
obesity leads to increased risks of CVD, diabetes and cancer; three of the leading 
causes of mortality. Obesity is caused by an imbalance between energy intake and 
expenditure, and is therefore, largely preventable.  
 
1.2.5.1 Metabolic dysregulation in obese AT 
A hallmark of AT disease and obesity is the dysregulated secretion of adipokines. 
Two major adipokines involved in the physiological regulation of lipid metabolism 
are dysregulated in obesity. Leptin deficient, ob/ob mice are severely obese, insulin 
resistant and hyperlipidaemic (312) highlighting the importance of leptin signalling 
in regulating lipid metabolism and appetite. Paradoxically, circulating levels of leptin 
are increased in diet-induced obesity. This may be a consequence of leptin 
resistance, perhaps due to decreased efficiency of leptin signalling in the 
hypothalamus (345). Contrastingly, circulating adiponectin levels are decreased in 
obese subjects (346). Plasma adiponectin levels directly correlate with insulin 
sensitivity and mutations in the adiponectin gene predisposes the carrier to IR 
(317,346). This draws attention to the insulin-sensitising role of adiponectin and 
suggests a causal role for reductions in adiponectin in the development of IR. 
Conversely, resistin which is increased in obesity induces IR by reducing the action 
of insulin (347). 
FABP4
-/-
 mice fed a high fat diet become obese but do not become insulin resistant. 
Additionally, these mice lacked TNF-α production in AT (associated with 
inflammation and IR). Together this suggests a direct link between FABP4 and the 
development of IR in obesity (324). In human studies, circulating levels and 
adipocyte expression of FABP4 are increased in subjects with obesity and metabolic 
syndrome (348,349). An inhibitor of FABP4 was also shown to prevent and treat 
T2D and atherosclerosis in an experimental model (350) indicating the inhibition of 
FABP4 may be an effective target for obesity-induced CVDs and co-morbidities. 
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1.2.5.2 Vascular dysfunction in obese AT  
Dysregulated adipokine secretion in obesity can also lead to a hypertensive, 
hypercoagulable state (351,352). PAI-1 is increased in obesity, positively correlating 
with BMI, and has been suggested as a link between obesity and CVD (305,329). 
The main increase in PAI-1 in obesity is due to elevated adipocyte-derived PAI-1 
production; expression was 5-fold higher in both SC and visceral AT of ob/ob mice 
compared to lean controls (353). Furthermore, PAI-1 expression is induced by TNF-
α, insulin, TGF-β and FFAs, all of which are elevated in obesity. Visceral AT PAI-1 
expression was also elevated compared to SC AT further emphasising the 
cardiovascular risk associated with android obesity (329). Moderate weight loss 
restored the haemostatic balance in obese subjects by reducing circulating levels of 
PAI-1 and hence reducing the risk of thrombosis (228). TF may also increase the 
hypercoagulable state in obesity. Several adipokines upregulated in obesity such as 
leptin, TNF-α and TGF-β induced TF expression in adipocytes (351). Expression of 
TF mRNA is increased in obese AT in response to TGF-β (331) perhaps highlighting 
TGF-β as a promoter of obesity-induced thrombosis. Furthermore, PPARγ and 
adiponectin modulate TF production, though their expression is decreased in obesity, 
relinquishing their inhibition of TF production (351). Leptin was also shown to 
induce platelet aggregation (354) suggesting increased leptin levels in obesity may 
contribute to a pro-thrombotic state and increase cardiovascular risk.  
Imbalances in adipokine secretion may also increase local and systemic blood 
pressure. AT angiotensinogen expression is elevated in obesity, particularly in 
visceral AT (336) suggesting greater activation of the adipocyte-RAS. Additionally, 
increased adipocyte angiotensin II expression induces ROS generation from NO, 
thereby enhancing endothelial dysfunction and vasoconstriction (328). Elevated 
angiotensin II also enhances PAI-1 and endothelial integrin expression, promoting 
leukocyte adhesion and migration (328). Circulating levels of visfatin are increased 
in obesity (326,355), although the reason for this is unclear. Visfatin may promote 
leukocyte adhesion to endothelial cells (via increased integrin expression) (356) and 
increase the instability and rupture of atherosclerotic plaques (357). 
AT VEGF expression may harbour a protective role in obesity. Mouse models have 
shown overexpression of VEGF in AT increases vascularisation and M2 Mϕ 
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recruitment (358). In response to a high fat diet, mice overexpressing VEGF 
displayed an increased insulin sensitivity, suggesting VEGF was able to protect 
against metabolic complications of diet-induced obesity. Furthermore, 
overexpression of VEGF in AT enhanced PPARγ expression and induced browning 
of white adipocytes by increasing UCP-1 expression (359). Conversely, ablation of 
VEGF within AT reduced the ability of AT to expand resulting an increase in ectopic 
lipid deposition (360). Therefore, AT VEGF may serve important functions not only 
in regulating angiogenesis and growth of AT, but in the maintenance of adipocyte 
lipid deposition and insulin sensitivity. VEGF has been proposed as a therapeutic 
target for improving adipocyte dysregulation in obesity (358,359). However, plasma 
VEGF is elevated in obese subjects and correlates with endothelial IL-8 expression 
which promotes atherogenesis (361). Therefore, further work is needed to elucidate 
whether targeting VEGF feasible for the treatment of obesity. 
 
1.2.5.3 AT-derived inflammation 
Dysfunctional AT in obesity has profound effects on the role of AT as an 
immunological organ by promoting a transition towards a proinflammatory state 
(Figure 1.2.5). Numbers of eosinophils, NK cells and Treg cells are all reduced in 
obese AT (337,339) thereby reducing the IL-4/IL-10-induced M2 phenotype of Mϕ. 
The loss of pro-M2 signals in combination with other obesity-driven factors 
promotes the transition of Mϕ towards a proinflammatory M1 phenotype (338). The 
proinflammatory, hypoxic environment of obese AT promotes adipocyte necrosis 
which leads to the classical arrangement of M1 Mϕ around necrotic adipocytes in so 
called “crown like structures” (CLSs). This further enhances AT inflammation 
through FFA release from ruptured adipocytes and enhanced TNF-α and IL-6 
secretion from M1 Mϕ. The overriding effect is vicious cycle of excessive local 
inflammation within AT which leads to systemic inflammation and IR.  
Sustained elevations in plasma leptin levels stimulates the release of 
proinflammatory cytokines from Mϕ (328) thereby adding to the systemic 
inflammation observed in obesity. Circulating and AT levels of TNF-α are elevated 
in obesity, showing a positive correlation with IR (259). TNF-α inhibits 
phosphorylation of the insulin receptor in AT and muscles thereby reducing insulin 
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sensitivity. Weight loss directly reduces levels of TNF-α and improves insulin 
sensitivity, suggesting the involvement of a network of obesity-related factors in the 
development of IR. For example, IL-6 has also been reported to affect hepatic insulin 
signalling and levels correlate strongly with adiposity (259). Furthermore, IL-6 has 
been shown to enhance hepatic C-reactive protein (CRP) release (259), an 
inflammatory cytokine used to predict cardiovascular risk (352). Levels of other 
proinflammatory cytokines such as IL-8, IL-1β and TGF-β are also elevated in obese 
AT, suggesting dysfunctional AT is a prime source of proinflammatory cytokines 
which may give rise to the systemic inflammation that is closely associated with 
obesity. In addition to the proinflammatory transition of AT Mϕ, the number of AT 
Mϕ also increases, suggesting an increased infiltration of Mϕ into AT. Resistin was 
shown to induce pro-inflammatory cytokine production and enhanced endothelial 
adhesion molecule expression, thereby promoting leukocyte adhesion (327). 
Furthermore, TNF-α induces adipocyte MCP-1 production to enhance Mϕ 
chemotaxis and infiltration in AT, further promoting AT inflammation. Visceral AT 
was shown to contain a higher number of M1 Mϕ, again supporting the notion that 
visceral AT plays a greater role in IR and metabolic syndrome in obesity (338,352). 
 
Figure 1.2.5: Obese AT inflammation. A simplified schematic summarising the transition 
of lean AT with an anti-inflammatory phenotype to obese AT with a proinflammatory 
phenotype.  
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1.2.6 Adipose tissue hypoxia 
Section 1.2.2.1 alluded to the presence of a “metabolically healthy” obese phenotype, 
where obesity is not accompanied by obesity-related metabolic co-morbidities such 
as T2D, IR and dyslipidaemia. A study of overweight and obese individuals reported 
~30% of the study population were metabolically healthy and were not at an 
increased risk of future cardiovascular events (282). Conversely, obese individuals 
with associated metabolic syndrome were at a greater risk of future cardiovascular 
events. As described in the previous section, AT tissue dysfunction is the initiator of 
the pathophysiological roles of AT in disease, suggesting dysfunctional AT is the 
root cause of co-morbidities in obesity with metabolic syndrome. The mechanism 
behind the development of AT dysfunction is not fully understood, though a number 
of theories have been proposed. One theory is that AT has a limited capacity to 
expand safely, which may vary on an individual basis (362). Therefore, controlled 
accommodation and storage of increases in energy influx into AT may retain 
metabolic health. Conversely, surpassing the limit of AT expandability may enhance 
ectopic lipid deposition and dysregulated adipokine secretion from maximally filled 
adipocytes. Deficiency of O2 (hypoxia) of AT has also been proposed to initiate and 
exacerbate AT dysfunction and inflammation in obesity (259). 
 
1.2.6.1 Rationale for AT hypoxia  
It has been suggested that progressive obesity is associated with localised regions of 
hypoxia and that AT dysfunction and inflammation may stem from a local response 
of adipocytes to hypoxia (259). Adipocyte hypertrophy in obese AT can result in 
adipocytes spanning between 100-200 μm in diameter (265,266) which may surpass 
the limit of the adipocyte for safe lipid accumulation. Additionally, large diameter 
adipocytes may single-handedly exceed the maximal diffusion distance of O2 from 
blood vessels, which is reported to be 100 μm (363). In general, WAT is considered 
to be poorly perfused (364), and this perfusion is further reduced in obese WAT 
(365,366). An abundance of large adipocytes in combination with poor vascular 
support is highly suggestive of a hypoxic environment. Unfortunately, the 
measurement of O2 tension (partial pressure, pO2) of AT in vivo or in situ is 
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challenging (Section 1.2.6.2), making it hard to concretely confirm the presence of 
hypoxia within AT. 
 
1.2.6.2 Measurement of AT hypoxia 
The presence of hypoxia in AT can be ascertained by monitoring the expression of 
molecular markers known to be associated with hypoxia, directly measuring AT O2 
tension, or by measuring the AT blood flow/perfusion (AT-BF). 
Molecular approaches to measuring hypoxia usually involve the measurement of 
HIF-1α expression. HIFs are a group of transcription factors that regulate the cellular 
response to O2 with HIF-1α being the most studied of the molecular O2 sensors. HIF-
1α is constitutively expressed but is immediately ubiquinated and targeted for 
degradation under normoxic conditions (364). In hypoxia, this inhibition is 
relinquished enabling HIF-1α to modulate gene expression. Elevated HIF-1α mRNA 
and protein expression has been detected in SC WAT of obese mice (367–369) and 
humans (370). The probe pimonidazole has also been used to report AT hypoxia at a 
molecular level in obese mice (367,369,371). Pimonidazole was originally used to 
detect hypoxic regions of tumours as the probe is activated in an O2-dependent 
manner (372). 
Alternatively, a number of studies have used electrodes and sensors to measure the 
pO2 of AT and thus gauge the level of oxygenation (Table 1.2.2). Though this 
approach allows direct in vivo measurement of AT pO2, results between studies show 
great variation both in lean and obese subjects. This may be because different of 
types of electrodes or sensors were used. Additionally, a caveat of electrode-based 
measurement is the limited area of sample measurement as only the region 
immediately surrounding the electrode or sensor will be measured (single point 
measure). AT hypoxia is more likely to exist in “pockets” of hypoxic tissue due to 
variations in adipocyte size and vascularisation throughout AT. Therefore, pO2 
measurements may not provide an accurate measure of the hypoxic state of AT. A 
number of studies have found decreases in AT pO2 in obese subjects, though others 
have found no difference or even increases compared to lean controls (Table 1.2.2). 
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Species (Reference) Technique Location Population PO2 Equivalent O2  
Human (373) Polarographic 
electrode tonometer 
SC, upper arm Lean (BMI 24) 
Obese (BMI 51) 
57 mmHg 
36 mmHg 
7.5% 
4.7% 
Human (374) Clark electrode SC, upper arm Lean (BMI 24) 
Obese (BMI 46) 
57 mmHg 
41 mmHg 
7.5% 
5.3% 
Mouse (369) Fibre-optic sensor Visceral, epididymal fat 
pad 
Lean controls 
ob/ob 
47.9 mmHg 
15.2 mmHg 
6.2% 
2.0% 
Human (375) Polygraphic micro-
oxygen sensor 
SC, deltoid Lean (BMI 22) 
Obese (BMI 46) 
52 mmHg 
58 mmHg 
6.8% 
7.6% 
Mouse (368) Fibre-optic sensor Visceral, epididymal fat 
pad 
Lean controls 
ob/ob 
60.4 mmHg 
20.1 mmHg 
7.9% 
2.6% 
Human (376) Clark electrode SC, abdominal Lean (BMI 22) 
Obese (BMI 32) 
55 mmHg 
47 mmHg 
7.2% 
6.1% 
Mouse (377) Fibre-optic sensor Visceral, epididymal fat 
par 
SC, Inguinal fat pad 
Young (6 months) 
Old (23 months) 
Young (6 months) 
Old (23 months) 
36 mmHg 
21.7 mmHg 
33 mmHg 
37 mmHg 
4.7% 
2.8% 
4.3% 
4.8% 
Human (365) Optochemical sensor 
with microdialysis 
SC, abdominal Lean (BMI 23) 
Obese (BMI 34) 
47.7 mmHg 
67.4 mmHg 
6.2% 
8.8% 
Table 1.2.2: A summary of studies measuring the partial pressure (PO2) in adipose tissue (AT). BMI = body mass index; SC = subcutaneous. 
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AT-BF has been used to indicate the oxygenation state of AT. Though the 
physiological growth of AT is dependent upon increases in vasculature (334), obese 
AT expansion is not accompanied by increases in blood flow (374). Lean AT-BF is 
highly responsive to changes in circulating nutrient levels, showing large 
postprandial increases. Therefore, AT-BF plays a major role in regulating AT lipid 
metabolism and clearance of lipids from the circulation (378). AT-BF is reduced in 
obese subjects (365) and hence may lead to a dysregulation of lipid metabolism. AT-
BF can be measured by monitoring removal of injected labels such as 
133
Xe and 
ethanol, or by imaging techniques such as PET scanning (277). Blood oxygen level-
dependent magnetic resonance imaging (BOLD-MRI) has recently been used to 
evaluate AT-BF and AT oxygenation of multiple fat depots simultaneously (379). 
Therefore BOLD-MRI may provide a promising alternative to assessing AT 
oxygenation that enables measurement of the tissue as a whole. 
 
1.2.6.3 Impact of hypoxia on AT function  
Hypoxia is known to induce functional changes in adipocytes which drive the 
dysfunction and inflammation of AT. Adipocyte hypoxia results in a metabolic 
switch from oxidative phosphorylation to anaerobic glycolysis (364). Consequently, 
reduced generation of ATP results in an increased requirement for glucose, thereby 
increasing the expression of glucose transporters (GLUTs) (380). GLUT-1 is 
particularly upregulated and is often used as a marker of adipocyte hypoxia (364). 
Increased anaerobic respiration also increases the lactate production, which again is 
used to indicate adipocyte hypoxia. Activation of HIF-1α downregulates PPARγ 
production in adipocytes and preadipocytes (381), thereby attenuating further 
adipocyte differentiation. This may favour expansion of AT by adipocyte 
hypertrophy rather than hyperplasia, hence exacerbating adipocyte hypoxia. 
Preadipocytes within hypoxic AT were also shown to secrete leptin (largely 
restricted to mature adipocytes) which may drive leptin resistance (364). 
In addition to metabolic alterations, hypoxia also induces changes in adipokine 
levels, reducing secretion of adiponectin and increasing expression of leptin, IL-6 
and IL-1β (380,382). Increases in these proinflammatory cytokines are associated 
with development of local and systemic IR (259,380,382) suggesting hypoxia-
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induced release of these adipokines may initiate and drive the progression of IR. 
Hypoxic AT displays increased numbers of Mϕ which are associated with the 
development of AT inflammation (367). Hypoxia may induce apoptosis and necrosis 
of adipocytes, driving subsequent Mϕ infiltration to neutralise the necrotic cell. The 
hypoxic and inflammatory environment may then induce Mϕ towards an M1 
phenotype forming CLSs around the necrotic adipocyte. Furthermore, MCP-1 
expression is increased in hypoxic adipocytes (380) suggesting hypoxia may initiate 
the infiltration of additional Mϕ into AT which are phenotypically modified by the 
local environment to an M1 phenotype, therefore aiding the progression of AT 
inflammation. 
Local hypoxia in obese AT may drive the dysregulation of adipokine secretion and 
adipocyte metabolism thereby stimulating local inflammation and Mϕ infiltration. 
Hypoxia may therefore be the initiator of AT dysfunction that leads to a 
metabolically unhealthy obese phenotype (Figure 1.2.6).  
 
Figure 1.2.6: The role of hypoxia in AT inflammation and dysfunction. Adipocyte 
hypoxia increases release of HIF-1α, IL-6, IL-1β, leptin and MCP-1 which together lead to 
metabolic dysfunction of adipocytes, IR, Mϕ infiltration and further AT inflammation. 
Hypoxia also induces adipocyte necrosis releasing free fatty acids (FFAs) and further 
enhancing Mϕ infiltration which surround necrotic adipocytes, forming CLSs.  
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1.2.7 EVs as novel adipocyte communicators 
In comparison with the wealth of data for both the adipocyte field and the EV field, 
studies into adipocyte-derived EVs are scarce. Some characteristics and functional 
aspects of adipocyte-derived EVs have been established using 3T3-L1 cells, primary 
adipocyte cultures, and AT explants. 
 
1.2.7.1 Characteristics of adipocyte-derived EVs 
Evidence for adipocyte-derived EVs was first published in 2007 where 3T3-L1 EVs 
were shown to contain the exosomal protein, MFG-E8 and adiponectin (66). EV 
release was also responsive to obese-mimicking conditions (high glucose, insulin 
and TNF-α), suggesting a role for EVs in adipocyte dysfunction. Studies using 3T3-
L1 cells have since shown the presence of adiponectin and FABP4 in EVs (383–
385). The majority (~99%) of EVs derived from visceral and SC AT explants were 
also shown to be positive for FABP4 (386), perhaps indicating this protein as a 
useful marker for adipocyte-derived EVs. However, little is known about the specific 
EV populations released from adipocytes and no data exist detailing the lipid 
composition of adipocyte-derived EVs. 
 
1.2.7.2 Effects of adipocyte-derived EVs on metabolism 
Adipocyte derived EVs may induce several metabolic effects on a variety of 
recipient cells. Large diameter rat primary adipocytes were shown to release EVs 
containing lipid droplet-associated factors such as perilipin, CD73 and specific mIRs 
which were able to induce lipogenesis in smaller adipocytes (387–389). Therefore, 
adipocytes may utilise EVs to shift the burden of lipid synthesis from large to small 
adipocytes thereby ensuring safe adipocyte hypertrophy. Conversely, adipocytes may 
utilise EVs to mediate pathological signals, for example, EVs derived from hypoxic 
3T3-L1 cells were enriched in enzymes for de novo lipogenesis (390). As outlined in 
Section 1.2.6, hypoxic AT may drive AT dysfunction and inflammation. Therefore, 
hypoxic EVs harbouring a pro-lipogenic cargo may promote ectopic lipid deposition. 
EVs derived from visceral and SC AT explants were also shown to impair insulin 
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and TGF-β signalling in hepatocytes, suggesting adipocyte-derived EVs may 
contribute to hepatic IR and dysfunction in vivo (307,391).  
 
1.2.7.3 Immunomodulatory properties of adipocyte-derived EVs 
A number of interactions of adipocyte-derived EVs with AT-resident immune cells 
have been reported. Both primary adipocytes and visceral and SC AT explant-
derived EVs induced differentiation of monocytes to Mϕ with a phenotype akin to 
AT Mϕ (306). Furthermore, EVs derived from visceral AT explants were enriched in 
IL-6 and MCP-1 compared to SC AT (307), were capable of inducing monocyte-to-
Mϕ differentiation, and contained elevated levels of FABP4 which induced 
proinflammatory cytokine release from Mϕ (392). A recent study also demonstrated 
the ability of EVs derived from lipotoxic 3T3-L1 cells to enhance Mϕ migration both 
in vitro and in vivo (48). Together, these data suggest adipocyte-derived EVs may 
help to mediate the detrimental effects of visceral AT by enhancing local and 
systemic inflammation. 
 
1.2.7.4 Other effects of adipocyte-derived EVs 
EVs derived from mature 3T3-L1 cells contained pro-angiogenic factors including 
leptin and fibroblast growth factor-α, and were able to stimulate in vitro migration of 
HUVECs and in vivo angiogenesis (393). Adipocytes derived from MSCs also 
released EVs containing adipogenic mRNAs (such as PPARγ) which could be 
transferred and expressed in osteoblasts derived from MSCs (394), suggesting a role 
for EVs in modulating MSC lineage. 
Though the majority of research into adipocyte-derived EVs has focused on mature 
adipocytes, interesting effects of preadipocyte-derived EVs have also been 
documented. For example, 3T3-L1 cells were shown to shed the adipogenic 
repressor, Src3 using EVs (akin to reticulocytes shedding the transferrin receptor 
(395)), to allow adipogenesis to occur (396). Conversely, 3T3-L1 preadipocyte EVs 
promoted tumour growth in vivo (397) suggesting preadipocyte-derived EVs can 
exert both physiological and pathophysiological functions.  
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1.3 Thesis aims and objectives 
1.3.1 Rationale 
EVs are emerging as novel cell-cell communicators that may have potential 
functions in a wide range of diseases, and hence could be a new avenue for 
therapeutics. However, the EV field is currently hampered by a lack of 
standardisation of isolation and measurement protocols. Our current knowledge of 
adipocyte-derived EVs is limited, despite the known homeostatic role of adipocytes 
and their known role in disease progression. Therefore, adipocyte-derived EVs may 
provide an additional facet to the endocrine functions of adipocytes in both health 
and disease. 
 
1.3.2 Hypothesis 
Adipocytes release EVs that reflect the functional characteristics of adipocytes and 
may help to aid physiological processes such as adipocyte differentiation. In 
conditions mimicking metabolic stress (hypoxia), adipocytes release EVs with 
altered characteristics that may then enhance metabolic risk and obesity-related 
disease progression. As such, adipocyte-derived EVs may provide a novel circulating 
biomarker of adipocytes in vivo. 
 
1.3.3 Global thesis aim 
The overarching aim of this thesis was to explore extracellular vesicles as a novel 
mechanism of signalling for adipocytes in vitro and in vivo whilst learning about the 
current limitations of the field. 
 
1.3.4 Specific aims 
1. To understand the practical limitations of EV methodologies in order to 
provide a firm background on which to base the experimental protocols for 
EV work in this thesis. 
Page | 80  
 
2. To characterise the homeostatic release of EVs from 3T3-L1 adipocytes, 
using the transition from pre- to mature adipocytes as a model of 
physiological adipocyte function. 
3.  To assess the effect of O2 concentration on the characteristics of mature 3T3-
L1 adipocyte EV release to determine whether the pathological stimulus of 
hypoxia could induce a change in the composition and release of EVs from 
adipocytes. 
4. To monitor the effect of hypoxic 3T3-L1 adipocyte EVs on THP-1 Mϕ 
function by assessing their ability to alter the phenotype and migratory 
potential of Mϕ. 
5. To apply the knowledge acquired from previous chapters to determine the 
existence of adipocyte-derived EVs in the human circulation. 
6. To apply knowledge acquired from Results Chapter 1 to a clinical cohort of 
patients with familial hypercholesterolaemia to assess the practicalities of EV 
measurements in the clinic and to determine whether apheresis treatment 
could impact upon circulating EV concentrations.  
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2. General Methods 
Page | 82  
 
2.1 Reagent list 
Reagent/Chemical Supplier 
Annexin V binding buffer BD Biosciences, UK 
Ammonium persulphate (APS)  
Formaldehyde  
Glycine  
Isopropanol  
Methanol Fisher Scientific, UK 
10X Phosphate buffer saline (PBS)  
Sodium chloride (NaCl)  
Sodium dodecyl sulphate (SDS)  
Tris(hydroxymethyl)aminomethane  
Tween 20  
Sterile water Fresenius Kabi, UK 
DMEM (high glucose 4.5 g/L)  
FCS  Gibco (Life Technologies), UK 
Ham‟s F12 nutrient mix  
30% (w/v) acrylamide National Diagnostics, UK 
DELFIA® buffers PerkinElmer, UK 
Radioimmunoprecipitation assay (RIPA) lysis buffer Santa Cruz, CA 
Chloroform  
Developer  
Dexamthasone  
Fixer  
Indomethacin   
Insulin solution from bovine pancreas (10 mg/mL) Sigma Aldrich, UK 
β-mercaptoethanol  
Oil Red O  
Pyronin Y  
TEMED  
Trypan blue  
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2.2 3T3-L1 cells 
2.2.1 3T3-L1 culture 
3T3-L1 cells were kindly provided by Dr Mohd Shazli Draman (previously obtained 
from the American Type Culture Collection, ATCC). Cells were grown in specific 
media depending on their stage of differentiation (Table 2.1). 
Table 2.1: Media used to culture 3T3-L1 cells. Compositions of media used throughout 
3T3-L1 experiments. All % given are (v/v). CM = control medium; DM = differentiation 
medium; DMEM = Dulbecco‟s Modified Eagle Medium; FCS = foetal calf serum; MM = 
maintenance medium. 
 
Preadipocytes were maintained at no more than 70% confluence between passages to 
retain a preadipocyte phenotype. Figure 2.1 summarises the basic protocol used to 
culture 3T3-L1 cells for experiments in this thesis. 
 
2.2.2 Cell counting and viability  
Cells were gently removed from flasks using a cell scraper and pelleted by 
centrifugation at 1000 x g for 5 minutes. Cells were then resuspended in medium, 
diluted 1:1 (v/v) with trypan blue solution and counted using a Cellometer Auto T4 
(Nexcelom Biosciences, USA).  
Component CM DM MM 
DMEM (high glucose 4.5 g/L) 45% 45% 45% 
Ham‟s F12 nutrient mix 45% 45% 45% 
FCS 10% 10% 10% 
Penicillin/Streptomycin 1% 1% 1% 
Insulin - 10 µg/mL 10 µg/mL 
Indomethacin - 50 µM - 
Dexamethasone - 1 µM - 
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Figure 2.1: Timeline of 3T3-L1 culture. Details of 3T3-L1 growth for experimentation with accompanying images of confluent preadipocytes at day 0 (left) 
and mature adipocytes at day 15 (right). CM = control medium, DM = differentiation medium, MM = maintenance medium.
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2.2.3 Oil Red O staining 
3T3-L1 cells were cultured in 12 well plates and washed in sterile PBS prior to 
staining. Cells were then fixed in 10% formaldehyde (v/v in PBS) for 15 minutes at 
room temperature and subsequently washed with distilled water (dH2O). Oil red O 
working solution was freshly prepared from 0.5% oil red O stock solution (w/v in 
isopropanol) which was diluted 3:2 (v/v) with dH2O and left to stand for 15 minutes 
before being filtered through Whatman filter paper to remove precipitates. Cells 
were then stained with working solution for 15 minutes at room temperature. Excess 
stain was removed with 60% isopropanol (v/v in PBS) and washed twice with PBS 
before cells were photographed (Nikon Diaphot microscope, Nikon) at 10X 
magnification using ViewFinder™ software (version 3.0.1., Better Light Inc., USA). 
Cells were then washed a further two times with PBS, the intracellular stain was 
extracted using 100% isopropanol, and the optical density measured at 490 nm 
(Multiskan EX, MTX Lab Systems, Inc., USA). 
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2.3 Extracellular vesicle processing 
2.3.1 Isolation of cell-derived extracellular vesicles  
We (159) and others (113,398,399) have previously shown FCS-containing media 
harbours EVs that are co-pelleted with cell-derived EVs and could potentially 
overestimate EV concentration. 3T3-L1 cells were incubated in serum-free media for 
24 hours before EV isolation. Conditioned culture medium was then removed from 
cells and subjected to differential ultracentrifugation as described previously (400). 
Firstly, medium was centrifuged at 1000 x g for 5 minutes to remove any cells in 
suspension. Supernatants were then centrifuged at 15,000 x g for 15 minutes at 4°C 
to eliminate any cell debris and larger vesicles (e.g. apoptotic bodies). Finally, 
supernatants were ultracentrifuged at 100,000 x g for 1 hour at 4°C to pellet EVs. 
Vesicle preparations were then resuspended in 1X PBS, filtered using a 0.22 µm 
Millex® filter unit (Merck Millipore, Ireland) unless otherwise stated. EVs were 
resuspended in a 40-fold concentrate, i.e. EVs were resuspended in 25 μL PBS per 1 
mL conditioned medium centrifuged. 
 
2.3.2 Isolation of plasma-derived extracellular vesicles  
Blood from healthy volunteers was drawn gently into a syringe using a 21G butterfly 
needle (Hospira, UK) and divided between 3.2% (v/v) sodium citrate vacutainers 
(BD, UK). As recommendations are continually updated in the EV field, two 
different isolation protocols were used in this thesis. The first method, used in 
Chapters 3 and 8, obtained platelet-poor plasma (PPP) by immediately centrifuging 
blood at 1058 x g for 10 minutes at 4°C. PPP was then ultracentrifuged and 
resuspended as in Section 2.3.1, using a 4-fold concentrate.  
The second method was used in Chapter 7 and follows more recent 
recommendations. Blood samples were centrifuged twice at 2500 x g for 15 minutes 
at 21°C to isolate PPP and subsequently platelet-free plasma (PFP). PFP was then 
ultracentrifuged and resuspended as in Section 2.3.1, using a 10-fold concentrate. 
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2.3.3 Storage of extracellular vesicles  
Wherever possible, EVs were analysed within 1 day of isolation. For short-term 
storage (1-3 days) EVs were stored at 4°C and for longer term storage (3-14 days), 
EVs were aliquoted and frozen at 1°C/minute using a Mr Frosty™ 
(ThermoScientific, UK) to -80°C.  
Page | 88  
 
2.4 Nanoparticle tracking analysis 
2.4.1 Theory of operation 
As discussed in Chapter 1.1.7.3, NTA is one of the most popular methods used by 
researchers in the EV field to determine the size and concentration of EV samples. 
NTA utilises the laser-scattering properties of vesicles in suspension over time to 
give a visual representation of EV distributions. A laser beam is refracted into a 
diluted sample of EVs through a glass prism, resulting in a fine beam of laser-
illuminated particles in suspension. These EVs are then visualised real-time by a 
conventional light microscope (x20 magnification) with a high sensitivity digital 
camera attachment to allow the movement of EVs in suspension over time 
(Brownian motion) to be recorded (Figure 2.2). 
 
Figure 2.2: NTA operation. A 405 nm laser is refracted into the fluid suspension by a glass 
prism causing particles to scatter the laser light. This is then visualised by a microscope with 
a video camera attachment which traces the Brownian motion of illuminated particles over a 
set time period to calculate the size and concentration of EV samples. Image (A) ©Malvern 
Instruments Ltd. 
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The velocity and distance of individual EVs is tracked frame-by-frame so that the 
diffusion coefficient (Dt) of each vesicle can be determined from the Brownian 
motion over time. This can then be used with constant parameters such as 
temperature (T) and diluent viscosity (η) to calculate the particle size using a 
modified Stokes-Einstein equation (161) (Figure 2.3). 
 
             
     
    
 
 
Figure 2.3: Stokes-Einstein equation used by NTA software. NTA software inputs data 
from individually tracked vesicles into a modified Stokes-Einstein equation which calculates 
the particle size from the particle motion in two dimensions. (x,y)
2
 =  the squared average 
distance moved in the two dimensions; Dt = diffusion coefficient; KB = Boltzmann‟s 
constant; T = temperature of the diluent (K); ts = sampling time (ms); η = viscosity of the 
diluent; d = sphere-equivalent hydrodynamic diameter (particle size). 
 
2.4.2 Experimental methodology 
All NTA analyses were undertaken using a NanoSight LM10 configured with a 405 
nm laser and using software version 2.3 (Malvern Instruments Ltd, UK). Polystyrene 
beads (100 nm diameter) were measured prior to analysis of samples to ensure the 
machine was functioning properly and that the sample preparation was clear of 
contamination. Pre- and post-analytical settings were kept consistent to allow for 
intra- and inter-study comparison (Table 2.2). 
Samples were diluted in particle-free sterile water (Fresenius Kabi, UK) to achieve a 
concentration between 2 x 10
8
 and 1 x 10
9
 particles/mL. Videos of 60 seconds were 
recorded in replicates of 5 per sample. EV size is presented as the mode of the 
population (nm). The concentration of plasma EV samples is presented as EVs/mL 
of plasma whilst the concentration of cell-derived EVs is presented as EVs/viable 
cell. Size distribution graphs were generated by totalling the concentration of 
EVs/mL plasma or EVs/viable cell in each 50 nm range (bin width) for plasma and 
cell-derived EVs respectively.  
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 Setting Beads EVs 
Pre-analytical Camera shutter  450 450 
 Camera gain 250 250 
 High threshold 3025 2275 
 Low threshold 0 0 
Post-analytical Temperature 22 to 26 °C 22 to 26 °C 
 Screen gain 9-10 13-15 
 Detection threshold 6 4-6 
Table 2.2: Pre- and post-analytical settings used for NTA experiments. Details of all 
pre- and post-analytical settings used when analysing bead and EV samples using NTA.  
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2.5 Tunable resistive pulse sensing 
2.5.1 Theory of operation 
As previously discussed (Chapter 1.1.7.3), tunable resistive pulse sensing (TRPS) is 
a method also used for EV quantification and sizing. TRPS is based on the “Coulter 
Principle” which measures the electrical impedance (usually of cells) passing 
through an aperture to determine the size and concentration (401). TRPS uses 
tunable thermoplastic polyurethane nanopores which are suspended between two 
fluid cells both containing silver/silver chloride electrodes. The pore is mounted on 
an adjustable stage ensuring the pore is fixed in place, but also allowing the stretch 
of the pore to be adjusted. Fluid cells are filled with electrolyte buffer so that when a 
voltage is applied, a current passes through the pore between the wells (Figure 2.4). 
Electrolyte in the upper fluid cell can be replaced with a sample (diluted in 
electrolyte buffer) and voltage applied so that suspended vesicles pass through the 
pore with the current. Passage of vesicles through the pore causes a displacement of 
the electrolyte within the pore, temporarily increasing the resistance and hence 
decreasing the current. This is represented digitally by a “blockade event” (Figure 
2.4 D). The magnitude of the blockade event is directly proportional to the volume of 
the vesicle. Therefore, calibration beads of known diameter and concentration can be 
analysed using TRPS to give uniform blockade parameters. The accompanying 
software can then use the calculated blockade parameters of individual calibration 
particles in an extraction algorithm to determine the size and concentration 
distributions of unknown spherical vesicles. 
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Figure 2.4: TRPS assembly and theory. (A) The assembled IZON qNano machine and 
variable pressure module (VPM) (left) and a schematic of the core individual components. A 
nanopore is fixed across the lower fluid cell and stretched to a specific width. The upper 
fluid cell is clipped onto the lower fluid cell on top of the nanopore to form a central seal 
between the 3 layers. (B) Electrolyte is added to the fluid cells and a voltage is applied 
creating a current two across the silver/silver chloride electrodes in each fluid cell caused by 
the movement of ions across the pore. (C) The electrolyte current is represented digitally by 
a flat baseline. (D) Particles passing through the pore displace the electrolyte and decrease 
the current resulting in individual “blockade events” - indicated by blue arrows. Images 
adapted from IZON training modules. 
 
A fluid cell cap is secured upon the upper fluid cell acting as a Faraday cage 
(reducing the background noise of the system) but also serving as a point of 
attachment for the variable pressure module (VPM). The VPM applies pressure to 
the system which replaces electrophoretic mobility as the dominant force for vesicle 
movement through the pore. This enables equal transition of charged and uncharged 
vesicles across the pore and allows for determination of EV concentration. 
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2.5.2 Experimental methodology 
TRPS experiments were performed using the qNano, CPC (carboxylated polystyrene 
particles) calibration beads, tunable nanopores and software version 2.2 (all IZON 
Science, NZ)). Prior to EV analysis, calibration beads (Table 2.3) were used to 
adjust the stretch of the nanopore and the voltage applied to achieve a blockade 
magnitude of 0.3 nA. This not only ensured that a range of EVs smaller and larger 
than the calibration beads could be analysed, but also that this same range could be 
analysed between different experiments. Fresh 1X PBS (prepared as in Section 2.3.1) 
was used as the electrolyte buffer and as a medium for calibration bead/sample 
dilution. A bandwidth filter of 5 kHz was applied and recordings were stopped if 
background noise exceeded 10 pA. Applied pressure was kept at 7 mbar and the 
minimum recordable blockade magnitude was set to 0.05 nA. 
EV concentration data are presented as particles/mL plasma and the mode particle 
size (nm). 
CPC  Mode size (nm) Stock concentration 
(particles/mL) 
Recommended pore 
100 115 1.0 x 10
13 
np100 
200 203 1.3 x 10
12 
np200 
400 335 5.5 x 10
11 
np400 
500 475 3.6 x 10
11 
np400 
800 766 5.0 x 10
10
 np800 
1000 900 5.5 x 10
10 
np800/1000 
Table 2.3: IZON CPC calibration beads. Calibration beads and recommended nanopores 
supplied for use with the qNano. The mode size and stock concentration of each calibration 
bead is given.  
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2.6 Flow cytometry 
Flow cytometry (FC) is often used to analyse phenotypic surface makers of cells and 
EVs (Chapter 1.1.7.2). Figure 1.1.9 outlines the basic mechanism of FC. Here, FC 
was used to analyse the annexin V positivity (PS exposure) of 3T3-L1 cells and EVs 
(obtained from T75 cm
2
 flasks), the presence of adipocyte markers in plasma EVs, 
and the cellular origin of plasma derived EVs in a patient cohort. Specific methods 
are given in Chapters 7 and 8 for the measurement of plasma-derived EVs. Analyses 
were performed using a FACS Canto and FACS Diva™ software version 6 (both BD 
Biosciences, CA). Data were exported and subsequently analysed using FlowJo 
software version 10 (Tree Star Inc., OR). 
 
2.6.1 Annexin V positivity of 3T3-L1 cells 
Cells were gated based on their linear forward and side scatter properties with the 
assistance of Dr Kirsty Richardson. 3T3-L1 cells in PBS at a concentration of 1 x 
10
6
 cells/mL were analysed as a negative control. Cells were then pelleted at 1000 x 
g for 5 minutes and resuspended in 1X 0.22 µm-filtered annexin V binding buffer 
(BD Biosciences). Annexin V-FITC (Biolegend, CA) was added and cells were left 
to incubate in the dark for 15 minutes. Cells were then pelleted as before and 
resuspended in PBS for analysis, where 10,000 events per sample were recorded.  
 
2.6.2 Annexin V positivity of EVs 
The EV gate used was determined by Dr Gareth Willis using the logarithmic scatter 
of CPC beads (200 nm, 500 nm and 1µm, IZON Science). 3T3-L1 EVs were 
resuspended in annexin V binding buffer following ultracentrifugation as described 
in Section 2.3.1 and ran as an unstained control. EVs were then stained and analysed 
as in Section 2.6.1.  
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2.7 Gas Chromatography 
Lipid and phospholipid analysis of cells and EVs was performed with Dr Irina 
Guschina using gas chromatography with flame ionisation detection (GC-FID). In 
order to obtain enough EVs to perform phospholipid analysis, 7 x T175 cm
2
 flasks 
were grown in parallel and pooled. GC experiments used repeats of EVs from 1 x 
T175 cm
2
 flasks. An index of fatty acids is provided on Page VIII. 
 
2.7.1 Lipid extraction 
A 2:1 (v/v) solution of chloroform:methanol was added to the resuspension of cells 
and EVs in PBS. Further chloroform was added with Garbus solution (2 M KCl, 500 
µM KPO4, pH 7.4) and samples were vortexed and centrifuged at 250 x g for ~ 5 
minutes to separate the inorganic and organic phases (402). The lower organic 
(chloroform) phase was carefully transferred to fresh tubes and completely dried 
down under a steady stream of N2 gas at room temperature before being resuspended 
in chloroform. Lipids in chloroform were directly methylated for GC or prepared for 
phospholipid separation. 
 
2.7.2 Fatty acid methylation and gas chromatography  
A 2.5% sulphuric acid solution (v/v) in methanol:toluene (2:1, v/v) was used to 
methylate fatty acids for 2 hours at 70°C. Fatty acid methyl esters (FAME) were then 
extracted thrice with hexane for GC analysis. A known amount of C17:0 (margaric 
acid; Nu-Chek Prep, Inc,. Elysian, MN) was added as an internal standard so that 
subsequent quantification of peaks (and consequently lipids) could be performed. 
GC was undertaken using a Clarus 500 gas chromatograph (Perkin-Elmer, CT) fitted 
with a 30 m x 0.25 mm, i.d., 0.25 µm film thickness capillary column (Elite 225, 
Perkin-Elmer). The column temperature was held at 170°C for 3 minutes before 
being temperature-programmed to reach 220°C at 4°C/minute. Nitrogen was used as 
the carrier gas at a flow rate of 2 mL/minute. Data were acquired using Total Chrom 
Navigator (Perkin-Elmer) and the retention times of external standards (Supelco 37 
Component FAME Mix, Sigma Aldrich) were used to identify FAME. An example 
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of a chromatogram is shown in Figure 2.5. Fatty acid concentration is expressed in 
mg/mL plasma, mg/10
6
 cells or ng/10
6
 EVs. Compositions of individual fatty acids 
were calculated as a percentage of total fatty acid concentration. 
 
 
Figure 2.5: GC chromatogram. Example GC chromatogram data; long chain fatty acids 
have greater retention times and therefore take longer to elute.  
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2.7.3 Phospholipid separation 
Lipids in chloroform were separated by two-dimensional thin layer chromatography 
(TLC) using silica gel 60 plates (10 x 10 cm, Sigma Aldrich) impregnated with boric 
acid (1.2% in ethanol/water; 1:1, v/v). Lipids were separated in the first dimension 
using a solution of chloroform:methanol:ammonium hydroxide (65:35:10, v/v/v) and 
using N-butanol:acetic acid: water (90:20:20, v/v/v) in the second. Plates were then 
completely dried and sprayed with a 0.05% solution of 8-anilino-4-napthosulphonic 
acid in dry methanol (v/v) and visualised under UV light to enable identification of 
lipid classes (Figure 2.6). Individual lipids were then scraped from the plates and 
methylated for GC as in Section 2.7.2. Phospholipids are presented as a proportion of 
the total lipid. Individual fatty acids of each phospholipid group are presented as a 
percentage of the total fatty acid concentration of the phospholipid. 
 
Figure 2.6: TLC separation of lipids. Extracted lipids in chloroform were spotted onto the 
corner of a silica gel plate impregnated with boric acid. Lipid classes were then separated in 
two dimensions (directions indicated by numbered arrows) and visualised under UV light. 
CL = cardiolipin; PC = phosphatidylcholine; PE = phosphatidylethanolamine; PI = 
phosphatidylinositol; PS = phosphatidylserine; and Sph = sphingomyelin.   
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2.8 BCA protein assay 
2.8.1 Background 
The bicinchoninic acid (BCA) protein assay measures a colourimetric change in the 
oxidation state of copper caused by the presence of protein. The assay initially 
utilises the principles of the biuret reaction where cupric ions (Cu
2+
) present in the 
alkaline working solution are reduced by chelation with protein to form cuprous ions 
(Cu
1+
). BCA then reacts with free Cu
1+
 causing a colour change from blue to purple 
which can be measured colourimetrically. The BCA assay was used to calculate 
protein concentrations of cells and EVs for EV immunophenotyping and Western 
blotting experiments.  
 
2.8.2 Experimental procedure 
The Pierce™ BCA protein assay kit (Thermo Scientific, UK) was used to determine 
protein concentration. Cell and EV samples were compared against serially diluted 
bonvine serum albumin (BSA) standards. Standards and samples were diluted in 
PBS and 25 µL of each was added to 200 µL of working reagent in a 96 well plate 
(Greiner Bio-One, Germany) in triplicate. The plate was mixed for 30 seconds, 
wrapped in foil and left to incubate for 30 minutes at 37°C according to the 
manufacturer‟s protocol. The absorbance was read at 562 nm and concentrations 
determined from the standard curve in µg/mL (Figure 2.7, r
2
 value >0.99 for each 
assay). 
 
Figure 2.7: BCA assay standard curve. A typical 6-point standard curve obtained from a 
BCA assay. BSA standards diluted to 250, 125, 50, 25, 5 and 0 µg/mL.   
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2.9 Extracellular vesicle immunophenotyping 
An immunophenotying assay developed in the lab of Dr Aled Clayton (158) was 
used to determine the protein content of 3T3-L1 EV samples. The assay entails 
isolated vesicles being adhered to “sticky” ELISA plates then probing for antibodies 
of interest (Figure 1.1.10). The use of europium ensures a highly fluorescent signal 
enabling detection of less abundant antigens.  
 
2.9.1 Immunostaining of EVs 
EVs were immobilised on high protein binding ELISA plates (Greiner Bio-One) at a 
concentration of 1 µg (determined as in Section 2.8.2) per well and allowed to settle 
overnight at 4°C. RIPA (radioimmunoprecipitation assay) buffer (Santa Cruz, CA) 
was added for 1 hour at room temperature to permeabilise EVs for staining of 
antigens within the vesicles. EVs were then probed with primary antibodies diluted 
to 1µg/mL (Table 2.4) for 2 hours at room temperature on a plate shaker. Antigens 
were detected using specific biotin-labelled secondary antibodies and a streptavidin-
europium conjugate (all Perkin-Elmer). Three washes were performed between each 
addition (6 washes following addition of streptavidin-europium) using DELFIA® 
wash buffer (Perkin-Elmer). Plates were analysed using time resolved fluorescence 
using both a Wallac Victor
2
 plate reader (Perkin-Elmer) and a FLUOstar OPTIMA 
(BMG Labtech, UK). The focal height was set to 7.8 mm and the gain to 2048 a.u.. 
Each well received 200 flashes and the detection measurement started at 400 μs after 
the last flash and was recorded for 400 μs (integration “start” and “time” 
respectively). Data are presented in arbitrary TRF units which have been adjusted for 
background fluorescence by deducting negative control (EVs with no primary 
antibody) TRF values. 
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Antibody Manufacturer and 
product code 
Source Dilution 
Adiponectin 
(anti-mouse) 
CST: #2789 Rabbit 1:10 
Adiponectin 
(anti-human) 
Abcam ab18065 Rabbit 1:15 
Alix CST: #2171 Mouse 1:450 
CD9 Santa Cruz: sc-9148 Rabbit 1:200 
CD63 Santa Cruz: sc-15363 Rabbit 1:200 
FABP4 CST: #3544 Rabbit 1:1000 
HIF-1α Abcam: ab179483 Rabbit 1:117 
IL-6 CST: #12912 Rabbit 1:101 
IL-10 CST: #12163 Rabbit 1:101 
MCP-1 CST: #2029 Rabbit 1:16 
PPARγ CST: #2443 Rabbit 1:50 
PREF-1 CST: #2069 Rabbit 1:50 
TNFα CST: #11948 Rabbit 1:101 
TSG101 Santa Cruz: sc-227 Rabbit 1:200 
Table 2.4 Antibodies used for EV immunophenotyping. Details of primary antibodies 
used for EV immunophenotyping experiments. One μg/mL of each antibody was added to 
each well, accounting for the differences in dilution. CD = cluster of differentiation; FABP4 
= fatty acid binding protein-4; HIF-1α = hypoxia inducible factor-1α; IL = interleukin; 
MCP-1 = monocyte chemoattractant protein-1; PPARγ = peroxisome proliferator-activated 
receptor γ; PREF-1 = preadipocyte factor-1; TNF-α = tumour necrosis factor-α; TSG101 = 
tumour susceptibility gene -101. 
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2.10 Western Blotting 
2.10.1 Lysis of cells  
Cells were washed with 1X PBS on ice, before the addition of cold lysis buffer (50 
mM Trizma® base, 150 mM NaCl, 5 mM EGTA, 1% (v/v) Triton X100 in dH2O, 
pH 7.6) supplemented with protease inhibitor cocktail (PIC, cOmplete tablets, 
Roche, UK). Cells were gently removed from flasks using a scraper. Samples were 
then centrifuged twice (13,000 x g, 4°C, 20 minutes) to pellet cell and vesicle debris. 
Supernatants were then analysed for their protein concentration as in Section 2.8.2 
and stored in sterile Eppendorf tubes at -20°C until required. 
 
2.10.2 Separation of proteins by SDS-PAGE 
Ten to twenty μg of protein was denatured by diluting 1:1 with loading buffer (Table 
2.5), boiling for 5 minutes at 100 °C and centrifugation at 13,000 x g for 5 minutes. 
 
Component Volume (mL) 
10% SDS 2 
Glycerol 1 
0.5 M Tris (pH 6.8) 1 
Water 0.8 
0.2% Pyronin Y 0.1 
β-mercaptoethanol 0.1 
10X PIC 0.5 
Table 2.5: Loading buffer. Constituents and volumes used to make loading buffer; 
Percentages are given in w/v. SDS = sodium dodecyl sulphate; PIC = protease inhibitor 
cocktail. 
 
Proteins were then loaded onto freshly prepared polyacrylamide gels (Table 2.6) and 
separated by sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-
PAGE). A pre-stained broad range colour ladder (11-245 kDa, Cell Signaling 
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Technologies, New England BioLabs, UK) was also loaded and samples were 
resolved at 200 V in 1X running buffer (Table 2.7) until bands reached the bottom 
of the running gel.  
 
Component Running gel (mL) 4% Stacking gel (mL) 
30% Acrylamide  
 
8% 
2.64 
10% 
3.30 
12% 
3.96 
15% 
4.95 
1.3 
Water 3.58 2.92 2.26 1.27 6.1 
1 M Tris (pH 8.8) 3.75 - 
0.5 M Tris (pH 6.8) - 2.5 
10% SDS 0.1 0.1 
10% APS 0.1 0.1 
TEMED 0.005 0.01 
Table 2.6: Polyacrylamide gels. Components and volumes of running and stacking gels 
used for SDS-PAGE. Running gels of differing acrylamide percentages were used 
depending on the size of the protein of interest. Gels and APS were freshly made on the day 
of experimentation. SDS = sodium dodecyl sulphate; APS = ammonium persulphate; 
TEMED = tetramethylethylenediamine. Percentages are given in w/v. 
 
Component Weight (g) 
Tris 15 
Glycine 72 
SDS 5 
Table 2.7: 5X Running buffer. Components of the running buffer made up to 1 L with 
distilled water and diluted 1:5 for running gels. 
 
2.10.3 Electroblotting 
Wet electroblotting was used to transfer proteins from the gel to a PVDF 
(polyvinylidene fluoride) transfer membrane (Amersham™ Hybond™-P 0.45, GE 
Healthcare, UK). Membranes were pre-wet briefly in methanol before transfer. 
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Proteins were transferred for 1 hour at 350 mA in blotting buffer (Table 2.8, cooled 
at -20°C for >1 hour prior to use) with a magnetic stirrer and ice pack. 
Component Amount 
Tris 3.025 g 
Glycine 13.66 g 
Water 800 mL 
Methanol 200 mL 
Table 2.8: Blotting buffer. Components and volumes used to make blotting buffer, stored 
at -20°C for >1 hour before use. 
 
2.10.4 Incubation of antibodies  
Following transfer of proteins, membranes were washed in tris-buffered saline with 
Tween 20 (TBS-T, Table 2.9). All subsequent washes were performed 3 times for 5 
minutes on an orbital shaker using TBS-T. 
 
Component Volume (mL) 
10X TBS* 100 
Water 900 
Tween 20 1 
Table 2.9: TBS-T wash buffer. Components and volumes of TBS-T wash buffer. *10X 
TBS was made from 24.2 g Tris, 80 g NaCl made up to 1 L with distilled water and adjusted 
to pH 7.6 with 10 M hydrochloric acid. 
 
Membranes were then blocked for 1 hour at room temperature on an orbital shaker in 
blocking buffer (5% (w/v) skimmed milk powder (Marvel, UK) in TBS-T). 
Membranes were incubated with rabbit anti-mouse monoclonal primary antibody 
(specific details given in each chapter) overnight at room temperature. Membranes 
were washed before adding ECL™ peroxidase labelled donkey anti-rabbit secondary 
antibody (GE healthcare) diluted 1:5000 in blocking buffer for 1 hour at room 
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temperature. Finally, membranes were washed thoroughly (2 x 30 seconds, 1 x 15 
minutes, and 3 x 5 minutes in TBS-T) to prepare for developing. 
 
2.10.5 Developing of blots  
Membranes were incubated in ECL Prime Western blotting detection reagent (GE 
Healthcare) for 5 minutes at room temperature before being exposed to photographic 
film (Amersham™ Hyperfilm ECL, GE Healthcare) in a dark room. Time of 
exposure varied with each antibody (see Table 2.10). Films were then developed 
using Kodak™ -D19 developer and fixer (Sigma Aldrich). 
 
2.10.6 Densitometry 
Densitometry analysis was conducted using ImageJ software (version 1.49, National 
Institutes of Health, USA). Raw densitometry values were then normalised to a 
control unless otherwise stated.   
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2.11 Statistical analysis 
Data in this thesis were analysed using GraphPad Prism (version 6.0, GraphPad 
sortware Inc., USA). Details of specific statistical analyses are given in the Methods 
section of each Results chapter. Data are presented as mean ± SD unless otherwise 
stated and a p value of <0.05 was considered statistically significant. 
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3. Results I: 
Developments in methodology 
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3. Perspective 
The work detailed in this chapter was conducted at the beginning of my PhD as I was 
learning about the practicalities of working with EVs and the field-wide lack of 
standardisation. Our lab was fortunate to have regular access to two EV 
measurement techniques; NTA and TRPS, the latter being an emerging/less-widely 
used technique. This therefore presented a good opportunity to compare the two 
techniques whilst learning about their relative benefits and weaknesses. Furthermore, 
our interests prior to beginning work with EVs were in clinical measurements and so 
we were first interested in studying EVs derived from plasma. Consequently, I 
decided to begin establishing the effects of different pre-analytical processes on EV 
measurements. This was conducted using TRPS with the support of IZON Science 
and in parallel with Chapter 8. 
Due to the novelty and ever increasing popularity of the EV field, much of the work 
in this chapter has since been conducted and published by others. Nevertheless, this 
chapter provides interesting and in-depth insights into methodological aspects and 
sample processing of EVs. 
 
 
 
 
 
 
  
Parts of this chapter have been published in: 
Connolly K, Morris K, Willis GR, Rees DA, James PE (2014). Do conditions of 
freezing and time-in-freezer really matter? Journal of Extracellular Vesicles. 3: 
24214; P8B-301. 
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3.1 Introduction 
In addition to discussing the potential of EVs as disease biomarkers and therapeutic 
targets, Chapter 1.1 also introduced the inconsistencies and lack of standardisation 
that exist within the EV field which make inter-study comparison difficult. This 
disparity has perhaps been exacerbated by the rapid growth in interest in EVs in 
recent years. Though attempts are being made to standardise EV isolation, analysis 
and storage (16), there are currently no gold standard protocols or techniques. 
At the outset of data collection for this chapter (2012-2013), many techniques were 
available to measure EV size and concentration including: TEM; DLS; FC; NTA 
(149,161,403) and the emerging TRPS. Each technique has its own advantages and 
disadvantages (149) and the use of a particular technique is often dependent on the 
desired outcome or variable to be measured (404). NTA, one of the most widely used 
of the techniques to measure EV size and concentration, video records the light 
scattering and Brownian motion of particles in suspension. NTA has been shown to 
give a better detection of polydispersity compared to DLS (405) which is often 
biased by the presence of larger vesicles, as scattered light from all EVs is pooled by 
a single detector (160,161). NTA is more user-friendly than TEM, requiring less 
sample preparation and hence reduces adverse effects on EV morphology (108). 
Finally, NTA provides superior sensitivity for EVs <300 nm compared with FC 
(161) where the lower detection limit and swarm detection of EVs may result in an 
underestimation of concentration (154). However, little was known about TRPS, 
which unlike other techniques, measures EVs on a particle-by-particle basis as they 
disrupt the current passing through a tuneable nanopore (406).  
As with EV measurement, there are no established protocols for the isolation and 
storage of EVs used prior to analysis. This is partly due to the diversity of EV 
sources (e.g. plasma, saliva, urine and conditioned culture media) that require 
different pre-analytical processing. This, combined with the use of different 
measurement techniques, results in significant inconsistencies in reported EV 
concentrations (407). Investigations into varying the time before processing, the 
anticoagulant, the number and speed of centrifugation steps, and freeze-thawing are 
all reported effect EV concentration (59,107,108,408,409). Increases in EVs were 
observed when blood was not processed immediately after isolation and following 
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storage at -80°C for 1 month (107). Additionally, chelating anticoagulants (citrate, 
ACD and EDTA) yielded fewer EVs compared with protease inhibitor 
anticoagulants (sodium heparin, hirudin) (59). Storage of platelet-poor plasma (PPP) 
at -80°C for 1 week also increased the detection of certain EV subtypes (409). 
However, freezing was also shown to decrease subsets of EVs (60,409) particularly 
with long-term storage (107). These conflicting effects of pre-analytical processing 
were measured directly using FC, which as discussed in Chapter 1, may be 
inaccurate due to the low refractive index and “swarming” of EVs (154). Therefore, 
the effects of pre-analytical processing on EV size and concentration (particularly 
EVs below the detection limit for FC) may have not been fully characterised. 
 
3.1.1 Aims 
This chapter sought to explore TRPS as an EV measurement technique and to utilise 
TRPS to measure changes in EVs prepared using different pre-analytical processes. 
The specific aims were: 
1. Using calibration beads, to test the technical aspects of TRPS in terms of; 
a. Linearity compared with NTA 
b. Limits of detection compared with NTA 
c. Detection of polydispersity compared with NTA, DLS and FC 
2. To use TRPS to assess the changes in plasma EV size and concentration 
following pre-analytical processing with: 
a. Citrate and EDTA vacutainers 
b. Filtering EV samples 
c. Method and length of storage of EVs 
 
3.1.2 Hypotheses 
TRPS may be an alternative technique for measuring EV size and concentration that 
overcomes the negatives of measuring EVs using light scattering-based techniques. 
Pre-analytical processing of EVs may change detected size and concentration of EVs 
detected by TRPS.  
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3.2 Methods 
3.2.1 Nanoparticle tracking analysis  
NTA analyses were carried out as described in Chapter 2.4.2 using the analytical 
settings for beads (Table 2.2). Calibration beads (50, 100, 300 and 1000 nm; 
Malvern, UK) were used for NTA experiments. To create a standard curve, six 
dilutions of 100 nm beads were prepared in sterile water over a 16-fold dilution 
range (1.5 x 10
8
 – 2.5 x 109 particles/mL). To test the limits of detection, 50, 100, 
300 and 1000 nm beads were individually analysed and plotted together on one 
graph in particles/mL. Finally to test how NTA dealt with polydispersity, 50, 100 
and 300 nm beads were prepared at a 1:1:1 ratio and analysed in triplicate.  
 
3.2.2 Tuneable resistive pulse sensing  
TRPS analyses were conducted as indicated in Chapter 2.5.2 using CPC calibration 
beads (IZON Science, NZ) (Table 2.3). For the standard curve, an np200 pore was 
used with six dilutions of CPC200 beads in 1x PBS (filtered through a 0.22 µm pore 
prior to dilutions) over a 16-fold dilution range (5.5 x 10
8
 – 8.8 x 109 particles/mL). 
For the limits of detection, CPC100, 200, 400, 500, 800 and 1000 nm beads were 
analysed using np100, np200, np400 and np800 pores. Nanopores were tested with 
each CPC bead until beads fell below the detection limit of the pore or the pore 
became blocked (which occurred frequently). Results were expressed as a percentage 
of the total count due to significant variations in concentrations between beads (see 
Table 3.3.1). Finally, to test the ability of TRPS to detect polydispersity, an np100 
pore was used to analyse a mix of CPC100, 200 and 400 beads prepared at a 1:1:1 
ratio. 
 
3.2.3 Dynamic light scattering 
A Zetasizer Helix (Malvern, UK) was assessed for its ability to detect individual 
populations of 50, 100 and 300 nm beads in a 1:1:1 mixture. 
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3.2.4 Flow cytometry 
A custom-built BD FACSAria II was used to analyse a mix of 200, 500 and 800 nm 
fluorescent beads (Submicron bead calibration kit, Bangs Laboratories Inc., USA) 
prepared at a 1:1:1 ratio. Experiments and analyses were performed with the help of 
Dr Kristin Ladell (Cardiff University). 
 
3.2.5 Isolation of plasma-derived extracellular vesicles  
Blood was collected from healthy volunteers as described in Chapter 2.3.2 using the 
first isolation method. Blood in this chapter was collected into both citrate and 
EDTA vacutainers for comparison of EV concentration. 
 
3.2.6 Filtering of extracellular vesicles  
Isolated plasma-derived EVs were further diluted in PBS (750 µL PBS for every 
250µL EVs) and 4 aliquots were prepared as depicted in Figure 3.2.1. Briefly, half 
of the EV aliquot was passed through a 1 µm filter and the filtrate was either 
analysed immediately (1) or frozen at -20°C overnight before being analysed (3). 
The remaining unfiltered aliquot was analysed immediately (2) and one aliquot was 
frozen at -20°C before being analysed (4). All EV samples were analysed using 
TRPS with np200, 400 and 1000 pores. 
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Figure 3.2.1: Filtering of EVs. Filtered and non-filtered plasma-derived EVs were analysed 
by TRPS. Freshly isolated EVs were filtered through a 1 µm pore (1) and analysed 
immediately by TRPS. Freshly isolated EVs were left unfiltered and analysed by TRPS (2). 
Filtered EVs were stored at -20°C overnight and analysed by TRPS (3) and finally unfiltered 
EVs were stored at -20°C overnight and analysed by TRPS (4). All samples were analysed 
using np200, np400 and np1000 pores where possible. 
 
3.2.7 Method and length of storage of extracellular vesicles  
Filtered (as above) plasma-derived EVs collected from 4 healthy volunteers were 
aliquoted and stored (Figure 3.2.2). Briefly, 6 different methods of storage and 4 
lengths of time in storage were analysed for their effect on EV size and 
concentration. Fresh samples were analysed immediately following collection using 
TRPS with an np200 pore. Methods of storage tested included fresh EV samples: put 
directly into the fridge; stored at -20°C; snap frozen in liquid nitrogen; slow frozen 
to -80°C in a Mr Frosty™ (Thermo Scientific, UK); mixed with 5% (v/v) glycerol 
(Fisher Scientific, UK) and slow frozen at -80°C in a Mr Frosty™; and mixed with 
0.05% (v/v) Tween 20 (Sigma Aldrich, UK) and slow frozen at -80°C in a Mr 
Frosty™. Aliquots were then stored for 1 day, 1 week, 1 month or 3 months and 
analysed by TRPS using an np200 pore. 
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Figure 3.2.2: Method and length of EV storage. Plasma EVs filtered through a 1 µm filter 
were analysed for the effect of storage on size and concentration using TRPS. Fresh EVs 
were analysed on the day of isolation and were used to compare other samples to. EVs were 
stored by 6 different methods for 1 day, 1 week, 1 month and 3 months. “Snap” refers to 
samples snap frozen in liquid nitrogen and then stored at -80°C. “Glycerol” and “Tween” 
refer to samples mixed with either 5% Glycerol (v/v) or 0.05% Tween 20 (v/v), slow frozen 
in a Mr Frosty and then stored at -80°C. 
 
3.2.8 Statistical analysis 
Data were analysed using GraphPad Prism version 6 (GraphPad software, USA). 
Samples were tested for normality using D‟Agostino and Pearson omnibus normality 
test to determine the need for a parametric or non-parametric statistical test. Data are 
presented as mean ± SD unless otherwise stated. An unpaired t-test or a Kruskal-
Wallis test (with a Dunn‟s multiple comparisons post-hoc test) were used to compare 
means whilst a general linear model was used to assess the difference in mean 
concentration of EVs over time of storage. A p value of <0.05 was considered 
statistically significant.  
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3.3 Results 
3.3 Part I: Comparison of EV methodologies 
Upon beginning this chapter of work and my research in the EV field (2012-2013), 
there was an evident lack of clarity across all EV research. This was recognised by a 
number of companies at the time leading to competition in supplying key 
instrumentation to researchers. However, little was known about the reliability of 
such instrumentation to measure EV size and concentration. Therefore, to learn 
about the practicalities and pitfalls, a comparison was undertaken between NTA 
(widely used at the time) and TRPS (an emerging technique at the time). 
 
3.3.1 Reliability of NTA and TRPS 
Calibration beads were measured using NTA and TRPS over a range of six dilutions. 
Both NTA and TRPS show good linearity between the actual and measured 
concentrations of calibration beads over a range of dilutions (r
2
 = 0.988 and 0.993 
for NTA and TRPS respectively; Figure 3.3.1 A/B). Mode size of beads detected 
was relatively uniform with varying concentrations of beads for both NTA and 
TRPS (Figure 3.3.1 C; dilutions are labelled 1-6 as different concentration ranges 
are covered by NTA and TRPS). NTA showed a slightly higher mode size for all 
dilutions which gradually increased with the concentration whereas TRPS showed 
more deviation from the manufacturer-provided mode (203 nm).  
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Figure 3.3.1: Calibration bead standard curves. Calibration beads were analysed over a range of dilutions using NTA with 100 nm beads (A) and TRPS 
with 200 nm beads and an np200 (B) respectively. The measured concentrations were then plotted against the diluted concentrations and fitted with linear 
regression. The effect of increasing bead concentration on mode size (C); circled points indicate the manufacturer recommended dilution. 
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3.3.2 Limits of detection 
Manufacturer-provided calibration beads of varying sizes were analysed using NTA 
and TRPS to assess detectability across the EV range. NTA was able to detect each 
size of bead as an individual population when a single bead size was analysed (50 
nm beads = 48 ± 6 nm, 100 nm beads = 97 ± 2 nm and 300 nm beads = 285 ±17 nm) 
though the size of 1000 nm beads was underestimated (703 ± 102 nm; Figure 3.3.2 
A). In order to view the beads detected with each nanopore on one graph, TRPS data 
are presented as a percentage of the population by count (Figure 3.3.2 B). TRPS 
detected individual bead sizes across the EV range when using different pores. 
However, the detected concentration and mode size of beads varied between 
nanopores, particularly at the upper and lower limits of each nanopore (Table 3.3.1).  
 
3.3.3 Detection of polydispersity  
EV samples often contain a range of vesicle sizes. Therefore it is important that the 
technique used to measure EVs is able to distinguish between sizes in polydispersed 
samples. Fortunately, at the time of undertaking this experiment, 4 techniques 
commonly used to measure EV samples were available to analyse polydispersed 
mixtures of beads (Figure 3.3.3). DLS detected beads from around 50 – 300 nm, 
however, this was represented by a single peak with a mode size of around 150 nm 
(A). NTA was able to clearly distinguish between 100 and 300 nm beads, however, 
50 nm beads were detected as a small shoulder on the 100 nm bead peak (B). The 
measured size of 300 nm beads was also underestimated in the polydispersed mix 
analysed with NTA. TRPS was able to identify each bead in the mixture as an 
individual population; however the measured mode size for each bead was under- or 
overestimated for CPC100/200 and CPC400 respectively (C). Finally, FC was able 
to distinguish between the 3 bead sizes (200, 500 and 800 nm); however, this was 
based on the fluorescence and side scatter of each bead (D). 
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Figure 3.3.2: Ranges of detectability. The ability of both NTA and TRPS to detect beads 
across the EV range was measured. (A) NTA; Individual bead preparations of 50, 100, 300 
and 1000 nm beads were analysed using NTA. (B) TRPS; CPC100, 200, 400, 500, 800 and 
1000 were analysed using np100, 200, 400 and 800. The expected mode size of each bead 
(as denoted by the manufacturer) is marked with a red cross. 
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Table 3.3.1: Variation between TRPS nanopores. Beads detected by each TRPS nanopore 
varied in both concentration and mode size. Mean concentration and mode size of beads are 
given in particles/mL and nm respectively. Designated calibration beads for each pore are 
highlighted in bold. Stock concentrations were: CPC100; 1.0 x 10
13
 particles/mL; CPC200; 
1.2 x 10
12
 particles/mL; CPC400; 5.5 x 10
11
 particles/mL; CPC500; 3.6 x 10
11
 particles/mL; 
CPC800; 5.0 x 10
10
 particles/mL and CPC1000; 5.5 x 10
10
 particles/mL. 
  
 np100 np200 np400 np800 
CPC100     
Concentration 
Mode size 
1.6 x 10
13 
115  
2.8 x 10
12
 
134 
  
CPC200     
Concentration 
Mode size  
2.5 x 10
12
 
203 
1.1 x 10
12
 
215 
1.4 x 10
12
 
194 
 
CPC400     
Concentration 
Mode size 
1.6 x 10
12
 
376 
1.2 x 10
12
 
350 
5.7 x 10
11
 
353 
3.7 x 10
10
 
360 
CPC500     
Concentration 
Mode size 
 3.7 x 10
11
 
524 
4.3 x 10
11
 
466 
7.9 x 10
10
 
513 
CPC800     
Concentration 
Mode size 
  1.3 x 10
11
 
723 
5.2 x 10
10
 
771 
CPC1000     
Concentration 
Mode size 
   1.6 x 10
10
 
947 
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Figure 3.3.3: Detection of polydispersity. Four techniques widely used in the field to analyse EVs were compared for their ability to separate individual 
populations in a polydispersed mixture of beads. DLS (A) and NTA (B) were tested with 50, 100 and 300 nm beads. TRPS (C) using an np100 pore was 
tested with 100, 200 and 400 nm beads and FC (D) was tested with fluorescent 200, 500 and 800 nm beads. 
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3.3 Part II: Effects of pre-sample processing 
Pre-sample processing of EVs - i.e. the steps taken to isolate EVs from the original 
source for analysis - is an area of great contention in the EV field. Again, a lack of 
standardisation makes comparisons between studies difficult. Therefore, the 
following experiments aimed to tackle some of the issues encountered with sample 
preparation and storage in relation to EV size and concentration. 
 
3.3.4 Choice of vacutainer 
Blood taken for subsequent EV isolation is usually treated with an anticoagulant. 
Here, EV concentration was compared in blood taken using citrate and EDTA 
vacutainers. TRPS analysis showed an increased number of EVs from blood taken 
into EDTA compared to citrate vacutainers (2.3 x 10
9
 ± 1.2 x 10
8
 vs. 7.2 x 10
8
 ± 4.1 
x 10
8
 particles/mL respectively; Figure 3.3.4). 
 
 
Figure 3.3.4: Choice of vacutainer. Citrate and EDTA vacutainers were used to collect 
blood from healthy volunteers. Isolated EVs from each vacutainer were then analysed by 
TRPS for their concentration. **p = 0.003 (n=3). EDTA = ethylenediaminetetraacetic acid.  
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3.3.5 Filtering of extracellular vesicles  
As EVs are classified as being submicron, a 1 µm filter was used to remove any 
potential contaminants from plasma-derived EVs before and after freezing (Figure 
3.3.5). Data from the np1000 showed a large reduction from unfiltered fresh to 
filtered fresh EVs (4.9 x 10
7
 to 1.7 x 10
6
 particles/mL; Figure 3.3.5 A/B). Frozen 
samples could not be detected with the np1000. The np400 also showed filtering 
fresh EVs reduced the concentration (7.6 x 10
8
 vs. 3.8 x 10
8
 particles/mL for fresh 
unfiltered and freshly filtered respectively; Figure 3.3.5 C/E). Filtering and then 
freezing EVs caused a slight increase in concentration (4.5 x 10
8
 particles/mL), but 
when EVs were frozen and then filtered, there was a large decrease in concentration 
(1.3 x 10
8
 particles/mL; Figure 3.3.5 D/E respectively). Finally, the np200 showed a 
large decrease in EVs that were filtered then frozen but a large increase in EVs that 
were frozen then filtered compared to fresh filtered EVs (Figure 3.3.5 F/G). 
Unfiltered fresh EVs could not be detected by the np200 due to frequent pore 
blocking. 
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Figure 3.3.5: The effects of filtering and freezing EVs. EVs isolated from plasma were 
analysed using TRPS after either being filtered through a 1 µm filter (fresh filtered), or left 
unfiltered. Both filtered and unfiltered EVs were then frozen at -20°C. Filtered EVs were 
then thawed and re-analysed using TRPS (filtered then (>) frozen). Unfiltered EVs were 
thawed and filtered through a 1 µm filter and analysed using TRPS as before (frozen then 
(>) filtered). Samples were analysed using np1000 (A/B), np400 (C-E) and np200 (F/G) 
nanopores (n=1). Concentration distributions generated with the Izon software are shown for 
the np1000 for unfiltered fresh and filtered fresh (A); for the np400 for unfiltered fresh and 
filtered fresh (C) and filtered then frozen and frozen then filtered (D); and the np200 for 
fresh filtered, filtered then frozen and frozen then filtered (F). Mean concentrations were 
then plotted in GraphPad Prism for np1000 (B), np400 (E) and np200 (G). 
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3.3.6 Method and length of extracellular vesicle storage  
Effective storage of EVs is vital to overcome the impracticalities of analysing 
samples on the same day as isolation. Therefore, it is important to know to what 
extent different methods and length of storage influence EV size and concentration. 
Five of the six methods of storage tested appeared to increase EV concentration 
compared to fresh EVs (analysed on the day of isolation) though this was not 
significant (Figure 3.3.6 A). Only EVs kept in the fridge seemed to retain the closest 
concentration to that of fresh EVs. Again, excluding EVs kept in the fridge, the 
method of freezing reduced the mode size of EVs, though this was not significant 
(Figure 3.3.6 B). Interestingly, the length of time for which EVs were stored caused 
an increase in EV concentration (p = 0.002, Figure 3.3.6 C). Past 1 week of storage, 
regardless of the initial method used to store EVs, measured concentration of EVs 
was increased, particularly by 3 months of storage compared with fresh samples 
(p<0.05). The mode size of EVs also decreased gradually with time in storage, 
however, this was not significant (Figure 3.3.6 D). Subsequent analysis using a 
general linear model indicated that length of storage was a significant factor in 
increasing EV concentration (p = 0.009).  
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Figure 3.3.6: The effect of storage on EV concentration and size. Plasma-derived EVs 
were analysed on the day of collection (fresh) by TRPS using an np200 pore. EVs were then 
aliquoted and stored by 6 different methods for 4 lengths of time. At each time point EVs 
were thawed and analysed as with fresh samples. Methods of freezing were then compared 
to EVs analysed fresh in terms of concentration (A) and mode size (B). The effect of storage 
time on EV concentration (C) and mode size (D) was also compared to fresh EVs. *p<0.05, 
Sample n numbers are provided; the 3 month time point has a lower n number due to 
insufficient EV sample. 
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3.4 Discussion 
3.4.1 Key findings 
Methodological comparisons: 
1. NTA and TRPS both show good linearity over a range of bead 
concentrations. 
2. TRPS accurately measures beads over a wider range than NTA, however this 
requires the use of multiple nanopores. 
3. Measured concentration between TRPS nanopores differs greatly, making it 
difficult to compare actual concentrations between nanopores. 
4. Techniques used to measure EVs differ vastly in their ability to detect 
individual populations in polydispersed samples. 
Pre-analytical processing: 
5. Blood collected in EDTA vacutainers yields a greater concentration of EVs 
than blood collected in citrate vacutainers.  
6. Filtering EVs (before or after freezing) reduces overall EV concentration. 
7. Length of storage, regardless of method, increases EV concentration. 
 
3.4.2 Main discussion 
One of the biggest challenges facing the EV field is the attainment of standardised 
methods for the isolation, storage and measurement of EV samples. Evidently, this is 
complicated by the heterogeneity of EV sources, user experience and available 
instrumentation. Complete clarity of methods used and fulfilment of ISEV “minimal 
requirements” (16) are currently the best available options for regulation of 
published EV data. Data presented in this chapter are from experiments conducted at 
the beginning of my PhD that helped me to learn about the methodological 
limitations faced in the field but also helped to make an informed decision on how to 
approach analysis of EVs in cell-based and clinical studies. 
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The measurement of EV size and concentration is often the first and most important 
step in EV analysis. Sizing of EVs confirms isolation of a submicron EV population 
or of singular populations such as exosomes. Determining EV concentration is 
important in identifying differences between groups, or if a set numbers of EVs is 
required in further experiments. Therefore the initial technique used to determine EV 
size and concentration should be reliable and relatively fast (if many samples need to 
be analysed or further experiments need to be undertaken). Despite there being a 
number of techniques available for measurement of EV size and concentration, there 
is no gold standard and each technique has accepted advantages and limitations. 
Here TRPS, a new technique in the EV field at the time, was assessed to compare the 
detection over a range of concentrations and sizes of calibration beads with NTA. 
Both NTA and TRPS showed good linearity over a range of concentrations of 
calibration beads with little deviation from the expected mode size. This is useful 
when dealing with biological samples which can show great inter-sample variability 
in size and concentration. Dilutions were chosen for each standard curve based 
around the recommended dilutions of the manufacturer and have since been 
presented by others for NTA (161,405,410) and for TRPS (411).  
It is essential for the measurement techniques to be able to accurately detect EVs 
over the whole EV range. Therefore the range of detection of both NTA and TRPS 
was measured using calibration beads of varying sizes. NTA accurately identified 
50, 100, and 300 nm beads; however the mode size of 1000 nm beads was 
underestimated. Others have measured beads at the upper end of the EV range (≥500 
nm) using NTA with greater accuracy (405,407,410). However, in these cases pre- 
and post-analytical settings were altered for each bead whereas in this chapter, they 
were kept the same. This means that here, although the settings may not be 
completely optimal for each bead size, the consistency of analysis was maintained 
between samples and the software was not then biased towards detecting a particular 
size. TRPS was able to detect six different bead sizes as distinct populations from 
100 – 1000 nm, though to achieve this, multiple nanopores were required. This was 
time consuming and often frustrating due to frequent pore blocking. Although 
nanopores are tuneable, they are limited to a particular size range and are typically 
best suited (as demonstrated here) to measure their namesake diameter, for example 
the np200 and CPC200 beads. Each pore was able to detect 3 or more different sizes 
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of beads; however the accuracy in the reported mode size was lost at either extreme 
of the pore. The reported concentration of the same beads seemed to differ greatly 
between pores, for example, the concentration of CPC400 beads differed by almost 
10 fold between np100 and np800 pore measurements. Generally, smaller nanopores 
reported higher concentrations of beads. This has been shown previously, though not 
directly alluded to (407) and little explanation has been offered (411).The most 
likely reason is that smaller nanopores are superior for the detection of small 
particles (which are able to have a higher concentration per unit volume than larger 
particles). Therefore larger pores report lower overall concentrations as smaller 
beads are below the detection limit or are indistinguishable from the noise of the 
pore. TRPS concentration is determined by comparing the particle rate and pressure 
of the sample to that of the calibration bead (164,411,412) used for the pore with a 
known stock concentration and mode size (Table 2.3). Here, the pores tended to 
overestimate the concentration of beads considered large for that pore and 
underestimate the concentration of beads considered small for that pore. For 
example, the concentration of CPC400 beads was overestimated 3-fold by the np100 
and underestimated 15-fold by the np800. Therefore the increased concentration of 
beads with smaller pores and decreased concentrations with larger pores cannot 
entirely be explained by the difference in sensitivity between pores. Perhaps because 
the stock concentration of beads used to calibrate smaller nanopores is higher (e.g. 1 
x 10
13
 particles/mL for CPC100 for np100), the pore is then predisposed to detect a 
higher overall concentration, particularly at the upper extremity of the pore. This 
could be tested by calibrating an np100 pore with CPC400 beads and seeing whether 
the concentrations of CPC100/200 beads are then underestimated.  
 
EV samples are almost always heterogeneous regardless of the biological source. 
When characterising a population of EVs it is important for the technique to be able 
to detect EVs across a range of diameters. Therefore, 4 techniques commonly used 
for EV detection were tested for their ability to separate beads of different sizes in a 
polydispersed mix. As outlined in Chapter 1.1.7.3, DLS calculates particle size and 
concentration from the scattered light of particles in suspension. The Brownian 
motion of particles causes a Doppler Shift (fluctuation in scattered light). These 
fluctuations in scattered light are measured by a photon detector and the data are 
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used in the Stokes-Einstein equation (Figure 2.3) to derive particle size and 
concentration. DLS has been shown to be highly accurate for sizing monodispersed 
suspensions, particularly those < 200 nm (413), though this accuracy is lost on 
heterogeneous samples. The scattered light is collected simultaneously (161) 
meaning the resulting size of particles is biased by a small number of large particles 
scattering more light (414). Here, DLS (using a mix of 50, 100 and 300 nm beads) 
showed a single peak from 50-300 nm with no distinction of bead populations, 
indicating the result was biased by the scattering of 300 nm beads. Others have 
shown that DLS gives more detailed size distributions and also detects differences in 
EV samples when the angles of detection for light scattering are increased and 
improved calculation algorithms are used (149,160). DLS is also simple to operate 
and requires minimal amounts of sample (415). However, until detection is 
improved, DLS is impractical and inaccurate for the measurement of polydispersed 
samples. 
NTA is technically similar to DLS though particles are visualised and video-tracked 
over time allowing measurement of individual particles (161). Here, NTA was able 
to distinguish 100 and 300 nm beads (as demonstrated by others (161)); however, 50 
nm beads were measured as a shoulder of the 100 nm peak. Though NTA gives 
superior detection compared to DLS, large particles can still influence measurements 
in polydispersed samples. With NTA, larger particles tend to scatter more light 
creating a “halo” effect around the particles (161) (Figure 3.4.1) which is sometimes 
measured as smaller particles leading to a decreased overall mode size. Alterations in 
pre- and post-analytical settings can also give rise to differences in size and 
concentration (411). However, despite the potential subjectivity, with a prior 
appreciation of the limitations and a small amount of training, NTA is a simple and 
rapid technique to measure EV size and concentration. A recent recommendation for 
measuring polydispersed EV samples is to use at least two dilutions of the sample 
and optimise pre- and post-analytical settings for each sample (149,161,162,407). 
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Figure 3.4.1: Measuring large particles with NTA. Still of a NTA video (left) measuring 
polydispersed beads. Larger beads scatter more light creating rings of light around the 
particle which are counted as smaller particles (right) causing an underestimation of mode 
size for larger particles.  
 
TRPS is a non-optical technique for measuring EV size and concentration that 
analyses samples on a particle-by-particle basis (416). Using an np100 pore, a mix of 
100, 200 and 400 nm beads were clearly visualised as individual populations. The 
mode size of each bead showed a slight deviation from the expected size though each 
was still within 15 nm of the actual size. Though TRPS (as illustrated here) is 
potentially more accurate in detecting individual sizes in polydispersed samples, the 
adoption of the qNano for measuring EV samples has been less successful than that 
for NTA. This may perhaps boil down to the usability of TRPS compared with NTA. 
Possibly the greatest limitation of TRPS is the frequent pore blocking due to a 
polydispersity range greater than that of the nanopore resulting in inconsistent data 
and time-consuming and frustrating measurements (411,412). Consequently TPRS 
requires at least one nanopore to measure an EV sample (containing vesicles ranging 
from 50 – 1000 nm) which has been referred to by others as “high and low 
sensitivity measurement” (407,411). Though in principle this is similar to measuring 
samples twice with NTA with different dilutions and settings, in reality the use of 
two pores requires more time and effort in changing and recalibrating new pores. 
Additionally, as discussed above the variation in measured concentration between 
pores may not entirely be due to differences in sensitivity. Therefore merging of data 
between pores (at the point of crossover of concentration) may lead to an 
overestimation of concentration. Finally, I and others have observed variation 
between different batches of the same nanopore, and also with the longevity of the 
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nanopore (411,417). This may be due to differences in the nanopore geometry 
(411,417,418) which result from inconsistencies in pore manufacturing. 
FC is one of the most widely-used applications to analyse EV populations (419), 
possibly because it is one of the most accessible of the four techniques and it has the 
potential to assess multiple functional markers. A flow cytometer measures the light 
scattered by samples as they pass through a laser beam. The use of different lasers 
allows for excitation of a variety of fluorophores, enabling measurement of surface 
markers as well as scatter profiles. Here, beads could be identified as separate 
populations when based on fluorescence but not when plotted by scatter. The 
forward and side scatter profiles give important information about the refractive 
index of particles. Unfortunately, the low refractive index of EVs (420) means that 
most flow cytometers are incapable of detecting EVs < 300 nm (149,155,421,422) 
which is the size range in which the vast majority of EVs fall (120,149). 
Furthermore, the refractive index of polystyrene beads (such as the ones used here) is 
much higher than that of EVs (423,424) causing incorrect assumptions of particle 
sizing and inaccurate gating strategies to be used for EVs (420). The current opinion 
is that FC is a useful tool to analyse surface markers (155) rather than size and 
concentration of EVs if it is employed correctly. Recent developments such as high 
resolution flow cytometers to detect EVs ~100 nm (155,425) and binding of EVs to 
micrometre beads (117) are helping to overcome the shortfalls of EV detection with 
FC.  
 
Every step taken from sample collection to the isolation of EVs introduces potential 
variation in final EV concentration. This is due to a lack of standardisation for pre-
analytical processing of EVs and results in great variations in reported EV 
concentrations. Therefore, the following work sought to identify and characterise 
sources where variation may be introduced in order to optimise our own protocols. 
When analysing blood-derived EVs, the anticoagulant used to collect the blood has 
been shown to affect EV concentration. Flow cytometric studies have found that 
chelating anticoagulants produce fewer EVs than protease inhibitor anticoagulants 
(59). Interestingly, administering heparin to thrombophilic women throughout 
pregnancy reduced in vivo EV concentration and reduced pregnancy loss (frequently 
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associated with thrombophilia) (426). Citrate has previously been shown to minimise 
changes in platelet morphology compared to EDTA (427), despite EDTA being a 
stronger chelator of Ca
2+
 (428). However, no study has compared the effects of 
anticoagulants on EV concentration using a more accurate technique than FC. Here, 
TRPS data showed that plasma-derived EVs from blood collected into EDTA 
vacutainers contained significantly higher concentrations of EVs than plasma EVs 
from citrated blood. Others have attributed the effects of different anticoagulants on 
EV counts to ex vivo microvesiculation from platelets (60,429) though György et al., 
observed a reduction in non-platelet as well as platelet-derived EVs in ACD 
vacutainers (429). This indicates that varying quiescence of platelets with differing 
anticoagulants does not entirely account for differences in EV counts. Jayachandran 
et al., concluded that differences in EV counts were due to a loss of EVs from 
calcium chelation rather than an ex vivo generation with protease inhibitors (59) no 
explanation is given as to how calcium chelation reduces EV production ex vivo. 
Furthermore, EV counts and origin were assessed using FC meaning the majority of 
EVs may not have been detected. In order for the effects of different anticoagulants 
on EV concentration and origin to be assessed completely, a direct comparison of the 
most commonly used anticoagulants (EDTA, citrate, ACD and heparin) needs to be 
undertaken using an accurate technique to enumerate and phenotype EVs. 
Differential ultracentrifugation is one of the most popular ways to isolate EVs from 
complex fluids. However, as well as requiring specialist equipment, pellets may also 
be contaminated with soluble components (125), protein aggregates and lipoproteins 
(118) which may contribute to the final EV concentration. Microfiltration has 
successfully been employed to enhance the isolation of exosomes from cell culture 
models (125,430). However, this has not been applied to the EV population as a 
whole. Here, the effect of passing plasma-derived EVs isolated with 
ultracentrifugation through a 1 µm filter was analysed across the EV range using 
TRPS with np1000, np400 and np200 nanopores. Initial analysis with the np1000 
confirmed removal of the majority of material above 1µm but also a great deal < 1 
µm with over a 96% reduction in EV concentration post-filtration. The same trend 
was observed when these samples were analysed with the np400 pore, though to a 
lesser extent with a 50% reduction in concentration. This difference in reduction may 
be because the np400 cannot measure larger particles present in the unfiltered fresh 
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sample but also because many smaller particles present in the filtered fresh sample 
are below the detection limit of the np1000. This is also illustrated by the np200 
which could not record the unfiltered sample due to frequent pore blocking from 
large particles. Unfortunately, as TRPS used in this context could only determine the 
size and concentration of samples, the identity of the material caught in the filter is 
unknown. Therefore though a reduction was seen using a 1 µm filter, we cannot be 
sure EVs were not also removed. The point at which EV samples were filtered was 
also analysed by filtering EV samples both before and after freezing (-20°C). Frozen 
EV samples could not be detected using the np1000, however the np400 showed that 
filtering before freezing had less of an effect on EV concentration than filtering after 
freezing, which decreased EV concentration. Interestingly, when the same samples 
were analysed with the np200, samples that were filtered before freezing showed a 
reduced concentration compared to freshly filtered EVs whilst EVs frozen and then 
filtered showed a large increase in concentration. One possible reason for this is that 
freeze-thawing of samples may cause damage and degradation of EVs. Therefore 
EVs filtered after freezing may appear to have a reduced concentration with an 
np400 but increased concentration with an np200 because larger particles present at 
the time of freezing disintegrated into smaller particles measured by the np200 but 
not the np400. Though filtering may well reduce the presence of large particulate 
contaminants, using TRPS alone we cannot be sure that EVs are not also removed by 
filtration. Future studies could assess this by monitoring changes in EV markers such 
as CD9 with filtration and visually check sample preparations with TEM. 
As EVs have the potential to be biomarkers for a number of diseases, it may become 
important for EV samples to be analysed in large scale studies where it would be 
impractical to analyse samples fresh. Previous studies have analysed the effects of 
storage on EV counts using FC with conflicting results (60,107,108,146,409,431). 
Therefore EV samples were stored using a variety of different methods and varying 
lengths of time to assess the effects on EV size and concentration. The method of 
storage used was not shown to have a significant effect on EV concentration or size, 
though all methods (apart from storing EVs in the fridge) seemed to increase EV 
concentration and decrease EV size compared with fresh EVs. Biological variation 
was high among volunteers so greater numbers may be required to further analyse 
the method of storage. However, others have also shown that the method of 
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cryopreservation had no effect on EV counts (432) or morphology (148). EV 
concentration was increased with the length of storage, independently of the method 
of storage used. After 3 months of storage, EVs were significantly increased 
compared to their original fresh samples. These effects may have been apparent after 
1 month of storage though this did not reach significance. There was also a decline in 
mode size, however this was not significant. Freezing by any method may cause an 
increase in EV concentration which becomes a significant problem the longer the 
sample is stored for. This increase may arise from fragmentation of EVs by the 
freeze-thaw process which is then measured as an overall rise in concentration. 
Others observing a rise in EV concentration with freezing have also attributed this to 
vesiculation from larger EVs and contaminants (146,409). Indeed, this may explain 
why some studies using FC observed a decrease in EV concentration with freezing 
(60,107,409) as larger EVs (>300 nm) normally detected by flow fragment and pass 
below the detection limit of the machine. Despite the reduced sensitivity of FC for 
particles <300 nm, reduced forward and side scatter profiles have been observed 
following freezing which was attributed to an increase in smaller EVs (409,431). 
Furthermore, flow cytometric studies (despite conflicting results of overall EV 
concentration), show increases in annexin V positivity and specific surface markers 
with freezing (59,60,107,409) with one study showing platelet-derived EVs to be 
more procoagulant following freezing (145). Effects on other EV components with 
freezing are not well characterised, though mRNA was reduced in EVs following 
freezing (148). Until the full effects of storage method and length are characterised 
for all aspects of EVs, measurements of EVs should be carried out fresh wherever 
possible or stored in the fridge and analysed within 1 week. It is important to keep 
methods the same between samples to allow for accurate comparison.  
 
3.4.3 Limitations 
Comparisons of DLS and FC with NTA and TRPS were only undertaken once for 
polydispersity measurements. Though our group have access to NTA and TRPS, we 
did not at the time have liberal access to DLS or FC. Therefore we were not able to 
make a complete methodological comparison of all 4 techniques here and relied on 
published data for comparisons of DLS and FC for reliability and limits of detection. 
Page | 135  
 
The effects of filtering EVs were only measured once using TRPS with 3 different 
pores. Therefore without repeating the study, the interpretations presented here are 
only speculations and require confirmation with repeated numbers. Finally, 
concentration measurements using TRPS were made using a one-point calibration 
(as advised by IZON at the time) where calibration beads were analysed once at one 
pressure (which was then maintained for samples). IZON have since updated their 
recommendations for concentration measurements to include a 3-point calibration 
where the calibration bead and subsequent samples are analysed at 3 different 
pressures (Figure 3.4.2). Particle concentration is now defined as being 
“proportional to the gradient of the fitted line” (IZON training module, version 3.2) 
as opposed to “calibration allows the particle rate to be used to determine the particle 
concentration of the sample” (IZON training module, version 2.0). This may help to 
account for differences observed in concentration of beads between pores if the 
incorrect gradient was applied.  
Figure 3.4.2: Revision of TRPS concentration analysis. Screenshots from the latest Izon 
training manual that explain how calibration beads are used to calculate sample 
concentration. The graph shows the importance of the relationship between applied pressure 
and particle rate between calibration beads and samples. The manual also indicates the 
negatives of using single-point calibration. 
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3.4.4 Conclusions 
The EV field as a whole is undergoing continuous development with a wide array of 
measurement, isolation and storage protocols being used. It may be impossible to 
completely standardise procedures due to the great variety of biological sources from 
which EVs can be derived. Here, TRPS and NTA were shown to be reliable 
techniques for measuring size and concentration of EV samples. However, 
knowledge of the theory of operation and training is required for each technique to 
avoid misuse and false reporting of EV size and concentration. FC is not suitable for 
determining EV size and concentration; however it is currently the simplest method 
for phenotyping surface antigens of EVs. Pre-analytical variables such as the choice 
of vacutainer, filtering and storage all affected EV concentration. Until some level of 
standardisation is introduced, it is imperative for researchers to understand the 
limitations and to report results of their chosen methodologies with complete clarity.  
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4. Results II: 
Characterisation of adipocyte-derived EVs 
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4. Perspective 
Having learnt about the variety of potential pitfalls with EV analysis from work 
presented in Chapter 3, I was able to implement this knowledge in work conducted 
in Chapter 4. For example, when EVs could not be analysed on the same day as 
isolation, they were slow frozen to -80°C in a Mr Frosty and stored for a maximum 
of 1 week to minimise the damaging effects of freezing. Also, NTA was chosen to 
size and quantitate EVs primarily because of its ease of use compared to TRPS. 
Multiple samples can quickly and easily be analysed in replicates with NTA, often 
meaning analysis can be performed on the same day as isolation of EVs. 
 
  
Parts of this chapter have been published in: 
Connolly KD, Guschina IA, Yeung V et al. Characterisation of adipocyte-derived 
extracellular vesicles pre- and post-adipogenesis. Journal of Extracellular Vesicles. 
2015 Nov 24; 4: 29159. 
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4.1 Introduction 
As discussed in Chapter 1, many different cell types secrete EVs into their 
extracellular space. The release of EVs from adipocytes is an emerging area in the 
EV field. The traditional view of AT as an inert storage organ has changed 
dramatically over recent years with the discovery of adipokines, revealing an 
endocrine role for adipocytes (433,434). Therefore, adipocyte EVs may provide a 
new dimension to adipocytes as endocrine communicators. 
The unipotent preadipocyte cell line 3T3-L1 is widely used to study adipocyte 
biology both at the pre- and mature adipocyte stage (294). The differentiation 
process of 3T3-L1 cells undergoes well defined stages of confluency and mitosis of 
preadipocytes followed by a growth arrest and commitment to a mature adipocyte 
phenotype (435). During this period, activation of various transcription factors 
trigger a variety of signalling pathways, inducing multiple changes in mRNA and 
protein expression (274). This tightly orchestrated process controls the transition of a 
fibroblast-like preadipocyte to a fully mature, rounded adipocyte capable of 
accumulating lipid (Figure 1.1.2). Previous research has focused on the intracellular 
role of transcription factors in adipocyte differentiation though there is evidence for 
external mediators in assisting the differentiation process (301). Adipocytes, 
including 3T3-L1 cells, have been shown to produce EVs in vitro 
(48,66,306,307,383,392,393). 3T3-L1 EVs contain both adipokines (66,383) and 
factors that promote angiogenesis in vivo (393). EVs derived from rat primary 
adipocytes act in an autocrine fashion to promote lipid esterification in neighbouring 
adipocytes (387). Human AT explants also produce EVs that modulate monocyte 
differentiation and alter insulin signalling in adipocytes (306) and hepatocytes (307). 
However, these studies have focused on potential functional aspects of adipocyte-
derived EVs without having first established the baseline characteristics of these EVs 
and how these characteristics may dictate EV function. Furthermore, these studies 
did not quantify adipocyte EVs by any means, or used sub-optimal techniques such 
as FC.  
Despite the growing evidence for roles of adipocyte EVs in autocrine and endocrine 
functions, little is known about the physiological characteristics of adipocyte EVs 
and whether these change (as the cell does) following adipogenesis. 
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4.1.1 Aims 
The aims of this chapter were to characterise adipocyte-derived EVs in terms of: 
 Morphology 
 Size and concentration 
 Annexin V positivity 
 Fatty acid concentration and composition 
 Phospholipid composition (and fatty acid composition) 
 Protein content 
This chapter aims to establish these parameters of the 3T3-L1 EVs, comparing them 
to their cell of origin and assessing the effect of adipogenesis on EV characteristics.  
 
4.1.2 Hypotheses 
EV release and character differs depending on the stage of differentiation. EVs share 
some characteristics of their cell of origin but may possess their own unique fatty 
acids and proteins.  
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4.2 Methods 
4.2.1 Cell culture 
3T3-L1 cells were cultured as outlined in Chapter 2.2. Post-confluence, serum-free 
CM was added to cells for 24 hours for subsequent EV isolation (day 0). Cells to be 
analysed at day 15 were differentiated (as outlined in Figure 2.1) and were placed in 
serum-free MM for 24 hours for EV isolation at day 15. Oil Red O staining was used 
to confirm the stage of adipogenesis of cells (methods detailed in Chapter 2.2.3). 
 
4.2.2 Western blotting 
Cell and EV lysates were prepared for Western blotting as described in Chapter 
2.10. Ten micrograms of protein was loaded for each sample, separated on running 
gels and probed for antigens of interest (Table 4.2.1). Loading controls were not 
used for cell lysates; however, FABP4 and PREF-1 blots of EV samples were 
washed in TBS-T overnight, blocked and re-probed with CD63. Densitometry was 
conducted as described in Chapter 2.10.6. 
Protein Polyacrylamide 
running gel 
Antibody dilution Typical exposure 
Adiponectin (CST 
#2789) 
12% 1:500 (5% 
BSA/TBS-T) 
15 minutes 
CD63 n/a 1:200 (5% 
milk/TBS-T) 
1 minute 
FABP4 15% 1:100 (5% 
BSA/TBS-T) 
15 seconds 
PREF-1 10% 1:100 (5% 
BSA/TBS-T) 
1 minute 
Table 4.2.1: Western blotting. Details of the proteins analysed by Western blotting and the 
acrylamide gels used to separate them. CD63 was used a control for EV proteins so an 
acrylamide percentage is not provided. BSA = bovine serum albumin; CD = cluster of 
differentiation; CST = Cell Signaling Technologies; FABP4 = fatty acid binding protein-4; 
PREF-1 = preadipocyte factor-1; TBS-T = tris-buffered saline – tween 20 (1% v/v).  
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4.2.3 Extracellular vesicle isolation  
After 24 hours in serum-free media, conditioned supernatants were immediately 
centrifuged and stored as described in Chapter 2.3.1 and 2.3.3 respectively. 
 
4.2.4 Scanning electron microscopy 
EM was performed with Dr Christopher Von Ruhland (Central Biotechnology 
Services, Cardiff University). Scanning EM (SEM) was used to visualise cells at day 
0 and day 15. Cells were cultured in 35 mm glass-bottomed dishes (Cellvis, USA). 
At day 0 and day 15, cells were washed in PBS and fixed in 1% gluteraldehyde (v/v 
in PBS) at room temperature for 1 hour. Fixed cells were kept in PBS at 4ºC until 
processing for SEM. Samples were then dehydrated through graded propan-1-ol (50, 
70, 90% and 2x100%) for 10 minutes at each grade followed by three exchanges in 
hexamethyldisilazane (5 minutes per exchange). Samples were air dried and splutter 
coated with gold and viewed at 5 kV in a JOEL 840 SEM (JEOL, Japan). Images 
were acquired with analysis software (Munster, Germany) and processed with 
Photoshop CS2 (Adobe, USA). 
 
4.2.5 Transmission electron microscopy 
TEM was used to visualise EVs at day 0 and day 15. EVs were isolated from cells 
grown in T175 cm
2
 flasks to ensure enough EV material for the TEM process and 
stored at 4ºC in PBS until analysis. EVs (50 µL droplets) were adsorbed onto 
formvar/carbon-coated grids for 20 minutes before fixation with 1% gluteraldehyde 
(v/v) for 10 minutes at room temperature. Grids were then washed (3 x 1 minute in 
PBS and 6 x 1 minute in water) before negative staining with 2% (w/v) uranyl 
acetate for 10 minutes. Surplus stain was shaken off and grids were allowed to air 
dry before being examined in a Philips CM12 TEM (FEI Ltd, UK) at 80 kV. Images 
were acquired with a Megaview III camera and processed using Photoshop CS2. 
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4.2.6 Optiprep™ separation of EVs 
Optiprep™ (60% w/v solution of Iodixanol in water, Sigma) was used to prepare 10 
fractions in 5% increments from 5-50% in PBS (v/v). Fractions (1 mL) were then 
carefully layered in ultracentrifuge tubes in a discontinuous gradient and EV samples 
from day 0 or day 15 (100 µL) were added to the top-most fraction (Figure 4.2.1). 
Centrifugation was then performed at 100,000 x g for 3 hours at 4ºC and 1 mL 
fractions were carefully removed and analysed using NTA (Chapter 2.4.2). 
 
Figure 4.2.1: Optiprep™ separation of EVs. Ten fractions (1 mL) of prepared Optiprep™ 
solution were layered into ultracentrifuge tubes as shown above. EV samples (100 µL) from 
day 0 or day 15 were gently floated on the top fraction before ultracentrifugation. 
 
4.2.7 Extracellular vesicle size and concentration analysis  
EV size, mean concentration and distributions were determined using NTA as 
detailed in Chapter 2.4.2. Cells to yield EVs were cultured using T175 cm
2 
flasks 
(Cellstar®, Greiner Bio-One, Germany).  
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4.2.8 Annexin V positivity  
Annexin V positivity of cells and their corresponding EVs at both day 0 and day 15 
was measured by FC (Chapter 2.6). Results are displayed as the percentage of 
annexin V positive events from the total population of cells or EVs. 
 
4.2.9 Fatty acid analysis 
GC-FID was used to determine fatty acid concentration and composition of cells and 
EVs at day 0 and day 15 (Chapter 2.7.1/2). Cells and EVs were isolated from T175 
cm
2
 flasks. Individual fatty acid data are presented as the change in composition 
from day 0 to day 15.  
 
4.2.10 Phospholipid analysis  
Proportions and fatty acid compositions of phospholipid groups of cells and EVs at 
day 0 and day 15 were determined by 2D-TLC followed by GC-FID (Chapter 2.7.3).  
 
4.2.11 Extracellular vesicle immunophenotyping 
EVs at day 0 and day 15 were probed for exosomal and adipocyte markers using an 
immunophenotyping assay described in Chapter 2.9. Details of EV (lightly shaded) 
and adipocyte (darker shaded) primary antibodies used are provided in Table 4.2.2. 
EV markers were chosen based on the ISEV minimal requirements for an EV 
population (Table 1.1.2) and adipocyte markers were selected to cover proteins 
expressed during different stages of adipogenesis (Figure 1.2.2). 
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Antibody Dilution 
Alix 1:450 
CD9 1:200 
CD63 1:200 
TSG101 1:200 
PREF-1 1:50 
PPARγ 1:49 
Adiponectin (CST #2789) 1:10 
FABP4 1:25 
Table 4.2.2 Antibodies used for EV immunophenotyping. Details of primary antibodies 
used for EV immunophenotyping experiments. One μg/mL of each antibody was added to 
each well, accounting for the differences in dilution. CD = cluster of differentiation; CST = 
Cell Signaling Technologies; FABP4 = fatty acid binding protein-4; PPARγ = peroxisome 
proliferator-activated receptor γ; PREF-1 = preadipocyte factor-1; TSG101 = tumour 
susceptibility gene -101. 
 
4.2.12 Statistical analysis  
Data were analysed using GraphPad Prism (version 6.0). Normality was tested using 
D‟Agostino and Pearson omnibus normality test before subjection to statistical 
analysis. An unpaired student‟s t-test or a one- or two-way ANOVA were used to 
analyse the differences between means. Data are presented as mean ± SD and p 
values <0.05 were considered statistically significant.  
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4.3 Results 
4.3.1 Confirmation of adipogenesis  
Oil red O staining was used for semi-quantitative analysis of lipid accumulation in 
cells at day 0 and day 15 (Figure 4.3.1). Lipid accumulation was greatly increased 
with differentiation, as illustrated by microscopy (Figure 4.3.1 A/B) and by 
absorbance (Figure 4.3.1 C). 
 
Figure 4.3.1 Confirmation of adipogenesis. 3T3-L1 cells at day 0 and day 15 were stained 
with oil red O to confirm the stage of adipogenesis. Degree of staining was analysed visually 
by microscopy: (A) day 0 cells and (B) day 15 cells; and by measuring the absorbance at 492 
nm (C). ****p<0.0001, (n=4).  
 
Adipogenesis was further confirmed by Western blot analysis of cell lysates from 
both timepoints (Figure 4.3.2). PREF-1 was significantly higher in day 0 cell lysates 
compared with day 15 (day 0: 57,801 ± 6,743; day 15: 572 ± 784 raw densitometry 
units, p = 0.0054; Figure 4.3.2 A). Both adiponectin and FABP4 were higher in day 
15 cell lysates compared to day 0 (adiponectin: day 0; 729 ± 824, day 15; 14,371 ± 
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2,849 raw densitometry units, p = 0.0076, Figure 4.3.2 B; FABP4: day 0; 1,547 ± 
2,629, day 15; 88,112 ± 6,688 raw densitometry units, p = 0.0014, Figure 4.3.2 C). 
 
 
Figure 4.3.2: Western blot analysis of cell lysates. Western blots of day 0 and day 15 cell 
lysates were probed for the preadipocyte marker, PREF-1 (A), and mature adipocyte 
markers adiponectin (B) and FABP4 (C). Raw differences in densitometry are shown for 
each protein. **p<0.01, (n=3). Western blots were performed without loading controls; 
therefore conclusions should not be drawn between differences in band density between 
markers. 
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4.3.2 Electron microscopy 
EM was used to visualise 3T3-L1 cells and EVs at both time points. SEM images 
show cells at day 0 are connected by long projecting networks that connect multiple 
cells (Figure 4.3.3 A). Preadipocytes also seem to be quite flat with little evidence of 
lipid accumulation. Cells at day 15 however, have a rounder morphology and are 
much larger in diameter (Figure 4.3.3 B). Mature adipocytes appear more 
individualised and spherical with large vacuole-like structures. 
TEM images show that EVs at both time points are polydispersed in nature and 
display a classic “cup-like” morphology (Figure 4.3.3 C/D). 
 
Figure 4.3.3: 3T3-L1 cells and EVs viewed by EM at day 0 and day 15. Cells pre- (A - 
day 0) and post-adipogenesis (B - day 15) were visualised using SEM. Isolated 3T3-L1 EVs 
at day 0 (C) and day 15 (D) indicated by red arrows were imaged using TEM. Note the 
differences in scale bars between preadipocytes and mature adipocytes and between cells 
and EVs. 
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4.3.3 Optiprep™ separation of extracellular vesicles  
Optiprep™ was used to examine any differences in buoyancy of EV isolates from 
day 0 and day 15. EVs from both day 0 and day 15 have a range of buoyant 
densities, however a greater proportion of EVs from day 15 were present in the 
lower density fractions compared to EVs from day 0 (Figure 4.3.4). 
 
Figure 4.3.4: Optiprep™ separation of EVs. EVs from both day 0 and day 15 were added 
to a discontinuous gradient of Optiprep™ solution. Each fraction was then analysed using 
NTA. Data are expressed as the percentage of the total EV sample present in each fraction at 
each time point (n=1). 
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4.3.4 Extracellular vesicle size and concentration  
The number of viable cells was measured using trypan blue exclusion and showed an 
increase of ~3 fold from day 0 to day 15 (1.7 x 10
6
 ± 5.1 x 10
5
 to 5.2 x 10
6
 ± 8.4 x 
10
5
cells/mL, p<0.0001, Figure 4.3.5 A). NTA was used for size and concentration 
analysis of EVs. EV production was higher per cell at day 0 compared with day 15 
(992.7 ± 226.2 to 276.5 ± 104.8 EVs/viable cell, p<0.0001, Figure 4.3.5 B). Mode 
size of EVs did not change between the two time points (135.4 ± 8.9 to 137.1 ± 7.6 
nm, p = 0.6,). When the concentration was split into 50 nm bin-widths, the decrease 
in EVs at day 15 was observed across the EV spectrum, particularly in EVs <300 nm 
(Figure 4.3.5 C).  
 
Figure 4.3.5: 3T3-L1 EV size and concentration. The effect of differentiation of 3T3-L1 
cells on: (A) viable cells/mL; (B) EV production per viable cell; and (C) EV size and 
concentration distribution. **** p<0.0001, ***p<0.001, ***p<0.01, day 0 (n=6) and day 15 
(n=5).  
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4.3.5 Annexin V positivity 
PS exposure of cells and EVs was determined by annexin V binding measured by 
FC. Annexin V positivity of cells fell from day 0 to day 15 (2.1 ± 1.7 to 0.4 ± 0.2%, 
p=0.04, Figure 4.3.6 A). The same trend was observed with EVs however this was 
non-significant (6.3 ± 6.6 to 2.9 ± 2.2%, p = 0.3, Figure 4.3.6 B). Generally, EVs 
possessed a higher annexin V positivity than that of cells. 
 
Figure 4.3.6: Annexin V positivity of 3T3-L1 cells and EVs. Changes in 
phosphatidylserine exposure of 3T3-L1 cells (A) and EVs (B) with differentiation were 
measured by annexin V binding. *p<0.05, (n=6). 
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4.3.6 Fatty acid concentration and composition  
GC-FID was used to determine the concentration and composition of fatty acids of 
cells and EVs. Total concentration of fatty acids in both cells and EVs was increased 
from day 0 to day 15 (Cells: 0.1 ± 0.04 to 0.7 ± 0.2 mg/10
6
 cells, p<0.0001, Figure 
4.3.7 A and EVs: 12.2 ± 1.7 to 27.3 ± 10.1 ng/10
6
 EVs, p=0.005, Figure 4.3.7 C). 
The fatty acid compositions of both cells and EVs were greatly altered by 
differentiation. Out of 25 fatty acids detected, the compositions of 18 in cells and 17 
in EVs changed significantly from day 0 to day 15 (Figure 4.3.7 B and D 
respectively). 
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Figure 4.3.7: Fatty acid analysis of 3T3-L1 cells and EVs. (A) Total fatty acid 
concentration of 3T3-L1 cells and (C) EVs at day 0 and day 15 of differentiation. (B) 
Proportional changes of individual fatty acids in cells and (D) EVs between day 0 and day 
15 of differentiation. **** p<0.0001, ***p<0.001, **p<0.01, *p<0.05, 
x
 indicates a fatty 
acid present at only one time point, day 0 (n=6) and day 15 (n=5). 
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The majority of fatty acids were reduced (in proportion to the total) with 
differentiation in cells and EVs, for example, arachidonic acid (C20:4n6). Generally, 
differentiation caused the same trends in proportional changes of fatty acids; 
however the effect was sometimes unique to the cell or EV. For example, oleic acid 
(C18:1n9) was decreased in cells but increased in EVs from day 0 to day 15. Certain 
fatty acids were also unique to the stage of differentiation, for example, 
eicosatrienoic acid (C20:3n3) was only present in cells and EVs at day 0.  
The composition of lipid classes was also altered with adipogenesis, and when 
comparing the EV to its corresponding cell (Figure 4.3.8). EVs in particular seemed 
to contain a higher proportion of polyunsaturated fatty acids (PUFAs) compared to 
cells. Individual changes in fatty acids within each class are provided in Appendix: 
Table I. 
 
Figure 4.3.8: Changes in lipid classes. Alterations in lipid classes between (A) day 0 cells, 
(B) day 15 cells, (C) day 0 EVs and (D) day 15 EVs. SFA = saturated fatty acids, MUFA = 
monounsaturated fatty acids; PUFA = polyunsaturated fatty acids, day 0 (n=6) and day 15 
(n=5).  
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4.3.7 Phospholipid analysis  
Phospholipids were separated from lipid extracts using 2D-TLC. The proportions 
(percentage of total) of each phospholipid class present in cells and EVs pre- and 
post-adipogenesis are presented in Figure 4.3.9. Between day 0 and day 15, the 
proportion of phosphatidylethanolamine (PE) increased in cells and EVs whereas the 
proportions of phosphatidylinositol (PI) and sphingomyelin decreased in cells but 
increased in EVs. Phosphatidylcholine (PC) was the most abundant phospholipid 
present in all samples (45.0 – 62.3%), slightly increasing in cells following 
adipogenesis but decreasing in EVs over the same time. Cells and EVs had higher 
proportions of PS at day 0. Cardiolipin was detectable only in cells, increasing with 
adipogenesis. 
 
Figure 4.3.9: Phospholipid composition pre- and post-adipogenesis. Proportions of 
individual phospholipids present in cells and EVs pre- and post-adipogenesis. Proportions 
were calculated as a percentage of the summed total of all phospholipids. (A) day 0 cells; 
(B) day 15 cells; (C) day 0 EVs; (D) day 15 EVs (n=1). PE = phosphatidylethanolamine; PC 
= phosphatidylcholine; PS = phosphatidylserine; PI = phosphatidylinositol.  
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Phospholipid extracts were also analysed by GC to give individual fatty acid 
compositions of each phospholipid (Appendix: Table II). Phospholipids contained a 
range of saturated fatty acids (SFAs), mono unsaturated fatty acids (MUFAs) and 
PUFAs in cells and EVs at both time points, and these seemed to differ both with 
differentiation and between cells and EVs. In particular, phospholipids from day 0 
cells and EVs were highly enriched in PUFAs, specifically arachidonic acid which 
decreased following adipogenesis. 
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4.3.8 Immunophenotyping of extracellular vesicles  
An immunophenotyping assay was used to measure the content of vesicular and 
adipocyte proteins within EVs at each time point (Figure 4.3.10). No differences 
were observed in exosomal markers pre- and post adipogenesis. Of the adipocyte 
markers, PPARγ showed no change. However, adiponectin showed an increase pre- 
to post-adipogenesis (76,242 ± 11,501 to 161,886 ± 30,371 arbitrary TRF units, 
p<0.0001). Both FABP4 and PREF-1 were shown to decrease in EVs following 
adipogenesis (108,256 ± 7,640 to 93,088 ± 4,804, p = 0.002 for FABP4 and 86,958 ± 
18,164 to 58,918 ± 7,485 arbitrary TRF units, p = 0.006 for PREF-1 respectively). 
 
Figure 4.3.10: Protein content of EVs pre- and post-adipogenesis. Exosomal (CD9, 
CD63, TSG101 and alix) and adipocyte (FABP4, PREF-1, adiponectin and PPARγ) proteins 
in EVs from day 0 and day15 cells were analysed by an immunophenotyping assay. 
Proteins were detected using a streptavidin-europium conjugate and measured using TRF 
(given in arbitrary units). **p<0.01, ****p<0.0001, (n=3).  
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4.3.9 Retrospective Western blot analysis  
Following analysis of data from the immunophenotyping of EVs using EV 
immunophenotyping, Western blots were performed for day 0 and day 15 EVs 
probing for PREF-1 and FABP4 (Figure 4.3.11). Western blots showed that in fact, 
PREF-1 was barely detectable at day 15 and FABP4 was highly abundant at day 15. 
This contradicts data from Figure 4.3.10 which shows a modest, but significant 
decrease in PREF-1 and FABP4 from day 0 to day 15.  
Figure 4.3.11: Western blot analysis of EV lysates. Lysed EVs were analysed for 
expression of the preadipocyte marker, PREF-1, the mature adipocyte marker, FABP4 and 
the exosomal protein, CD63. Densitometry was then performed and PREF-1 (A) and FABP4 
(B) are presented as relative expression to CD63. *p<0.05, **p<0.01 (n=3). 
  
Page | 159  
 
4.4 Discussion 
4.4.1 Key findings 
1. EVs from 3T3-L1 adipocytes display a classic EV morphology. 
2. EV release is higher prior to adipogenesis, particularly vesicles <300 nm. 
3. Cellular and EV fatty acid composition is altered following adipogenesis. 
4. EVs display a different fatty acid composition to that of their cells of origin. 
5. Adipogenesis seems to alter phospholipid (and associated fatty acid) 
composition in EVs and cells. 
6. EVs contain exosomal and adipocyte proteins, some of which are altered 
following adipogenesis. 
 
4.4.2 Main discussion 
From Chapter 3, it is clear that the EV field is still developing, requiring further 
clarity and standardisation. As such, a fundamental protocol was developed when 
our group began to study adipocyte-derived EVs. This method has been used 
throughout the thesis to ensure consistency, but these methods also addresses key 
elements outlined in the ISEV position paper (16). With the growing popularity of 
EV research, more and more cell types are being reported to release EVs, yet often 
little information is given concerning the characteristics of these vesicles. In this 
chapter, I sought to characterise EVs from pre- and mature adipocytes using the 
well-established 3T3-L1 adipocyte cell line. 
Until relatively recently, AT was regarded as little more than a passive store of 
excess energy. It is now recognised as an endocrine organ that plays an influential 
role in many important physiological processes both within AT itself and 
systemically with other organs and tissues. These interactions are primarily 
orchestrated through the secretion of adipokines released directly from adipocytes 
(316). More recently, adipocytes have been shown to shed EVs in vitro, perhaps 
providing an additional method of adipocyte communication 
(66,306,307,383,387,393). However, little is known about the characteristics of these 
EVs. 
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Transition from a preadipocyte to a mature adipocyte phenotype is a complex 
process involving a chronological pattern of gene expression and changes in cell 
cycle status (294). At day 0, the cell-cell contact between preadipocytes is crucial in 
initiating differentiation (436) and intercellular communication is known to peak in 
preadipocytes at confluency then rapidly decline during differentiation (437). 
Consistent with this, SEM images of 3T3-L1 cells at day 0 show long projections 
suggesting networks of intercommunication between cells. Additionally, EV 
production per cell was greater at day 0, particularly in exosomes and smaller 
microvesicles (<300 nm) despite there being no change in the overall mode size of 
EVs. This may be a consequence (or perhaps a cause) of the differentiation process 
such that EVs act as intercellular communicators to aid initiation of the transition to 
a mature adipocyte. Conversely, cells at day 15 are much larger and rounder with 
multiple lipid vacuoles. Taken together with the lower EV production per cell, this 
suggests that cells at this time point may be less communicative. 
 
Many studies support the principle that the release of EVs is preceded by a 
disruption of the normal phospholipid asymmetry of the plasma membrane, 
subsequently exposing PS. However, it is debated whether this externalised PS is 
retained on the EV (63,67). Therefore PS exposure of EVs and their original cells 
was characterised using annexin V binding. Cells and EVs at both time points 
showed a relatively low annexin V positivity (<10%); lower than the reported 50-
90% reported for plasma-derived EVs (55,56,76). However, it is hypothesised that 
the majority of plasma-derived EVs are of platelet origin and that their high annexin 
V positivity - and hence high density PS exposure - can aid promotion of coagulation 
(438). It is unlikely that adipocyte-derived EVs would promote coagulation perhaps 
partially explaining their lower annexin V positivity. 
 
Much of the research within the EV field is focused towards how changes in the 
quantity or genetic content of EVs may potentially affect their function. Little has 
been reported about the potential effects of lipid composition on EV function, 
despite the known role of lipids as precursors to many signalling pathways and their 
importance as signalling molecules in their own right. Therefore GC-FID was used 
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to comprehensively characterise the fatty acid composition of 3T3-L1 cells and EVs 
pre- and post-adipogenesis. As expected, the total lipid content of cells increased 
with adipogenesis and interestingly, this was also reflected in the EVs. Perhaps as 
the cells at day 15 are so lipid laden, the resulting EV incorporates some of this lipid 
during its formation. EVs at day 15 certainly seemed to have a lower overall density 
as shown by their Optiprep™ separation where the majority of EVs at this time point 
were found in the upper fractions containing the least Optiprep™ solution. This 
suggests these EVs are less dense, perhaps because they contain more lipid per 
volume. 
The fatty acid composition of cells and EVs was clearly affected by differentiation, 
likely reflecting the transition in function from a preadipocyte to mature adipocyte. 
For instance, palmitic acid, the most abundant storage fatty acid in animals (439) 
showed a large increase with adipogenesis as cells accumulated lipid. The transition 
in function was also represented by the presence or lack of some fatty acids at each 
time point. For example, the PUFA eicosatrienoic acid is generally detected in 
tissues where levels of FFAs are low. Here, eicostrienoic acid was present at day 0 
but not at day 15. Cells at day 15 are likely to be abundant in FFAs perhaps 
ameliorating the need for eicosatrienoic acid at this time point. Additionally it has 
been reported that PUFAs, particularly n-3 PUFAs, are better activators of PPARγ 
(upon which adipocyte differentiation is dependent) than other fatty acids (440). 
Here, cells at day 0 contained a greater proportion of PUFAs than cells at day 15 
suggesting that preadipocytes are equipped with a greater reserve of PUFAs to aid 
PPARγ activation. Cells and EVs at day 0 also had a greater proportion of 
arachidonic acid - a major precursor for many signalling pathways - than those at day 
15. Taken together with the increased concentration of EVs at day 0, this supports 
the notion that EVs may be enhancing intercellular communication in the initial 
stages of differentiation. In keeping with this, exosome isolates from human adipose-
derived stem cells (hASCs) undergoing adipogenic differentiation were recently 
shown to assist the transition of undifferentiated hASCs towards a mature adipocyte 
phenotype (441). 
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As well as maintaining the structural integrity of cells, organelles and vesicles, 
phospholipids are also part of a variety of signalling pathways. The major 
phospholipid classes of 3T3-L1 cells and their corresponding EVs pre- and post-
adipogenesis were separated by TLC before subsequent GC-FID to determine 
individual fatty acid composition of individual phospholipids. A common theme 
among the fatty acids within phospholipid groups was the high degree of saturation. 
The primary role of phospholipids is to form a bilayered membrane to support the 
structure of the cell and to enclose its contents. The predominance of SFA acid tails 
of phospholipids here likely provides enough rigidity to the cell membranes for 
structural support but the presence of MUFAs and PUFAs ensure enough fluidity 
remains for membrane components to remain dynamic. 
PC and PE were the most abundant phospholipids in all samples, accounting for 
around half of all phospholipids measured. PC and PE have previously been shown 
to be the most abundant phospholipids in adipocytes (442) and in blood-derived 
microparticles (443); the data in this thesis suggests this is also the case for 
adipocyte-derived EVs. The proportion of PE in 3T3-L1 cells and EVs increased 
with differentiation, a concept previously reported in 3T3-L1 cells (444). 
As observed with the total fatty acid composition of cells and EVs, arachidonic acid 
was more abundant in cells and EVs at day 0 within 4 of the 6 phospholipids 
analysed here. Arachidonic acid is a major precursor to many intracellular signalling 
molecules, principally eicosanoids (445). Therefore higher proportions of 
arachidonic acid at day 0 suggest both cells and EVs harbour a greater reserve of 
signalling fatty acids. The composition of PUFAs at day 0 was also much higher 
compared with day 15. PUFAs, as described before can act as ligands for PPARγ 
(445) which is essential to differentiation. Increased amounts of PUFAs at day 0 may 
help to initiate PPARγ activation to bring about differentiation and also illustrates the 
role of PE in cell signalling as well as membrane structure.  
Sphingomyelin is often associated with brain tissues where this class of 
phospholipids coat axons to accelerate transmission of action potentials. However, 
sphingomyelin is also an important phospholipid in many eukaryotic plasma 
membranes providing structural support and sphingolipid signalling molecules such 
as ceramide which as described in Chapter 1.1.3.1, play a role in classical exosome 
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formation (25,446). Sphingomyelin has been shown to form a high content in EVs 
providing structural rigidity and resistance to physiochemical changes (169). Here, 
sphingomyelin was decreased in cells following adipogenesis, suggesting day 0 cells 
have a higher capacity for ceramide production and subsequent exosome formation. 
This is reflected in the EV concentration data, which shows a greater proportion of 
EVs in the exosomal range at day 0. 
Cardiolipin was present in cells at both time points but was not detected in EVs. 
Cardiolipin is a major phospholipid of the mitochondrial membrane and is known to 
interact with and facilitate the actions of mitochondrial proteins such as cytochrome 
c (447). As well as mitochondrial proteins, cardiolipin is also known to interact with 
adipocyte cytosolic proteins such as FABP4, particularly when there is a greater 
degree of unsaturation (448). Here, the composition of cardiolipin was higher in day 
15 cells and the level of unsaturation at this time point was also greater. Cellular 
FABP4 was increased at day 15 perhaps reflecting the increased need to interact with 
proteins such as FABP4 at this time point.  
PS is an anionic phospholipid which resides predominantly on the inner membrane 
leaflet (under physiological conditions) and consequently has roles in many 
intracellular signalling pathways (449). The negative charge associated with PS 
allows interaction with key signalling molecules bearing positively charged moieties 
such as tyrosine kinases, Ras/Rho GTPases, protein kinase C and annexin V (450). 
The overall proportion of PS was higher in cells and EVs at day 0 as was the 
composition of arachidonic acid of PS at day 0. Taken together, this suggests that 
cells at day 0 have an increased intracellular signalling capacity which may also 
transferred to day 0 EVs. Therefore, EVs at day 0 are potentially equipped with a 
greater cargo of bioactive signalling fatty acids which could be used to enhance 
intercellular communication and initiate differentiation.  
 
A subject of great interest in the EV field is how changes in EV protein expression 
can occur following stimulation or stress of the cell of origin (451). The most 
popular techniques for measuring changes in vesicular protein expression are 
currently FC and Western blotting. However, as discussed in Chapter 3, there are 
several disadvantages to these techniques, primarily the limits of detection and lack 
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of sensitivity for FC and the amount of EV sample required for Western blotting. 
Here, an immunophenotyping method (36,158)) was used to analyse surface and 
intravesicular EV proteins pre- and post-adipogenesis. Analysis of EV proteins by 
this method allows simultaneous analysis of multiple markers, using low amounts of 
sample (1 µg/well). The use of europium as the reporter probe allows detection of 
signal over a wide dynamic range ensuring a good sensitivity for lowly and highly 
expressed antigens. Results have been shown to be comparable with Western blot 
data (36,158) and the technique has been used by others in the EV field (119). Levels 
of transmembrane (CD9/CD63) and intravesicular (alix/TSG101) exosomal markers 
showed no change in EVs pre- vs. post-adipogenesis. This suggests that although the 
number of EVs (particularly exosomes) is higher at day 0, the relative expression of 
exosomal proteins within EVs does not change between time points. A range of 
adipocyte markers that are known to be present at different stages of adipogenesis 
(301,320) were selected for analysis within EVs. PREF-1 represses differentiation 
and promotes a preadipocyte phenotype (452). As confirmed by Western blot 
analysis of cell lysates (Figure 4.3.2 A), PREF-1 expression is higher at day 0. In 
keeping with this, EV PREF-1 decreased from day 0 to day 15, allowing progression 
to a mature adipocyte phenotype. However, at day 15 there is still PREF-1 present in 
EVs whereas expression within cells seems to be absent. The reasons for this could 
be a combination of factors. Firstly, the immunophenotyping detection is more 
sensitive than Western blotting and so PREF-1 may still be present in cells but the 
expression far less than that at day 0. Secondly, in vitro differentiation of adipocytes 
is never 100% efficient and therefore some preadipocytes are still present in the 
culture. Therefore these residual preadipocytes may be producing EVs containing 
PREF-1 that is detectable by immunophenotyping but not by Western blotting in the 
total day 15 cell lysate. PPARγ is a nuclear receptor required for both the induction 
(including the growth arrest of cells (301)) and the maintenance of adipogenesis 
(320). Here, EV PPARγ content was unchanged pre- vs. post-adipogenesis 
suggesting that PPARγ produced by cells to initiate growth arrest around day 0, and 
by cells at day 15 to maintain an adipocyte phenotype is transferred to corresponding 
EVs. Adiponectin is an adipocyte-specific adipokine produced by mature adipocytes 
(453) with roles in regulating insulin sensitivity and glucose metabolism (454). The 
content of adiponectin in cells was higher at day 15 compared with day 0 (Figure 
4.3.2 B), which was again mirrored in the EVs at this time point. Finally, FABP4 is a 
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cytosolic fatty acid trafficking protein (455) that is highly expressed in mature 
adipocytes (confirmed in Figure 4.3.2 C) accounting for ~1% of the total protein of 
the cytosolic fraction (323). FABP4 within EVs decreased from day 0 to day 15 
perhaps reflecting a role for EVs that is independent of their cell of origin or perhaps 
a specific packaging of FABP4 into EVs. 
Retrospective Western blot data contradicted the results of EV immunophenotyping 
for PREF-1 and FABP4. Indeed, blots were conducted in hindsight for these two 
proteins after evaluating the immunophenotyping results, which were unexpected. It 
is not clear why these two techniques gave such differing results. One potential 
explanation is that the immunophenotyping may need validation for different types 
of EV and for different antibodies. Concentrations of EVs and antibodies used in this 
chapter were based on a protocol for prostate cancer-derived exosomes, which 
yielded similar results when analysed by Western blot (119,232). Additionally, the 
exosomes used for immunophenotyping in these studies had been washed following 
isolation and therefore may have a higher purity than the EVs in this chapter. 
Therefore, 1 µg (the amount of EVs loaded per well) may be very different between 
the two EV preparations. Furthermore, as the immunophenotyping is a novel 
technique, commercial antibodies that were used to probe for the antigens are not yet 
validated for this technique as they are for Western blotting. Hence, a different 
working concentration of antibody may be required for optimal detection. 
 
4.4.3 Limitations 
There are several potential limitations of this study. Firstly, 3T3-L1 cells were used 
throughout the chapter for characterisation. Others have successfully isolated EVs 
from primary adipocyte sources such as mouse AT (392), rat primary adipocytes 
(387,456) and human AT explants (306,307). Though 3T3-L1 cells are not a primary 
cell line, they are widely used as a reliable model to study adipocyte biology (294). 
Their use here also enabled more detailed analyses requiring large sample amounts 
such as TLC and GC-FID to yield novel data about lipid and phospholipid profiles of 
adipocyte EVs. The data presented here also tally with data from primary adipocyte 
EV sources in terms of the presence of adipocyte and exosomal protein within EVs. 
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There are currently a number of issues surrounding standardisation of protocols in 
the EV field, meaning preparatory techniques are constantly being updated. Here, 
differential centrifugation was used to isolate adipocyte EVs as described previously 
(393). Intermediary centrifugation steps of 10,000 – 20,000 x g have recently been 
reported to pellet larger microvesicles (17). Therefore the use of a 15,000 x g spin 
may pellet larger microvesicles as well as cell debris and apoptotic bodies, thus 
removing them from the final EV sample. However, NTA detected EVs up to 1 µm 
in diameter (Figure 4.3.5 C), indicating the presence of larger microvesicles. 
A further practical limitation of this study was the use of FC to assess the annexin V 
positivity of EVs. As discussed in Chapter 3, many conventional flow cytometers 
have a practical lower limit of ~300 nm due to the low refractive index of EVs (420), 
meaning smaller microvesicles and exosomes may not be detected by this method. 
Therefore the annexin V positivity may have been underestimated here, particularly 
if a proportion of larger microvesicles (known to have a greater annexin V positivity) 
were removed by the 15,000 x g spin. Future studies could couple EVs to 1 µm latex 
beads before assessment with FC (117) or use a dedicated small particle high 
resolution flow cytometer (155) to ensure capture of the whole EV spectrum. 
Immunophenotyping of EVs, whilst potentially less time- and sample-consuming 
than Western blotting, was not optimised for use with adipocyte-derived EVs in this 
chapter. Background fluorescence of day15 EVs alone (without primary antibody), 
was often significantly higher than day 0 EVs. Interestingly, when cells and EVs 
were analysed by FC for annexin V positivity, unstained day 15 cells (and EVs to a 
lesser extent) showed significant auto-fluorescence in the FITC channel. Perhaps 
because cells (and EVs) at day 15 contain more lipid, this may auto-fluoresce to 
cause higher levels of background noise compared to day 0 samples which contain 
significantly less lipid. My colleagues have since performed a validation of the 
immunophenotyping assay for the detection of EV proteins in plasma-derived EVs. 
Firstly, the concentration of EVs used per well was found to be extremely important. 
Lower concentrations of EVs per well gave higher background TRF readings 
(without the presence of primary antibody). This effect was eventually saturated for 
plasma EVs by using higher concentrations of around 5 x 10
10
 particles/mL of EVs 
in each well. Therefore, the number of EVs per well must be titrated for each source 
of EV. Here, 1 µg of EVs were added to each well which equated to around 2 x 10
8
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particles at day 0 and 5 x 10
7
 particles at day 15. Therefore, too few EVs may have 
been added per well (particularly for day 15 EVs) resulting in higher background 
signals. Secondly, the concentration of primary and secondary antibodies was shown 
to be important. Following titration, it was found that a concentration of 3 µg/mL of 
primary antibody was sufficient to detect maximal signal. Here, a concentration of 1 
µg/mL was used, so some antibodies may not have been at an optimal concentration 
to detect the entirety of available antigen. Evidently, validation is needed to ensure 
agreement with Western blot analysis before this technique can replace Western blot 
for adipocyte EV protein analysis. 
Finally, serum-free media was used for the 24 hour conditioning period prior to EV 
isolation to avoid contamination of FCS-derived EVs (159). The requirements of the 
cells at each time point are different and hence serum-free media was supplemented 
with insulin prior to EV isolation at day 15, whereas media at day 0 was not. This 
was to minimise changes to normal media components at each time point, however, 
it is possible that the addition of insulin may have affected EV release at day 15. 
 
4.4.4 Conclusions 
To summarise, the production of adipocyte EVs is shown to be significantly affected 
by the differentiation process. Prior to adipogenesis, EV concentration is higher and 
EVs are enriched in fatty acids and phospholipids with known involvement in cell 
signalling. This suggests that EVs released prior to adipogenesis may aid 
communication between preadipocytes to enhance the transition to mature 
adipocytes. EVs retained certain aspects of their cell of origin including annexin V 
positivity, fatty acid content and protein expression, but also possessed unique 
differences in fatty acid composition and protein content. These concurrent 
similarities and differences may allow EVs to represent their cell of origin but to also 
harbour unique qualities that potentially confer different functional properties. Future 
studies should explore the functional impact of EVs on the control of adipogenesis 
and their wider implications in the role of AT as an endocrine organ. 
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5. Results III: 
Effects of hypoxia on adipocyte-derived EV 
production 
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5. Perspective 
Having completed a comprehensive characterisation of adipocyte-derived EVs using 
3T3-L1 cells in Chapter 4, I was able to apply these techniques to analyse EVs 
derived from adipocytes exposed to disease-like conditions (hypoxia). It should be 
noted that EV immunophenotyping used and described in Chapter 4 was also used in 
this chapter to characterise vesicular protein content. However, a set number of EVs 
were added per well instead of a set amount of EV protein to attempt to address 
some of the issues experienced in Chapter 4. The number of EVs used (5 x 10
9
 EVs) 
was based on pilot data from my colleague, Mr Nick Burnley-Hall, who had found 
this concentration of EVs to be sufficient for the detection of exosomal and other 
markers in EVs derived from an endothelial cell line. 
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5.1 Introduction 
As discussed in Chapter 1, dysfunctional adipose tissue AT is a risk factor for 
obesity-related complications such as IR and T2D (378), though the root cause of 
dysfunction remains to be elucidated. AT hypoxia has been proposed as a potential 
instigator of impaired AT functioning and AT from obese subjects is known to have 
a reduced blood supply compared to that from lean subjects (366). Hypoxic 
conditions have also been shown to alter EV release and functionality in prostate 
cancer cells (457). Therefore, hypoxic adipocyte EVs may play a role in the 
development of AT dysfunction. 
Growth and expansion of AT occurs through adipocyte hyperplasia and hypertrophy 
(458). In obese AT, hypertrophy of adipocytes can result in cells up to 200 µm in 
diameter (265,266) which is at the upper limit of the diffusion distance of oxygen 
(O2) in a tissue (363). Despite the increase in AT mass, blood flow to AT is reduced 
in obesity (365,366), suggesting that blood vessel growth in AT is insufficient to 
maintain the same blood flow as provided to lean AT. It is likely therefore, that 
obese AT is littered with regions of hypoxia. Indeed, obese AT has been shown to 
have a reduced oxygen tension (partial pressure, pO2) in both obese mice models 
(368,369,377) and human studies of obesity (373–376), though the reported pO2 of 
AT varies greatly between studies (Table 1.2.2). In vitro studies of adipocytes in 
hypoxia shows the transition towards a pro-inflammatory state through the 
production of inflammatory adipokines such as TNF-α, IL-6 and PAI-1 (380). 
Upregulation of these adipokines is primarily attributed to the activation of HIF-1α 
during hypoxia (459). HIF-1α in hypoxia also targets the activation of genes 
controlling angiogenesis and metabolism such as VEGF and leptin to attempt to 
restore oxygenation (380). Unfortunately, the overarching effect is AT inflammation 
which leads to dysregulation of lipid metabolism, storage and adipokine secretion 
(352,460–462). Obesity is associated with low grade systemic inflammation (352), 
though whether this is the cause or consequence of AT inflammation is unknown.  
Given that EV release is often increased in response to conditions of cellular stress, it 
is no surprise that hypoxia has been shown to increase EV generation in a number of 
cell types (241,463,464). HIF-1α is thought to play a central role in this response as 
data from our lab and others show that knockdown or silencing of HIF-1α reduces 
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hypoxia-induced EV formation (241,463). Studies into the hypoxic enhancement of 
EV release have largely focused on cancer cell lines, where the hypoxic EVs can 
promote angiogenesis to fulfil the demands of the growing tumour and to encourage 
metastasis (253,463,465,466). 3T3-L1-derived EVs from unstimulated cells have 
been shown to induce angiogenesis in vivo (393); an effect which may been 
enhanced in hypoxic conditions. Despite the potential similarities between the 
growth of obese AT to tumour progression (259), to date only one study exists 
detailing hypoxic adipocyte-derived EVs (390). This study focused on the metabolic 
enhancement of de novo lipogenesis by hypoxic 3T3-L1 exosomes; however, the 
authors did not quantitate the effects of hypoxia on EV characteristics such as EV 
size and concentration, lipids and protein content. 
 
5.1.1 Aims 
The aims of this chapter were to determine the effects of different ambient O2 levels 
on: 
1. Cell morphology, viability and lipid accumulation 
2. EV size and concentration 
3. Cell and EV annexin V positivity 
4. Cell and EV fatty acid composition 
5. Cell and EV phospholipid (and fatty acid) composition 
6. Cell and EV adipocyte and inflammatory protein expression 
 
5.1.2 Hypotheses 
Hypoxia may elevate EV concentration but also alter the lipid/protein content of the 
EV compared to normoxic EVs, and perhaps compared to hypoxic cells. 
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5.2 Methods 
5.2.1 Cell culture 
3T3-L1 cells were cultured as outlined in Chapter 2.2. Serum-free media was added 
to cells at day 14 post-differentiation and cells were either kept in the incubator (95% 
air with 5% CO2, “normoxic”), or transferred to an Invivo 2 hypoxic workstation 400 
(Baker Ruskinn, UK) and maintained under set Oxygen conditions (“hypoxic”) for 
24 hours. Oxygen (O2) conditions included: 1, 2, 5, 10 and 21% O2 and were 
monitored using a i-CO2N2 gas mixing system (Baker Ruskinn, UK).  
Cells were counted as described in Chapter 2.2.2; hypoxic cells were removed from 
flasks and added into cell counting slides in the hypoxic chamber. Morphological 
changes of cells were observed using a Nikon Diaphot microscope (Nikon) and 
images captured at 10X magnification using ViewFinder™ software (version 3.0.1, 
Better Light Inc., USA). Oil Red O staining was used to quantify changes in lipid 
droplets as described in Chapter 2.2.3 in 1% O2 experiments; fixing of 1% O2 cells 
was carried out in the hypoxic chamber. 
 
5.2.2 Isolation and measurement of extracellular vesicles  
After 24 hours of incubation, serum-free media was removed from cells and 
processed as described in Chapter 2.3.1. Media from cells in hypoxia was collected 
in the hypoxic chamber. Isolated EVs were stored as described in Chapter 2.3.3. 
NTA was used to measure EV samples as outlined in Chapter 2.4.2.  
 
5.2.3 Flow cytometry 
Flow cytometric analyses were conducted to assess the annexin V positivity of cells 
and corresponding EVs isolated from 1, 2, 5 10 and 21% O2, each with normoxic 
controls as described in Chapter 2.6. Due to variation between analyses, results are 
expressed as a delta change in percentage positivity from normoxic controls. 
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5.2.4 Gas chromatography 
Fatty acid concentration and composition of normoxic and hypoxic cells was 
measured using GC-FID as outlined in Chapter 2.7. Due to variation in reported 
fatty acid concentration for normoxic controls between experiments, fatty acid 
concentration of cells and EVs is presented as a change from the respective 
normoxic control (delta change).  
 
5.2.5 Thin layer chromatography 
Two-dimensional TLC was used to determine proportions of phospholipids present 
in normoxic and 1% O2 cells and EVs as described in Chapter 2.7.  
 
5.2.6 Western blotting 
Normoxic and 1% O2 cells were lysed as described in Chapter 2.10.1. Twenty to 
fifty µg of protein was loaded per well and were separated using specific running 
gels (Table 5.2.1) and probed with primary antibodies (incubated at room 
temperature overnight). Membranes were washed thoroughly in TBS-T overnight 
before being blocked and subsequently re-probed for β-actin. Densitometry was 
conducted as described in Chapter 2.10.6. 
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Protein Running gel Antibody dilution Typical 
exposure time 
β-Actin n/a 1:2000 (1% milk/TBS-T) 1 minute 
Adiponectin (CST 
#2789) 
12% 1:500 (5% BSA/TBS-T) 15 minutes 
FABP4 15% 1:1000 (5% BSA/TBS-T) 15 seconds 
HIF-1α 8% 1:500 (1% milk/TBS-T) 20 minutes 
IL-6 12% 1:500 (5% BSA/TBS-T) 15 minutes 
IL-10 15% 1:500 (5% BSA/TBS-T) 15 minutes 
MCP-1 15% 1:500 (5% BSA/TBS-T) 15 minutes 
PPARγ 10% 1:1000 (5% BSA/TBS-T) 2 minutes 
TNF-α 15% 1:500 (5% BSA/TBS-T) 15 minutes 
Table 5.2.1: Details of Western blotting. Details of the proteins analysed by Western 
blotting and the percentage of acrylamide gels used to separate them. Note, β-actin was used 
as a control for all proteins so a running gel acrylamide percentage is not provided. Dilutions 
and diluents for antibody preparation and exposure times for the development of membranes 
are given for each protein. BSA = bovine serum albumin; CD = cluster of differentiation; 
CST = Cell Signaling Technologies; FABP4 = fatty acid binding protein-4; HIF-1α = 
hypoxia inducible factor-1α; IL = interleukin; MCP-1 = monocyte chemoattractant protein-
1; PPARγ = peroxisome proliferator-activated receptor γ; TBS-T = tris-buffered saline – 
tween 20 (1% v/v); TNF-α = tumour necrosis factor – α. 
 
5.2.7 Extracellular vesicle immunophenotyping  
EVs from 1% O2 and normoxic cells were added to wells at a concentration of 5 x 
10
9
 EVs/well and analysed using TRF as described in Chapter 2.9 for an array of 
markers (Table 5.2.1). A set concentration of EVs was added per well as opposed to 
a set amount of protein of EVs per well (1 µg) following validatory data collected by 
Mr Nick Burnley-Hall using an endothelial cell line. The data indicated a level of 
background fluorescence from the ELISA plate. This could be abrogated by using a 
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concentration of EVs to sufficiently cover the bottom of each well. This 
concentration was found to be 5 x 10
9
 EVs per well for endothelial-derived EVs and 
so this concentration was applied to TRF in this chapter. 
 
Antibody Dilution 
CD9 1:200 
Adiponectin (CST #2789) 1:10 
FABP4 1:25 
PPARγ 1:49 
IL-10 1:101 
IL-6 1:101 
TNFα 1:101 
MCP-1 1:16 
HIF-1α 1:117 
Table 5.2.2: Primary antibodies used for EV immunophenotyping. Antibodies and 
dilutions used for EV immunophenotyping experiments. CD= cluster of differentiation; CST 
= Cell Signaling Technologies; FABP4 = fatty acid binding protein-4; HIF-1α = hypoxia 
inducible factor-1α; IL = interleukin; MCP-1 = monocyte chemoattractant protein-1; PPARγ 
= peroxisome proliferator-activated receptor γ; TNF-α = tumour necrosis factor – α. 
 
5.2.8 Statistical analysis 
Data were analysed using GraphPad Prism software (version 6.0). As hypoxic 
experiments were conducted at different times, each level of hypoxia required a 
normoxic control. Therefore, the variation between normoxic controls was compared 
using a one-way ANOVA with multiple comparisons for each parameter presented 
in this chapter. With the exception of flow cytometry and gas chromatography 
samples, normoxic control samples did not significantly vary between experiments, 
and so “normoxia” refers to normoxic data averaged from different hypoxic 
experiments.  
  
Page | 176  
 
5.3 Results 
5.3.1 Effect of hypoxia on adipocyte morphology, number and viability  
Following 24 hours incubation in normoxia or hypoxia, cells were imaged for 
potential morphological changes (Figure 5.3.1). Compared with normoxic cells 
(Figure 5.3.1 A), cells incubated from 2-21% O2 (Figure 5.3.1 C-F) showed no 
significant changes in cell morphology with cells still appearing rounded and lipid 
laden. However, cells at 1% O2 appeared less rounded with fewer lipid droplets 
(Figure 5.3.1 B). Cell number and viability showed no significant change with 
varying levels of hypoxia compared to normoxia (Figure 5.3.1 G/H respectively). 
 
 
Figure 5.3.1: Effect of hypoxia on adipocyte characteristics. Representative images of 
adipocytes after incubation in normoxia (A) or hypoxia: (B) 1%; (C) 2%, (D) 5%, (E) 10% 
and (F) 21% O2. Cell number (G) and viability (H) was measured from each condition using 
Trypan Blue exclusion, (n=3).  
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5.3.2 Oil Red O staining 
When lipid accumulation was assessed by Oil Red O staining, there was no 
significant difference between 1% O2 and normoxic cells (Figure 5.3.2). 
 
Figure 5.3.2: Oil Red O staining. Cells from normoxia (A) and 1% O2 (B) were fixed and 
stained with Oil Red O to assess lipid accumulation. (C) The stain was then extracted and 
the absorbance measured at 492 nm (n=4).  
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5.3.3. Effect of hypoxia on extracellular vesicle size and concentration  
EV concentration and size from 3T3-L1 cells incubated in normoxia and hypoxia 
were measured using NTA (Figure 5.3.3). EVs from 1% O2 cells were significantly 
increased compared to normoxia (137.3 ± 42.4 to 391.1 ± 219.8 EVs/viable cell, p = 
0.003; Figure 5.3.3 A). Other hypoxic conditions showed no effect on EV 
concentration compared to normoxia. The mode size of EVs showed no change with 
varying levels of hypoxia (Figure 5.3.3 B).  
 
Figure 5.3.3: EV concentration and size following hypoxia. EVs collected from normoxic 
and hypoxic cells were measured using NTA and (A) expressed as concentration of 
EVs/viable cell and (B) mode particle size in nm **p = 0.003 (n=6). 
 
When EV concentration was split into 50 nm bin-widths, the most significant 
changes were observed in 1% O2 EVs which were increased between 50 and 200 nm 
compared to normoxic controls (Figure 5.3.4). EVs from 2% O2 cells were also 
significantly elevated compared to normoxic controls between 100 and 200 nm. No 
significant changes were observed in other hypoxic conditions. 
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Figure 5.3.4: Size and concentration distribution. EV concentration was split into 50 nm bin-widths over the EV range for normoxic (n=5) and hypoxic (1, 
2, 5, 10 and 21% O2, n=6) EVs. ****p<0.0001, **p<0.01.
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5.3.4 Effect of hypoxia on annexin V positivity 
FC was used to assess the annexin V positivity of adipocytes and corresponding EVs 
in response to hypoxia. Unfortunately, measurements varied greatly between O2 
experiments, particularly within normoxic controls (Figure 5.3.5/6 A). However, 
when normalised to their respective normoxic control, 1% O2 cells were significantly 
more annexin V positive (1.0 ± 0.0 to 1.3 ± 0.05 for normoxic and 1% O2 cells 
respectively; p = 0.0004; Figure 5.3.5 B). Annexin V positivity of cells from 2-21% 
O2 was not different from respective normoxic controls (Figure 5.3.5 C-F).  
 
Figure 5.3.5: Cellular annexin V positivity. (A) Raw percentage of annexin V positivity. 
Delta change compared to normoxic controls was calculated for (B) 1%, (C) 2%, (D) 5%, 
(E) 10% and (F) 21% O2 by normalising to respective normoxic values. ***p = 0.0004, 
(n=3). 
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EVs from 5% O2 cells had a lower annexin V positivity than normoxic EVs (1.0 ± 
0.0 to 0.4 ± 0.3 for normoxic and 5% O2 EVs respectively, p = 0. 04; Figure 5.3.6 
D). EVs from other percentages of O2 were not significantly different from normoxic 
controls. 
 
Figure 5.3.6: EV annexin V positivity. (A) Raw percentage of EV annexin V positivity. 
Delta change compared to normoxic controls was calculated for (B) 1%, (C) 2%, (D) 5%, 
(E) 10% and (F) 21% O2 by normalising to respective normoxic values. *p = 0.04, (n=3).
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5.3.5 Effect of hypoxia on fatty acid concentration and composition  
Total fatty acid concentration and individual compositions of cells and EVs was 
determined by GC-FID. Due to variation in fatty acid concentrations of normoxic 
cells and EVs between hypoxic experiments, results are presented as delta change 
from respective normoxic controls. No changes were observed between cells or EVs 
in fatty acid concentration compared to normoxic controls (Figure 5.3.7). 
 
Figure 5.3.7: Fatty acid concentration of cells and EVs. Total fatty acid concentrations of 
(A) cells and (B) EVs at varying percentages of O2 were determined by GC-FID. Due to 
inter-experiment variation between normoxic samples, data are presented as delta change 
(n=3). 
 
Analysis of individual fatty acids by GC-FID revealed significant changes in 4 fatty 
acids between normoxic and hypoxic cells (Figure 5.3.8). Palmitic acid was 
increased in 1, 2 and 5% O2 cells compared with normoxia (normoxia: 42.0 ± 2.0% 
to: 1% O2; 45.2 ± 1.0%, 2% O2; 44.0 ± 0.1%, 5% O2; 45.4 ± 2.0%, p<0.0001 for all) 
and was decreased in 21% O2 cells compared with normoxia (normoxia: 42.0 ± 
2.0%, 21% O2: 37.2 ± 1.2%, p<0.0001). Palmitoleic acid was decreased in 1, 2 and 
5% O2 cells compared with normoxic controls (normoxia: 32.9 ± 1.5% to: 1% O2; 
27.8 ± 0.9%, 2% O2; 27.6 ± 0.1%, 5% O2; 29.4 ± 1.2%, p<0.0001 for all) and was 
increased in 21% O2 cells compared with normoxia (normoxia: 32.9 ± 1.5%, 21% 
O2: 35.5 ± 0.9%, p<0.0001). Stearic acid was increased in 1 and 2% O2 cells 
compared with normoxic controls (normoxia: 3.1 ± 0.2% to: 1% O2; 4.3 ± 0.05%, 
2% O2; 4.3 ± 0.07%, p<0.05 for both).  
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Figure 5.3.8: Cellular fatty acid composition. Significant changes in individual fatty acid compositions of normoxic and hypoxic cells. ****p<0.0001, 
**p<0.01, *p<0.05, normoxia (n=15) and 1, 2, 5, 10, 21% O2 (n=3). 
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Finally, oleic acid was increased in 2% O2 cells compared to normoxic controls 
(normoxia: 12.1 ± 0.7%, 2% O2: 13.6 ± 0.08%, p<0.001). No changes were observed 
in the remaining detected fatty acids between normoxic and hypoxic cells 
(Appendix: Table III).  
The same 4 fatty acids differed significantly between normoxic and hypoxic EVs 
(Figure 5.3.9). Palmitic acid was increased in 1 and 21% O2 EVs compared to 
normoxic controls (normoxia: 36.2 ± 2.6% to: 1% O2; 40.5 ± 0.05%, p<0.05, 21% 
O2; 45.1 ± 3.0%, p<0.0001). Palmitoleic acid was decreased in 1% O2 EVs and 
increased in 2 and 10% O2 EVs compared to normoxia (normoxia: 19.2 ± 6.4 to: 1% 
O2; 8.3 ± 0.1%, 2% O2; 26.2 ± 0.01%, 10% O2; 23.8 ± 0.01%, p<0.0001 for all). 
Stearic acid was decreased in 2% O2 EVs compared with normoxia (normoxia: 14.5 
± 3.7%, 2% O2: 10.3 ± 0.0%, p<0.05). Finally, oleic was increased in 1% O2 EVs 
compared with normoxic controls (normoxia: 13.1 ± 2.4%, 1% O2: 16.9 ± 0.03%, 
p<0.05). No changes were detected in other fatty acids in EVs or fatty acids classes 
from normoxia to hypoxia (Appendix: Table IV). 
Differences were observed in classes of fatty acids in cells with hypoxia, particularly 
with 1% O2 (Figure 5.3.10). For example, SFA were higher in 1% O2 cells compared 
with normoxic cells (normoxia: 48.1 ± 2.6% to: 1% O2; 52.6 ± 1.2% p<0.01). 
MUFA were significantly lower in 1% O2 cells compared with normoxic cells 
(normoxia: 49.2 ± 2.9% to: 1% O2; 41.4 ± 1.2%, p<0.0001). No differences were 
observed in cellular PUFA or EV lipid classes with hypoxia, however, similarly to 
Chapter 4, PUFAs were enriched in EVs compared with cells. The effects of the 
remaining hypoxic conditions on cellular lipid classes and individual fatty acids are 
given in Appendix Table III. 
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Figure 5.3.9: EV fatty acid composition.  Significant changes in individual fatty acid composition between normoxic and hypoxic EVs. ****p<0.0001, 
**p<0.01, *p<0.05, normoxia (n=15) and 1, 2, 5, 10, 21% O2 (n=3).
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Figure 5.3.10: Changes in lipid classes with hypoxia. Alterations in major lipid classes 
between (A) normoxic cells, (B) 1% O2 cells, (C) normoxic EVs, and (D) 1% O2 EVs. SFA 
= saturated fatty acids, MUFA = monounsaturated fatty acids; PUFA = polyunsaturated fatty 
acids, (n=3). 
 
When comparing the fatty acid composition of cells with their corresponding EVs, 
hypoxic EVs showed more differences compared to hypoxic cells than normoxic 
samples (Appendix: Table V). In particular, hypoxic EVs were enriched in PUFAs 
such as arachidonic acid and α-linolenic acid compared to hypoxic cells.  
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5.3.6 Effect of hypoxia on phospholipid composition  
From here on in, 1% O2 was chosen (and is referred to) as the hypoxic challenge. 
From the data presented above, 1% O2 gave the most significant hypoxic challenge 
(without affecting the cell viability) and also the remaining experiments required a 
large amount of EV sample, so only one hypoxic challenge was practical.  
Two-dimensional TLC was used to separate phospholipid groups in normoxic and 
hypoxic cell and EV samples. Proportions of each phospholipid were calculated as a 
percentage of the total concentration (Figure 5.3.11). Changes in phospholipids were 
marginal in normoxic and hypoxic cells. EVs showed increases in PC and PS and 
decreases in PE, sphingomyelin and cardiolipin in hypoxia compared with normoxia. 
PC and PE were the most abundant phospholipids present in all samples. 
 
Figure 5.3.11: Phospholipid composition of cells and EVs. Phospholipids were separated 
using TLC in normoxic and hypoxic (1%) cells and EVs. Proportions of each phospholipid 
were calculated as a percentage of the total concentration of all phospholipids. (A) normoxic 
cells; (B) hypoxic cells; (C) normoxic EVs; (D) hypoxic EVs (n=1). PE = 
phosphatidylethanolamine; PC = phosphatidylcholine; PS = phosphatidylserine; PI = 
phosphatidylinositol.   
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Separated phospholipids were then further analysed by GC to identify individual 
fatty acids present within phospholipid fractions (Appendix: Table VI). Similarly to 
Chapter 4, EVs were enriched in PUFAs, particularly in hypoxic conditions where 
arachidonic acid was abundant. Interestingly, the PUFA, α-linolenic acid was 
reduced in hypoxic EV samples. 
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5.3.7 Effect of hypoxia on cellular protein content  
Cell lysates from normoxic and hypoxic cells were analysed for their expression of 
adipocyte and inflammatory proteins by Western blotting (Figure 5.3.12). Of the 
adipocyte proteins, adiponectin appeared to be decreased in hypoxic cells, though 
this was not significant (A). Expression of FABP4, though not significant, increased 
in hypoxic cells (B). PPARγ expression was significantly reduced in hypoxic cells 
(normoxia: 2.37 ± 0.08; hypoxia: 0.85 ± 0.2 relative expression compared to β-actin, 
p = 0.0003; C). Inflammatory proteins (TNF-α and IL-10) showed no change 
between normoxia and hypoxia (D/E). IL-6 could not be detected by Western 
blotting despite maximisation of the amount of protein loaded, the concentration of 
antibody used and exposure time. No change was observed in MCP-1 (F), however 
hypoxic cells contained significantly more HIF-1α (normoxia: 0.2 ± 0.2; hypoxia: 
1.7 ± 0.7 relative expression compared to β-actin, p = 0.02; G). 
 
 
30 kDa 15 kDa 
57 and 
53 kDa 
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Figure 5.3.12: Western blot analysis. Western blots of cell lysates from normoxia and 1% 
O2 cells probed for adipocyte markers: (A) adiponectin, (B) FABP4, (C) PPARγ and 
inflammatory markers: (D) TNF-α, (E) IL-10, (F) MCP-1 and (G) HIF-1α. Differences in 
densitometry values compared to β-actin are presented as well as representative bands of the 
protein of interest and β-actin control. Observed molecular weights are given for each 
protein (β-actin = 42 kDa)*p<0.05, ***p<0.001 (n=3). 
  
~12 kDa ~130 kDa 
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5.3.8 Effect of hypoxia on EV protein content  
EV protein content of normoxic and hypoxic EVs was measured using EV 
immunophenotyping (Figure 5.3.13). The exosomal protein CD9 and adipocyte 
proteins, adiponectin, FABP and PPARγ, showed no difference between normoxia 
and hypoxia. Levels of inflammatory proteins, IL-6, TNF-α and IL-10 were not 
changed with 1% O2. MCP-1 was significantly increased in hypoxic EVs (17,615 ± 
3,249 to 26,946 ± 6,928 arbitrary TRF units, p = 0.01). No change was observed in 
EV HIF-1α between normoxia and hypoxia. 
 
 
Figure 5.3.13: Protein content of normoxic and hypoxic EVs. The exosomal protein CD9, 
adipocyte proteins; adiponectin, FABP4 and PPARγ, inflammatory proteins; IL-6, TNF-α 
and IL-10, and MCP-1 and HIF-1α were analysed in normoxic and hypoxic EVs using EV 
immunophenotyping. Europium was used as the assay reporter and was measured using 
time resolved fluorescence (TRF). Data are presented in arbitrary TRF units, *p<0.05 (n=3). 
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5.4 Discussion 
5.4.1 Key findings 
1. Hypoxia (1-21% O2) had no effect on adipocyte number or viability. 
a. Cells in 1% O2 had an altered morphology but their lipid storage was 
unchanged. 
2. EV production is increased in hypoxia (1% O2), particularly EVs <200 nm. 
3. Hypoxia (1% O2) increased cellular annexin V positivity, EVs from 5% O2 
cells were less annexin V positive than controls. 
4. Fatty acid composition was affected by hypoxia with similar compositional 
changes in cells and EVs. 
5. Apportion and fatty acid composition of phospholipids was effected by 
hypoxia in cells and EVs. 
6. Cellular expression of PPARγ and HIF-1α were altered by hypoxia. 
7. MCP-1 was increased in hypoxic EVs. 
 
5.4.2 Main discussion 
Obesity is associated with local inflammation in AT and increases in circulating 
inflammatory makers, both of which increase the risk of cardiovascular co-
morbidities (352). Obese AT is prone to hypoxic areas which leads to a functional 
reprogramming of endocrine and metabolic processes within AT and results in AT 
inflammation (Figure 1.2.6). EV release is also increased during hypoxic conditions 
and functional studies have shown hypoxic EVs may enhance disease pathology. 
Therefore, EVs released from hypoxic adipocytes may initiate or enhance the shift 
towards inflamed adipocytes which are associated with an increased cardiovascular 
risk. This chapter sought to characterise the effects of O2 on adipocyte EV release. 
 
The actual concentration of O2 surrounding adipocytes in vivo is unknown, largely 
due to the complexity and diversity of AT between individuals. The most recent 
estimation of AT pO2 is between 3 and 11% (365) though values vary greatly 
between studies. A major reason for the observed differences in reported pO2 values 
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may be due to the use of different techniques to measure AT oxygenation (see 
Chapter 1.2.6). Furthermore, the majority of techniques used to measure AT pO2 are 
probe-based meaning O2 is only measured in a specific part of the tissue so the 
reading may not represent that of the whole tissue. Therefore in this chapter, 3T3-L1 
adipocytes were incubated at a range of different O2 levels (1% to 21%) for 24 hours 
to compare differences in both the cells and the EVs following this period, but also 
to establish a pathologically relevant “hypoxic” condition for 3T3-L1 adipocytes. 
Morphology, cell number and viability were unchanged between different O2 
conditions, though 1% O2 cells bore more of a resemblance to preadipocytes. Lipid 
droplet accumulation has been shown to be reduced in 3T3-L1 adipocytes incubated 
in 5% O2 (for 1 week) due to increased lipolysis (467). Mobilisation of FFAs is 
increased in hypoxic adipocytes (368,467) and in obesity (468,469). Oil Red O 
staining of 1% O2 cells showed no difference compared to normoxic cells, though 
this technique may not be sensitive enough to detect more subtle metabolic changes 
(470). 
 
Previous studies have shown increased concentrations of EVs in hypoxia in: cancer 
cell lines (241,463,471); endothelial cells (472); and increased exosomal protein 
content of placental- (473) and adipocyte-derived EVs (390) from hypoxia. Data 
presented in this chapter are in agreement with these studies. A significant elevation 
in adipocyte-derived EV concentration was observed only in 1% O2, with no 
difference in overall mode size compared to normoxic controls. Interestingly, when 
EV concentrations were plotted in 50 nm bin-widths, this increase in 1% O2 samples 
was shown to be attributable to EVs in the range of 50 – 200 nm. Also EVs from 2% 
O2 samples were increased in the range of 100 – 200 nm compared to normoxia. This 
suggests a propensity for hypoxia to induce secretion of exosomes and small 
microvesicles in adipocytes which has been previously attributed (in part) to HIF-1α. 
Silencing of HIF-1α abates the hypoxia-induced increase in EV production in breast 
cancer cells (463) though the exact mechanisms through which this occurs and 
whether other transcription factors are involved are unknown. Hypoxia may induce a 
stress response (perhaps via HIF-1α) causing alterations in plasma membrane lipids 
and receptors. Such alterations may lead to an endocytic remodelling of the plasma 
membrane which may in turn favour an increase in EV formation (474). Indeed, 
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induction of HIF-1α has been shown to activate reorganisation of the actin 
cytoskeleton (475); a key requirement for EV formation (476). 
 
Plasma membrane remodelling during hypoxia may also lead to changes in 
phospholipid distribution across the plasma membrane. Reorganisation of the normal 
phospholipid asymmetry is thought to be a precursory event in EV generation, 
primarily though the externalisation of PS. To assess this, hypoxic (1-21% O2) and 
normoxic cells and EVs were analysed for their annexin V positivity, a measure of 
PS exposure. Unfortunately, there was great variation in the reported baseline 
annexin V positivity of cells and EVs between hypoxic experiments, therefore 
hypoxic samples were expressed as a delta change from normoxic annexin V 
positivity for a given experiment. Cells from 1% O2 were significantly more annexin 
V positive than normoxic cells. This is in keeping with hypoxia increasing exposure 
of PS on the outer leaflet of the plasma membrane as a precursor to increased EV 
generation. Interestingly, there was no change in the annexin V positivity of 1% O2 
EVs compared to normoxic controls. As discussed in Chapter 4, the PS exposure of 
EVs is often used as an indicator of the procoagulant potential of EVs which is 
unlikely to be an important feature of adipocyte-derived EVs. Furthermore, the 
increased PS positivity of 1% O2 cells may serve as a reservoir for increased EV 
generation and therefore the concentration of EVs increases but the annexin V 
positivity of individual EVs remains the same. The annexin V positivity of 5% O2 
EV was significantly reduced compared to normoxic EVs indicating exposed PS was 
reduced in 5% O2 EVs. However, the raw percentage of annexin V positivity 
(Figure 5.3.6 A) shows great deviation between 5% EV replicates, meaning the data 
are likely to be skewed by an outlier. Therefore, greater „n‟ numbers may be required 
to ensure this reduction is real. 
 
Lipids play fundamental roles in forming energy reserves and in maintaining cell and 
organelle structure, though they are often overlooked as potential signalling 
mediators. It is estimated that up to two-thirds of the EV volume is composed of 
lipids (78), indicating an important role for lipids in EV function. Here, the fatty acid 
composition of normoxic and hypoxic (1-21% O2) cells and EVs was analysed to 
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evaluate potential functional changes. No changes were observed in overall fatty acid 
concentration between hypoxic and normoxic cells and EVs. Fatty acid 
concentration of 1% O2 cells was reduced compared to normoxic cells though this 
was not significant. This is in agreement with morphological data of 1% O2 cells 
which looked to have reduced lipid droplet accumulation, though no difference was 
observed in Oil Red O staining. GC-FID is a more sensitive assessment of the 
presence of lipids than Oil Red O staining which may account for difference between 
the two techniques. 
Analysis of individual fatty acids revealed compositional differences in four fatty 
acids between normoxic and hypoxic EVs. Palmitic acid was increased in hypoxic 
cells compared to normoxic cells. Palmitic acid is a major storage fatty acid (439) 
however, lipid storage (as indicated by total fatty acid concentration and Oil Red O 
staining) was not different between normoxic and hypoxic cells. Diets enriched in 
SFAs promote ectopic lipid storage, increase mean adipocyte size, and promote 
adipose tissue inflammation (477). Here both stearic acid and SFAs overall were 
increased in lower O2 conditions (<2% O2) perhaps indicating a shift towards 
dysfunction compared to normoxic cells. Conversely, MUFAs as a whole, including 
palmitoleic acid were decreased in hypoxic cells. Palmitoleic acid has been shown to 
have beneficial effects on glucose metabolism in adipocytes compared to palmitic 
acid (478). Therefore glucose metabolism in lower O2 conditions may be impaired 
due to a decreased abundance of palmitoleic acid. A simultaneous increase in SFAs 
and decrease in MUFAs in hypoxia may be due to reduced activity of stearoyl-CoA 
desaturase enzymes which require O2 to desaturate SFAs to MUFAs (479). 
Interestingly, the MUFA oleic acid was upregulated in 2% O2 cells. Oleic acid has 
been shown to improve IR and have anti-inflammatory effects (480) suggesting the 
negative effects of lower O2 may be abrogated slightly in 2% O2 cells. 
The same four fatty acids were altered in EVs with hypoxia though the effects were 
not always the same as in the cell of origin. Palmitic acid was increased and 
palmitoleic acid was decreased in 1% O2 EVs compared to normoxia, largely 
reflecting 1% O2 cells. Oleic acid was increased in 1% O2 EVs, however, suggesting 
EVs may reflect the fatty acid profile of the cell to some extent, but also possess 
unique differences. The enrichment of oleic acid in 1% O2 EVs may help to 
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counteract the potential negative effects of palmitic acid in EVs. Intriguingly, when 
the fatty acid composition of 1% O2 EVs was compared directly with 1% O2 cells, a 
number of compositional differences were observed. Hypoxic EVs (1% O2) were 
preferentially enriched in SFAs and less abundant in MUFAs than 1% O2 cells. In 
tumour cells, increased SFAs in hypoxia were shown to promote stress of the 
endoplasmic reticulum (ER) (479), suggesting hypoxic EVs may be more potent at 
inducing ER stress. Furthermore, hypoxic EVs were richer in PUFAs compared to 
hypoxic cells, particularly arachidonic acid and α-linolenic acid. This suggests that 
hypoxic EVs harbour greater signalling potential compared to their corresponding 
cells as arachidonic acid and α-linolenic acid are precursors for eicosanoid signalling 
molecules (445,481). Additionally, α-linolenic acid can also induce PAI-1 
expression, an adipokine with connotations in the development of inflammatory AT 
(482,483). However, α-linolenic acid is an ω-3 fatty acid, and is generally regarded 
as anti-inflammatory (484). Together, the results confirm that EVs are specifically 
packaged with a particular cargo and do not merely reflect uptake of the cellular 
milieu. 
 
Phospholipids form the structural basis of cell membranes, providing a permeability 
barrier but also a source of bioactive fatty acids (485). Two-dimensional TLC was 
used to identify the major phospholipid groups followed by GC to characterise 
individual fatty acids within each phospholipid group in normoxic and hypoxic cells 
and EVs. No changes were observed in the proportions of phospholipids between 
normoxic and hypoxic cells. One may have expected an increased proportion of PS 
in hypoxic cells given their increased annexin V positivity. However, annexin V 
positivity is a measure of the external exposure of PS whereas TLC with GC-FID 
measures the total proportion of PS in the phospholipid membranes of the cell. 
Therefore, externalisation of PS may be higher in hypoxic cells but the overall 
proportion of cellular PS is not changed from normoxia. EVs showed a number of 
proportional changes in phospholipids between normoxia and hypoxia which are 
discussed below with respect to changes in individual fatty acids. 
Across all phospholipid samples measured, the most abundant fatty acids were 
usually palmitic acid, palmitoleic acid and stearic acid and hence overall, SFAs and 
Page | 197  
 
MUFAs were the dominant classes of lipids. This is likely due to their roles in 
membrane structure as SFAs maintain structural rigidity of membranes (439) whilst 
MUFAs add flexibility to preserve membrane dynamics. Again, as noted in Chapter 
4, EVs contained a higher composition of PUFAs compared to cells. PUFAs can be 
used to generate eicosanoids such as arachidonic acid that can go on to activate a 
number of signalling pathways. Indeed, arachidonic acid was also enriched in EVs, 
particularly hypoxic EVs, suggesting EVs may be equipped with a greater cargo of 
signalling fatty acids compared to cells and normoxic EVs. 
PE and PC were the dominant phospholipids detected in both cells and EVs, as 
reported in Chapter 4 and elsewhere (442,443). The proportion of PE was reduced in 
hypoxic EVs despite no change in cellular PE. PE and PS are known to be co-
regulated (486) so perhaps the increase in PS in hypoxic EVs caused a concurrent 
decrease in PE.  
Sphingomyelin, a major structural lipid and component of plasma membrane lipid 
rafts, was reduced in hypoxic EVs. Reduced sphingomyelin content has previously 
been shown to enhance insulin sensitivity in cells (487). Impaired insulin sensitivity 
is a hallmark of obesity and related disorders, therefore hypoxic EVs may have a 
reduced sphingomyelin content in an attempt to maintain insulin sensitivity in 
deteriorating AT. As in Chapter 4, sphingomyelin samples contained high 
proportions of SFAs which may contribute to the structural role of sphingomyelin. 
Sphingomyelin is also known to be required for exosome secretion by providing the 
required lipids for ceramide production (25). Unfortunately, ceramide content of EVs 
was not measured here, though the proportion of sphingomyelin was reduced in 
hypoxic EVs, perhaps indicating an increased conversion to ceramide in order to 
generate the increased concentration of EVs observed in hypoxia. 
The mitochondrial phospholipid, cardiolipin, was found to be present in all samples, 
and was decreased in hypoxic EVs. A previous study found no change in the 
proportion of cardiolipin between normoxic and hypoxic prostate cancer cells (488). 
Though the proportion of cardiolipin was not changed between normoxic and 
hypoxic cells, the fatty acid composition was very different. Cardiolipin in normoxic 
cells was rich in MUFAs whilst hypoxia cells were rich in SFAs. A greater degree of 
unsaturated fatty acids is associated with an increased interaction with cytosolic 
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proteins such as FABP4 (448). Therefore, the increased saturation of fatty acids in 
hypoxic cells may impair their ability to interact with cytosolic proteins such as 
FABP4. Despite being a mitochondrial-associated phospholipid, cardiolipin was 
detected in both normoxic and hypoxic EVs. This may be due to experimental error 
when scraping TLC plates for GC as cardiolipin is close to PE after separation 
(Figure 2.5), perhaps resulting in PE contamination. However, the profiles of fatty 
acids of cardiolipin in EVs detected are very different to those detected in PE in EVs, 
arguing against significant PE contamination. Profiles of fatty acids in EVs were also 
similar to those of cells, suggesting EVs contain cardiolipin in a similar composition 
to that of the cell. 
As discussed before, PS is predominantly distributed on the inner leaflet of the 
plasma membrane. The anionic nature of PS allows it to serve as a point of initiation 
for intracellular signalling cascades for second messengers such as protein kinase C 
(449,450). PS was increased in hypoxic EVs, again suggesting that hypoxic EVs 
have an increased signalling capacity compared to normoxic EVs. Normoxic EVs 
had a higher composition of α-linolenic acid compared to hypoxic EVs in PS, but 
also in the majority of other phospholipids. α-linolenic acid has been shown to be 
important in normal adipocyte functioning (440) and may have anti-inflammatory 
effects (484), suggesting that a reduced amount (as in hypoxic EVs) may be 
detrimental to the recipient adipocytes. 
 
Adipocytes are known to synthesise and secrete an array of adipokines, many of 
which are dysregulated in obese AT. Here, a selection of adipocyte, hypoxia-
associated, and inflammatory proteins were analysed in cells and EVs to determine 
differences between normoxia and hypoxia. Cell lysates were analysed using 
Western blotting and compared using optical density of bands relative to that of β-
actin. EVs were analysed using an immunophenotyping method, described in 
Chapter 4. 
Of the three adipocyte proteins analysed, cellular levels of FABP4 appeared to be 
increased by hypoxia whilst adiponectin showed a slight reduction and PPARγ was 
significantly reduced. No changes were observed in EV adipocyte proteins between 
normoxia and hypoxia. FABP4 expression is abundant in AT due to its role in 
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shuttling fatty acids and lipid molecules around and between cells (455). However, 
FABP4 has been implicated in a number of obesity-related pathologies such as heart 
disease (489), metabolic syndrome (349) and atherosclerosis (490). Indeed, mouse 
models have illustrated that silencing FABP4 prevents mice from developing IR 
(324) and can ameliorate the symptoms of type 2 diabetes and atherosclerosis (350). 
Here, hypoxia looked to increase cellular protein expression of FABP4 despite 
previous studies indicating a reduction in FABP4 expression in hypoxic adipocytes 
(491,492). However, these studies measured the mRNA levels of FABP4 which 
were not monitored here. The apparent increase in cellular FABP4 here is likely due 
to decreased β-actin content in hypoxic cells probed for FABP4. β-actin was not 
shown to be different in other Western blots, suggesting a slight discrepancy in the 
β-actin result of the FABP4 blot. Vesicular FABP4 content was not changed between 
normoxic and hypoxic cells, indicating no effect of hypoxia on EV FABP4 content. 
The nuclear receptor PPARγ is required for both the induction and maintenance of 
adipogenesis (320). Previous studies have shown that hypoxia blunts preadipocyte 
differentiation through inhibition of PPARγ gene expression, and levels of PPARγ 
mRNA are lower in hypoxic adipocytes (371,381). Here, PPARγ protein expression 
was significantly reduced in hypoxic adipocytes, suggesting hypoxia effects PPARγ 
expression at both the gene and protein level. PPARγ content of hypoxic EVs, 
however, was not different to normoxic EVs suggesting this change in PPARγ 
expression was not passed on to the EV. 
Adiponectin is an adipokine that can be detected in the circulation with metabolic 
and anti-inflammatory properties (371). Circulating adiponectin levels of obese 
subjects have been shown to be lower than those of healthy subjects (493) suggesting 
a role for adiponectin in physiological AT function. Cellular adiponectin expression 
was decreased in hypoxic cells though this was not significant. Previous studies have 
found that hypoxia reduces adiponectin mRNA expression through negative 
regulation of the adiponectin promoter (371). Adiponectin content of EVs was not 
different between normoxia and hypoxic EVs again suggesting this change in 
adipocyte protein expression was exclusive to the cell. 
Of the inflammatory markers measured in cell lysates, no changes were observed in 
TNF-α or IL-10 between normoxia and hypoxia, and IL-6 could not be detected. No 
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changes were observed in the EV protein content of TNF-α, IL-6 or IL-10 between 
normoxia and hypoxia. The systemic inflammation in obesity is characterised by 
elevated circulating levels of IL-6 and TNF-α (364) and levels of IL-6 and TNF-α 
mRNA have been shown to be elevated in hypoxic adipocytes (380). The latter study 
also conducted a time-course of expression of inflammatory genes showing that 
upregulation of TNF-α mRNA is transitory, peaking at 2 hours incubation in hypoxia 
then returning to normoxic levels by 4 hours. Therefore, the hypoxia-induced 
increase in TNF-α may have been missed in the experiments conducted as part of 
this thesis due to the 24 hour incubation time. Wang et al., also showed that IL-6 
mRNA expression reached a peak at 24 hours in hypoxia (380) though here cellular 
IL-6 protein expression could not be detected after 24 hours in hypoxia. IL-6 is often 
secreted into the supernatant or extracellular space, so if the protein expression did 
indeed change, this protein may have been secreted from the cell without changing 
the intracellular levels. Indeed, hypoxia has previously been shown to induce IL-6 
and TNF-α secretion into 3T3-L1 supernatants (494). Perhaps the same is also true 
for IL-10, an anti-inflammatory adipokine, which showed no change in cellular 
protein expression following hypoxia. IL-10 has previously been detected in 3T3-L1 
supernatants (495), suggesting the majority of these cytokines may be secreted. IL-6, 
TNF-α and IL-10 were detected in EVs but no changes were observed between 
normoxia and hypoxia suggesting that hypoxic EVs do not have an altered 
inflammatory protein profile to normoxic EVs.  
Hypoxia in any cell type is usually characterised by an elevated expression of HIF-
1α, a transcription factor which regulates the cellular response to hypoxia. In fact, 
HIF-1α is thought to inhibit the gene expression of PPARγ and adiponectin (369) 
which may explain the reduced level of PPARγ and the non-significant reduction in 
adiponectin here in hypoxic adipocytes. Cellular levels of HIF-1α were significantly 
increased in hypoxic cells, confirming hypoxia at the molecular level and in keeping 
with previous in vitro hypoxia studies. Furthermore, HIF-1α expression is increased 
in obese mouse (369) and human AT (370), confirming both a role for HIF-1α in the 
adipocyte response to hypoxia, and also the presence of hypoxia in AT. No change 
was observed in HIF-1α content of EVs; however, recent data from our lab suggests 
that increased EV release from endothelial cells in hypoxia may, in part, be mediated 
by HIF-1α. 
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Adipocyte hypoxia is thought to stimulate the activation and migration of tissue-
resident and distal Mϕ towards the site of hypoxia where they become 
proinflammatory and create AT dysfunction (Figure 1.2.6). MCP-1 is a protein 
secreted from a number of cell types (including adipocytes) to stimulate recruitment 
of monocytes and T cells. Cellular MCP-1 mRNA and secretory protein has 
previously been shown to be elevated in hypoxic adipocytes and was subsequently 
shown to be responsible for Mϕ recruitment to hypoxic adipocytes (494). Here, 
cellular MCP-1 protein showed no change between normoxia and hypoxia, though 
again, this may be because the majority of MCP-1 is secreted from the cell into the 
surrounding milieu. Interestingly, levels of MCP-1 were increased in hypoxic EVs, 
suggesting that hypoxic vesicles have an increased capacity to drive Mϕ migration.   
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5.4.3 Limitations 
Many of the same limitations outlined in Chapter 4.4.3 apply to this chapter 
including the use of 3T3-L1 cells to study adipocyte EVs, the differential 
ultracentrifugation protocol to isolate EVs, the use of FC to assess the annexin V 
positivity of EVs, and the use of serum-free media for EV isolation. 
A hypoxic chamber was used to control O2 levels, meaning only one hypoxic 
condition could be analysed at a time. Therefore different O2 conditions were 
conducted as individual experiments with their own normoxic controls so that 
comparisons could be made between experiments. Variation was observed between 
different hypoxic experiments meaning some data had to be expressed as a change 
from the respective control. However, great care was taken to ensure consistency 
was maintained between experiments to minimise potential variation. 
The duration of the hypoxic challenge used in this study was 24 hours in serum-free 
media. Proteins such as TNF- α have a rapid response to hypoxia (<2 hours) (380) 
meaning peaks in protein expression may have returned to baseline by 24 hours. 
However, 24 hour incubation was required to ensure adequate EV generation for 
subsequent analyses. Future experiments could look to analyse changes in cellular 
and EV protein over a series of time points in order to capture the full spectrum of 
changes. Other studies have also observed changes in mRNA expression with 
hypoxia. These could also be analysed in EVs to see whether functional changes in 
mRNA in hypoxic adipocytes are incorporated into hypoxic vesicles. 
Immunophenotyping in this chapter was conducted slightly differently to that 
described in Chapter 4 in an attempt to reduce the previous limitations. However, the 
concentration of EVs used per well was based on pilot data from endothelial EVs, 
which may possess different characteristics to adipocyte-derived EVs; therefore EV 
immunophenotyping data should be validated using Western blotting. 
The increased exposure of PS measured in 1% O2 cells could be inferred as hypoxia-
induced is induced apoptosis in these cells. Apoptosis also causes PS externalisation 
and release of apoptotic bodies (which are included in by many in the EV field as 
EVs, though they often form vesicles > 1µm) (17). However, the overall viability of 
1% O2 cells was not affected and the hypoxia-induced increase in EV concentration 
was observed in the exosomal and smaller microvesicle range. This suggests that 1% 
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O2 presented a genuine hypoxic challenge that did not induce apoptosis, and release 
of apoptotic bodies was not responsible for the observed increase in EV release. To 
completely confirm this however, propidium iodide could be used in combination 
with annexin V to fully assess the apoptotic state of adipocytes using FC. 
Finally, “normoxia” in this thesis refers to a standard cell culture incubator which 
provides cells with a gas mixture of 95% air and 5% CO2. As previously described, 
the actual pO2 of adipocytes and AT is unknown, but is estimated to be 3-11% O2 
(365). Therefore a “normoxic” condition of 95% air (containing 21% O2) may 
provide slightly hyperoxic conditions to adipocytes. However, AT pO2 measurement 
is extremely difficult and is often representative of the area surrounding the oxygen 
probe, meaning measurements are only reflective of small sections of tissue. Until 
more accurate measurements of adipocyte and AT pO2 are published, the most 
sensible option for normoxic conditions seems to be cell culture incubators. 
 
5.4.4 Conclusions 
In summary, hypoxia significantly affected the production of adipocyte-derived EVs, 
particularly at 1% O2. Hypoxic cells released a greater overall concentration of EVs 
(predominantly exosomes and small microvesicles). These hypoxic EVs were 
equipped with fatty acids associated with negative effects on adipocyte function, and 
a change in phospholipid fatty acids that is suggestive of an increased signalling 
potential. Hypoxia seemed to interfere with specific aspects of adipocyte functioning 
such as regulation of adipokine production and lipid droplet storage. Hypoxic EVs 
were also enriched with MCP-1 suggesting these EVs may facilitate the recruitment 
of Mϕ to hypoxic adipocytes thereby promoting a proinflammatory, hypoxic 
environment. Therefore, hypoxic EVs may assist the progression of adipocyte 
dysfunction in hypoxia. Future studies should look to further characterise these EVs 
for functional changes in mRNA and microRNA expression and determine whether 
these EVs can have a detrimental effect on adipocytes and other cells resident in AT 
such as Mϕ and endothelial cells. 
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6. Results IV: 
The effects of hypoxic adipocyte-derived 
extracellular vesicles on macrophage function 
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6. Perspective 
Having shown that hypoxia could increase the concentration and change the 
characteristics of EVs released from adipocytes in Chapter 5, I wanted to test 
whether this translated into differential functionality. Therefore, this chapter 
examines the potential effects of hypoxic EVs on Mϕ phenotype and migration. 
Unfortunately due to logistical problems and practical issues with establishing the 
model system at the laboratory of a collaborator, experimental repetitions could not 
be completed in time and thus data presented in this chapter present beginnings of 
work that is on-going. 
 
 
 
 
 
  
Parts of this chapter have been published in: 
Connolly KD, Guschina IA, Chauhan P, Devitt A, Hassan N, Morris K, Clayton A, 
Rees DA, James PE (2015). Extracellular vesicles secreted from adipocytes 
exposed to hypoxia and their effects on macrophage chemotaxis and phenotype. 
Journal of Extracellular Vesicles. 4: 27783; P-VIII-16. 
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6.1 Introduction 
As discussed in Chapters 1 & 5, obesity is complex condition associated with a 
variety of comorbidities and diseases such as CVD, T2D, metabolic syndrome, 
cancer and many others (496–498). Obesity is also characterised by a low grade of 
systemic inflammation and inflamed AT (352) though the sequence of events leading 
to obesity-associated inflammation are unknown. Hypoxia, caused by expanding AT, 
is one possible initiator of the production of localised and circulating 
proinflammatory factors by adipocytes and AT-resident Mϕ (352,371,460,461). 
Chapter 5 illustrated how hypoxic conditions can enhance EV release, suggesting 
hypoxic adipocyte-derived EVs could have a part to play in the initiation of 
inflammation induced by hypoxia. 
Tissue resident Mϕ are highly heterogeneous (499) and are found in a variety of 
tissues including the liver, kidneys, bone, the central nervous system and AT (500). 
As well as tissue specific functions, tissue-resident Mϕ are important regulators of 
innate immunity as they are able to phagocytose foreign and necrotic material and 
initiate the recruitment of additional Mϕ and leukocytes (501). However, a specific 
role for Mϕ in AT has not been identified. The heterogeneity of Mϕ allows their 
phenotype to be influenced by the tissue microenvironment. Changes in Mϕ 
phenotype generally follow two lines of polarisation: M1 and M2 (499). 
Proinflammatory mediators such as lipopolysaccharide and interferon-γ induce 
polarisation towards a classically activated (M1) phenotype which further promotes a 
proinflammatory environment through the production of cytokines such as TNFα, 
IL-1β and IL-6 (338,502). Alternatively activated (M2) Mϕ are produced in response 
to anti-inflammatory stimuli such as IL-4, and promote an anti-inflammatory 
phenotype through increased generation of IL-10, IL-1 receptor antagonist (IL-1Ra) 
and dectin-1 (338,503,504). Mϕ in lean AT are predominantly of an M2 phenotype, 
whereas Mϕ in obese AT are of an M1 phenotype (Figure 1.2.5) (338,502). High-fat 
feeding of mice has been shown to induce a phenotypic shift in polarisation of AT 
Mϕ from an anti-inflammatory M2 state to a pro-inflammatory M1 phenotype (338). 
Furthermore, the production of proinflammatory cytokines such as TNFα and IL-6 
by M1 Mϕ in obese AT can inhibit insulin signalling within adipocytes, contributing 
to the emergence of IR (460). 
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In addition to an altered phenotype of tissue-resident Mϕ, obese AT is also infiltrated 
by increased numbers of Mϕ (460,500,505), though the mechanism by which this 
occurs is unknown. Mϕ within obese AT often form crown-like structures (CLSs), 
surrounding necrotic and apoptotic adipocytes (506). CLSs in obese AT have also 
been found in association with hypoxia (507), suggesting a link between hypoxia and 
the infiltration of Mϕ (Figure 1.2.6). Hypoxia is likely to induce activation of 
adipocytes and eventually apoptosis and necrosis if the hypoxia persists or remains 
unresolved (e.g. by new blood vessel growth). Chapter 5 illustrated how hypoxia 
(1% O2) induced the release of EVs from adipocytes that were enriched in MCP-1 
and pro-signalling fatty acids. Recently, Eguchi et al., demonstrated how adipocytes 
activated by palmitic acid produced microparticles that actively cause Mϕ migration 
in vitro and in vivo (48) highlighting the potential functional interactions of 
adipocyte EVs with Mϕ. Therefore, hypoxic adipocyte-EV release may cause 
recruitment of Mϕ to hypoxic AT which may further exacerbate the 
hypoxic/inflammatory environment and contribute to the development of obesity-
associated inflammation. 
 
6.1.1 Aims 
This chapter aimed to compare the effects of normoxic and hypoxic adipocyte-
derived EVs on: 
 M1 Mϕ cytokine release  
 M2 Mϕ gene expression markers 
 Mϕ migration 
 
6.1.2 Hypotheses 
Hypoxic adipocyte-derived EVs may promote a proinflammatory phenotype in Mϕ 
by increasing M1 cytokine production, decreasing M2 gene expression and 
enhancing Mϕ migration. The release of EVs from hypoxic adipocytes may therefore 
contribute to the initiation of inflammation in obese AT.  
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6.2 Methods 
6.2.1 3T3-L1 culture and extracellular vesicle isolation 
3T3-L1 cells were cultured using T175 cm
2
 flasks to a mature phenotype (14 days 
post-differentiation) as described in Chapter 2.2. Cells were then exposed to 
normoxic or hypoxic conditions as outlined in Chapter 5.2.1. Conditioned serum-
free media for EV isolation was collected and processed as before (Chapter 5.2.1). 
The concentration of EV isolates was measured by NTA on the day of isolation and 
EVs were then stored as described in Chapter 2.3.3. 
 
6.2.2 THP-1 phenotype assay 
Human promyelocytic cells (THP-1) were cultured by Mr Nurudeen Hassan (Cardiff 
Metropolitan University) in RPMI 1640 (Gibco, UK) supplemented with 10% heat-
inactivated FCS (Labtech International), 1% sodium pyruvate, 1% non-essential 
amino acids and 1% penicillin (100 IU/mL )/streptomycin (100 µg/mL, all given 
(v/v), Gibco). THP-1 were differentiated into Mϕ in vitro using 6 x 105 cells/mL 
treated with 8 nM phorbol-myristate-acetate (PMA; Sigma) for 48 hours. 
Differentiation was maintained using serum-free media without PMA for a further 
48 hours. Normoxic or hypoxic EVs (100µL) were then added to cells in 6 well 
plates. Following a 24 hour incubation with EVs, cell supernatants were collected for 
assessment of classical M1 cytokine secretion by ELISA. Cells were then processed 
for RNA isolation and qPCR of classical M2 markers. 
 
6.2.3 ELISA 
Human TNF-α and IL-1β DuoSet® ELISA kits (R&D systems, UK) were used to 
quantify the release of M1 cytokines into cell supernatants following incubation with 
normoxic or hypoxic EVs. M1 cytokines were analysed by ELISA as they are more 
readily secreted compared to M2 cytokines. Assays were completed according the 
standard manufacturers protocol.  
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6.2.4 Quantitative reverse transcription PCR 
RNA was isolated from Mϕ following incubation with EVs using TRI Reagent (Life 
Technologies, ThermoFisher, UK) according to the manufacturer‟s instructions. 
Isolated RNA was converted to cDNA using a High Capacity cDNA Reverse 
Transcription kit (Applied Biosystems, UK). M2 marker gene expression was then 
analysed using reverse transcription (RT)-PCR with Fast SYBR® Green and a Fast 
7500 Real-Time PCR System (Applied Biosystems). Relative gene expression was 
compared to GAPDH and calculated using the comparative CT method (2
-ΔΔCT
). 
Primer sequences are given in Appendix: Table VII. 
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6.2.5 THP-1 migration assay 
THP-1 cells for migration assays were cultured by Miss Parbata Chauhan (Aston 
University). A sterile glass coverslip (22 x 22 mm) was carefully added to each well 
of a 6 well plate and coated with poly-D-lysine hydrobromide solution (0.1 mg/mL 
in sterile water). THP-1 culture medium consisted of RPMI 1640 (Sigma, UK) 
supplemented with 10% (v/v) FCS, 2 mM L-glutamine, 100 µg/mL streptomycin and 
100 IU/mL penicillin (all Gibco, UK). THP-1 cells (at a density of 4 x 10
5
 cells) 
were stimulated with 100 nM 1,25-dihydroxvitamin 3 and added to each well 
containing a coverslip. Mϕ were then incubated for up to 3 days at 37°C and 5% 
CO2. 
Once the Mϕ had sufficiently adhered to the glass coverslips, the Dunn chamber 
(DCC100, Hawksley, UK) was prepared for the migration assay (Figure 6.2.1 A). 
Both inner and outer wells were filled with chemically defined Mϕ medium (Gibco, 
UK) and the glass coverslip was placed atop the Dunn chamber with the adhered Mϕ 
on the underside. The coverslip was then gently positioned to expose a small slit of 
the outer well and was fixed into place using candle wax. The outer well was drained 
of Mϕ medium using Whatman filter paper, and 100 µL of normoxic or hypoxic EVs 
was slowly introduced, avoiding any air bubbles. The outer well and edges of the 
coverslip were then completely sealed with candle wax and coated with Vaseline® 
petroleum jelly (Unilever, UK) to prevent air bubbles being introduced and drying 
out of the chamber.  
The Dunn chamber was then placed under a Zeiss Axiovert 200 M fluorescent 
microscope (Carl Zeiss Ltd., UK) in a humidity-controlled sealed chamber that was 
preheated to 37°C. The microscope was focused over the bridge between wells 
(Figure 6.2.1 B) at 10X magnification for 2 hours, with an image being captured by 
a Hamamatsu Orca camera driven by Volocity™ (version 6.3, Perkin-Elmer, UK) 
every 10 minutes (eventually creating 13 frames).  
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Figure 6.2.1: Mϕ migration assay using a Dunn chamber. Schematic summarising the 
experimental theory of using a Dunn chamber to monitor Mϕ migration. (A) Set-up of the 
Dunn chamber. A glass coverslip with Mϕ adhered to the underside was positioned so that a 
small slit of the outer well was exposed allowing for draining and filling. The coverslip was 
secured in place using wax and the outer well was filled with 100 µL of normoxic or 
hypoxic EVs. The filling slit and the edges of the coverslip were then completely sealed with 
wax. (B) A cross-section of the Dunn chamber illustrates how Mϕ adhered to the coverslip 
can migrate across the bridge between inner and outer wells, which is 20 µm in diameter. 
 
Images collected over the course of the assay were then exported as stacked tagged 
image file format files, and imported into ImageJ software (version 1.49, National 
Institutes of Health, USA). Forty cells were individually tracked per sample using 
the “Manual Tracking” plugin (Figure 6.2.2 A). Tracks were then saved and 
imported into the Chemotaxis and Migration Tool plugin (Ibidi GmbH, Germany). 
Mϕ migration was then plotted as illustrated in Figure 6.2.2 B (with Mϕ beginning 
at the intersect and the hypothesised chemoattractant at the northern point). Mϕ were 
then assessed for: 
 Angle of migration 
 Accumulated distance (cumulative distance migrated, μm) 
 Euclidean distance (as the crow flies, μm) 
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 Directionality (Euclidean distance/accumulated distance): 0 (indirect) → 1 
(direct) 
 yFMI (forward migration index along the y axis/accumulated distance) 
 Velocity (speed of migration, µm/sec). 
 
Figure 6.2.2: Tracking and analysis of Mϕ. Stacked images of Mϕ were manually tracked 
using ImageJ software and analysed using a chemotaxis and migration tool. (A) An example 
of the manual tracking of an individual Mϕ over 13 frames creating a path of migration 
(yellow). (B) An example plot of forty individual Mϕ tracks from which the overall 
migration of the sample is analysed by a series of parameters. The intersect marks the 
starting position of the cells and the northern point indicates the position of the hypothesised 
chemoattractant. 
 
6.2.6 Statistical analysis 
Data were analysed using GraphPad Prism software (version 6.0). Normoxic and 
hypoxic data were compared using an unpaired Students t-test, data are presented as 
mean ± SD (unless otherwise stated) and a p values of <0.05 was considered 
statistically significant. 
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6.3 Results 
6.3.1 M1 cytokine secretion 
The effect of normoxic and hypoxic adipocyte EVs on M1 cytokine secretion was 
measured by ELISA. No difference was observed in the secretion of IL-8 and TNF-α 
with incubation of normoxic or hypoxic EVs (IL-8: normoxia; 55.6 ± 14.8 pg/mL vs. 
hypoxia; 65.2 ± 8.7 pg/mL, Figure 6.3.1 A, TNF-α: normoxia; 9.5 ± 1.2 pg/mL vs. 
hypoxia; 10.7 ± 0.2 pg/mL, Figure 6.3.1 B). Mϕ secretion of IL-1β was reduced 
following incubation with hypoxic adipocyte EVs (normoxia; 2.4 ± 0.06 pg/mL vs. 
hypoxia; 1.0 ± 1.2 pg/mL, Figure 6.3.1 C). 
 
6.3.2 M2 mRNA expression 
The effect of normoxic and hypoxic EVs on M2 gene expression was measured 
using qRT-PCR. Mϕ expression of IL-10 and IL-1Ra were unchanged between 
incubations of normoxic or hypoxic EVs (IL-10: normoxia; 1.2 ± 0.3 fold change vs. 
hypoxia; 1.2 ± 0.1 fold change, Figure 6.3.1 D, IL-1Ra: normoxia; 1.4 ± 0.3 fold 
change vs. hypoxia; 1.3 ± 0.2 fold change, Figure 6.3.1 E). Expression of dectin-1 
showed a slight increase following incubation with hypoxic EVs (normoxia; 0.9 ± 
0.1 fold change vs. hypoxia; 1.3 ± 0.2 fold change, Figure 6.3.1 F). 
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Figure 6.3.1: Effects of hypoxic adipocyte EVs on Mϕ phenotype. Alterations in the 
phenotypic characteristics of THP-1 Mϕ following incubation with normoxic or hypoxic 
3T3-L1 adipocyte-derived EVs. Release of M1 cytokines including (A) IL-8, (B) TNF-α and 
(C) IL-1β (pg/mL) were measured by ELISA. Gene expression of M2 markers including (D) 
IL-10, (E) IL-1Ra and (F) Dectin-1 (fold change compared to GAPDH) were measured by 
qRT-PCR. Technical repeats (n=3), experimental repeats (n=1).  
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6.3.3 Mϕ migration 
The migration of Mϕ towards normoxic and hypoxic vesicles was measured using a 
Dunn chamber. Of the parameters measured (Figure 6.3.2), the distance migrated 
(both accumulated and Euclidean) and the velocity of migration showed no 
difference between normoxic and hypoxic EVs (accumulated distance: normoxia; 
189 ± 13.9 μm vs. hypoxia; 183.7 ± 19.8 μm, Figure 6.3.2 B, euclidean distance: 
normoxia; 105.6 ± 15.9 μm vs. hypoxia; 112.8 ± 23.9 μm, Figure 6.3.2 C, velocity: 
normoxia; 4.3 ± 0.9 μm/min vs. hypoxia; 4.5 ± 0.5 μm/min, Figure 6.3.2 F). There 
was a trend towards a decreased angle of migration (normoxia; 109.5 ± 20.2° vs. 
hypoxia; 91.2 ± 11.6°, Figure 6.3.2 A) and an increased directionality and yFMI 
(directionality: normoxia; 0.4 ± 0.1 a.u. vs. hypoxia; 0.6 ± 0.9 a.u., Figure 6.3.2 D, 
yFMI: normoxia; 0.3 ± 0.1 a.u. vs. hypoxia; 0.5 ± 0.1 a.u., Figure 6.3.2 E) towards 
hypoxic EVs compared to normoxic EVs. 
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Figure 6.3.2: Mϕ migration towards adipocyte-derived EVs. The migration of THP-1 Mϕ towards normoxic and hypoxic adipocyte-derived EVs was 
measured using a Dunn chamber setup. Migration was assessed by (A) the angle of movement (degrees), (B) the accumulated distance (μm), (C) the 
Euclidean distance (μm), (D) directionality (a.u.), (E) the FMI (a.u.) and (F) velocity (µm/min). Technical repeats (n=3), experimental repeats (n=1).
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6.4 Discussion 
6.4.1 Key observations 
The key observations of this chapter were: 
1. Hypoxic EVs may reduce the secretion of the inflammatory M1 marker, IL-
1β. 
2. Hypoxic EVs may enhance the gene expression of the anti-inflammatory M2 
marker, dectin-1. 
3. Mϕ may tend to migrate more efficiently towards hypoxic EVs. 
 
6.4.2 Main discussion 
Hypertrophy of adipocytes combined with a lack of supporting vascular growth in 
obesity highly increases the risk of localised hypoxia within AT (259,365). 
Alterations in adipocyte gene expression in response to hypoxia results in the release 
of an altered adipokine profile that promotes local inflammation, IR and Mϕ 
infiltration (Figure 1.2.6). Chapter 5 showed that hypoxic adipocytes also release an 
increased concentration of EVs that are enriched in MCP-1. Therefore, hypoxia may 
provide a mechanism for the onset of AT dysfunction that ultimately leads to local 
and systemic inflammation that is characteristic of obesity. This chapter sought to 
investigate whether hypoxic adipocyte-derived EVs may exacerbate this process by 
promoting the migration and phenotypic transition of Mϕ. 
Circulating monocytes and tissue-resident Mϕ are highly plastic cells, capable of 
responding rapidly to changes in the microenvironment by altering their phenotype 
and thus their function (508). AT contains a variety of immune cells, the majority of 
which are M2 Mϕ that help to maintain insulin sensitivity, glucose homeostasis and 
limit inflammation (337,508). An M2 phenotype is promoted in lean AT through the 
actions of IL-10 and PPARγ (338). However, expression of M2 polarising agents are 
reduced in obese AT and secretion of proinflammatory cytokines (such as IL-6 and 
TNF-α) from dysfunctional adipocytes is elevated, resulting in a phenotypic shift of 
AT-resident Mϕ towards an M1 phenotype (338). As hypoxia may initiate 
dysregulated adipokine secretion and alter EV production from adipocytes, M1 and 
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M2 markers were measured using THP-1 Mϕ following incubation with normoxic 
and hypoxic 3T3-L1 adipocyte-derived EVs. The M1 Mϕ phenotype is very well 
defined and M1 cytokines are readily secreted. Therefore, M1 phenotype was 
measured using ELISA to assess the release of M1 cytokines into THP-1 
supernatants. The pilot data presented here indicated that the secretion of M1 
cytokines IL-8 and TNF-α is no different between normoxic and hypoxic adipocyte 
EV incubation. The secretion of IL-1β however is reduced following incubation of 
Mϕ with hypoxic EVs. Levels of IL-1β are increased in obese AT, most likely due to 
the predominance of M1 Mϕ, and levels of IL-1β correlate with IR (502). Therefore, 
a decrease in IL-1β secretion following incubation with hypoxic EVs suggests that 
these EVs may aim to attenuate the proinflammatory response and improve insulin 
signalling. TNF-α also plays an important role in regulating insulin sensitivity in 
obesity (259) and secretion of TNF-α was not reduced by hypoxic EVs, indicating 
the anti-inflammatory properties of hypoxic adipocyte EVs may act in a TNF-α-
independent manner. In contrast to M1 Mϕ, the M2 Mϕ phenotype seems less well 
defined and may follow more of a continuum of multiple phenotypes with subtle 
changes in cytokine expression. Furthermore, markers of an M2 phenotype are not as 
widely secreted as M1 cytokines, therefore qRT-PCR was used to identify potential 
alterations in gene expression of classical M2 markers. Gene expression of IL-10 and 
IL-1Ra did not differ between normoxic and hypoxic adipocyte EV incubation. 
Previous studies have found IL-1Ra to be elevated in obese AT (509). As IL-1Ra is 
an endogenous antagonist of the proinflammatory cytokine, IL-1, this increase in 
obesity may be an attempt to combat the proinflammatory environment by blocking 
IL-1. Conversely, IL-10 expression is reduced in obese AT though expression of the 
IL-10 receptor is unchanged between lean and obese AT (338). Together, this 
suggests that obese AT attempts to maintain an anti-inflammatory environment but is 
eventually overwhelmed by proinflammatory cytokine expression. Dectin-1, a 
pattern recognition receptor expressed on the Mϕ cell surface, was slightly increased 
with hypoxic EV incubation compared to normoxic EVs. Previous studies have 
shown dectin-1 activation to lead to IL-10 mRNA expression (503) again suggesting 
the initial interaction of hypoxic adipocyte EVs with Mϕ may stimulate anti-
inflammatory pathways. 
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In addition to a transition of AT-resident Mϕ towards a proinflammatory M1 
phenotype in obese AT, the number of Mϕ present within AT is also increased 
(460,500,505), suggesting a higher rate of infiltration. Adipocyte-derived MCP-1 
seems to play a critical role in the recruitment of Mϕ to obese AT and is also 
elevated in circulating plasma and AT of obese subjects (510). Interestingly, a recent 
study found that MCP-1 expression was partially controlled by specific microRNAs 
which are dysregulated in obese subjects leading to elevated Mϕ infiltration and AT 
inflammation (511). MCP-1 mRNA and secretory protein have previously been 
found to be elevated in hypoxic adipocytes (494), and analysis of the protein content 
of EVs in Chapter 5 showed increases in MCP-1 protein in hypoxic EVs. Therefore, 
in addition to secreted MCP-1 protein, hypoxic adipocyte-derived EVs may also be 
capable of inducing Mϕ migration. Therefore, the ability of normoxic and hypoxic 
adipocyte EVs to stimulate THP-1 Mϕ migration was assessed using a Dunn 
chamber. No difference was observed in the distance (accumulated or euclidean) or 
the velocity of Mϕ movement between normoxic and hypoxic adipocyte EV. The 
angle of Mϕ movement was slightly reduced and the index of directionality was 
slightly increased with hypoxic EVs. Furthermore, the y fmi, which provides an 
indication of the efficiency of forward migration of cells along the y axis (Figure 
6.2.2 B) showed a slight increase with hypoxic EVs. Together this suggests Mϕ may 
migrate more directly towards hypoxic EVs than towards normoxic EVs. Mϕ 
migration was recently shown to be enhanced by EVs derived from adipocytes 
stimulated with palmitic acid (48). FFAs such as palmitic acid are often released 
from apoptotic and necrotic adipocytes and are able to stimulate Mϕ migration in 
order to resolve the resultant lipotoxicity. Interestingly, palmitic acid content was 
increased in hypoxic cells and EVs (Figure 5.3.8/9), suggesting hypoxia may act 
upstream of adipocyte apoptosis and necrosis by altering fatty acid metabolism to 
increase reservoirs of chemotactic lipids. Therefore, hypoxic EVs may aid the 
progression of initial Mϕ migration into hypoxic AT, perhaps due to their increased 
cargo of MCP-1 and chemotactic fatty acids. 
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6.4.3 Limitations 
The major limitation of this chapter is the lack of experimental repeats. Due to 
unforeseen circumstances, the remaining repeats could not be analysed in time for 
the submission of this thesis. It is however, anticipated that these data will be 
completed to form part of a paper on the effects of hypoxia on adipocyte-derived 
EVs and the potential influence on Mϕ migration and phenotype. The delay in 
sample processing has given me an opportunity to evaluate the experimental 
methodology and therefore, 2 alterations will be made to future experiments. Firstly, 
EVs will be added to Mϕ at set concentrations (5 x 109 and 1 x 1010 EVs and a 1:10 
dilution of the EV resuspension) to determine whether the effects are concentration-
dependent and/or whether any observed effects are due to changes in EV 
composition between normoxia and hypoxia. Secondly, chemotaxis experiments will 
be undertaken with a pre-incubation of EVs with Mϕ, and the migration towards a 
standard chemoattractant (such as MCP-1) monitored. The EVs themselves may not 
be strong chemoattractants, however, in vivo, these EVs may be able to enhance Mϕ 
migration into hypoxic AT.  
Though MCP-1 was found to be increased in hypoxic EVs and is suspected to play a 
role in the potential chemotactic ability of hypoxic adipocyte-derived EVs, the role 
of MCP-1 was not assessed in these experiments. Future experiments could look to 
downregulate MCP-1 expression of adipocytes to see if phenotypic alterations and 
migratory ability of Mϕ are changed. However, it is also important to highlight that 
Mϕ infiltration of AT may not be solely due to increases in MCP-1 and that other 
factors may play a role. A recent study indicated that knockdown of MCP-1 only 
partially inhibited Mϕ infiltration into AT of mice fed a high fat diet (512), 
indicating a role for other adipocyte-derived chemoattractants. 
A further limitation of this study may be the time point used for Mϕ supernatant 
collection for ELISA experiments. As outlined in Chapter 5, some cytokines such as 
TNF-α may have a more rapid response time, and therefore may have peaked and 
returned to baseline by the 24 hour measurement point. Therefore, future 
experiments may seek to analyse a range of time points in order to capture the 
spectrum of response.  
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Additionally, these pilot experiments have used 3T3-L1 adipocytes and THP-1 Mϕ 
which are well-established cell lines of adipocytes and monocytes/Mϕ respectively. 
In addition to these sources being cell-lines, they are also of differing origin, with 
3T3-L1 cells being of murine origin and THP-1 cells being of human origin. 
Therefore there is a potential for sub-optimal interactions between these two cell 
lines due to species differences. However, it is hoped that these studies will provide 
important pilot data for our group that will be used to examine the interaction 
between human adipocytes and leukocytes in obesity. 
 
6.4.4 Conclusions 
To summarise, hypoxic adipocyte-derived EVs may enhance an M2 Mϕ phenotype 
by reducing IL-1β secretion and increasing dectin-1 expression. Furthermore, these 
hypoxic EVs may increase the directionality of Mϕ migration. Taken together, EVs 
derived from hypoxic adipocytes may initially intend to recruit Mϕ into hypoxic AT 
to resolve the consequences of adipocyte hypoxia (including adipocyte necrosis and 
lipotoxicity) by promoting an M2 phenotype. However, upon entering the hypoxic 
AT, the recruited Mϕ may be forced towards an M1 phenotype by the 
proinflammatory milieu generated by hypoxic adipocytes. Infiltrated Mϕ may then 
exacerbate AT inflammation by forming CLSs and adding to local secretion of 
proinflammatory cytokines which increase systemic inflammation and IR. Future 
studies should assess the ability of hypoxic adipocyte-derived EVs to stimulate Mϕ 
migration into AT in vivo and examine mechanisms to reduce this, such as inhibitors 
of EV biogenesis. 
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7. Results V: 
Evidence for adipocyte-derived extracellular 
vesicles in vivo
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7. Perspective 
The overarching focus of this thesis was to characterise the release of EVs from 
adipocytes; thus, I sought to confirm their existence in vivo. The work in this chapter 
presents pilot data to show the presence of adipocyte markers in plasma-derived EVs 
using the variety of methods used to characterise adipocyte EVs in this thesis. Data 
in this chapter also formed the basis for a successful project grant application that is 
currently on-going and continuing on from this work. 
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7.1 Introduction 
Chapter 1.2 details the importance of the autocrine, paracrine and endocrine actions 
of adipocytes and AT both in health and disease. As illustrated in Chapters 4, 5 and 
6 and by other researchers, adipocytes produce EVs in vitro (66,383,387,393). These 
EVs may facilitate differentiation of adipocytes (Chapter 4); are able to respond to 
conditions of hypoxia (Chapter 5) through interaction with Mϕ (Chapter 6 and 
(48,306)); are able to affect metabolism of neighbouring adipocytes (387) and 
promote angiogenesis in vivo (393). Despite growing evidence for autocrine and 
paracrine roles of adipocyte-derived EVs, their potential endocrine roles in vivo 
remain largely unexplored. This may be due to a number of reasons. Firstly, although 
“adipocyte-specific” proteins exist (e.g. adiponectin and PPARγ2), these adipokines 
are secretory making it difficult to identify a specific marker for adipocyte-derived 
EVs. Secondly, adipocytes in vivo exist within AT, therefore presenting a number of 
barriers between adipocyte-derived EVs and the systemic circulation.  
The initial hypothesis when undertaking this work was that adipocyte EVs could be 
identified in the circulation using adipocyte markers such as FABP4, PPARγ and 
adiponectin. During the course of undertaking this project, preliminary evidence has 
emerged for the presence of these adipocyte markers in plasma-derived EV fractions. 
FABP4-containing microvesicles in human plasma have been detected using FC 
(54). However, the use of FC for EV measurement is sub-optimal as the lower limit 
of many conventional flow cytometers is ~300 nm. Though FABP4 is largely 
generated in adipocytes, it is also expressed in Mϕ (513) and therefore should not be 
used in isolation to determine an adipocyte-derived EV population. Circulating 
levels of FABP4 correlate with IR and the metabolic dysfunction associated with 
obesity (324,348,349). Therefore, adipocyte EV-associated FABP4 may provide an 
important indication of the metabolic status of AT. Adiponectin has also been shown 
to be associated with exosomes isolated from mouse serum using Western blotting 
(514), though this has not been confirmed in human plasma-derived EVs. 
Adiponectin is specifically generated in adipocytes and is involved in maintaining 
insulin sensitivity and vascular function (319,328). Therefore, the presence of 
adiponectin in adipocyte EVs may provide a reflection of the physiological 
functioning of AT. Proteomic profiling of plasma-derived EVs also revealed an 
association of PPARγ with human plasma-derived exosomes (515). PPARγ is a 
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transcription factor predominantly produced in adipocytes with a critical role 
adipogenesis and maintaining adipocyte function (321). Therefore, similarly to 
adiponectin, detection of PPARγ in plasma-derived EV fractions could provide an 
indication of the regular functioning of AT. None of the above studies detecting 
adipocyte markers in plasma EVs measured the size or concentration of EVs to 
confirm an EV population, with the exception of Looze et al., who used TEM to 
confirm an EV population (515). Recently, it has also been suggested that adipocyte-
specific material packaged within exosomes may circulate in vivo following transfer 
into leukocytes (516).  
There is evidently great potential for an endocrine role of adipocyte-derived EVs in 
vivo. However, lack of specific markers and use of sub-optimal techniques has so far 
prevented confirmation of their existence in circulating plasma-EV fractions. 
Therefore, there is a need for comprehensive evidence for the existence of adipocyte-
derived EV in vivo in order to further explore their potential as novel circulating 
communicators of adipocytes and AT in vivo. 
 
7.1.1 Aims 
This chapter aimed to detect adipocyte-derived EVs within the population of 
circulating EVs of healthy volunteers, specifically by: 
1. Isolating and measuring the size and concentration of plasma-derived EVs. 
2. Assessing isolated plasma-derived EVs for the presence of FABP4, 
adiponectin and PPARγ using: 
a. Western blotting 
b. Flow cytometry 
c. Time resolved fluorescence 
3. Testing isolated leukocytes for the presence of adipocyte makers. 
 
7.1.2 Hypotheses 
Adipocyte-derived EVs can be detected in a population of circulating plasma-derived 
EVs using multiple adipocyte-markers and measurement techniques.  
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7.2 Methods 
7.2.1 Cell culture and extracellular vesicle isolation  
3T3-L1 cells were cultured to a mature adipocyte phenotype (14 days post-
differentiation) as described in Chapter 2.2.1. EVs were isolated as described in 
Chapter 2.3.1 using a 24 hour incubation with serum-free media and differential 
ultracentrifugation. Cells and isolated EVs were then lysed and processed to isolate 
protein as outlined in Chapter 2.10.1 and stored at -20°C until analysis.  
 
7.2.2 Plasma extracellular vesicle isolation  
Plasma-derived EVs were isolated from the blood of healthy volunteers using the 
second isolation method outlined in Chapter 2.3.2. Isolated EVs were resuspended in 
either 1 X PBS (0.22 µm-filtered) for NTA measurements, FC analyses and TRF 
measurements, or lysis buffer for Western blotting.  
 
7.2.3 Nanoparticle tracking analysis  
Cell and plasma-derived EVs were quantified using NTA as described in Chapter 
2.4.2. To compare the distribution of EVs between 3T3-L1- and plasma-derived 
EVs, the raw NTA distributions were plotted without adjusting for NTA dilution and 
ignoring differences in reported concentrations.  
 
7.2.3 Leukocyte isolation 
Blood (10 mL, collected as above) was gently transferred to a universal container 
containing 100 µL heparin sodium solution (5000 I.U./mL; Wockhardt Ltd). To this, 
2.5 mL 6% (w/v) Dextran (Sigma Aldrich) was added, mixed gently by inversion 
and transferred to a fresh universal container to settle for ~45 minutes at room 
temperature. The “buffy coat” layer was carefully transferred to a fresh universal 
container and centrifuged (258 x g, 1 minute) to pellet leukocytes. Leukocytes were 
briefly resuspended in 1 mL distilled water to lyse any contaminating erythrocytes, 
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and then osmolarity was restored by adding 20 mL balanced salt solution (130 mM 
NaCl, 2.65 mM KCl, 8 mM Na2HPO4 adjusted to pH 7.4). Leukocytes were 
centrifuged (258 x g, 2 minutes) and resuspended in lysis buffer, processed and 
stored as outlined in Chapter 2.10.1. 
 
7.2.4 Western Blotting 
Western blotting was undertaken using protocols described in Chapter 2.10. Ten µg 
of cell lysate and 20 µg of EV lysate were loaded per well using running gels and 
primary antibodies outlined in Table 7.2.1. Two antibodies were required to detect 
both human (leukocytes/ plasma EVs) and mouse (3T3-L1 cells and EVs) 
adiponectin. Loading controls were not used as only the presence/lack of markers 
was being observed. However, for this reason, no comparisons between band 
densities should be made. 
Antibody Polyacrylamide 
running gel 
Antibody dilution Typical exposure 
Adiponectin 
(Abcam ab18065) 
12% 1:2500 (5% 
milk/TBS-T) 
15 minutes 
Adiponectin (CST 
#2789) 
12% 1:500 (5% 
BSA/TBS-T) 
1 minute 
FABP4 15% 1:1000 (5% 
BSA/TBS-T) 
15 seconds 
PPARγ 10% 1:1000 (5% 
BSA/TBS-T) 
1 minute 
Table 7.2.1: Details of Western blotting. Details of the antibodies and polyacrylamide gels 
used for Western blotting. Two antibodies were required for detection of human (Abcam) 
and mouse (CST) adiponectin in leukocyte/plasma EV samples and 3T3-L1 samples 
respectively. BSA = bovine serum albumin, CST = Cell Signalling Technologies, FABP4 = 
fatty acid binding protein-4, PPARγ = peroxisome proliferator-activated receptor γ, TBS-T = 
tris-buffered saline – Tween 20 (1% v/v).  
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7.2.5 Flow cytometry 
Isolated plasma EVs in PBS were immediately placed on ice and fixed in cold 
formaldehyde (2% v/v) for 5 minutes. EVs were then pelleted by ultracentrifugation 
(as before) and resuspended in 1 X PBS tween (0.1%, v/v). EVs were blocked in 
rabbit serum for 1 hour at room temperature before being pelleted and resuspended 
as before. EVs were incubated with antibodies to adiponectin (Abcam ab18065), 
FABP4 and PPARγ or no antibody (negative control) overnight at room temperature. 
EVs were again pelleted and resuspended to allow for incubation with 
AlexaFluoro®488 goat anti-rabbit IgG (Life Technologies) for 1 hour at room 
temperature. EVs were pelleted for the final time and resuspended in 1X PBS (0.22 
µm-filtered), gated and analysed with a BD FACSCanto as outlined in Chapter 2.6. 
 
7.2.6 Extracellular vesicle immunophenotyping 
Immunophenotyping of adipocyte markers in plasma EVs was conducted as 
described in Chapter 2.9 using TRF by Dr Justyna Witczak as part of a larger 
clinical study. A concentration of 5 x 10
10
 EVs were laid down per well in duplicate 
and allowed to settle overnight. EVs were then probed with anti-human rabbit 
monoclonal antibodies to adiponectin (Abcam, ab18065), FABP4 (Abcam, 
ab92501), PPARγ (Abcam, ab191407), CD9 as a marker for EVs (Abcam ab92726) 
and a negative control (no primary antibody).  
 
7.2.7 Statistical analysis 
Graphical representation of data was generated using GraphPad Prism software 
(version 6.0). Where applicable, data are presented as mean ± SD. No statistical 
analyses were conducted in this chapter as data were not being compared and only 
the presence or lack of adipocyte markers was being assessed.  
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7.3 Results 
7.3.1 Quantitation of adipocyte- and plasma-derived extracellular 
vesicles 
The raw NTA distributions of EVs from 3T3-L1 adipocytes were compared to those 
of plasma derived-EVs (Figure 7.3.1). 3T3-L1-derived EVs (mode size ~140 nm) 
showed a greater distribution across the EV range compared to plasma EVs (mode 
size ~90 nm). Due to the 100 fold difference in reported concentrations of 3T3-L1 
and plasma-derived EVs, distributions were not adjusted for NTA dilutions so that 
the range of EV sizes of both samples can be compared on the same graph. 
 
Figure 7.3.1: NTA distributions of 3T3-L1- and plasma-derived EVs. Raw size 
distributions (not adjusted for NTA dilutions) for 3T3-L1- and plasma-derived EVs. Data are 
presented as the mean (solid line) ± the SD (lighter shade), (n=5).  
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7.3.2 Western blot analysis of adipocyte markers  
Western blotting was used to analyse samples for the presence of adipocyte markers 
(Figure 7.3.2). 3T3-L1 cells and corresponding EVs were used as controls (to 
illustrate characteristic expression). FABP4 and PPARγ were enriched in 3T3-L1 
cells compared with corresponding EVs, however adiponectin seemed to be enriched 
in 3T3-L1 EVs. No adipocyte markers were detected in leukocyte samples whilst all 
adipocyte markers were present in plasma-derived EVs. 
 
Figure 7.3.2: Western blot analysis of adipocyte markers. Adiponectin, FABP4 and 
PPARγ were analysed by Western blot in 3T3-L1 cells, 3T3-L1 EVs, leukocytes and 
plasma-derived EVs. Representative blots (n=3). As the presence/lack of markers was being 
observed, loading controls were not used. 
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7.3.3 Flow cytometric analysis of adipocyte markers  
Plasma-derived EVs were probed for adiponectin, FABP4 and PPARγ and analysed 
using flow cytometry (Figure 7.3.3). EVs were positive for both adiponectin and 
FABP4; PPARγ could not be detected. Overall positivity of plasma-derived EVs for 
adipocyte markers was low (adiponectin: 0.4 ± 0.7%; FABP4: 0.5 ± 0.6%). 
 
Figure 7.3.3: Flow cytometric analysis of adipocyte markers. Isolated plasma-derived 
EVs were fixed, blocked and stained with antibodies to adiponectin, FABP4 and PPARγ. 
EVs falling within the pre-defined gate (A) were then analysed for their fluoresence 
compared to a negative control and plotted as a percentage of the total plasma EVs (B). 
FSCA- = forward scatter area; SSC-A = side scatter area, (n=3). 
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7.3.4 Detection of adipocyte markers using immunophenotyping 
Isolated plasma-derived EVs were probed for adipocyte markers using 
immunophenotyping (Figure 7.3.4). The exosomal marker, CD9, was detected in 
plasma-derived EVs (11,666 ± 2,716 arbitrary TRF units). Adiponectin, FABP4 and 
PPARγ could all be detected within plasma-derived EVs (adiponectin: 26,400 ± 
2,339; FABP4: 3,850 ± 2,459; PPARγ: 3,144 ± 2,407 arbitrary TRF units). Negative 
control values (EVs with no primary antibody) were subtracted to give the raw TRF 
values presented below. 
 
Figure 7.3.4: Immunophenotyping of adipocyte markers. Adipocyte markers were 
detected in plasma-derived EVs using TRF. Data are presented as raw TRF values (with 
negative IgG control values subtracted), (n=3). 
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7.4 Discussion 
7.4.1 Key findings 
The key findings of this chapter were: 
1. The size distribution of plasma EVs are different to those of 3T3-L1 
adipocyte-derived EVs. 
2. Adiponectin, FABP4 and PPARγ can be detected in plasma-derived EVs by 
Western blotting. No adipocyte markers were detected in lysed leukocytes. 
3. Adiponectin and FABP4 could be detected by flow cytometry in plasma-
derived EVs; PPARγ was not detected. 
4. Adiponectin, FABP4 and PPARγ were detected by TRF along with the 
exosomal marker, CD9. 
 
7.4.2 Main discussion 
The endocrine role of adipocytes and AT in both health and disease is becoming 
ever-more apparent. EVs released from adipocytes are being shown to play a novel 
part in crosstalk between adipocytes and other systems such as the vasculature, the 
immune system and the brain. However, the measurement of adipocyte-derived EVs 
in the circulation has not been concretely reported. This chapter therefore aimed to 
strengthen the evidence for the existence of adipocyte-derived EVs in plasma by 
using three markers of adipocytes and using three different measurement techniques. 
The distribution of EV sizes was compared between 3T3-L1- and plasma-derived 
EVs. Though not shown here, the concentration of plasma-derived EVs was ~100 
fold higher than that measured for 3T3-L1 derived EVs. This is unsurprising given 
they represent two very different model systems: the greater reservoir of EV sources 
in blood (such as platelets, endothelial cells, leukocytes and erythrocytes) compared 
to the singular source of adipocyte-derived EVs from 3T3-L1 cells. Furthermore, 
EVs in culture are collected from a limited amount of medium and a restricted 
number of cells in a flask, whereas plasma will come in contact with many more 
cells and will represent the circulating EV population. When the relative size 
distributions of EVs were compared by NTA, the majority of 3T3-L1 EVs detected 
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were between 50 – 400 nm, showing a greater range of EV sizes compared to plasma 
EVs which were mainly between 50 – 200 nm. This suggests that circulating plasma-
derived EVs contain a higher proportion of exosomes compared to EVs from 
adipocyte culture.  
Mature adipocytes can be characterised by the expression of hallmark proteins such 
as FABP4, adiponectin and PPARγ (320,323,453). Their secretion into the 
circulation, in combination with the lack of a distinct marker for adipocyte-derived 
EVs presents a challenge for their detection on EVs in vivo. Therefore, plasma EVs 
from healthy volunteers were probed for all three adipocyte markers using a range of 
techniques. Firstly, EVs were assessed for adipocyte markers using Western blotting, 
with 3T3-L1 cell and EV lysates as adipocyte and antibody controls. Adiponectin, 
FABP4 and PPARγ were all detected in plasma EV lysates, suggesting the presence 
of these adipocyte markers in the plasma EV fraction. Ogawa et al., have previously 
illustrated that adipocytes can transfer mRNA to Mϕ via EVs and that this may in 
part account for the presence of adipocyte-specific mRNA in the circulation (516). 
However, in our studies none of the adipocyte markers could be detected in 
leukocytes isolated from the same blood sample as plasma-derived EVs, suggesting 
that the presence of these markers in plasma-derived EVs is due to direct adipocyte 
origin. The expression looked to be fairly consistent between adipocyte markers in 
plasma EVs, though a loading control was not used to confirm this.  
As previously discussed in this thesis, the use of FC to analyse EVs often results in 
inaccuracies as the majority of EVs pass below the detectability of conventional 
cytometers, as evidenced by NTA data presented above. However, it remains widely 
used as a technique to phenotype the origin of EVs due to its potential for dual (or 
multiple) staining of markers. Therefore, plasma-derived EVs were assessed for 
adipocyte markers using FC. As all three adipocyte markers are likely to be 
contained within EVs (as opposed to surface-bound - adiponectin and FABP4 are 
cytoplasmic and secreted, and PPARγ is nuclear-localised), EVs were first fixed and 
permeabilised to allow antibody access. Both adiponectin and FABP4 could be 
detected by FC though the percentage of total plasma-derived EVs exhibiting these 
markers was very low (<0.5%). FABP4 has previously been reported to be present in 
adipocyte-derived microvesicles at ~0.5% of the total population (54). PPARγ could 
not be detected in plasma-derived EVs using FC. The low detection of adiponectin 
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and FABP4 and lack of PPARγ may represent the low relative population of 
adipocyte-derived EVs in comparison to the total plasma EV pool. Alternatively, 
adipocyte markers may be more closely associated with smaller microvesicles and 
exosomes which are below the detection limit of FC. Indeed, previous data has found 
both adiponectin and PPARγ to be associated with plasma exosomes (514,515). As 
illustrated by the size distribution of plasma-derived EVs, the majority of EVs are 
<300 nm and so are unlikely to have been detected by the cytometer. 
Adipocyte markers in plasma-derived EVs were also assessed using TRF 
immunophenotyping. All three adipocyte markers could be detected in EVs, with 
adiponectin giving the highest fluorescent signal. This again supports the presence of 
adipocyte-derived material in the circulating plasma EV fraction. Furthermore, CD9 
was also detected in this fraction, a marker commonly associated with EVs (16) 
indicating a “true” EV fraction. Indeed, data recently amassed by our group indicate 
a strong positive correlation (r=0.54, p<0.001) of CD9 with FABP4 in a population 
of forty healthy individuals across a range of BMIs, indicating FABP4 is likely 
associated with EVs (Figure 7.4.1). No correlations were observed between 
adiponectin and PPARγ with CD9 though, as suggested above, these markers may be 
specifically associated with exosomes (514,515). As CD9 may now emerging as a 
more generic EV marker (53), the correlations with adiponectin and PPARγ may 
have been lost. Therefore, future work should look to compare these markers with 
exosomal markers such as CD63, alix or TSG101. 
 
Figure 7.4.1: Relationship between CD9 and FABP4. Correlation between CD9 and 
FABP4 TRF values of healthy individuals over a range of BMIs (n=40). Data are courtesy of 
Dr Justyna Witczak, a.u. = arbitrary units.  
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Evidence presented in this chapter is highly suggestive of the presence of adipocyte-
derived EVs amongst the plasma EV population. However, adipocytes are located 
within AT, which presents a physiological barrier between adipocyte-derived EVs 
and access to the circulation. Hence, an obvious question is how do adipocyte-
derived EVs make it into the systemic circulation? Lean AT is relatively well 
vascularised by capillary networks and evidence is emerging for the intracellular 
trafficking of EVs in a number of different cell types (Chapter 1.1.5). Therefore, 
adipocyte-derived EVs in the AT extracellular matrix could traverse single 
endothelial cells of capillaries and be transported intact into the AT microcirculation. 
As outlined in Chapter 1.2, obese AT is often poorly vascularised, which may 
reduce the likelihood of this route of exit for adipocyte EVs from AT. Local and 
systemic inflammation result in an increased vascular permeability due to a loss of 
endothelial tight junction barriers (517). Therefore, the inflammation associated with 
obesity may increase the permeability of AT microvasculature, thereby providing a 
route for adipocyte-derived EVs exit from AT in between “leaky” endothelial cells 
into the circulation. These hypotheses will be tested by our group as part of the 
newly awarded grant, using endothelial cell transwell experiments and monitoring 
adipocyte-derived EVs in upper and lower wells. Different conditions will also be 
tested including inflammatory endothelial cells, and also adipocyte-derived EVs will 
be generated under hypoxic and inflammatory conditions. 
 
7.4.3 Limitations 
The data presented in this chapter harbours some potential limitations. Western 
blotting experiments were performed without the use of a housekeeping gene such as 
β-actin for cells and CD9 or CD63 for EVs. This therefore prevented semi-
quantitative analysis to compare the levels of the three markers. However, as the aim 
of the present chapter was to simply illustrate the detectability of adipocyte-derived 
EVs in vivo, future studies could quantify the proportions of these markers in 
plasma-derived EVs.  
Leukocytes were isolated and lysed from the buffy coat without further separation of 
leukocyte subsets, such as Mϕ. Therefore adipocyte protein may have been present 
within Mϕ, but diluted by the total protein in the leukocyte fraction. Further 
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experiments could specifically isolate Mϕ to lyse and analyse for adipocyte markers 
to ensure the detection in plasma EV fractions is not due to Mϕ EV contamination. 
Additionally, the leukocyte fraction would have ideally been probed for a typical 
leukocyte maker such as CD45, to confirm the successful isolation of the leukocyte 
population. 
As EVs were isolated by differential ultracentrifugation, the co-pelleting of soluble 
proteins with EVs cannot be eliminated. Therefore, our group are currently trialling 
SEC columns, density gradient ultracentrifugation and immuno-affinity magnetic 
bead methods to determine the extent of soluble protein contamination of EV 
samples following ultracentrifugation. 
 
7.4.4 Conclusions 
To summarise, adipocyte-derived EVs can be reliably detected in plasma-derived EV 
fractions. Adipocyte markers within plasma EVs were clearly visible by Western 
blot and TRF. Flow cytometry could barely detect adiponectin and FABP4 and was 
unable to detect PPARγ within plasma EVs, most likely due to the majority of EVs 
being <300 nm. Future studies could use the markers presented in this chapter to 
specifically isolate adipocyte-derived EVs from plasma and compare the properties 
of these EVs between lean and obese and healthy and diseased individuals. 
Adipocyte-derived EVs in vivo could eventually be novel circulating markers for the 
functional status of AT and hence act as important indicators of future cardiovascular 
risk. As stated above, this work is currently being pursued in a newly awarded grant 
based on the data presented in this chapter. 
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8. Results VI: 
Lipoprotein apheresis reduces circulating EVs 
in individuals with familial 
hypercholesterolaemia 
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8. Perspective 
At the time of starting my PhD, our group was beginning a clinical study to evaluate 
EVs in individuals with familial hypercholesterolaemia with an interest in the 
potential cardiovascular applications of EV concentrations in a patient cohort. This 
work was carried out in parallel with Chapter 3 and therefore it was also a good 
opportunity to compare two of the most widely-used techniques to measure EVs 
(TRPS and NTA) in a clinical setting. The study represented an in vivo model that 
allowed us a unique opportunity to study the influence of a method that could 
selectively remove certain EV populations.  
At the time, FC was the most established technique for the detection of cellular 
epitopes on the surface of EVs. It is important to highlight that during the course of 
this PhD study and in line with the fast moving development in the EV field, 
Chapters 3 – 7 show how technical and methodological aspects have been further 
developed and/or superseded. Nevertheless, techniques used in this chapter were 
optimised at the time of study. 
 
 
 
 
 
 
  
Parts of this chapter have been published in: 
Connolly KD*, Willis GR*, Datta DB, Ellins EA, Ladell K, Price DA, Guschina 
IA, Rees DA, James PE (2014). Lipoprotein-apheresis reduces circulating 
microparticles in individuals with familial hypercholesterolemia. Journal of Lipid 
Research. 55 (10): 2064-72. 
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8.1 Introduction 
High cholesterol, particularly low-density lipoprotein (LDL) cholesterol is a risk 
factor for CVD. Familial hypercholesterolaemia (FH) is a common genetic disorder 
that causes elevated levels of atherogenic lipoproteins in the plasma, particularly 
LDL. The LDL receptor is mutated in more than 85% of cases of FH, rendering 
these receptors unable to bind or internalise LDL and leading to an accumulation of 
LDL in the plasma (518). FH is an autosomal dominant disorder, resulting in 
heterozygote, or more serious homozygote forms (519). Severe FH is typically 
difficult to treat by alterations in diet or lipid lowering medications alone as these 
interventions are insufficient to adequately lower LDL levels to completely abate 
atherosclerotic plaque formation (520). These patients therefore require frequent 
lipoprotein-apheresis (hereafter termed “apheresis”) treatments in combination with 
dietary and pharmacological intervention to regulate LDL levels (521). 
Apheresis involves the blood being drawn from one arm and passed through a 
column to remove atherogenic lipoproteins before being returned to the body via the 
other arm. Different types of apheresis columns and procedures may be utilised, 
though all show equal efficacy, with approximately 70% of circulating LDL 
removed immediately following treatment (522–525). However, LDL levels are 
known to rebound to 50% of pre-treatment values within 2-4 days of apheresis 
treatment (526). Despite this transiency, apheresis is associated with superior long-
term cardiovascular benefits compared with alternative therapies (527–531). 
Increased concentrations of EVs in the circulation, particularly platelet-derived EVs, 
have been previously reported in CVD (Chapter 1.1.9.1, (532,533)). Platelet EVs are 
thought to amplify the physiological and pathophysiological roles of platelets, for 
example helping to regulate haemostasis but also promoting coagulation and 
thrombus formation. The surface of platelet EVs is reportedly up to 100-fold more 
procoagulant than that of the surface of activated platelets (438), highlighting platelet 
EVs as important biomarkers for risk of CVD. Furthermore, EVs contain a bioactive 
cargo of lipid and genetic signalling mediators that can be transferred to target cells, 
though the mechanism of interaction is still unclear and may be cell-specific 
(Chapter 1.1.5). To date, little is known about the lipid composition and profile of 
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plasma-derived EVs, though platelet EVs have been shown to transfer 
proinflammatory lipids to platelets leading to activation (534). 
Individuals with FH have previously been shown to have increased circulating levels 
of endothelial- and leukocyte-derived EVs compared to individuals with non-FH 
hypercholesterolaemia (535,536). However, quantification of EVs in these studies 
was achieved using FC, and therefore may be suboptimal, due to the techniques lack 
of sensitivity for vesicles <300 nm. To date, no data exist detailing the effects of 
apheresis treatment on EVs in individuals with FH, though other extracorporeal 
methods have been previously shown to remove EVs (537,538). 
 
8.1.1 Aims 
The aims of this chapter were to characterise the effect of apheresis on individuals 
with FH in terms of: 
1. EV size and concentration 
2. EV origin 
3. Plasma and EV fatty acids 
4. EV thrombin generation 
This chapter also aimed to compare the profile of EVs from individuals with FH to 
those of healthy volunteers. Finally, this chapter sought to compare the results of two 
well-established techniques for EV measurement in a clinical cohort. 
 
8.1.2 Hypotheses 
Routine apheresis treatment may alter the profile of circulating EVs in individuals 
with FH. The concentration of EVs may be elevated in individuals with FH 
compared to healthy volunteers. 
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8.2 Methods 
8.2.1 Apheresis and sample collection  
Twelve patients undergoing fortnightly apheresis consented to take part in the study. 
The individuals were previously characterised by Dr Dev Datta as having clinically 
significant dyslipidaemia and were attending the Lipid Unit at University Hospital 
Llandough, Cardiff for apheresis treatment as part of their routine clinical care. For 
clinical reasons, three different apheresis techniques (described previously (539)) 
were used: polyacrylate whole blood adsorption (DALI®; n=8), whole blood dextran 
sulphate adsorption (n=1) and plasma dextran sulphate adsorption (n=3). Individuals 
had fasted for at least 4 hours prior to apheresis treatment and had continued to take 
prescribed medications for at least 1 hour prior to the study. Individuals taking 
vasoactive medications were asked to refrain from taking these prior to the study. 
Routine anthropometric measurements were carried out prior to apheresis treatment. 
Ethical approval for collecting blood samples was obtained by Miss Elizabeth Ellins 
(as part of a parallel study) and was provided by South East Wales Research Ethics 
Committee. Individuals were rested for 15 minutes before vascular access using 16 
gauge 25 mm fistula needles into two anatomically distinct upper limb veins, or by 
arteriovenous fistula. Blood samples were then drawn prior to, and immediately 
following completion of apheresis (approximately 3 hours later). Seven healthy 
volunteers (free from CVD and medication) also consented to take part in the study 
for comparison of EV concentration, size distribution, cellular origin and fatty acids 
with FH individuals. 
 
8.2.2 Biochemical measurements  
Blood samples were collected as described above into EDTA or citrate vacutainers. 
Total serum cholesterol (TC), HDL and triglycerides were measured using an 
Architect automated analyser (Abbott Diagnostics, UK). LDL was then estimated 
using the Friedwald equation (Figure 8.2.1). Glucose levels were determined using 
the Architect chemistry system (Abbot Diagnostics) and high sensitivity C-reactive 
protein (hs-CRP) was measured using nephelometry (BN™ II system, Dade Behring, 
UK). Blood pressure (BP) measurements were taken by Miss Elizabeth Ellins with 
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individuals seated using the Vicorder system (Skidmore Medical, UK) as part of a 
separate study into vascular measurements following apheresis. 
 
                (
             
   
) 
Figure 8.2.1: The Friedwald equation. Details of the Friedwald equation used to calculate 
LDL cholesterol (LDLc) from the levels of total cholesterol (TC), HDL cholesterol (HDLc) 
and triglycerides. 
 
8.2.3 Isolation of extracellular vesicles  
Blood samples were collected into both EDTA and citrate vacutainers and were 
processed by myself and Dr Gareth Willis using the first isolation method (Chapter 
2.3.2). PPP from EDTA vacutainers was snap frozen in liquid nitrogen for GC 
analysis. PPP from citrate vacutainers used to pellet EVs. The EV pellet was then 
either resuspended in filtered PBS (as in Chapter 2.3.1) and snap frozen in liquid 
nitrogen (for GC analysis), or resuspended in 1X filtered PBS containing 0.05% 
(v/v) Tween 20 (for EV size and concentration analysis). The latter was then passed 
through a 1 µm filter (Supelco, Sigma, UK) and slow-frozen overnight at -80°C in a 
Mr Frosty (Nalgene, ThermoScientific, UK). Plasma and EVs were maintained at -
80°C until analysis. 
 
8.2.4 Nanoparticle tracking analysis  
Size and concentration of EV samples was analysed using NTA as described in 
Chapter 2.4.2 by Dr Gareth Willis.   
Page | 244  
 
8.2.5 Tunable resistive pulse sensing  
Size and concentration of EV samples was also analysed using TRPS (undertaken by 
myself) as outlined in Chapter 2.5.2 using np100 and np200 nanopores.  
 
8.2.6 Flow cytometry 
Cellular origin of EVs was analysed using FC and conducted by myself and Dr 
Kirstin Ladell (Cardiff University) using a custom-built BD FACSAria II (BD 
Biosciences, USA) in the laboratory of Dr David Price. Forward scatter area (FCS-
A) and side scatter area (SSC-A) were set to log scale and EVs were gated based on 
their FSC-A/SSC-A profile and in relation to platelets in fresh plasma. EVs were 
resuspended in 1X 0.22 µm-filtered annexin V binding buffer (BD Biosciences) and 
100 µL of this was used for staining. EVs were stained (in the dark for 15 minutes at 
room temperature) with annexin V-FITC,  and antibodies against CD41-
phycoerythrin (PE)- cyanine (Cy) 5, CD11b-PE-Cy7, CD144-allophycocyanin 
(APC) and CD235a-pacific blue (PB) as markers of EVs, platelets, monocytes, 
endothelial cells and erythrocytes respectively (BioLegend, USA). Data were 
exported and analysed as described in Chapter 2.6. 
 
8.2.7 Gas chromatography 
GC-FID was conducted by Dr Gareth Willis and Dr Irina Guschina to determine the 
fatty acid concentration and composition of plasma and EV fractions. Lipids were 
extracted as described in Chapter 2.7.1 from 200 µL plasma or 250 µL isolated EVs.  
 
8.2.8 Thrombin generation 
The procoagulant potential of EVs was tested by their ability to stimulate thrombin 
generation and was conducted by myself and Dr Gareth Willis. To provide a working 
reservoir of plasma in which to test the thrombin generation of EVs, blood from 
healthy volunteers was taken into a syringe containing trisodium citrate (Sigma) and 
20 µg/mL corn trypsin inhibitor (Cambridge BioScience, UK). Blood was 
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immediately centrifuged as in Section 8.2.3 to isolate “vehicle” PPP which was 
stored at -80°C until analysis. 
Calibrated automated thrombography (CAT) was used with minor modifications to a 
previously described protocol (540) to assess EV thrombin generation. Samples were 
measured in duplicate using 96-well plates (round-bottomed, Immulon 2HB, 
ThermoScientific). Eighty microliters of vehicle PPP (containing endogenous 
clotting factors) was added to each well with 20 µL of diluted HEPES/NaCl buffer 
(pH 7.4) tissue factor (TF) solution to yield a final concentration of 1 pM (Innovin, 
Sysmex UK Ltd., UK). FH EV samples were assayed for thrombin generation with 
and without exogenous TF addition. Therefore, EVs (20 µL) were added to sample 
wells with the addition of either saline (20 µL, 0.9 % (w/v) NaCl) or TF (20 µL, 1 
pM final). Each sample was calibrated to a well containing 80 µL of PPP and 40 µL 
of thrombin calibrator (600 nM, Synapse BV, Netherlands). The plate was then 
warmed to 37°C for 5 minutes before addition of fluorogenic substrate (20 µL, 
benzyloxycarbonyl-Gly-Gly-Arg-7-amido-4-methylcoumarin, Bachem, UK). The 
fluorescent signal was then measured using a Fluoroskan Ascent plate reader 
(ThermoLabsystems, Finland) equipped with a 390/460 nm filter set 
(excitation/emission) at 15 second intervals until the thrombin generation reaction 
was complete. Data were analysed using Thrombinoscope™ software (Synapse BV) 
and correlated with EV concentration data. 
 
8.2.9 Statistical analysis 
Data were analysed by myself and Dr Gareth Willis using GraphPad Prism (version 
6.0) and are presented as mean ± SEM. A paired t-test (two-tailed) or a Wilcoxon 
matched pairs test was used for parametric and non-parametric data respectively. A p 
value of <0.05 was considered statistically significant.  
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8.3 Results 
8.3.1 Anthropometric and biochemical data  
Of the 12 participants in the study, 9 were male and 3 were female with a mean age 
of 57.9 ± 10.3 years and a mean BMI of 30.0 ± 4.0 kg/m
2
. The healthy volunteer 
comparison group were 7 males with a mean age of 34.0 ± 8 years and a mean BMI 
of 25.0 ± 3.0 kg/m
2
. A summary of biochemical measurements is given in Table 
8.3.1. TC, HDL, triglycerides, LDL, and hsCRP were reduced post-apheresis. 
Systolic BP was increased following apheresis. No changes were observed in 
glucose levels, diastolic BP or heart rate with apheresis. 
Parameter Pre-apheresis Post-apheresis p-value 
TC (mmol/L) 6.1 ± 0.5 2.7 ± 0.2 <0.0001 
HDL (mmol/L) 1.1 (0.4 – 2.3) 0.9 (0.2 – 2.1) 0.003 
Triglycerides (mmol/L) 1.8 ± 0.2 0.9 ± 0.1 <0.0001 
LDL (mmol/L) 4.1 ± 0.4 1.4 ± 0.2 <0.0001 
TC/HDL 5.8 (3.3 – 10.0) 3.1 (1.9 – 8.2) 0.0005 
Glucose (mmol/L) 5.7 ± 0.3 6.1 ± 0.3 0.07 
hsCRP 0.8 (0.2 – 16.9) 0.6 (0.2 – 13.8) 0.003 
Systolic BP (mmHg) 140 ± 5 148 ± 6 0.02 
Diastolic BP (mmHg) 81.8 ± 2.8 82.8 ± 2.7 0.45 
Heart rate (bpm) 55.8 ± 2.9 58.8 ± 3.4 0.09 
Table 8.3.1: Biochemical and physiological measurements pre- and post-apheresis. 
Baseline and post-apheresis biochemical and physiological measurements with 
accompanying p values. Data are presented as mean ± SD for parametric data or as median 
(interquartile range) for non-parametric data. Significant p values are in italics, (n=12). TC = 
total cholesterol, HDL = high density lipoprotein, LDL = low density lipoprotein, hsCRP = 
high sensitivity C-reactive protein, BP = blood pressure, bpm = beats per minute. 
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8.3.2 Effect of apheresis on extracellular vesicle size and concentration  
The concentration and size distribution of EVs from individuals with FH (pre-
apheresis) were compared with those of healthy volunteers (Figure 8.3.1). No 
change was observed in the mean concentration of EVs, though there was a trend 
towards an increased concentration of EVs in FH (A). Comparison of the size 
distributions revealed an increase in EVs between 50 – 100 nm in individuals with 
FH compared to healthy volunteers (B). 
 
Figure 8.3.1: EVs of healthy volunteers vs. individuals with FH. Comparison of the mean 
EV concentration (A) and the size distribution of EVs (B) from healthy volunteers vs. 
individuals with FH, as measured by NTA. Healthy volunteers (n=7), FH (n=12), *p<0.05. 
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To assess the effect of apheresis on EV size and concentration, two techniques were 
used: TRPS (using np100 and np200 nanopores) and NTA (Figure 8.3.2). No 
difference in mode EV size was detected using TRPS np100 (81.1 ± 19.6 nm to 78.4 
± 16.7 nm, p = 0.3; Figure 8.3.2 A). No significant difference was observed in EV 
concentration pre-post apheresis with this technique (4.6 x 10
11
 ± 1.3 x 10
11
 
particles/mL to 3.1 x 10
11
 ± 1.0 x 10 
11
 particles/mL, p = 0.2; Figure 8.3.2 B). TRPS 
np100 showed no preferential reduction according to EV size (Figure 8.3.2 C). 
 
Figure 8.3.2 A-C: TRPS np100 EV size and concentration pre- and post-apheresis. EV 
samples pre- and post-apheresis were measured using TRPS with an np100 nanopore. (A) 
Mode size of EVs, (B) mean concentration of EVs and (C) size distribution of EV 
concentration (n=12). 
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No difference was found in mode size of EVs with TRPS np200 (170.3 ± 40.6 nm to 
163.6 ± 29.2 nm, p = 0.18; Figure 8.3.2 D. Concentration of EVs measured by 
TRPS np200 was significantly reduced post-apheresis (4.7 x 10
10
 ± 8.8 x 10
9
 
particles/mL to 3.1 x 10
10
 ± 5.6 x 10
9
 particles/mL, p = 0.01; Figure 8.3.2 E). TRPS 
np200 size distribution revealed this reduction predominantly to be in EVs between 
200-249 nm (p = 0.01, Figure 8.3.2 F). 
 
Figure 8.3.2 D-F: TRPS np200 EV size and concentration pre- and post-apheresis. EV 
samples pre- and post-apheresis were measured using TRPS with an np200 nanopore. (D) 
Mode size of EVs, (E) mean concentration of EVs and (F) size distribution of EV 
concentration. *p<0.05, (n=12).  
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As with TRPS, NTA detected no change in overall mode EV size following 
apheresis (93.3 ± 21.0 nm to 88.2 ± 14.7 nm, p = 0.3; Figure 8.3.2 G). Mean 
concentration as measured by NTA was reduced post-apheresis (1.9 x 10
12
 ± 2.4 x 
10
11
 particles/mL to 1.5 x 10
12
 ± 2.4 x 10
11
particles/mL, p = 0.03; Figure 8.3.2 H). 
However, no specific reduction in EV size distribution was observed with NTA 
(Figure 8.3.2 I). 
 
Figure 8.3.2 G-I: NTA EV size and concentration pre- and post-apheresis. EV samples 
pre- and post-apheresis were measured using NTA. (G) Mode size of EVs, (H) mean 
concentration of EVs and (I) size distribution of EV concentration *p<0.05 (n=12). 
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Following measurement of all apheresis samples using both techniques, the range of 
detection of TRPS and NTA was compared using pre-apheresis samples. The range 
of EVs detected by TRPS (np100 and np200) and NTA were similar (Figure 8.3.3), 
though the reported concentration of EVs varied greatly between the two techniques, 
and also between TRPS nanopores (Table 8.3.3). 
 
Figure 8.3.3: Range of detection of EV measurement techniques. Comparison of the 
ranges of detection of TRPS (np100 and np200) and NTA. Data are presented as mean ± 
SEM, (n=12). 
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Size range (nm) np100 np200 NTA 
0 – 49 7.2 x 10
7
 ± 7.2 x 10
7 
0 1.3 x 10
11
 ± 4.9 x 10
10
 
50 – 99 3.6 x 10
11
 ± 1.1 x 10
11
 0 7.8 x 10
11
 ± 1.2 x 10
11
 
100 – 149 8.25 x 10
10
 ± 2.6 x 10
10 
1.2 x 10
10
 ± 5.7 x 10
9 
6.8 x 10
11
 ± 1.1 x 10
11 
150 – 199 1.1 x 10
10
 ± 4.3 x 10
9
 1.8 x 10
10
 ± 4.7 x 10
9 
2.5 x 10
11
 ± 4.8 x 10
10 
200 – 249 2.4 x 10
9
 ± 1.1 x 10
9
 1.2 x 10
10
 ± 3.6 x 10
9 
7.2 x 10
10
 ± 1.8 x 10
10 
250 - 299 1.1 x 10
9 
± 6.0 x 10
8 
3.3 x 10
9
 ± 1.1 x 10
9 
2.2 x 10
10
 ± 7.1 x 10
9 
300 – 349 6.5 x 10
7
 ± 4.8 x 10
7 
1.0 x 10
9
 ± 2.6 x 10
8 
7.4 x 10
9
 ± 1.8 x 10
9 
350 – 399 0 4.0 x 10
8
 ± 1.5 x 10
8 
2.1 x 10 ± 6.8 x 10
8 
400 – 449 4.6 x 10
7
 ± 4.6 x 10
7
 2.0 x 10
8
 ± 7.7 x 10
7 
9.8 x 10
8
 ± 3.5 x 10
8 
450- 499 0 1.1 x 10
8
 ± 4.4 x 10
7 
7.1 x 10
8
 ± 3.5 x 10
7
 
500 -549 0 7.2 x 10
7
 ± 3.3 x 10
7
 3.8 x 10
8
 ± 2.1 x 10
8 
550 -599 0 4.0 x 10
7
 ± 1.9 x 10
7
 4.5 x 10
8
 ± 4.0 x 10
8
 
600 – 649 0 3.5 x 10
7
 ± 2.8 x 10
7
 4.1 x 10
8
 ± 4.1 x 10
8
 
650 – 699 0 1.9 x 10
7
 ± 1.4 x 10
7
 1.2 x 10
8
 ± 1.2 x 10
8
 
700 - 749 0 1.8 x 10
7
 ± 1.4 x 10
7
 1.0 x 10
7
 ± 1.0 x 10
7
 
Table 8.3.3: Concentration differences between EV measurement techniques. 
Differences in detected concentrations of EVs measured by TRPS (np100 and np200) and 
NTA. Data are presented as mean ± SEM, (n=12). 
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8.3.3 Extracellular vesicle origin pre- and post-apheresis 
The majority of EVs from both healthy volunteers and individuals with FH (pre-
apheresis) were annexin V positive with no difference between healthy volunteers 
and FH (healthy volunteers: 88.1 ± 4.8%; FH: 88.9 ± 3.7%; Figure 8.3.4 A). 
Individuals with FH had a significantly higher proportion of endothelial-derived EVs 
(healthy volunteers: 0.4 ± 0.2%; FH: 1.9 ± 0.6%; p = 0.03; Figure 8.3.4 B). No 
differences were found in apportions of platelet, monocyte or erythrocyte EVs 
between healthy volunteers and individuals with FH. 
 
Figure 8.3.4: Flow cytometric analysis of EVs from healthy volunteers and FH. (A) EVs 
from healthy volunteers and individuals with FH were first compared for their annexin V 
positivity. (B) Annexin V positive EVs were then subsequently analysed for positivity of 
platelet (CD41), endothelial (CD144), monocyte (CD11b) and erythrocyte (CD235a) 
markers. Healthy volunteers (n=7), FH (n=12),* p<0.05. 
 
The gate used to analyse EVs was determined by analysing FSC-A and SSC-A 
profiles of EVs in relation to platelets in fresh plasma, and was subsequently used to 
analyse EVs from FH samples pre- and post-apheresis (Figure 8.3.5 A). No 
difference was observed in EV annexin V positivity following apheresis, though the 
majority of EVs were found to be annexin V positive (pre-apheresis: 88.9 ± 3.7%; 
post-apheresis: 88.4 ± 5.1%, p = 0.9, Figure 8.3.5 B). Annexin V positive EVs were 
then analysed for their expression of platelet (CD41), endothelial (CD144), 
monocyte (CD11b) and erythrocyte (CD235a) markers (Figure 8.3.5 C). No changes 
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were observed in the markers tested in EVs pre- to post-apheresis. Annexin V-
platelet positive EVs occupied the greatest proportion in pre- and post-apheresis 
samples (~90%). 
 
Figure 8.3.5: The effect of apheresis on EV origin. EVs from pre- and post-apheresis 
samples were analysed using flow cytometry to determine their cellular origin. The FSC-A 
and SSC-A properties of EVs were compared to those of platelets in fresh plasma in order to 
define a submicron gate (A). (B) EVs falling within this gate were then assessed for their 
annexin V positivity. (C) Annexin V positive EVs were then stained for markers of platelets 
(CD41), endothelial cells (CD144), monocytes (CD11b) and erythrocytes (CD235a). Data 
are presented as mean ± SEM, (n=12). 
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8.3.4 Effect of apheresis on fatty acid concentration and composition  
GC-FID was used to compare the fatty acids of the EV fraction to those of the 
surrounding plasma (Figure 8.3.6). Total fatty acid concentration was elevated in 
plasma (healthy volunteers: 1.5 ± 0.2 mg/mL plasma; FH: 2.4 ± 0.4 mg/mL plasma; 
p = 0.02; A) and EVs (healthy volunteers: 0.01 ± 0.002 ng/10
6
 EVs; FH: 0.03 ± 
0.006 ng/10
6
 EVs; p = 0.02; C) in individuals with FH compared to healthy controls. 
The composition of several plasma and EV fatty acids differed between healthy 
volunteers and individuals with FH (Figure 8.3.6 B/D). Generally, the same fatty 
acids were altered in both plasma and EVs. cis-vaccenic acid (C18:1n7) and 
eicosapentaenoic acid (EPA; C20:5n3) were increased in both plasma and EVs of 
individuals with FH. Stearic acid, docosanoic acid (C22:0), docosapentaenoic acid 
(C22:5n3) and lignoceric acid (C24:0) were decreased in plasma and EVs of 
individuals with FH. Whilst palmitoleic acid was increased in plasma of FH 
individuals, it was decreased in corresponding EVs. Similarly, cis-7-hexadecanoic 
acid (C16:1n9) was decreased in plasma in FH individuals but increased in 
corresponding EVs. Oleic acid was also decreased specifically within EVs of FH 
individuals. 
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Figure 8.3.6: Fatty acid analysis. Comparison of the total fatty acid concentration of plasma (A) and EVs (C) and the individual fatty acid composition of 
plasma (B) and EVs (D) of healthy volunteers versus FH. Healthy volunteers (n=7), FH (n=12); ****p<0.00001, **p<0.01, *p<0.05. 
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Total plasma fatty acid concentration was reduced following apheresis (pre: 2.4 ± 1.3 
mg/mL to post: 1.3 ± 0.2 mg/mL, p = 0.01; Figure 8.3.7 A) though this was not 
mirrored in the EV fraction (pre: 0.03 ± 0.006 ng/10
6
 EVs to post: 0.04 ± 0.009 
ng/10
6
 EVs, p = 0.2; Figure 8.3.7 C). 
The composition of five fatty acids were significantly altered post-apheresis in the 
plasma (Figure 8.3.7 B). Myristic acid (C14:0), cis-vaccenic acid, EPA, and 
docosatrienoic acid (C22:3n3) were increased in post-apheresis plasma samples 
whilst stearic acid was decreased following apheresis. Three of these fatty acids were 
also altered in EV samples following apheresis (Figure 8.3.7 D). Stearic acid was 
increased whilst myristic acid and cis-vaccenic acid were decreased post-apheresis in 
EV samples. 
A number of significant differences were also observed from directly comparing 
plasma fatty acid composition with corresponding EV fatty acids (Table 8.3.4). Ten 
fatty acids were compositionally different between plasma and EVs in both pre- and 
post-apheresis samples. Interestingly, these 10 fatty acids were not the same in pre-
and post-apheresis samples. 
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Figure 8.3.7: Effect of apheresis on fatty acids. Comparison of the total fatty acid concentration of plasma (A) and EVs (C) and the individual fatty acid 
composition of plasma (B) and EVs (D) pre- and post-apheresis (n=12); ****p<0.00001, **p<0.01, *p<0.05. 
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 Pre-apheresis Post-apheresis 
Fatty acid Plasma (%) EVs (%) p value Plasma (%) EVs (%) p value 
C14:0 0.6 ± 0.1 1.1  ± 0.1 0.04 0.9 ± 0.1 0.6 ± 0.07 0.008 
C14:1 0.04 ± 0.01 0.1 ± 0.02 0.006 0.06 ± 0.1 0.1 ± 0.08 NS 
C16:0 15.7 ± 3.2 27.3 ± 3.2 NS 10.5 ± 3.9 25.1 ± 1.2 0.002 
C16:1n9 2.5 ± 0.6 3.4 ± 0.4 NS 2.0 ± 0.8 4.6 ± 0.7 0.02 
C16:1n7 5.0 ± 0.8 8.2 ± 0.9 NS 3.1 ± 1.3 10.6 ± 0.6 <0.001 
C18:0 15.0 ± 4.2 6.2 ± 3.3 0.04 10.1 ± 6.0 17.7 ± 5.4 NS 
C18:1n9 11.3 ± 4.2 32.5 ± 3.4 0.003 31.8 ± 7.0 17.4 ± 5.4 NS 
C18:1n7 22.2 ± 5.8 13.3 ± 1.7 0.03 14.0 ± 3.6 15.3 ± 1.2 NS 
C20:2n6 1.7 ± 1.0 0.6 ± 0.09 NS 1.5 ± 0.1 0.8 ± 0.09 <0.001 
C20:5n3 0.9 ± 0.2 0.7 ± 0.15 0.03 2.2 ± 0.4 0.9 ± 0.15 0.002 
C22:0 0.3 ± 0.05 0.1 ± 0.06 0.02 0.5 ± 0.07 0.1 ± 0.04 0.001 
C22:3n3 0.1 ± 0.03 0.2 ± 0.09 NS 0.2 ± 0.04 0.02 ± 0.01 <0.001 
C22:3n6 0.4 ± 0.1 0.2 ± 0.1 NS 0.9 ± 0.4 0.03 ± 0.03 0.004 
C22:5n3 0.2 ± 0.06 0.07 ± 0.04 0.04 0.2 ± 0.1 0.3 ± 0.3 NS 
C24:0 0.07 ± 0.03 0.002 ± 0.002 0.009 0.2 ± 0.05 0.02 ± 0.02 0.003 
C24:1n9 0.9 ± 0.2 0.2 ± 0.1 0.006 1.6 ± 0.7 0.04 ± 0.02 NS 
Table 8.3.4: Comparison of plasma and EV fatty acids. Individual fatty acid 
compositions of plasma and EV samples were directly compared pre- and post-apheresis. 
Data are presented as mean ± SEM (n=12), only statistically significant p values are given, 
NS = non-significant. 
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8.3.5 Extracellular vesicle thrombin generation 
Thrombin generation of EVs pre- and post-apheresis was measured using CAT. EV 
thrombin generation over time was not shown to change following apheresis (pre: 
764.8 ± 171.0 area under curve (AUC); to post: 676.0 ± 133.4 AUC; p = 0.7; Figure 
8.3.8 A). However, EV thrombin generation over time showed significant correlation 
with EV concentration as measured by TRPS (np100) and NTA (r= 0.6, p = 0.001 
for TRPS np100; Figure 8.3.8 B; and r=0.4, p = 0.04 for NTA; Figure 8.3.8 D). No 
correlation was found between thrombin generation over time and EV concentration 
as measured by TRPS using the np200 nanopore (r= -0.1, p = 0.7; Figure 8.3.8 C). 
 
Figure 8.3.8: Thrombin generation potential of EVs in FH. (A) Thrombin generation of 
EVs over time was measured pre- and post-apheresis. EV thrombin generation over time 
was then correlated against EV concentration measured using TRPS: (B) np100, (C) np200 
and (D) NTA; (n=12), AUC = area under curve. 
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8.4 Discussion 
8.4.1 Key findings 
The key findings of this chapter were: 
1. Circulating exosomes were elevated in individuals with FH compared to 
healthy volunteers. Apheresis reduced the concentration of EVs, particularly 
those between 200 – 250 nm. 
2. The origin of circulating EVs in individuals with FH was similar to that of 
healthy volunteers, though endothelial-derived EVs were elevated in FH. 
Apheresis did not alter the proportion of circulating EVs from a particular 
cellular origin, the majority of which were annexin V/platelet-positive. 
3. Plasma and EV fatty acid concentration was elevated in FH compared to 
healthy volunteers. Fatty acid composition of plasma and EVs was altered 
between healthy volunteers and FH. Apheresis reduced plasma fatty acid 
concentration and altered the composition of certain fatty acids in both 
plasma and EVs. The fatty acid composition of EVs was different to that of 
surrounding plasma. 
4. The thrombin generation potential of EVs did not differ following apheresis. 
However, thrombin generation was positively correlated with EV 
concentration in FH as measured by TRPS np100 and NTA. 
 
8.4.2 Main discussion 
Circulating EVs are elevated in a number of diseases including in patients with 
severe hypercholesterolaemia (541,542). This chapter presents novel data regarding 
the effects of apheresis on EV size, concentration, origin, fatty acid concentration 
and thrombin generation in patients with FH. Apheresis reduces the circulating EV 
concentration, the majority of which are annexin V/platelet-positive EVs. 
Several methods exist to measure EVs, though often the technique employed is 
heavily dictated by the research question and protocol, and each exhibits unique 
advantages/limitations. Thus two well-established methods for EV measurement 
were employed in order to capture the full spectrum of EV sizes. At the time, TRPS 
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and NTA had not previously been subjected to a direct comparison in biological 
samples. The data presented here illustrate that the range of detectability of TRPS 
(np100 and np200) and NTA are similar, and although they differ vastly in reported 
EV concentration reported, taken together there is considerable agreement. This is 
consistent with bead-based experiments conducted in Chapter 3. 
No change was observed with TRPS or NTA in mode particle size pre- versus post-
apheresis. TRPS using the np200 and NTA both measured a fall in EV concentration 
pre- versus post-apheresis. EVs within the range of 200-250 nm were reduced the 
most, which is greater than the size of LDL particles (543), indicating the techniques 
are measuring a reduction EVs and not LDL. No difference was found in EV 
concentration with the np100 following apheresis. This further supports that the 
observed fall in EV concentration by the np200 and NTA was not due to either 
technique detecting LDL, as the particulate size of LDL lies within the sensitivity of 
the np100 pore range. Compared to health volunteers, EVs were elevated in the 
exosomal range in individuals with FH, despite apheresis reducing EVs between 
200-250 nm. However, the healthy volunteers used for comparison to FH individuals 
were not matched for age and BMI and therefore do not represent true matched 
controls. Total EV concentration was elevated in individuals with FH though this did 
not quite reach significance.  
Flow cytometric measurement of EVs revealed no changes in annexin V positivity or 
cellular origin following apheresis. In keeping with data at the time (56,542,544), 
EVs were mostly annexin V positive and of platelet origin (88.9 ± 13%). Taken 
together with the fall in EV concentration this would suggest that apheresis non-
selectively removes EVs, the majority of which are annexin V positive and derived 
from platelets. These EVs have not only been shown to be elevated in an array of 
disease states (545–550) but also to promote coagulation (438), atherosclerotic 
plaque formation (551) and to be associated with atherothrombotic events (547). 
Non-selective removal of these EVs by apheresis may reduce the risk of thrombus 
formation by slowing the progression of atherosclerotic lesions thereby 
complementing the effect of LDL removal. EVs in healthy volunteers were also 
found to be mainly annexin V positive and of platelet origin, though individuals with 
FH had a greater concentration of these circulating annexin V/platelet positive EVs 
compared to healthy volunteers. Individuals with FH had a greater proportion of 
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endothelial-derived EVs, perhaps suggesting a higher level of endothelial activation 
compared to healthy volunteers, although the percentage of the total population of 
EVs was still relatively low (<2%). 
GC-FID was used to measure fatty acid concentration and composition of plasma 
and EVs pre- and post-apheresis. The relative atheroprotective mechanisms of 
MUFAs and PUFAs are well documented (552) as are the data implicating SFAs in 
arterial wall lipid accumulation and atherosclerotic plaque formation (553). EVs 
have been shown to carry a specific cargo of proteins, genetic material and small 
molecules including fatty acids (554) that can initiate a pro-inflammatory response in 
target cells (534). Here, concentration of fatty acids was increased in both plasma 
and EV fractions of FH individuals compared to healthy volunteers. Evidently, 
individuals with FH have an increased circulating reservoir of lipids compared to 
healthy volunteers, though intriguingly, some of these excess lipids are incorporated 
into EVs. Apheresis reduced total fatty acid concentration of plasma. However, this 
was not reflected in the EV fraction following apheresis. Thus, although the overall 
number of EVs decreases pre- versus post-apheresis, the fatty acid concentration per 
EV remains the same. The composition of several fatty acids were different in 
individuals with FH compared to healthy volunteers in both plasma and EVs, 
however affected fatty acids and the trends (i.e. increase or decrease) were the same. 
Surprisingly, plasma and EVs from individuals with FH were more enriched in 
mono- and polyunsaturated fatty acids such as EPA and contained fewer saturated 
fatty acids compared to healthy volunteers. However, further work with more 
reliable healthy controls is needed to confirm these potential differences. EV fatty 
acids altered following apheresis in FH were the same as those altered in the plasma 
fraction with apheresis, however the trend of change was specific to EVs or plasma. 
The physiological relevance of these contradictory changes between plasma and EVs 
remains to be elucidated. Furthermore, when plasma was directly compared with the 
EV fraction, the composition of fatty acids was found to be different between 
compartments. This suggests that the fatty acid composition of EVs is independent to 
that of surrounding plasma, a concept previously found in a separate cohort of 
patients with PCOS (76) and data presented in Chapter 4 (159).  
The potential of EVs to generate thrombin was assessed using CAT. No change was 
observed in EV peak thrombin generation following apheresis. However, total EV 
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concentration measured by either TRPS (np100) or NTA showed a positive 
correlation with the total thrombin AUC whereas EV concentration measured by 
TRPS (np200) showed no correlation. Taken together, this suggests a reduction in 
EVs is associated with decreased thrombin generation capacity and that smaller EVs, 
particularly exosomes, are associated with an increased total thrombin generation 
over time. This conclusion was met based on the fact that both TRPS (np100) and 
NTA have an increased sensitivity for EVs in the exosomal range compared to TRPS 
(np200). Furthermore, individuals with FH were shown to have an increased 
circulating population of smaller EVs compared with healthy volunteers. Both TRPS 
(np100) and NTA showed a trend towards reduction in exosomal populations of EVs 
following apheresis, though this did not reach significance. This may suggest that the 
increased circulating population of exosomes in individuals with FH contributes to a 
more procoagulant EV fraction. Apheresis treatment non-selectively removes EVs 
and could potentially reduce the procoagulant potential of exosomes and smaller 
EVs. In keeping with previous data, (555,556) our results confirm EVs have 
endogenous TF activity and can stimulate thrombin generation. When exogenous TF 
was added to EVs to stimulate thrombin generation, the correlation between EV 
concentration and AUC was lost, indicating saturation of thrombin generation. 
 
8.4.3 Limitations 
As this study was an additional part of the normal clinical care received by 
individuals with FH, three different types of apheresis treatment were used. The 
present study was not designed to address the effects of the type of apheresis 
treatment on EVs in FH, though observationally, there were no differences in EV 
concentration between the techniques. In vitro studies have shown that the surface 
morphology of the adsorbent polymer may effect EV production (557), though this 
requires confirmation in vivo. Having now established that apheresis directly reduces 
EV concentration, future longitudinal studies should establish whether the reduction 
in atherogenic EVs is maintained between apheresis treatments and explore the 
physiological relevance this reduction in EVs has in regards to CVD pathology.  
FC measurements to assess cellular origin of EVs pose some potential limitations. 
EVs were initially gated based on their annexin V positivity meaning only annexin V 
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positive EVs were analysed for cellular origin. However, not all EVs display annexin 
V positivity (63). Given the majority of EVs measured in this study were annexin V 
positive (~90%) and the routine use of annexin V positivity to gate EV populations 
(56,558,559), these EVs were selected for subsequent staining for markers of cellular 
origin. In hindsight, the cellular origin of annexin V positive and negative EVs 
should have been assessed for cellular origin. The rationale at the time however was 
based on data showing annexin V positive EVs to be more procoagulant (63). 
As discussed in previous chapters, many flow cytometers have a practical lower limit 
of ~300 nm. Therefore smaller EVs, particularly exosomes, are below the 
detectability of these cytometers, and the fluorescence data obtained from a given 
sample does not completely reflect the full range of EV sizes observed by NTA and 
TRPS. Despite this, FC is still one of the most popular techniques to assess surface 
antigen expression of EVs, mainly because of its wide availability.  
Finally, the thrombin generation of patient EV samples was measured in the 
presence of pooled, healthy plasma to specifically test the activity of EVs as opposed 
whole patient plasma (that would likely reflect the influence of apheresis). Future 
studies should assess the procoagulant activity of plasma pre- to post-apheresis to 
confirm this reduction in atherogenic EVs. 
 
8.4.4 Conclusions 
In summary, apheresis reduces the concentration of circulating EVs in patients with 
FH, the majority of which are annexin V/platelet-positive. Though EV concentration 
was reduced, apheresis had no effect on the total fatty acid concentration of EVs. 
Fatty acid composition of EVs is unique and does not reflect that of surrounding 
plasma. EV concentration (particularly in the exosomal range) positively correlated 
with total thrombin generation, suggesting that a reduction in EV concentration via 
apheresis in FH may reduce the ability of EVs to produce thrombin. The removal of 
EVs that are predominantly annexin V and platelet-derived is a novel finding, 
supporting the notion that apheresis may have beneficial cardiovascular effects 
beyond lipoprotein removal. Future work should establish whether EV reduction 
during apheresis correlates with the longer-term benefits of this treatment.
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9. General Discussion 
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9.1 Thesis overview 
The primary aim of this thesis was to explore the characteristics and potential 
functional applications of adipocyte-derived EVs. Initially, this thesis sought to 
address issues surrounding methodological and pre-analytic processing of EVs to 
provide a firm background and understanding which could be applied to the 
remaining chapters. Adipocyte-derived EV release was then characterised using the 
well-established adipocyte cell line, 3T3-L1. The physiological characteristics of 
adipocyte EV release were monitored during adipogenesis. Hypoxia was then used 
as a pathophysiological stimulus for adipocyte EV generation, and these EVs were 
characterised according to the methods derived in earlier chapters and assessed for 
their ability to influence Mϕ function. The potential clinical implication of EVs in 
vivo was then considered. A variety of methodologies were used to assess the 
presence of adipocyte-derived EVs within plasma EV isolates. Finally, plasma EVs 
were analysed in a clinical cohort undergoing a routine treatment to determine the 
profile of EVs in CVD and the effects of an acute treatment modality on circulating 
EVs. 
The promise of EVs as novel circulating biomarkers is great in both physiological 
and disease states. However, EV research is currently hampered by an overall lack of 
standardisation in the isolation, storage and measurement of EVs, resulting in gross 
inconsistencies of reported EV protocols and data. It is important to reflect that 
during the course of this work, the field has progressed and my work has adapted 
accordingly – thus practice adopted in earlier experiments may not be mirrored in 
later chapters. Recent recommendations encourage EV researchers to provide 
evidence of an EV population from “minimal requirements” outlined in Table 1.1.2 
(16). Currently, these are preferably achieved using isolation techniques such as 
density ultracentrifugation or SEC to ensure separation of EVs from contaminating 
materials, particularly in plasma samples. EVs are then typically measured using a 
combination of TEM to visualise and size EV populations; NTA to determine EV 
concentration and FC (with micrometre beads) or proteomics/lipidomics to 
phenotype EVs. However, there are still no gold standard protocols or techniques for 
EV measurements. As such, different methods of EV detection and pre-analytical 
processing may be used to achieve these outlined requirements for an EV population; 
therefore, it is important to understand how these methodologies compare.  
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Two techniques used for EV size and concentration measurements, NTA and TRPS, 
were compared in Chapter 3. At the time of undertaking this comparison, TRPS was 
an emerging technique for EV quantification and little was known about how this 
non-optical, impedance-based method compared with the more popular technique, 
NTA which uses light scattering. Data presented in this thesis suggest that both NTA 
and TRPS are able to measure calibration beads over a wide range of concentrations, 
with TRPS being able to detect beads over a greater size range than NTA. However, 
to achieve this greater range of detection, TRPS requires the use of multiple 
nanopores. Not only does this increase the labour intensiveness of sample 
measurement, but data presented in Chapter 3 also showed that the detected 
concentration of the same calibration bead varied between nanopores; a concept 
since observed by others (407,411). Therefore, the additional time taken and the 
discrepancy in accuracy between pores may render TRPS less advantageous over 
NTA, despite the greater range of detection of calibration beads of TRPS. 
Furthermore, TRPS pores were subject to frequent blocking when using polydisperse 
samples, making measurements frustrating. NTA and TRPS were also compared in a 
clinical cohort in Chapter 8 (discussed below) for their measurement of EV size and 
concentration in individuals with FH. Interestingly, in contrast to bead measurements 
in Chapter 3, polydisperse plasma EVs were detected over a similar size range using 
NTA and TRPS (np100 and np200), though the total reported concentration of EVs 
varied greatly between techniques. 
Since the completion of this work, guidelines have been proposed for the use of high 
and low-sensitivity settings for both NTA and TRPS measurements 
(149,161,162,407,411). These settings for TRPS involve two different combinations 
of voltage and stretch being applied to each nanopore to improve accuracy of 
detection at the extremities of the pore. For NTA, larger particles measured using 
NTA tend to scatter more light, resulting in a “halo” of scattered light which may be 
counted by NTA software as smaller particles (Figure 3.4.1), perhaps partially 
explaining the reduced sensitivity of NTA for larger particles. Therefore, recent 
suggestions to analyse polydisperse samples at two dilutions (high and low 
sensitivity) with optimised analytical settings may overcome this problem. 
Furthermore, NTA software has been updated since this work was undertaken to 
reduce the subjectivity of analytical settings (162).  
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Despite the limitations of both NTA and TRPS, both techniques were superior at 
detecting individual populations within polydisperse bead samples compared to FC 
and DLS (Chapter 3). In addition to technical comparisons, Chapter 3 also 
addressed a selection of the methodological issues of the EV field by comparing 
protocols at different stages of pre-analytical processing. As others have since 
shown, the choice of anticoagulant used to collect blood for EV processing, and 
subsequent isolation and purification steps (such as filtering) can all impact upon the 
resultant EV population. As current guidelines are still lacking clarity, the best 
approach currently seems to be consistency in isolation protocols between samples, 
and to be clear and honest in reporting of protocols to allow comparison with others 
in the field. As such, from data presented in Chapter 3 which showed the negative 
effects of long-term storage on EV size and concentration, experiments conducted in 
later chapters (Chapters 4-7) aimed to utilise freshly isolated EVs wherever possible. 
As outlined in Chapter 1, AT is a highly active endocrine organ with diverse roles in 
regulating lipid metabolism, appetite, blood pressure and androgen levels through the 
secretion of adipokines (347). EVs have also been implicated in a number of 
homeostatic mechanisms, though research generally focuses on EVs derived from 
platelets and endothelial cells. However, little is known about EV release from 
adipocytes and their potential roles in local and endocrine AT function. Data 
presented in Chapter 4 provide a detailed characterisation of EVs released from 
adipocytes pre- and post-adipogenesis. EVs released from both pre- and mature 
adipocytes display a classical EV morphology and EV markers including CD9, in 
accordance with the ISEV minimal requirements for an EV population (16). 
Adipocyte EVs also bear adipocyte protein markers such as PPARγ and adiponectin 
that reflect their stage of adipogenesis. Data presented in Chapter 4 were also the 
first to show detailed analyses of the lipid composition of adipocyte EVs including 
fatty acid composition, phospholipid composition and phospholipid fatty acid 
composition. Interestingly, preadipocytes were shown to release more EVs per cell 
than mature adipocytes which were enriched in fatty acid signalling entities such as 
arachidonic acid. This suggests that EVs released from preadipocytes may facilitate 
communication in the early stages of differentiation; a notion recently supported by 
evidence from hASCs (441). Data has also shown that adipocyte-derived EVs are 
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able to modulate lipogenesis in neighbouring adipocytes (388) providing further 
evidence for a functional role of EVs in adipocyte intercommunication. 
In addition to the physiological role of EVs in the cardiovascular system, EVs are 
also elevated in a number of CVDs, and have been shown to have a detrimental role 
in atherosclerotic plaque formation (207) and arterial stiffening (213). Obesity is a 
major risk factor for the development of CVD and other comorbidities due to the 
dysregulation of adipocyte and AT functioning. Chapters 5 and 6 exposed 
adipocytes to hypoxia, a potential instigator of adipocyte dysfunction in obesity, to 
determine the effects on EV characteristics and function. Hypoxia at 1% O2 was 
found to induce a significant increase in EV production, without affecting adipocyte 
viability, and was therefore selected as the hypoxic stimulus. Previous studies have 
observed increases in EV release following stimulation with 1% O2 (241,463,471) 
though never before in adipocytes, with just one study finding an increase in 
exosomal protein from adipocytes following a hypoxic insult (390). This hypoxic 
induction of adipocyte-derived EV release could be mediated via HIF-1α as HIF-1α 
protein was increased in hypoxic adipocytes and silencing of HIF-1α has previously 
been shown to abate hypoxia-induced EV secretion (463). However, further work is 
needed to confirm this in hypoxic adipocyte-derived EV release. Chapter 5 also 
presents novel data on the effect of hypoxia on lipid and phospholipid composition 
of adipocytes and adipocyte-derived EVs. A similar profile of fatty acids was altered 
in adipocytes and corresponding EVs in hypoxia, suggesting that hypoxia-induced 
changes in cellular lipid metabolism are transferred to the EV. However, comparison 
of the fatty acid compositions between hypoxic adipocytes and corresponding EVs 
highlighted a number of compositional differences, generally suggesting EVs were 
enriched with a greater repertoire of signalling PUFAs. Therefore a greater number 
of EVs may be released by adipocytes in hypoxia that have a higher signalling 
capacity, promoting intercellular communication in AT. Indeed, the monocyte 
chemoattractant protein, MCP-1 was found to be enriched in hypoxic EVs, 
suggesting a greater potential of these EVs to communicate with monocytes and Mϕ. 
Obese AT is associated with an increased infiltration of proinflammatory Mϕ which 
feed the inflammation and dysfunction of AT in obesity. Hypoxia is able to induce 
AT dysfunction (380) and data in this thesis indicates that hypoxia also increases the 
release of EVs from adipocytes capable of interacting with Mϕ. I therefore 
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hypothesised that hypoxic adipocyte-derived EVs may participate in this cycle of 
adipocyte hypoxia and Mϕ inflammation by inducing a phenotypic shift of Mϕ 
towards a proinflammatory, M1 phenotype and stimulating the migration of 
additional Mϕ. Unfortunately, due to experimental issues with collaborators, 
experimental repeats could not be completed. However, preliminary data presented 
in Chapter 6 suggest that hypoxic adipocyte-derived EVs may have an alternative 
motive to that originally hypothesised in Mϕ interaction. The migration of Mϕ 
indeed looked to be more direct towards hypoxic adipocyte EVs, suggesting a 
greater chemotactic potential of these EVs. However, the M1 cytokine, IL-1β was 
decreased and the M2 marker, dectin-1 was increased in Mϕ following incubation 
with hypoxic adipocyte EVs. This suggests that the initial interaction of hypoxic 
adipocyte EVs with Mϕ may intend to encourage an M2, anti-inflammatory 
phenotype, perhaps to promote the resolution of hypoxia-induced damage in AT. 
However, upon recruitment to hypoxic AT, the local environment of dysfunction and 
inflammation may stimulate the transition of Mϕ to an M1 phenotype, thereby 
further exacerbating the metabolic dysregulation. However, further repeats need to 
be completed to ascertain the true intention of hypoxic adipocyte-derived EVs 
towards Mϕ.  
In vitro experiments played an important part in establishing the characteristics and 
potential functional interactions of adipocyte-derived EVs in this thesis, enabling the 
identification of specific markers which may be used to probe for the existence of 
adipocyte-derived EVs in vivo. The metabolic and inflammatory status of adipocytes 
in vivo may dictate the development and severity of obesity-related co-morbidities, 
and therefore adipocyte-derived EVs may provide a novel circulating biomarker of 
adipocyte functioning. However, the presence of adipocyte-derived EVs in the 
circulating plasma EV fraction had not previously been reported. Data presented in 
Chapter 7 confirms the presence of adipocyte markers in plasma EV isolates and 
was used to secure a project grant application. Adiponectin, FABP4 and PPARγ 
were detected in plasma EVs using a range of techniques from previous chapters in 
this thesis and others have also confirmed our findings (54,514,515). As discussed in 
Section 9.2 below, our group is continuing this work to attempt to isolate adipocyte-
derived EVs from circulating plasma EVs in order to investigate these EVs in 
different patient populations as potential biomarkers of disease. 
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Alterations in circulating EVs have been associated with a number of diseases, 
generally manifesting as an increase in circulating EV concentration. Therefore, the 
therapeutic reduction of EVs in diseases with elevated EV concentrations may help 
to abate EV-mediated disease progression. Novel data presented in Chapter 8 show 
that individuals with FH have higher circulating levels of plasma EVs compared to 
healthy volunteers. Furthermore, routine apheresis treatment received by these 
individuals as part of their normal clinical care reduced the concentration of 
circulating EVs as well as LDL. These EVs were primarily annexin V positive and 
of platelet origin which, as discussed in Chapter 1.1.8.2, can be strongly 
procoagulant. Additionally, the thrombin generation potential of EVs correlated with 
EV concentration, which indicates that a reduction in these EVs by apheresis may 
reduce the EV-mediated procoagulant potential in FH individuals. Intriguingly, 
apheresis treatment provides a long-term reduction in cardiovascular risk for 
individuals with FH, though the reduction of LDL following apheresis treatment is 
transient (526). This suggests that the removal of LDL alone by apheresis does not 
completely account for the long-term cardiovascular benefits of the treatment. The 
removal of procoagulant EVs by apheresis may therefore provide additional 
cardiovascular benefits to individuals with FH, though further work is needed to 
determine whether this removal of EVs accounts for the long-term benefits of 
apheresis treatment. 
Data presented in this thesis provide new insights into the characteristics and 
potential functions of adipocyte-derived EVs in normal adipocyte processes such as 
adipogenesis and in disease-like conditions such as obesity-induced hypoxia. 
Though the EV field is hampered by a lack of standardisation, EVs are emerging as 
novel cellular communicators and adipocyte-derived EVs in particular may 
participate in the autocrine, paracrine and endocrine functions of AT. EVs are 
therefore likely to feature heavily in future biomarker and therapeutic research in a 
number of different diseases. As such, adipocyte-derived EVs may become 
important biomarkers of AT function and metabolic risk in obesity. 
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9.2 Future research 
It is hoped that future research into EVs will resolve many of the standardisation 
issues in EV isolation and measurement. Although this is a challenging task due to 
the breadth and variety of research within the EV field, it is essential for progression 
of the field towards the use of EVs as biomarkers of disease and potentially as 
therapeutic targets.   
From an adipocyte EV perspective, data in this thesis provide a number of interesting 
opportunities for continuation. For example, Chapter 4 indicated that preadipocytes 
were much more active in generating EVs than mature adipocytes. The main focus of 
the pathological role of adipocyte-derived EVs however focused on EV release from 
mature adipocytes (Chapters 5 and 6). Preadipocytes and adipocyte precursors form 
an important part of AT, largely accounting for the tissue‟s innate plasticity. 
Therefore, the release of preadipocyte-derived EVs may be an interesting avenue of 
research. For instance, a recent study has observed that exposure of preadipocytes 
undergoing differentiation to intermittent hypoxia results in a population of mature 
adipocytes with greater insulin sensitivity and ability to store triglycerides (560). 
Our own work with adipocyte-derived EVs will continue with data from Chapters 5 
and 6 currently being extended to analyse the effects of hypoxia and inflammation 
on adipocyte-derived EV release. It is hypothesised that the combination of hypoxia 
and inflammation may have a synergistic effect on stimulating adipocyte-derived EV 
release, which may in turn enhance leukocyte recruitment to AT via breakdown of 
endothelial barriers. Characterisation of adipocyte-derived EVs will also continue 
using more primary adipocyte sources; both commercial primary adipocyte cells and 
those isolated by our group directly from human AT. We hope to continue our 
characterisation of adipocyte-derived EVs and confirm our results from 3T3-L1 
adipocytes, but also to examine adipocyte-derived EVs from adipocytes from 
patients of varying BMIs and diseases (such as T2D). It may be that adipocyte-
derived EVs from obese or metabolically dysfunctional individuals differ to those 
from healthy individuals, thus potentially leading to the identification of novel 
biomarkers. 
In parallel with this, our in vivo research into adipocyte-derived EVs will also 
continue by applying data from this thesis to attempt to isolate adipocyte-derived 
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EVs from circulating plasma EV populations. Our group are currently trialling a 
magnetic bead-based approach to selectively isolate specific populations of EVs, 
including adipocyte-derived EVs. It is hoped this technique can be combined with 
other techniques such as FC and TRF to allow for dual staining of adipocyte markers 
to definitively confirm an adipocyte origin. 
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 DAY 0 DAY 15 
Fatty acid Cells (%) EVs (%) p value Cells (%) EVs (%) p value 
SFA 39.96 ± 1.55 53.42 ± 4.49 <0.0001 51.81 ± 1.64 34.89 ± 4.65 <0.0001 
C14:0 0.43 ± 0.05 0.16 ± 0.13 0.003 3.27 ± 0.27 0.34 ± 0.16 <0.0001 
C15:0 0.36 ± 0.07 0.67 ± 0.11 0.0004 0.36 ± 0.02 0.24 ± 0.08 0.03 
C16:0 16.81± 0.47 23.45 ± 2.08 0.0004 44.22 ± 1.16 17.51 ± 3.67 <0.0001 
C18:0 20.82 ± 0.70 26.12 ± 1.76 0.0003 3.79 ± 0.18 15.79 ± 0.65 <0.0001 
C20:0 0.72 ± 0.18 2.19 ± 0.28 <0.0001 0.10 ± 0.00 0.79 ± 0.04 <0.0001 
C24:0 0.82 ± 0.08 0.83 ± 0.13 ns 0.07 ± 0.01 0.22 ± 0.05 0.003 
MUFA 23.38 ± 1.39 24.75 ± 5.51 <0.0001 39.33 ± 1.35 26.51 ± 6.23 <0.001 
C14:1 0.15 ± 0.09 0.05 ± 0.09 ns 0.10 ± 0.02 0.04 ± 0.04 0.02 
C16:1n9 1.88 ± 0.17 2.37 ± 0.31 0.0004 23.39 ± 0.67 7.21 ± 3.37 <0.0001 
C16:1n7 1.31 ± 0.10 2.16 ± 0.67 0.03 ND ND - 
C18:1n9 14.02 ± 0.65 11.63 ± 1.35 0.006 12.86 ± 0.51 14.96 ± 0.89 0.003 
C18:1n7 3.69 ± 0.21 3.66 ± 0.16 ns 2.80 ± 0.13 1.11 ± 0.78 0.008 
C20:1n9 0.74 ± 0.07 0.44 ± 0.11 0.0004 0.13 ± 0.01 2.98 ± 1.00 0.003 
C22:1n9 ND 3.15 ± 2.58 - ND ND - 
C24:1n9 1.38 ± 0.10 1.29 ± 0.24 ns 0.05 ± 0.01 0.21± 0.15 ns 
PUFA 32.13 ± 2.39 19.34 ± 6.99 <0.0001 1.1 ± 0.1 37.54 ± 8.76 <0.0001 
C18:2n6 2.63 ± 0.37 12.05 ± 4.44 0.003 0.23 ± 0.01 32.80 ± 7.77 0.0007 
C18:3n3 1.02 ± 0.60 1.09 ± 1.11 ns 0.05 ± 0.01 3.63 ±0.38 <0.0001 
C20:2n6 3.57 ± 0.10 0.96 ± 0.18 <0.0001 0.12 ± 0.01 0.15 ± 0.05 ns 
C20:3n3 1.40 ± 0.07 0.60 ± 0.13 <0.0001 ND ND - 
C20:4n6 13.92 ± 0.68 2.91 ± 0.52 <0.0001 0.56 ± 0.04 0.63 ± 0.33 ns 
C22:2 0.88 ± 0.04 0.28 ± 0.09 <0.0001 ND ND - 
C22:3 1.81 ± 0.10 ND - ND ND - 
C22:5n3 2.66 ± 0.19 0.63 ± 0.34 <0.0001 0.13 ± 0.01 0.21 ± 0.09 ns 
C22:6n3 4.14 ± 0.24 0.82 ± 0.18 <0.0001 0.01 ± 0.02 0.15 ± 0.14 ns 
Other 2.93 ± 0.55 2.12 ± 0.38 ns 0.92 ± 0.05 0.74 ± 0.17 ns 
C16 Ac 2.18 ± 0.31 1.76 ± 0.30 0.04 0.53 ± 0.03 0.43 ± 0.13 0.15 
C18 Ac 0.75 ± 0.24 0.36 ± 0.08 0.009 0.39 ± 0.02 0.31 ± 0.04 0.009 
Table I: Cell to EV fatty acid analysis. Comparison of individual fatty acid proportions of 
3T3-L1 cells and their corresponding EVs at day 0 (n=6) and day 15 (n=5). Ac = acetals; 
SFA = saturated fatty acid; MUFA = monounsaturated fatty acid; PUFA = polyunsaturated 
fatty acid; ND = not detected, ns = non-significant.  
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A 
Fatty acids (% 
of total) 
Day 0 Day 15 
Cells EVs Cells EVs 
Phosphatidylethanolamine 
SFA 16.6 32.5 25.6 37.9 
C16:0 3.2 11.0 15.7 16.4 
C18:0 13.4 20.9 9.9 17.8 
C20:0 - 0.6 - 0.9 
C24:0 - - - 2.8 
MUFA 11.0 24.3 38.3 34.3 
C16:1n9 0.8 3.3 - 6.4 
C16:1n7 0.7 1.3 21.7 11.5 
C18:1n9 7.4 15.1 12.6 13.1 
C18:1n7 2.1 3.8 4.0 3.3 
C20:1n9 - 0.8 - - 
PUFA 66.9 37.9 28.2 23.0 
C18:2n6 0.9 1.7 0.8 0.7 
C18:3n3 0.7 5.2 - 8.8 
C20:2n6 7.4 4.3 1.4 1.3 
C20:3n6 1.5 1.7 - 0.6 
C20:4n6 37.7 13.5 13.9 7.8 
C20:5n3 5.4 1.5 3.1 1.4 
C22:2n6 2.1 1.3 - - 
C22:3n3 4.2 2.5 - - 
C22:4n6 0.9 - - - 
C22:5n3 6.1 3.0 2.6 - 
C22:6n3 - 3.2 6.4 2.4 
Other 4.2 4.6 5.0 3.9 
C16 acetals 4.2 4.6 5.0 3.9 
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B 
  
Fatty acids (% 
of total) 
Day 0 Day 15 
Cells EVs Cells EVs 
Sphingomyelin 
SFA 67.3 62.6 81.3 61.8 
C14:0 - 0.7 0.6 0.9 
C16:0 26.9 34.8 44.4 31.6 
C18:0 15.1 17.7 16.1 16.9 
C20:0 4.9 3.3 5.8 2.8 
C22:0 8.9 6.1 10.5 4.9 
C24:0 11.5 - 3.9 4.7 
MUFA 30.9 6.2 12.6 14.1 
C16:1n9 0.9 4.4 1.9 7.9 
C16:1n7 0.6 - 1.4 - 
C18:1n9 0.6 1.8 0.9 1.9 
C24:1n9 28.8 - 8.4 4.3 
PUFA 1.9 31.4 5.8 24.0 
C18:2n6 - 0.7 - 0.6 
C18:3n3 - 0.8 1.7 - 
C18:3n6 1.9 7.7 2.9 8.7 
C20:2n6 - 1.6 - 2.2 
C20:3n6 - - - 0.6 
C20:4n6 - - - - 
C22:3n3 - - 1.2 3.8 
C22:4n6 - - - 8.1 
C22:5n3 - 8.2 - - 
C22:6n3 - 12.4 - - 
Page | 320  
 
C 
  
Fatty acids (% 
of total) 
Day 0 Day 15 
Cells EVs Cells EVs 
Phosphatidylcholine 
SFA 37.3 52.1 41.1 48.7 
C14:0 - 0.7 - 0.6 
C16:0 21.8 37.8 29.7 30.9 
C18:0 15.5 13.6 11.4 17.2 
MUFA 30.3 36.4 52.9 43.1 
C16:1n9 2.3 3.9 0.6 2.1 
C16:1n7 1.6 1.9 32.1 20.6 
C18:1n9 18.4 22.9 15.0 14.8 
C18:1n7 7.4 7.1 5.2 5.6 
C20:1n9 0.6 0.6 - - 
PUFA 28.9 9.6 4.6 6.3 
C18:2n6 2.7 1.8 0.5 0.7 
C18:3n3 - 1.2 0.3 2.9 
C20:2n6 3.6 1.0 0.5 - 
C20:3n6 1.8 0.9 0.3 - 
C20:4n6 13.6 2.9 2.0 1.4 
C20:5n3 2.1 - 0.5 - 
C22:2n6 - - 0.0 - 
C22:3n3 1.0 - 0.1 - 
C22:5n3 1.5 0.9 0.3 0.6 
C22:6n3 2.6 0.9 0.6 0.7 
Other 1.1 - - - 
C16 acetals 1.1 - - - 
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D 
  Fatty acids (% of 
total) 
(% of total) 
Day 0 
Cells 
Day 15 
Cells 
Cardiolipin 
SFA 26.7 11.3 
C16:0 12.1 7.4 
C18:0 14.6 3.9 
MUFA 35.4 79.0 
C16:1n9 2.4 - 
C16:1n7 2.6 54.6 
C18:1n9 19.4 14.1 
C18:1n7 11.0 10.3 
PUFA 36.3 7.2 
C18:2n6 9.6 2.2 
C18:3n3 4.3 1.6 
C20:2n6 2.3 - 
C20:3n6 4.2 0.8 
C20:4n6 9.9 1.7 
C20:5n3 1.5 - 
C22:3n3 0.9 - 
C22:4n6 - - 
C22:5n3 1.3 - 
C22:6n3 2.3 0.9 
Other 0.8 0.8 
C16 acetals 0.8 0.8 
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E 
  
Fatty acids (% 
of total) 
Day 0 Day 15 
Cells EVs Cells EVs 
Phosphatidylserine 
SFA 46.0 59.0 49.3 62.5 
C14:0 - - - 1.5 
C16:0 1.0 13.0 7.3 22.9 
C18:0 43.8 44.2 42.0 33.4 
C20:0 - 1.1 - - 
C22:0 0.6 - - - 
C24:0 0.6 0.7 - 4.7 
MUFA 22.3 24.5 33.7 18.2 
C16:1n9 0.7 3.4 0.7 7.0 
C16:1n7 - - 15.7 3.9 
C18:1n9 18.6 16.4 12.8 7.3 
C18:1n7 2.4 3.5 3.8 - 
C20:1n9 0.6 - - - 
C24:1n9 - 1.2 0.7 - 
PUFA 30.2 14.9 15.1 19.3 
C18:2n6 1.3 1.3 0.9 1.1 
C18:3n6 - 0.9 - - 
C18:3n3 0.7 6.8 1.6 13.1 
C20:2n6 2.2 0.6 - 4.4 
C20:3n6 3.3 1.8 0.6 - 
C20:4n6 8.1 1.4 3.2 0.7 
C20:5n3 0.6 - - - 
C22:2n6 1.3 0.6 - - 
C22:3n3 3.0 - 0.9 - 
C22:5n3 4.5 0.7 2.8 - 
C22:6n3 5.2 0.8 5.1 - 
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F 
Table II: Phospholipid fatty acid compositions following adipogenesis. Individual 
phospholipids from cells and EVs pre- and post-adipogenesis were separated using 2D-TLC 
and then subjected to GC. Compositions of individual fatty acids are presented for (A) 
phosphatidylethanolamine; (B) sphingomyelin; (C) phosphatidylcholine; (D) cardiolipin; (E) 
phosphatidylserine; and (F) phosphatidylinositol. Only fatty acids >0.5% are presented. 
Totals of saturated, monounsaturated and polyunsaturated fatty acids (SFA, MUFA and 
PUFA respectively) are given (n=1). 
Fatty acids(% 
of total) 
Day 0 Day 15 
Cells EVs Cells EVs 
Phosphatidylinositol 
SFA 43.1 54.9 39.3 65.1 
C14:0 - 0.6 - 0.8 
C16:0 1.6 17.5 19.9 21.5 
C18:0 41.5 36.8 19.4 34.3 
C20:0 - - - 1.6 
C24:0 - - - 6.9 
MUFA 7.1 19.5 33.1 11.2 
C16:1n9 - 8.9 - 3.8 
C16:1n7 - - 7.6 - 
C18:1n9 5.5 8.9 18.3 7.4 
C18:1n7 1.6 1.7 7.2 - 
PUFA 49.2 25.2 26.0 23.7 
C18:2n6 - 1.1 0.7 0.8 
C18:3n3 1.1 17.1 1.0 15.2 
C20:2n6 9.9 2.4 3.2 4.5 
C20:3n6 1.1 - 0.7 1.2 
C20:4n6 30.0 4.6 14.9 2.0 
C20:5n3 1.4 - 1.9 - 
C22:2n6 0.6 - - - 
C22:3n3 1.3 - 0.6 - 
C22:5n3 2.2 - 1.5 - 
C22:6n3 1.6 - 1.5 - 
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 O2 condition 
Fatty acid Normoxia 1% 2% 5% 10% 21% 
SFA 48.1 ± 2.6 52.6 ± 1.2 50.7 ± 0.2 52.2 ± 2.4 45.1 ± 0.8 43.1 ± 1.4 
C14:0 2.9 ± 0.3 3.2 ± 0.2 2.5 ± 0.09 3.2 ± 0.3 3.0 ± 0.03 2.8 ± 0.2 
C16:0 42.0 ± 2.0 45.2 ± 0.9 44.0 ± 0.07 45.4 ± 2.0 41.9 ± 0.8 37.2 ± 1.2 
C18:0 3.1 ± 0.2 4.3 ± 0.05 4.3 ± 0.07 3.6 ± 0.2 3.2 ± 0.02 3.1 ± 0.1 
MUFA 49.2 ± 2.9  41.4 ± 1.2 45.6 ± 0.2 45.2 ± 2.1 49.0 ± 0.6 53.1 ± 1.7 
C14:1 0.6 ± 0.1 0.5 ± 0.1 0.5 ± 0.02 0.3 ± 0.1 0.5 ± 0.03 0.8 ± 0.2 
C16:1n9 0.6 ± 0.1 0.9 ± 0.01 0.7 ± 0.03 0.4 ± 0.06 0.5 ± 0.02 0.8 ± 0.05 
C16:1n7 32.9 ± 1.5 27.8 ± 0.9 27.6 ± 0.1 29.4 ± 1.2 33.3 ± 0.4 35.5 ± 0.9 
C18:1n9 12.1 ± 0.8 12.3 ± 0.1 13.6 ± 0.08 11.9 ± 0.4 11.4 ± 0.06 11.9 ± 0.2 
C18:1n7 3.2 ± 0.5 2.9 ± 0.1 3.2 ± 0.02 3.2 ± 0.3 3.4 ± 0.1 4.2 ± 0.4 
PUFA 1.4 ± 0.4 1.3 ± 0.03 1.9 ± 0.04 1.4 ± 0.2 1.6 ± 0.1 1.9 ± 0.2 
C18:3n3 0.3 ± 0.06 0.3 ± 0.01 0.3 ± 0.01 0.2 ± 0.04 0.3 ± 0.02 0.4 ± 0.05 
C20:4n6 0.6 ± 0.2 0.6 ± 0.01 0.9 ± 0.03 0.6 ± 0.07 0.7 ± 0.04 0.8 ± 0.08 
C20:5n3 0.2 ± 0.05 0.2 ± 0.00 0.2 ± 0.01 0.2 ± 0.03 0.2 ± 0.02 0.2 ± 0.02 
C22:5n3 0.1 ± 0.05 0.1 ± 0.01 0.2 ± 0.01 0.1 ± 0.01 0.1 ± 0.01 0.2 ± 0.02 
C22:6n3 0.3 ± 0.06 0.2 ± 0.01 0.4 ± 0.03 0.3 ± 0.02 0.3 ± 0.02 0.3 ± 0.02 
Table III: Fatty acid composition of hypoxic cells. Compositional changes in cellular fatty 
acids between normoxic controls and hypoxic conditions. Data are presented as the mean 
percentage composition ± standard deviation. Significant changes (p<0.05) from normoxic 
values are in bold italics. Normoxia (n=15), 1, 2, 5, 10, 21% O2 (n=3). SFA = saturated fatty 
acids; MUFA = monounsaturated fatty acids; PUFA = polyunsaturated fatty acids. 
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 O2 condition 
Fatty acid Normoxia 1% 2% 5% 10% 21% 
SFA 51.2 ± 6.9 59.1 ± 0.1 46.3 ± 0.02 48.0 ± 0.06 49.7 ± 0.02 56.8 ± 8.3 
C14:0 0.6 ± 0.6 1.5 ± 0.0 1.6 ±0.0  ND ND  0.5 ± 0.9 
C16:0 36.2 ± 2.6 40.5 ± 0.1 34.3 ± 0.01 32.7 ± 0.03 37.3 ± 0.01 45.1 ± 3.0 
C18:0 14.5 ± 3.7 17.1 ± 0.1 10.3 ± 0.0 15.3 ± 0.03 12.4 ± 0.01 11.2 ± 4.4 
MUFA 39.1 ± 12.1 31.6 ± 0.2 46.1 ± 0.03 44.2 ± 0.06 44.0 ± 0.03 37.7 ± 4.6 
C14:1 0.1 ± 0.2 0.4 ± 0.0 0.9 ± 0.01 ND ND 0.1 ± 0.2 
C16:1n9 0.6 ± 0.5 0.4 ± 0.01 1.0 ± 0.0 ND 0.4 ± 0.0 0.2 ± 0.4 
C16:1n7 19.2 ± 6.4 8.3 ± 0.1 26.2 ± 0.01 20.7 ± 0.03 23.8 ± 0.01 20.6 ± 2.6 
C18:1n9 13.1 ± 2.4  16.9 ± 0.03 13.1 ± 0.01 15.0 ± 0.01 13.4 ± 0.01 11.5 ± 0.5 
C18:1n7 4.6 ± 1.4 5.0 ± 0.01 4.5 ± 0.0 6.1 ± 0.01 4.9 ± 0.0 4.4 ± 0.3 
C20:1n9 1.5 ± 1.3 0.7 ± 0.0 0.4 ± 0.0 2.5 ± 0.01 1.4 ± 0.0 0.9 ± 0.6 
PUFA 8.6 ± 12.6 7.4 ± 0.02 5.1 ± 0.01 6.9 ± 0.01 4.7 ± 0.01 3.9 ± 1.5 
C18:2n6 0.6 ± 0.5 1.3 ± 0.0 ND± 0.7 ± 0.0 0.5 ± 0.0 0.3 ± 0.2 
C18:3n3 2.4 ± 1.3 3.6 ± 0.01 2.0 ± 0.0  2.5 ± 0.01 1.3 ± 0.0 1.0 ± 0.6 
C20:2n6 0.4 ± 0.3 0.6 ± 0.0 0.3 ± 0.0 0.5 ±0.0 0.5 ± 0.0 0.5 ± 0.1 
C20:4n6 1.6 ± 0.6 1.4 ± 0.0  2.0 ± 0.0 2.3 ± 0.01 1.9 ± 0.0 1.7 ± 0.4 
C20:5n3 2.1 ± 5.5 0.6 ± 0.0 0.3 ± 0.0 0.6 ± 0.0 0.5 ± 0.0 0.4 ± 0.1 
C22:6n3 1.9 ± 4.6 ND 0.5 ± 0.0 0.4 ± 0.0 0.03 ± 0.0 ND 
Table IV: EV fatty acid composition. Compositional changes in EV fatty acids between 
normoxia and hypoxia. Data are presented as the mean percentage composition ± SD. 
Significant changes (p<0.05) from normoxic values are in bold italics. Normoxia (n=15), 1, 
2, 5, 10, 21% O2 (n=3), ND = not detected; SFA = saturated fatty acids; MUFA = 
monounsaturated fatty acids; PUFA = polyunsaturated fatty acids. 
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 Normoxia Hypoxia (1% O2) 
Fatty acid Cells (%) EVs (%) p value Cells (%) EVs (%) p value 
SFA 48.1 ± 2.6 51.2 ± 6.9 - 52.6 ± 1.2 59.1 ± 0.1 **** 
C14:0 2.9 ± 0.3 0.6 ± 0.6 * 3.2 ± 0.2 1.5 ± 0.0 **** 
C16:0 42.0 ± 2.0 36.2 ± 2.6 **** 45.2 ± 0.9 40.5 ± 0.1 **** 
C18:0 3.1 ± 0.2 14.5 ± 3.7 **** 4.3 ± 0.1 17.1 ± 0.1 **** 
MUFA 49.2 ± 2.9 39.1 ± 12.1 ** 41.4 ± 1.2 31.6 ± 0.2 **** 
C16:1n7 32.9 ± 1.5 19.2 ± 6.4 **** 27.8 ± 0.9 8.3 ± 0.1 **** 
C18:1n9 - - - 12.3 ± 0.1 16.9 ± 0.0 **** 
C18:1n7 - - - 2.9 ± 0.1 5.0 ± 0.0 **** 
C20:1n9 ND 1.5 ± 1.3 - ND 0.7 ± 0.0 ** 
PUFA 1.4 ± 0.4 9.0 ± 12.6 * 1.3 ± 0.0 7.4 ± 0.0 **** 
C18:2n6 ND 0.6 ±  0.5 - ND 1.3 ± 0.0 **** 
C18:3n3 - - - 0.3 ± 0.0 3.6 ± 0.0 **** 
C20:2n6 ND 0.4 ± 0.3 - ND 0.6 ± 0.0 * 
C20:4n6 - - - 0.6 ± 0.0 1.4 ± 0.0 *** 
C22:5n3 0.1 ± 0.1 ND - 0.1 ± 0.0 ND - 
Table V: Composition of cell versus EVs in hypoxia. Significant changes in fatty acid 
composition of normoxic and hypoxic cells versus their corresponding EVs. Values are 
given as a percentage of the total fatty acid composition. *p<0.05, **p<0.01, ***p<0.001, 
****p<0.0001. Normoxia (n=15), hypoxia (n=3), „-‟ indicates no change, ND = not detected 
(or below 0.05%). 
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A 
Fatty acid 
(% total) 
Cells EVs 
Normoxia Hypoxia Normoxia Hypoxia 
Phosphatidylethanolamine 
SFA 23.10 22.04 43.38 27.51 
C15:0 - - 0.99 0.51 
C16:0 13.36 11.23 27.49 11.91 
C18:0 9.74 10.81 14.38 15.09 
C20:0 - - 0.52 - 
MUFA 34.54 32.25 37.39 29.79 
C16:1n9 - - 1.67 1.63 
C16:1n7 20.73 17.65 18.37 13.21 
C18:1n9 9.41 9.05 12.33 11.12 
C18:1n7 4.40 5.55 5.02 3.83 
PUFA 28.11 31.24 14.18 31.84 
C18:2n6 0.81 1.00 0.74 - 
C18:3n3 - 0.61 6.32 5.60 
C20:2n6 1.33 1.80 4.50 1.95 
C20:3n3 - - - 0.73 
C20:4n6 12.38 13.76 - 11.96 
C20:5n3 4.53 4.71 1.48 3.79 
C22:2n6 - 0.53 - - 
C22:5n3 2.26 2.61 - 2.96 
C22:6n3 6.80 6.22 1.14 4.85 
Acetals 11.46 12.00 3.26 8.78 
C16 acetals 8.22 8.22 2.26 7.84 
C18 acetals 3.24 3.78 1.00 0.94 
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B 
Fatty acid 
(% total) 
Cells EVs 
Normoxia Hypoxia Normoxia Hypoxia 
Sphingomyelin 
SFA 78.85 74.42 65.79 71.41 
C14:0 0.64 0.68 - - 
C15:0 0.50 0.59 1.23 0.57 
C16:0 43.68 38.99 31.80 34.53 
C18:0 10.68 11.70 21.23 13.38 
C20:0 4.51 3.87 - 3.90 
C22:0 9.94 9.55 6.45 9.83 
C24:0 8.90 9.04 5.26 9.20 
MUFA 12.87 16.26 19.76 13.60 
C16:1n9 0.53 0.80 2.84 1.53 
C16:1n7 2.19 4.24 4.61 - 
C18:1n9 1.02 1.85 6.05 1.19 
C18:1n7 0.59 1.00 1.52 0.57 
C24:1n9 8.54 8.37 4.74 10.31 
PUFA 7.40 7.06 13.45 13.76 
C18:3n6 1.41 0.95 - 1.25 
C18:3n3 3.80 4.05 11.68 9.29 
C20:2n6 0.72 0.79 1.77 2.12 
C22:3n3 1.47 1.27 - 1.10 
Acetals - 0.71 - - 
C16 acetals - 0.71 - - 
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C 
Fatty acid 
(% total) 
Cells EVs 
Normoxia Hypoxia Normoxia Hypoxia 
Phosphatidylcholine 
SFA 37.22 40.88 44.06 41.90 
C14:0 0.42 0.72 - - 
C16:0 28.15 29.98 25.86 28.42 
C18:0 8.65 10.18 15.50 13.48 
MUFA 53.89 49.34 43.55 44.91 
C16:1n9 - - 2.00 1.30 
C16:1n7 34.81 30.57 17.65 20.30 
C18:1n9 12.42 11.12 15.74 15.31 
C18:1n7 6.66 7.65 8.16 8.00 
PUFA 5.37 5.59 12.46 10.07 
C18:2n6 0.63 0.76 0.95 0.88 
C18:3n3 - - 5.48 1.83 
C20:2n6 0.52 0.52 - 0.57 
C20:3n3 - - 0.87 0.78 
C20:4n6 2.42 2.60 2.31 2.66 
C20:5n3 1.03 0.93 0.64 0.71 
C22:5n3 - - 1.12 1.21 
C22:6n3 0.77 0.78 1.09 1.43 
Acetals 0.72 0.99 0.90 0.61 
C16 acetals 0.72 0.99 0.90 0.61 
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D 
Fatty acid 
(% total) 
Cells EVs 
Normoxia Hypoxia Normoxia Hypoxia 
Cardiolipin 
SFA 15.01 69.11 46.51 58.35 
C14:0 0.81 - 0.83 0.54 
C15:0 0.74 1.03 1.89 1.29 
C16:0 9.01 19.56 29.71 18.22 
C18:0 3.45 45.87 11.52 24.70 
C20:0 - 1.25 0.79 0.90 
C22:0 - 1.40 - - 
C24:0 - - 1.77 12.70 
MUFA 75.78 22.71 35.22 23.61 
C14:1 - 0.93 - - 
C16:1n9 - - 3.25 5.47 
C16:1n7 59.42 6.97 19.61 12.43 
C18:1n9 9.10 6.55 10.35 5.71 
C18:1n7 7.26 6.14 2.01 - 
C24:1n9 - 2.12 - - 
PUFA 6.99 5.75 15.79 16.56 
C18:2n6 1.45 1.12 0.64 - 
C18:3n3 4.07 2.18 12.82 13.07 
C20:2n6 - 1.89 2.33 2.70 
C20:3n3 0.57 - - - 
C20:4n6 0.90 0.56 - 0.79 
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E 
Fatty acid 
(% total) 
Cells EVs 
Normoxia Hypoxia Normoxia Hypoxia 
Phosphatidylserine 
SFA 42.20 49.34 39.75 49.06 
C15:0 - 0.54 1.75 1.91 
C16:0 10.35 7.28 17.14 18.04 
C18:0 31.83 40.96 20.86 27.99 
C20:0 - - - 1.12 
C22:0 - 0.56 - - 
MUFA 31.78 26.52 26.94 27.31 
C16:1n9 0.64 1.08 5.38 6.51 
C16:1n7 14.04 12.66 4.88 3.33 
C18:1n9 12.49 9.12 12.17 13.95 
C18:1n7 4.61 3.66 4.51 3.52 
PUFA 22.69 21.11 31.88 22.53 
C18:2n6 0.95 0.80 0.68 1.16 
C18:3n3 3.18 6.53 21.07 9.73 
C20:2n6 1.63 1.89 4.00 2.85 
C20:3n3 0.85 0.80 - - 
C20:4n6 8.35 4.28 6.13 7.52 
C20:5n3 1.69 0.79 - 1.27 
C22:2n6 0.60 0.63 - - 
C22:5n3 2.11 2.14 - - 
C22:6n3 3.33 3.25 - - 
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F 
Fatty acid 
(% total) 
Cells EVs 
Normoxia Hypoxia Normoxia Hypoxia 
Phosphatidylinositol 
SFA 34.41 39.08 51.91 50.89 
C14:0 - 2.25 - - 
C15:0 1.10 0.71 1.25 0.88 
C16:0 16.36 16.85 12.88 11.69 
C18:0 16.95 19.27 37.78 37.72 
C20:0 - - - 0.60 
MUFA 28.43 29.17 24.26 29.29 
C16:1n9 - - 4.57 1.88 
C16:1n7 7.24 8.79 7.36 11.72 
C18:1n9 15.86 13.14 10.26 11.56 
C18:1n7 5.33 7.24 2.07 4.13 
PUFA 34.80 27.29 21.71 18.24 
C18:2n6 - 1.38 - 0.56 
C18:3n3 9.31 6.96 16.51 9.01 
C20:2n6 3.33 2.74 2.86 1.42 
C20:3n3 0.75 0.85 - - 
C20:4n6 15.16 10.01 2.34 3.32 
C20:5n3 3.16 2.30 - - 
C22:3n3 - 0.82 - - 
C22:5n3 1.39 1.07 - 1.90 
C22:6n3 1.70 1.16 - 2.03 
Table VI: Phospholipid fatty acid composition of hypoxic and normoxic adipocytes. 
Individual fatty acids compositions of (A) PE; (B) sphingomyelin; (C) PC; (D) cardiolipin; 
(E) PS; and (F) PI. Only fatty acids >0.5% are presented. The most abundant individual fatty 
acid and class are highlighted in bold for each sample. Totals of saturated, monounsaturated 
and polyunsaturated fatty acids (SFA, MUFA and PUFA respectively) are given (n=1).  
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Gene Forward primer sequence Reverse primer sequence 
GAPDH 5‟-CATTGACCTCAACTACATG-3‟ 5‟-TCTCCATGGTGGTGAAGAC-3‟ 
IL-10 5‟-ACGGCGCTGTCATCGATT-3‟ 5‟- TGGAGCTTATTAAAGGCATTCTTC-3‟ 
IL-1Ra 5‟- GGCCTCCGCAGTCACC-TAATCAC-3‟ 5‟- GGACAGGCACATCTTCCCTCCAT-3‟ 
Dectin-1 5‟-GGAAGCAACACATTGGAGAATGG-3‟ 5‟-CTTTGGTAGGAGTCACACTGTC-3‟ 
Table VII: qRT-PCR primers. Details of the primers used for qRT-PCR. 
